CA2933480C - Inhibitors of lysine specific demethylase-1 - Google Patents

Inhibitors of lysine specific demethylase-1 Download PDF

Info

Publication number
CA2933480C
CA2933480C CA2933480A CA2933480A CA2933480C CA 2933480 C CA2933480 C CA 2933480C CA 2933480 A CA2933480 A CA 2933480A CA 2933480 A CA2933480 A CA 2933480A CA 2933480 C CA2933480 C CA 2933480C
Authority
CA
Canada
Prior art keywords
compound
optionally substituted
pharmaceutically acceptable
acceptable salt
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2933480A
Other languages
French (fr)
Other versions
CA2933480A1 (en
Inventor
Young K. Chen
Toufike Kanouni
Stephen W. Kaldor
Jeffrey Alan Stafford
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Priority to CA3161836A priority Critical patent/CA3161836A1/en
Publication of CA2933480A1 publication Critical patent/CA2933480A1/en
Application granted granted Critical
Publication of CA2933480C publication Critical patent/CA2933480C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds of Formula (III), and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1.
Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
(see formula III)

Description

CROSS REFERENCE
[0001]
BACKGROUND
[0002] A need exists in the art for an effective treatment of cancer and neoplastic disease.
BRIEF SUMMARY OF THE INVENTION
[0003] Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition lysine specific demethylase-1 (LSD-1).
Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. The substituted heterocyclic derivative compounds described herein are based upon a central heterocyclic ring system, such as 4-azaindole,
4-azaindazole, pyrimidine or pyrazole, or the like. Said central heterocyclic ring system is further substituted with a 4-cyanophenyl group and a heterocyclyl group.
[0004] One embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, Y H
H
I / Z
H
H (I) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
Z is chosen from C-H or N;
R is chosen from hydrogen, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, or aralkyloxy;
W is ¨L-G, heterocyclyl, or heteroaryl;
L is alkylene;
G is ¨N(R1)2, heterocyclyl, or heteroaryl; and Date Recue/Date Received 2021-05-21 Rl is hydrogen or alkyl.
[0005] One embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, _N
N ,¨z H )--z=vv (II) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
W is chosen from C-H, C-F, C-C1, C-CH3, C-CF3, C-OCH3, C-OCH2CH3, or N;
Z is chosen ¨G, -CH2-G, ¨CH2-CH2-G, ¨N(R1)-G, ¨N(R1)-CH2-G, ¨0-G, -0-CH2-G, or ¨C(0)N(R2)(R3);
G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
RI is hydrogen or alkyl;
R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an N-linked heterocyclyl ring system;
R is chosen from aryl, halogen, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, or heteroaralkyloxy.
[0006] One embodiment provides a compound having the structure of Formula UM, or a pharmaceutically acceptable salt thereof, NC, X
y N Z
H ..1r H Rf N
R4 (III) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
Z is chosen ¨G, -CH2-G, ¨CH2-CH2-G, ¨N(R1)-G, ¨N(R1)-CH2-G, ¨0-G, -0-CH2-G, or ¨C(0)N(R2)(R3);
G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
Rl is hydrogen or alkyl;
R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an N-linked heterocyclyl ring system;

R is chosen from alkoxy, carbocyclylalkyloxy, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, alkynyl, carbocyclylalkynyl, heterocyclylalkynyl, or heteroarylalkynyl; and R4 is hydrogen, halogen, Ci-C3 alkyl, Ci-C3 alkoxy, or ¨N(R2)(R3).
[0007] One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0008] One embodiment provides a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0009] One embodiment provides a pharmaceutical composition comprising a compound of Formula (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0010] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (I).
[0011] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (II).
[0012] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (ha)
[0013] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (III).
[0014] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (IIIa)
[0015] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (1), or a pharmaceutically acceptable salt thereof
[0016] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (11), or a pharmaceutically acceptable salt thereof
[0017] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (ha), or a pharmaceutically acceptable salt thereof.
[0018] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (III), or a pharmaceutically acceptable salt thereof.
[0019] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (Ma), or a pharmaceutically acceptable salt thereof.
[0020]
DETAILED DESCRIPTION OF THE INVENTION
[0021] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise.
Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the cell" includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary between 1% and 15% of the stated number or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, may "consist of' or "consist essentially of' the described features.

Date Recue/Date Received 2021-05-21 Definitions
[0022] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.
[0023] "Amino" refers to the ¨NH2 radical.
[0024] "Cyano" refers to the -CN radical.
[0025] "Nitro" refers to the -NO2 radical.
[0026] "Oxa" refers to the -0- radical.
[0027] "Oxo" refers to the =0 radical.
[0028] "Thioxo" refers to the =S radical.
[0029] "Imino" refers to the =N-H radical.
[0030] "Oximo" refers to the =N-OH radical.
[0031] "Hydrazino" refers to the =N-NH2 radical.
[0032] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C1-C15 alkyl). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C1-C13 alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., C1-C8 alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (e.g., C1-05 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., Ci-C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C1-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., Ci-C2 alkyl). In other embodiments, an alkyl comprises one carbon atom (e.g., CI alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15 alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C5-C8 alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C2-05 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C3-05 alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl). The alkyl is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR", -SR', -0C(0)-Ra, -N(R0)2, -C(0)R3, -C(0)01Z0, -C(0)N(12a)2, -N(Ra)C(0)0Ra, -0C(0)- N
(Ra)2, -N(Ra)C(0)Ra, -N(Ra)S(0)tRa (where t is 1 or 2), -S(0)-t0R3 (where t is 1 or 2), -S(0)Ra (where t is 1 or 2) and -S(0)N(Ra)2 (where t is 1 or 2) where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).
[0033] "Alkoxy" refers to a radical bonded through an oxygen atom of the formula ¨
0-alkyl, where alkyl is an alkyl chain as defined above.
[0034] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i.e., allyl), but-l-enyl, pent-l-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -01e, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)OR', -C(0)N(R3)2, -N(Ra)C(0)0Ra, -0C(0)-N
(Ra)2, -N(Ra)C(0)Ra, -N(Ra)S(0)1Ra (where t is 1 or 2), -S(0)10R3 (where t is 1 or 2), -S(0)1R3 (where t is 1 or 2) and -S(0)tN(R3)2 (where t is 1 or 2) where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).
[0035] "Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having from two to twelve carbon atoms. In certain embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl comprises two to six carbon atoms. In other embodiments, an alkynyl comprises two to four carbon atoms. The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -0Ra, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)0Ra, -C(0)N(Ra)2, -N(Ra)C(0)0Ra, -0C(0)-N
(Ra)2, -N(Ra)C(0)Ra, -N(Ra)S(0)-tRa (where t is 1 or 2), -S(0)-tOle (where t is 1 or 2), -S(0)tR3 (where t is 1 or 2) and -S(0)-tN(Ra)2 (where t is 1 or 2) where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).
[0036] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like.
The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon in the alkylene chain or through any two carbons within the chain. In certain embodiments, an alkylene comprises one to eight carbon atoms (e.g., Ci-C8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., C1-05 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C1-C4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., Ci-C3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., Ci-C2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., C1 alkylene). In other embodiments, an alkylene comprises five to eight carbon atoms (e.g., C5-C8 alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C2-05 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C3-05 alkylene). Unless stated otherwise specifically in the specification, an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -0Ra, -SRa, -0C(0)-Ra, -N(Ra)2, -C(0)Ra, -C(0)0Ra, -C(0)N(Ra)2, -N(Ra)C(0)0Ra, -0C(0)-N
(Ra)2, -N(Ra)C(0)Ra, -N(Ra)S(0)-tRa (where t is 1 or 2), -S(0)-tORa (where t is 1 or 2), -S(0)tRa (where t is 1 or 2) and -S(0)-tN(Ra)2 (where t is 1 or 2) where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).
100371 "Alkynylene" or "alkynylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond, and having from two to twelve carbon atoms. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. In certain embodiments, an alkynylene comprises two to eight carbon atoms (e.g., C2-C8 alkynylene). In other embodiments, an alkynylene comprises two to five carbon atoms (e.g., C2-05 alkynylene). In other embodiments, an alkynylene comprises two to four carbon atoms (e.g., C2-C4 alkynylene). In other embodiments, an alkynylene comprises two to three carbon atoms (e.g., C2-C3 alkynylene). In other embodiments, an alkynylene comprises two carbon atom (e.g., C2 alkylene). In other embodiments, an alkynylene comprises five to eight carbon atoms (e.g., C5-C8 alkynylene). In other embodiments, an alkynylene comprises three to five carbon atoms (e.g., C3-05 alkynylene).
Unless stated otherwise specifically in the specification, an alkynylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -0Ra, -SRa, -0C(0)-R', -N(R3)2, -C(0)Ra, -C(0)0Ra, -C(0)N(R3)2, -N(Ra)C(0)0Ra, -0C(0)-N
(R3)2, -N(Ra)C(0)Ra, -N(Ra)S(0)-tRa (where t is 1 or 2), -S(0)-tORa (where t is 1 or 2), -S(0)tRa (where t is 1 or 2) and -S(0)1N(Ra)2 (where t is 1 or 2) where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroaryl alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).
[0038] "Aryl" refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
The aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) 7c¨electron system in accordance with the Hiickel theory. The ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene. Unless stated otherwise specifically in the specification, the tem' "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted earbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R b-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(Ra)2, -Rb_N (Ra) 2, -Rb-C (0)Ra, -Rb-C (0)0Ra, -Rb-C(0)N(Ra)2, -Rb- 0 -111c-C (0)N(Ra)2, -Rb-N(Ra)C(0)OR
a, -Rb-N(Ra)C (0)Ra, -Rb-N(Ra)S(0)-tRa (where t is 1 or 2), -Rb-S(0)-tORa (where t is 1 or 2), -Rb-S(0)tOR2 (where t is 1 or 2) and -Rb-S(0)-tN(Ra)2 (where t is 1 or 2), where each Rd is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Re is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0039] "Aralkyl" refers to a radical of the formula -Re-aryl where Re is an alkylene chain as defined above, for example, methylene, ethylene, and the like. The alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
[0040] "Aralkenyl" refers to a radical of the formula ¨Rd-aryl where Rd is an alkenylene chain as defined above. The aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group. The alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
[0041] "Aralkynyl" refers to a radical of the formula -R0-aryl, where Re is an alkynylene chain as defined above. The aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group. The alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
[0042] "Aralkoxy" refers to a radical bonded through an oxygen atom of the formula -0-Re-aryl where Re is an alkylene chain as defined above, for example, methylene, ethylene, and the like. The alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
[0043] "Carbocycly1" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms. In certain embodiments, a carbocyclyl comprises three to ten carbon atoms. In other embodiments, a carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is attached to the rest of the molecule by a single bond. Carbocyclyl may be saturated, (i.e., containing single C-C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds.) A fully saturated carbocyclyl radical is also referred to as "cycloalkyl."
Examples of monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. An unsaturated carbocyclyl is also referred to as "cycloalkenyl." Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cyclohcptcnyl, and cyclooctenyl. Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, the term "carbocyclyl" is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R'-OR, -R''-OC(0)-R', -Rb-OC(0)-01e, -Rb-OC(0)-N(Ra)2, -Rb_N(Ra) 2, -Rb-C(0)Ra, -R3-C(0)0Ra, -Rb-C(0)N(R1)2, -Rb-O-Rc-C(0)N(Ra)2, -Rb-N(Ra)C(0)OR
a, -Rb-N(R2)C(0)Ra, -Rb-N(Ra)S(0)-tRa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2), -Rb-S(0)tOR2 (where t is 1 or 2) and -Rb-S(0)-EN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0044] "Carbocyclylalkyl" refers to a radical of the formula ¨Rc-carbocyclyl where RC is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
[0045] "Carbocyclylalkynyl" refers to a radical of the formula ¨Rc-carbocycly1 where Rc is an alkynylene chain as defined above. The alkynylene chain and the carbocyclyl radical is optionally substituted as defined above.
[0046] "Carbocyclylalkoxy" refers to a radical bonded through an oxygen atom of the formula ¨O-R'-carbocyclyl where Rc is an alkylene chain as defined above.
The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
100471 As used herein, "carboxylic acid bioisostere" refers to a functional group or moiety that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety. Examples of carboxylic acid bioisosteres include, but are not limited to, 0 0 N-Ns N."
AN N _OH A ,cN µ,N 0 H, , OH
Ss, 0 N IN I I
OH OH 0 and the like.
[0048] "Halo" or "halogen" refers to bromo, chloro, fluoro or iodo substituents.
[0049] "Fluoroalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethy1-2-fluoroethyl, and the like. The alkyl part of the fluoroalkyl radical may be optionally substituted as defined above for an alkyl group.
100501 "Heterocycly1" refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. The heteroatoms in the heterocyclyl radical may be optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl radical is partially or fully saturated. The heterocyclyl may be attached to the rest of the molecule through any atom of the ring(s).
Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, the term 'heterocyclyl" is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl alkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rh-ORa, -Rb-OC(0)-Ra, -Rh-OC(0)-01V, -Rh-OC(0)-N(Ra)2, -Rb-N(Rd) 2, -Rb-C(0)Ra, -Rh-C(0)OR3, -Rh-C(0)N(Rd)2, -Rh-O-RL-C(0)N(Rd)2, -Rb-N(Ra)C(0)OR
a, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)-tRa (where t is 1 or 2), -Rb-S(0)tOR, (where t is 1 or 2), -Rh-S(0),ORa (where t is 1 or 2) and -Rb-S(0)-tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), hetcroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rc is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0051] "N-heterocyclyl" or "N-attached heterocyclyl" refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. An N-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals. Examples of such N-heterocyclyl radicals include, but are not limited to, 1-motpholinyl, 1-piperidinyl, 1-piperazinyl, 1-pyrrolidinyl, pyrazolidinyl, imidazolinyl, and imidazolidinyl.
[0052] "C-heterocyclyl" or "C-attached heterocyclyl" refers to a heterocyclyl radical as defined above containing at least one heteroatom and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a carbon atom in the heterocyclyl radical. A C-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals. Examples of such C-heterocyclyl radicals include, but are not limited to, 2-morpholinyl, 2- or 3- or 4-piperidinyl, 2-piperazinyl, 2-or 3-pyrrolidinyl, and the like.
[0053] "Heterocycly1 alkyl" refers to a radical of the formula ¨R'-heterocyclyl where Rc is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain. The heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
[0054] "Heterocyclylalkoxy" refers to a radical bonded through an oxygen atom of the formula ¨0-Re-heterocycly1 where RC is an alkylene chain as defined above.
If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heterocyclylalkoxy radical is optionally substituted as defined above for an alkylene chain. The heterocyclyl part of the heterocyclylalkoxy radical is optionally substituted as defined above for a heterocyclyl group.
[0055] "Heteroaryl" refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) 7c¨electron system in accordance with the Hilckel theory.
Heteroaryl includes fused or bridged ring systems. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quatemized.
The heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo [b][ 1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, ,6,6a,7,8 ,9, 1 0, 1 0 a-octahydrob enzo [h] quinazolinyl, 1 -phenyl- 1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pridinyl, and thiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, the term "heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -Rb-ORa, -Rb-OC(0)-Ra, -Rb-OC(0)-0Ra, -Rb-OC(0)-N(Ra)2, -Rb_N(Ra) 2, -R-C(0)R, -Rb-C(0)0R3, -Rb-C(0)N(Ra)2, -Rb-O-Re-C(0)N(Ra)2, -Rb-N(Ra)C(0)OR

a, -Rb-N(Ra)C(0)Ra, -Rb-N(Ra)S(0)-tRa (where t is 1 or 2), -Rb-S(0)-tORa (where t is 1 or 2), -Rb-S(0)tORa (where t is 1 or 2) and -Rb-S(0)-tN(Ra)2 (where t is 1 or 2), where each Ra is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), hcteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rb is independently a direct bond or a straight or branched alkylene or alkenylene chain, and Re is a straight or branched alkylene or alkenylene chain, and where each of the above substituents is unsubstituted unless otherwise indicated.
[0056] "N-heteroaryl" refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
100571 "C-heteroaryl" refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical. A C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
[0058] "Heteroarylalkyl" refers to a radical of the formula ¨Re-heteroaryl, where Re is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
The alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.

[0059] "Heteroarylalkoxy" refers to a radical bonded through an oxygen atom of the formula ¨0-Re-heteroaryl, where Re is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain. The heteroaryl part of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.
[0060] The compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z geometric isomers (e.g., cis or trans.) Likewise, all possible isomers, as well as their raccmic and optically pure forms, and all tautomeric forms are also intended to be included. The term "geometric isomer" refers to E or Z
geometric isomers (e.g., cis or trans) of an alkene double bond. The term "positional isomer" refers to structural isomers around a central ring, such as ortho-, meta-, and para-isomers around a benzene ring.
[0061] A "tautomer" refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible. The compounds presented herein may, in certain embodiments, exist as tautomers. In circumstances where tautomerization is possible, a chemical equilibrium of the tautomers will exist. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:

-\55 N-H H

\N
H2 NH2 \ NH \N \ N
N erss H vsss NI\ Nr---=---- I , N
N ¨N N=zsN'NH
N HN N' css5 /
NrN 5 5 e...N1 5 -rNH

[0062] "Optional" or "optionally" means that a subsequently described event or circumstance may or may not occur and that the description includes instances when the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
[0063] "Pharmaceutically acceptable salt" includes both acid and base addition salts. A
pharmaceutically acceptable salt of any one of the substituted heterocyclic derivative compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
100641 "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that arc formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and.
aromatic sulfonic acids, etc. and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, suceinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Also contemplated arc salts of amino acids, such as arginates, gluconates, and galacturonates (see, for example, Berge S.M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)).
Acid addition salts of basic compounds may be prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
[0065] "Pharmaceutically acceptable base addition salt" refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, argininc, histidine, caffeine, procaine, NN-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, /V-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. See Berge et al., supra.
[0066] As used herein, "treatment" or "treating," or "palliating" or "ameliorating" are used interchangeably herein. These terms refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By "therapeutic benefit" is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the Date Recue/Date Received 2021-05-21 underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
[0067] "Prodrug" is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound described herein. Thus, the term "prodrug" refers to a precursor of a biologically active compound that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject, but is converted in viva to an active compound, for example, by hydrolysis. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
[0068] A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
[0069] The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject. Prodrugs of an active compound, as described herein, may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amine functional groups in the active compounds and the like.
Substituted Heterocyclic Derivative Compounds [0070] Substituted heterocyclic derivative compounds are described herein that are lysine specific demethylase-1 inhibitors. These compounds, and compositions comprising these compounds, are useful for the treatment of cancer and neoplastic disease. The compounds described herein are useful for treating prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Date Recue/Date Received 2021-05-21 [0071] One embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, H
Z
R N
H (I) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
Z is chosen from C-H or N;
R is chosen from hydrogen, halogen, aryl, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, or aralkyloxy;
W is ¨L-G, heterocyclyl, or heteroaryl;
L is alkylene;
G is ¨N(R1)2, heterocyclyl, or heteroaryl; and R1 is hydrogen or alkyl.
[0072] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R is chosen from aryl, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, or aralkyloxy.
[0073] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is C-H. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is N.
[0074] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-H. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-F. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-CH3. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is N.
[0075] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Y is C-H. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Y is C-F. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Y is C-CH3. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Y is N. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-H, and Y is C-H. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-H, and Z is C-H.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-H, and Z is N.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-CH3, and Z
is C-H.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-CH3, and Z
is N.
[0076] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is heterocyclyl.
[0077] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is heteroaryl.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the L is chosen from a C1 alkylene, C1-C2 alkylene, C1-C4 alkylene, or C2-05 alkylene. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the L is a Ci alkylene. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the G is a heterocyclyl.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the G is a heteroaryl.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the G is ¨N(R1)2.
Another embodiment provides a compound having the structure of Formula (1), or a pharmaceutically acceptable salt thereof, wherein W is L-G, the L is chosen from a C1 alkylene, C1-C2 alkylene, C1-C4 alkylene, or C2-05 alkylene, and the G is ¨N(R1)2.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the G is ¨NH2.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the G is ¨
NH(alkyl).Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, and the G is ¨
N(alkyl)2.
[0078] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, the G is a heterocyclyl and the heterocyclyl is a nitrogen-containing heterocyclyl.
Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, the G is a heterocyclyl, the heterocyclyl is a nitrogen-containing heterocyclyl and the nitrogen-containing heterocyclyl is a 5- or 6-membered heterocyclyl. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is L-G, the G is a heterocyclyl and the heterocyclyl is chosen from:
sss3b ssrc_,F iro\i/_,Me isrn 5.5.53F si F
N N N N N N
sivini vv,Aivv avitv /.1.. X XVI e _.)<.F 3 F F=Tt= F
N.. ..-- N.. ..-- N.. .../. N.. ..--- N.... ...--N N N N N N
H , H , H , H , , H H, A or N
N =
H H
[0079] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the heterocyclyl is chosen from:

,rvine .iviry .nrini Srrl NH sNH' Jvinl N
..- =-=., 1 N
...-- --...
)..)-..., NH -------NH2 NH -I\JH , NH2 , H
/
NNH

NN _NI fli.jvN .-1¨'N
..--- --..
H , .ruiry 7' *nr .A74 7' s'sr N N N N
..--- =-=.
\
NH H L
NH NH H ' __________ H
, , H , .rviiv 4vint I 'Arj --r-N N ( (------) \ N N ,,N1 Ny ....- -.. -- ====.
) F'y HICI N
H N NH2, N
H
NH2 NH2 H , , 1¨
N
( __ ?
or NH2 .
100801 Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a heterocyclyl and the heterocyclyl is a nitrogen-containing heterocyclyl. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a heterocyclyl, the heterocyclyl is a nitrogen-containing heterocyclyl and the nitrogen-containing heterocyclyl is a 5- or 6-membered heterocyclyl. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a heterocyclyl and the heterocyclyl is a nitrogen-containing heterocyclyl chosen from:

1-553 ssi4f) ssLM e ssr sc4F rss' F
) ___________________________________________________________ F
, H , iv alivy avini XVI e ,)(F 3 F F
N N N N N
H H H H H

A or =
[0081] Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the R is an aryl group or a heterocyclyl group. Another embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the R is an aryl group. Another embodiment provides a compound having the structure of Formula (1), or a pharmaceutically acceptable salt thereof, wherein the aryl group is an optionally substituted phenyl group. Another embodiment provides a compound having the structure of Formula (1), or a pharmaceutically acceptable salt thereof, wherein the optionally substituted phenyl group is chosen from 4-methylphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, 4-(methylsulfonyl)phenyl, or 4-trifluoromethylphenyl.
[0082] One embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, NC,Xsy HT>N
N z H w (II) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
W is chosen from C-H, C-F, C-C1, C-CH3, C-CF3, C-OCH3, C-OCH2CH3, or N;
Z is chosen ¨G, -CH2-G, ¨CH2-CH2-G, ¨N(R1)-G, ¨N(R1)-CH2-G, ¨0-G, -0-CH2-G, or ¨C(0)N(R2)(R3);

G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
is hydrogen or alkyl;
R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an N-linked heterocyclyl ring system;
R is chosen from aryl, halogen, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, or heteroaralkyloxy.
[0083] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-H. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-F. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-CH3. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is N.
[0084] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Y is C-H. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Y is C-F. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Y is C-CH3. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Y is N. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-H
and Y is C-H.
[0085] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein W is N. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein W is C-H. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-H and W is N. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-H
and W is C-H. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-H, and W is N. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-H, and W is C-H.
[0086] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is -0-CH2-G.
Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨0-G. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(RI)-CH2-G.
[0087] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(RI)-G.
Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨CH2-CH2-G.
[0088] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is -CH2-G.
Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨G.
[0089] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3).
Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, or alkyl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclyl.
[0090] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclylalkyl.
[0091] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 are both alkyl, and R2 and R3 join to form an N-linked heterocyclyl ring system.
Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 are both alkyl, R2 and R3 join to faun an N-linked heterocyclyl, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
[0092] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, and R1 is hydrogen. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G, and R1 is hydrogen.
[0093] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, and R1 is alkyl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, R1 is alkyl, and the alkyl is a C1-C4 alkyl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨
N(R1)-G, and R1 is alkyl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein Z is ¨
N(R1)-G, R1 is alkyl, and the alkyl is a Ci-C4 alkyl.
[0094] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the nitrogen-containing heterocyclyl is a 5- or 6-membered heterocyclyl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl, and the heterocyclyl is chosen from:

issS____\ sscz_xF iscit_IMe srsc_µCF3 sci 5.0" F
( ) ( ) ( ) & ) ( ) ____________ F
N N N N N N
H , H , H , H , H , H , . . .
..nivv \"*L" )(F.. 1 \./1 e .../..< F3 )1,..F. F F-../L.,....F
--...
N N N N N N
H , ' ' ' ' H H H H H
, 4.A.,v ;ssLO) 6 or N
H H .
100951 Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the heterocyclyl is chosen from:
..n.A.n., -r= --1¨.
scssNH 33<NH
..- --...
H )) F
-F-:\aNH y '-------NH2 NH

H
i ¨1¨
r2 '7' snr I N N ss'NH
N N N
--- ---.

NH N N , N
H ' H ' , H , H H , ¨1-'rviv -I- -7- N
Nj --- .....
\
CNH H L <--NH
NH N , QH ' ____________ N
NH , , H , ...WV JV;JV I 4V7 1¨

c N N Ny .-- =====, F-)-"/- HOr N
H N NH.,, N
, H
NH2 NH2 H , , I-N
( __ ?
or NH2 .

[0096] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
[0097] Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein R is chosen from aryl, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, aralkyloxy, or heteroaralkyloxy. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein R is aryl. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein R is aryl, and the aryl group is an optionally substituted phenyl group. Another embodiment provides a compound having the structure of Formula (II), or a pharmaceutically acceptable salt thereof, wherein R is aryl, the aryl group is an optionally substituted phenyl group, and the optionally substituted phenyl group is chosen from 4-methylphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, 4-(methylsulfonyl)phenyl, or 4-trifluoromethylphenyl.
[0098] One embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, N
H )-vv (Ha) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
W is chosen from C-H, C-F, C-C1, C-CH3, C-CF3, C-OCH3, C-OCH2CH3, or N;
Z is chosen ¨G, -CH2-G, ¨CH2-CH2-G, ¨N(R1)-G, ¨N(R1)-CH2-G, ¨0-G, -0-CH2-G, or ¨C(0)N(R2)(R3);
G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
RI is hydrogen or alkyl;
R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an N-linked heterocyclyl ring system;
R is chosen from aryl, halogen, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, or aralkyloxy.

[0099] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-H. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-F. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-CH3. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is N.
[00100] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Y is C-H. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Y is C-F. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Y is C-CH3. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Y is N. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-H
and Y is C-H.
[00101] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein W is N. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein W is C-H. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-H and W is N. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-H and W is C-H. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-H, and W is N. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein X is C-H, Y is C-H, and W is C-H.
[00102] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is -0-CH2-G.
Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨0-G. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G.
[00103] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G.
Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨CH2-CH2-G.
[00104] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is -CH2-G.
Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨G.
[00105] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3).
Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, or alkyl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclyl.
[00106] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclylalkyl.
[00107] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 are both alkyl, and R2 and R3 join to form an N-linked heterocyclyl ring system.
Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 are both alkyl, R2 and R3 join to form an N-linked heterocyclyl, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
[00108] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, and R1 is hydrogen. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G, and R1 is hydrogen.

1001091 Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, and R1 is alkyl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, R1 is alkyl, and the alkyl is a C1-C4 alkyl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G, and R1 is alkyl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein Z is ¨
N(R1)-G, R1 is alkyl, and the alkyl is a C1-C4 alkyl.
1001101 Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the nitrogen-containing heterocyclyl is a 5- or 6-membered heterocyclyl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl, and the heterocyclyl is chosen from:
sisix,L,CF3 stssiF srs' ) _____________________________ F
win/ 1v vinf XVle .)<F3 F
ativti 0 ) 6 or =
1001111 Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.

[00112] Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein R is chosen from aryl, heteroaryl, heterocyclyl, carbocyclyl, alkoxy, cycloalkylalkyloxy, or aralkyloxy. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein R is aryl. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein R is aryl, and the aryl group is an optionally substituted phenyl group. Another embodiment provides a compound having the structure of Formula (Ha), or a pharmaceutically acceptable salt thereof, wherein R is aryl, the aryl group is an optionally substituted phenyl group, and the optionally substituted phenyl group is chosen from 4-methylphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, 4-(methylsulfonyl)phenyl, or 4-trifluoromethylphenyl.
[00113] One embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, Ir)fN(Z
H RfN
R4 (III) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
Z is chosen ¨G, -CH2-G, ¨CH2-CH2-G, ¨N(R1)-G, ¨N(R1)-CH2-G, ¨0-G, -0-CH2-G, or G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
RI is hydrogen or alkyl;
R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an N-linked heterocyclyl ring system;
R is chosen from alkoxy, carbocyclylalkyloxy, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, alkynyl, carbocyclylalkynyl, heterocyclylalkynyl, or heteroarylalkynyl; and R4 is hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, or ¨N(R2)(R3).
[00114] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein X is C-H.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein X is C-F. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein X is C-CH3. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein X is N.
[00115] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Y is C-H.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Y is C-F. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Y is C-CF13. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Y is N. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein X is C-H
and Y is C-H.
[00116] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is -0-CH2-G.
[00117] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨0-G.
[00118] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(121)-CH2-G, and 121 is hydrogen. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(RI)-CH2-G, and 12' is alkyl.
[00119] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G, and R1 is hydrogen.
Another embodiment provides a compound having the structure of Formula (111), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G, and R1 is alkyl.
[00120] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨CH2-CH2-G.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is -CH2-G. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨G. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3).
[00121] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, or alkyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclylalkyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 join to form an N-linked heterocyclyl ring system.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 join to form an N-linked heterocyclyl ring system, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 are both alkyl, and R2 and R' join to form an N-linked heterocyclyl ring system.
[00122] Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (III), wherein R4 is hydrogen. Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (III), wherein R4 is Ci-C3 alkoxy. Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (III), wherein R4 is ¨N(R2)(R3). Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (III), wherein R4 is ¨N(R2)(R3) and R2 is hydrogen and R3 is methyl. Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (III), wherein R4 is ¨N(R2)(R3) and R2 is hydrogen and R3 is ethyl. Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (11I), wherein R4 is ¨N(R2)(R3) and R2 is methyl and R3 is methyl.
[00123] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the nitrogen-containing heterocyclyl is a 5- or 6-membered heterocyclyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the heterocyclyl is chosen from:
rb sss3\4_,F srs4\4_,Me s.ssc_,CF3 i,ssiF .54-54 F
N N N N N N
. .
aviry aviry F.,(1...,,, F
N N N N N N
H , , , , H H H H H
, , 6 or N .
H H
[00124] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the heterocyclyl is chosen from:
37 ...A, sAis, a H NH F A . vNN .. sss' avi.tv , ri\l=
a ',..'"'NH 2 Fµ " iN CC i NH
N , , H

nN _NI
,...N.,,, N'e 0 ( ) H , 4viry .nitn, IA' la' =Ar -r NI 1 "Iw N l'a N
NH LNH K. ...õ-N.,...
N N
(L, <-1\IFI
NH NH n , N
NH N ' -1- -r -ri- 1 =7 -7 -ry F
( HO
Li.
\ cN ?
N N H2, cN_7 or N
H N N
H NH2 .
NH2 NH2 H , , [00125] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
[00126] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is chosen from alkynyl, carbocyclylalkynyl, heterocyclylalkynyl, or heteroarylalkynyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is chosen from alkoxy, or carbocyclylalkyloxy.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is chosen from heteroaryl, or heterocyclyl. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is chosen from carbocyclyl, carbocyclylalkyl, aryl, or aralkyl.
[00127] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is aryl.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is aryl, and the aryl group is an
38 optionally substituted phenyl group. Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is aryl, and the aryl group is an optionally substituted phenyl group chosen from methylphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, 4-(methylsulfonyl)phenyl, or 4-trifluoromethylphenyl.
[00128] Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is heteraryl.
Another embodiment provides a compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein R is heteroaryl, and the heteroaryl group is optionally susbstituted pyrrazolyl, imidazolyl, pyrolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl.
[00129] Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (III), wherein R is a bicyclic nitrogen-containing ring. Another embodiment provides a compound, or pharmaceutically acceptable salt thereof, of Formula (III), wherein R is chosen from:
\ N \
.... , -....
R5-1\1µ .... -- 1101 )V IP sIV 0 R5-N'N-- 0 R5-N
R.5 N ----R5 \ 'X'i \ ,N7-\, ----µ11 \ r,,,,..,____ /, N N, I N I
N's 1161 R5- N N N )1 N--=.- R5- N' = , ,. = , ,.
, IV N N R5 , R5 N N
, , , , R5 N N,1%,õ,\ N VA
N 5 3C,).
N 1VDC., \ .., ,..:\ a N'' ---/ N
-z.--'" ===,--- = ./ IV ' Re-N' N2 I R5-N N
....,...
..
N 1\1--- , R , IR
, , R5 \
'-µ\
\ N;\ I\L..1\1==-=\ \ 1DC( --1"-----"-- = ' N
R5-N N R5-14 N , I R5-N'( IV ------ sIVN l'R
, , , ,N -......*\ R5 N
NI 1101 \
' I m N.,,....\\
R5-N' ,i\rr,,,, ,,N,..õ;\
R5-N ,,, N , I N, N
R5 sr\r'N --- ....- iN `N---,...õ2--, I A

' / /
N N 0 \ R5-N =:( / *
N \ µN 0 \ I
/1--------" - N N---''N'' R5 \N------ N ,R5 N , R5 , ,
39 N IDI I \ í-- R5 I , / '''\ Ti j Nr"--`N"'"
R5 , R5 Ri'o N N'"- R's , , N-..N..,)\ R5 N....,,.....;\
I N N -,)\ e--1 1\1_,N),õ I
R5-N'SYj NI-- JG N----N
R5 ---- --N , Rs N - R5 , N....--,k._..A /;--_-, \ Rµ5 I I I S 0 \ \
N'N N---..N1 ii 110 0 R5 ,R5 N-----%-N N N , N \ 1\1 \ \ ------.----A, N, _.õ--, Al R5-N . R5-N R5-N
-,,....õ,, .,...;,.
0 MP S 0 - 1\1- N N sN---- , (\.% IV N / N ' I N I , `N----...N:-R5-N m sN
µ11--"\%.'" , R5 , R5 , R5 , R5 , N,-,.....,,-\ ,N11\1.)\ ,N \
R5-N Re-N' R5-N
Re-NN
ne.
,N ...,,. N ./\4 /N=-=::--- .1\1,^.N..)\, _kJ - N
I I % I
-N,N,-,i-N
Nr"-N% N- N
I\IP -N N
N ----, , , µ H2N N 0 \
\N- -N,)\ N-N `'µ`, N 1-.\
...._Y R5-N 0 N F
N N N---C%-,N N , R5 , , N'1\1 0 \ e 1110 \
N F N F
R5 ,or R5 F wherein R5 is hydrogen, C1-C6 alyl, or C1-C6 alkoxy.
[00130] One embodiment provides a compound having the structure of Formula (IIIa), or a pharmaceutically acceptable salt thereof, z H N
1 '1-H Rf.,- N
H (Ma) wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;

Z is chosen ¨G, -CH2-G, ¨CH2-CH2-G, ¨N(R1)-G, ¨N(R1)-CH2-G, ¨0-G, -0-CH2-G, or ¨C(0)N(R2)(R3);
G is carbocyclyl, aryl, heterocyclyl or heteroaryl;
R1 is hydrogen or alkyl;
R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an N-linked heterocyclyl ring system;
R is chosen from alkoxy, carbocyclylalkyloxy, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, alkynyl, or carbocyclylalkynyl.
[00131] Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein X is C-H. Another embodiment provides a compound having the structure of Formula (Ina), or a pharmaceutically acceptable salt thereof, wherein X is C-F. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein X is C-CH3. Another embodiment provides a compound having the structure of Formula (Illa), or a pharmaceutically acceptable salt thereof, wherein X is N.
[00132] Another embodiment provides a compound having the structure of Formula (IIIa), or a pharmaceutically acceptable salt thereof, wherein Y is C-H.
Another embodiment provides a compound having the structure of Formula (Ina), or a pharmaceutically acceptable salt thereof, wherein Y is C-F. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein Y is C-CH3. Another embodiment provides a compound having the structure of Formula (Ina), or a pharmaceutically acceptable salt thereof, wherein Y is N. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein X is C-H
and Y is C-H.
[00133] Another embodiment provides a compound having the structure of Formula (IIIa), or a pharmaceutically acceptable salt thereof, wherein Z is -0-CH2-G.
[00134] Another embodiment provides a compound having the structure of Formula (Illa), or a pharmaceutically acceptable salt thereof, wherein Z is ¨0-G.
[00135] Another embodiment provides a compound having the structure of Formula (Ilia), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G.
Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, and R1 is hydrogen. Another embodiment provides a compound having the structure of Formula (11Ia), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-CH2-G, and R1 is alkyl.
[00136] Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G.
Another embodiment provides a compound having the structure of Formula (Ina), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G, and R1 is hydrogen.
Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein Z is ¨N(R1)-G, and R1 is alkyl.
[00137] Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein Z is ¨CH2-CH2-G. Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein Z is -CH2-G. Another embodiment provides a compound having the structure of Formula (l11a), or a pharmaceutically acceptable salt thereof, wherein Z is ¨G. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3).
[00138] Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, or alkyl. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and 123 are independently selected from hydrogen, alkyl, or heterocyclyl. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclylalkyl. Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein Z
is ¨C(0)N(R2)(R3), and R2 and R3 join to form an N-linked heterocyclyl ring system.
Another embodiment provides a compound having the structure of Formula (111a), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 join to form an N-linked heterocyclyl ring system, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein Z is ¨C(0)N(R2)(R3), R2 and R3 are both alkyl, and R2 and R3 join to form an N-linked heterocyclyl ring system.
[00139] Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl. Another embodiment provides a compound having the structure of Formula (Ina), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the nitrogen-containing heterocyclyl is a 5- or 6-membered heterocyclyl. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein G is a nitrogen-containing heterocyclyl, and the heterocyclyl is chosen from:
srsb 55=0\4_,F sr54\a/_,Me scs"\4_,C F3 iJsj )N. __________________________________________________________ F
JV1JV ,IV;111 JWV JNAIV
\ !le ,F3 F
,====== =====..
srviAr =
[00140] Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein G is a heterocyclyl, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
[00141] Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein R is chosen from alkynyl, or carbocyclylalkynyl. Another embodiment provides a compound having the structure of Formula (Ma), or a pharmaceutically acceptable salt thereof, wherein R is chosen from alkoxy, or carbocyclylalkyloxy. Another embodiment provides a compound having the structure of Formula (Ina), or a pharmaceutically acceptable salt thereof, wherein R
is chosen from heteroaryl, or heterocyclyl. Another embodiment provides a compound having the structure of Formula (IIIa), or a pharmaceutically acceptable salt thereof, wherein R is chosen from carbocyclyl, carbocyclylalkyl, aryl, or aralkyl.
[00142] Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein R is aryl.
Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein R is aryl, and the aryl group is an optionally substituted phenyl group. Another embodiment provides a compound having the structure of Formula (II1a), or a pharmaceutically acceptable salt thereof, wherein R
is aryl, and the aryl group is an optionally substituted phenyl group chosen from 4-methylphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-cyanophenyl, 4-(methylsulfonyl)phenyl, or 4-trifluoromethylphenyl.
[00143] In some embodiments, the substituted heterocyclic derivative compound described herein has the structure provided in Table 1.

Chemical Synthesis Structure Example 1/%11'0 H
445-(4-methylpheny1)-1-[[(3R)-1 / pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-ylThenzonitrile 2 411) I io"C\IH
4-[5-chloro-1-[[(3R)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-CI N /
=%, 6-ylThenzonitrile N
rOIH
4-[5-(4-methylpheny1)-1-[[(35)-3 I / pyrroli din-3-*
yl]methyl]pyrrolo[3,2-b]pyridin-6-ylThenzonitrile Chemical :.::, :
!: Synthesis !:! I!: Structure! Nam &
.
!I Example I! , N.
ro H
=4-[5-chloro-1-[[(35)-pyrrolidin-3-4 / yl]methyl]pyrrolo[3,2-b]pyridin-I / 6-yl]benzonitrile CI
N N.
ok, ro H
4-[5-(4-fluoropheny1)-1-[[(3S)-* =Ni I / pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-ylMenzonitrile N ..
N. 404[5-morpholin-4-y1-1-[[(3R)-,, 6 I , N
pyrrolidin-3-/
yl]methyl]pyrrolo[3,2-b]pyridin-r N
6-yl]benzonitrile 0.,) N...
N. opriP=CNH
N 4-[5-morpho1in-4-y1-1-[[(3S)-7 I / pyrrolidin-3-rN .%.1\1 yl]methyl]pyrrolo[3,2-b]pyridin-0.,) 6-ylMenzonitrile N -. N. r.....\c7F
%. *
NH 4-11-[(3-fluoropyrro1idin-3-,/
8 I / Amethy1]-5-morpholin-4-("N N ylpyrrolo[3,2-b]pyridin-6-0.,) ylThenzonitrile r.....\c.F
NH 4-[1-[(3-fluoropyrrolidin-3-,1 N
yl)methy1]-5-(4-= N I /
methylphenyl)pyrrolo[3,2-b]pyridin-6-yl]benzonitrile -Chemical ... ,!:,. ...
:
...
..
- :õ = ....
Synthesis :: Structure] ,... :.IN a m w '. ,:.=
..
- :]]:
Example ' , .:.
...
,..::::::........................
.............................,.
..................................t.........t........k.........................
................ ............................ii ii..................................!........1........!.......................1 ........................................................11 N....
-..0/""C--4H
.,01 N e1-45-(4-methylpheny1)-1-[[(2R) -I / tnorph olin-2-Si .N y I] rn e El wityrrolo { 3,2-b]pyri din -6-ylThenzon itril e === iiili 445 -(4-11 llorop henyl.)-1 -[[(2R)-=,- N
11 I / ni o rphol in -2-%.
Oil N ylijrnothy1ipyrro1o[3,2-b]pyridin-6-y1ibeazonitrile \
Si ... N 4-[1 -(3-aminopropy1)-5 -(4-methylphenyl)pyrro lo [3,2-* 'N b]46yridine-6-yl]benzonitrile N..
\
. rOH
4-[5-(4-methylpheny1)-1 -13 I (pyrro lidin-3-...= ;NI ylmethyl)pyrazo to [4,3 -b]pyridin-* N
6-y1Th enzonitrile N...
r01H
4-[5-(4-m ethyl ph eny1)-1 -14 I )\1 (pip eridin-4-ylmethyppyrazo lo [4,3 -b]pyridin-* N
6-y1Th enzonitrile H
NC ropp H
, ¨ = azabicyclo[3.1.0]hexan-6-1 / N ylimethy1]-5-(4-N
methylphenyl)pyrazo lo [4,3 -b]pyridin-6-yl] b enzonitrile Chemical :
Synthesis I: StructureI : : =N \a me e: , .. .,:. :
Example , , :
N.
N .
NH,CNH 445-(4-methylpheny1)-2- {[(3S)-N
16 1 pyrrolidin-3-* ", N ylmethyl] amino} pyrimidin-4-yilbenzonitrile N,%,=:.
17 411 H ,mooeCN H 4-(5-chloro-2- { [(3S)-pyrrolidin-N N ylmethyl] amino} pyrimid in-4-I yl)benzonitrile CI
N N, N. I*N FNI,..eCNH 4-[5-(4-fluoropheny1)-2- {[(3S)-18 I .r pyrrolidin-3-N ylmethyl] amino) pyrimidin-4-yllbenzonitrile F *
N.
. N IFI.,....CNH 445-(4-chloropheny1)-2- { [(3S)-19 I pyrrolidin-3 -* .., N ylmethyl] amino } pyrimi din-4-yilbenzonitrile CI
N'.'.
N. .CNH 445 -(4-methylpheny1)-2- [(3R)-..zy, =%Ø pyrrolidin-3 -laiii ,, N ylmethoxy]pyrimidin-4-yilbenzonitrile N'., H
r N Ng 4- {2- [(3 aR,6aS)-Ø N H
octahydropyrrolo[3,4-c]pyrrol-2-* yl] -5-(4-methy1phenyOpyrimidin-4-y1} b enzonitrile Chemical :
. ::
!: Synthesis !=!:! !tructur6 : .N a m e , !I Example p , :
N's.
\ lot NH 445-(4-methylpheny1)-2-N N {octahydro-1H-pyrrolo[3,4-22 I N c]pyridin-5-y1{ pyrimidin-4-0 .., yl Then zonitri le H
N.
40 N (3 H
\ 5 4- {2- [(3aR,8aS)-N H
23 I µ.( decahydropyrrolo [3,4-d] azepin-6-(110 ... N yl]-5-(4-methylpheny1)pyrimidin-4-34{ benzonitrile H
N N, (5..71H
\
SI N N H
24 I decahydropyrrolo [3,4-d]) azepin-6-* ,, N y1]-5 -(4-fluorophenyOpyrimidin-4-y1} b enzonitrile F
N \ , \
. N 11 õveCNH 4-(2- { [(3S)-pyrrolidin-3 -25 I ylmethyl]aminol-544-* N (trifluoromethyl)phenyl]pyrimidin -4-yl)benzonitrile N N, \ ilti NNH 4- [5 -(2-cyclopropylethyny1)-2-26 I %.Y {[(3S)-pyrrolidin-3-N
.." ylmethyl] amino{ pyrimidin-4-/ ylThenzonitrile T
N N, \ I* 4-(2-{[(3aR,5S,6aS)-N H
H octahydrocyclopenta[c]pyrrol-5-N
27 I yl ] amino{ -5-(4-* ,- N
41:141N H
methylphenyOpyrimidin-4-H
yl)benzonitrile Chemical :
:
, Synthesis Structure] : .N a m e :
Example P
:
N...
`s. .
H

N .%)CF NH ( )-4-(2- { [(3-fluoropyrrolidin-N
28 I s'r yl)methyl]aminol-5-(4-0 === N methylphenyl)pyrimi din-4-yl)benzonitrile N'%.
H ( )-445-(4-methylpheny1)-2-29 1 N..Z.T' N NH [(piperi din-3-yl)amino]pyrimidin-IP.. N 4-y1Th enzonitrile N..., \ opH
N NN NH 445-(4-methy 1pheny1)-2-30 1 %Y [(pip eridin-4-yl)amino]pyrimidin-N NH
* 4-ylThenzonitrile N.% H
H N.%.,..0 ( )-445-(4-methy1pheny1)-2-N N [(pip eridin-3-31 I *r ylmethypamino]pyrimidin-4-0 . = . N
yllbenzonitrile N =%, `s H.01H 445-(4-methylpheny1)-2-N N [(p ip eridin-4-ylmethyl)amino]pyrimidin-4-yl Then zonitri le N.... H
%.. N,,, ( )-445-(4-methylpheny1)-2-1-NIN. #',....X ) [(morpholin-2-33 I *I 0 ylmethypamino]pyrimidin-4-401 .= N
ylThenzonitrile Chemical :
, Synthesis ].]:: !Structure : .Nam & , .
.:::.
!I Example ' N N.,1 EN* N ,....JC ) ( )-445 -(4-fluoropheny1)-2-34 1 Rmorpholin-2-IP ..= N
ylmethyl)amino]pyrimidin-4-yl Thenzonitri le F
N N.
N .N CONH 4-(2- {2,7-diazaspiro [4.4]nonan-2-*
, N 1 yll -5-(4-methylph enyl)pyrimi din-4-yl)benzonitrile rs) N.,...
36 . N N 4-(2- {2,8-diazaspiro[4.5]decan-2-y1} -5-(4-methylphenyl)pyrimidin-N
I .r. 4-yl)benzonitrile * .., N... r1H
N
445-(4-methylpheny1)-2-140 N N {octahydro-1H-pyrro10 [3,4-37 I S.

e]pyridin-2-y1} pyrimidin-4-* ., N
ylThenzonitrile N .N NC) 445-(4-methylpheny1)-2-38 I .r. f octahydro-1H-pyrrolo [3 ,2-* .., N c]pyridin-5 -y1 1 pyrimidin-4-yllbenzonitrile N..
N. roNH
. NS. N 4-(2- {2,8-diazaspiro[4.5] decan-8-3 9 1 e N 10 yl} -5-(4-methylphenyl)pyrimidin-, 4-yl)benzonitrile = =
Chemical ::::: ,.!:,= .:: ...
:
_. :.==
:
]Structu r0 ..
:
:::: :Nam0 ...
Synthesis ]] ...
'. , ...
..
..
Example = = =
...
iUt........................
..............................i!i ...:
.........................A........t.......A....................................
......... ...................ii ii..................................2........1.......!.........................
!..........................................................11 N
=N N r 1 ...1 1 4-(2- {1,8-diazaspiro[4.5] decan-8-*
,. N
40 I yl} -5-(4-methylphenyl)pyrimidin-4-yl)benzonitrile N.., %.. %rõ..<:).)1H
. N N, 4-[5-(4-methylpheny1)-2- {9-oxa-IP. N
41 I %*r 3,7-diazabicyclo[3.3.1]nonan-3 -.=
yl}pyrimidin-4-yl]benzonitrile N%.
=..
1411 N N ,.(52 5 H 4- [5-(4-fluoropheny1)-2- {9-oxa-
42 I 3,7-diazabicyclo [3.3.1]nonan-3 -N yl}pyrimidin-4-yl]benzonitrile F
N.
* " ,,,õN NH r-CH 445-(4-methylpheny1)-3-\
43 (pyrrolidin-3-* ylmethylamino)pyrazol-1-yllbenzonitrile N..
N.
1411 _N POH 4- [5-(4-methylpheny1)-3-[[(35)-
44 = NH pyrrolidin-3 -, *
yl]methylamino]pyrazol- 1-yllbenzonitrile N ..
...
* N,N ,,".0H 445-(4-methylpheny1)-3 -[ [ (3R)-...: NH pyrrolid in-3 -yl]methylaminolpyrazol- 1-yllbenzonitrile ' i Chemical :
Synthesis I.I!! Itructure : =Nam &
Example :
k . :
!I
:]]: , .:::. : I!
:
N N.
N.
1.1 OIFI
m..N r 445-(4-methylpheny1)-3-¨ µ NH
46 , (pip eridin-4-10 ylmethylamino)pyrazol- 1 -yllbenzonitrile NC ...N H 443-[[(1S,5R)-3-N \ NI-s-IINH azabi cyclo [3 .1 .0Thexan-6-, 47 yl]methylamino] -5 -(4-* H methylphenyl)pyrazol- 1 -N,..
ci yllbenzonitrile ll N.
48 14111 . 4-[5-(4-methylpheny1)- 1 -/ N
I µN pip eridin-4-ylpyrazolo [4,3-N
N i b]pyridin-6-ylThenzonitrile lip N N, 4- 1 1 -[((3R)pyrro lidin-3 -=N . twH .. yl)methyll -5 -(4-methoxyphenyl)pyrro lo [3 ,2-. I / b]pyrid in-6-* yl} b enzeneearbonitrile i '.. / 4-{1 -[((3R)pyrrolidin-3 -0 1411 . " I NI/ H yl)methyl] -5 -(3 -fluoro-4-methoxyphenyl)pyrro lo [3 ,2-*
F RI
b]pyridin-6-yl} benzeneearbonitrile I

' Chemical :
:
Synthesis ]Structure : .Name , Example p :' N N, = 4- {1-[((3S)pyrrolidin-3-011) rOH y pmethyl] -5 -(3 -fluoro-4-51 methoxyphenyl)pyrro lo [3 ,2-I /
F b]pyri din-6-=., * N yl} b enzenecarbonitrile 52 0 .," I r H 4- { 1-[((3R)pyrrolidin-3 -yl)methyl] -544-methoxyphenyl)pyrro lo [3 ,2-/
IN N b]pyridin-6-yll fluorobenzenecarbonitrile I
N N, 4- { 1-[((3R)pyrro lidin-3 -H l = yl)methyl] -5 -(3 -fluoro-4-N 53 iel "O
methoxyphenyl )pyrrolo [3 ,2-./ blpyridin-6-y4 -2-F
101 ==
N I /
fluorobenzenecarbonitrile I
N N. 445-morpholin-4-y1-1- [ [(3R)-=

. r0 H pyrrolidin-3-yl]methyl]pyrrolo [3 ,2-blpyridin-..=
= I / 6-y1]b enzonitrile N., * N

Chemical :
_ :
Synthesis Structure . .N a m e Example p :
, N.
4- { 1-[((3R)pyrro lidin-3-lit r0 H y pmethyl] -5 -(3-fluoro-4-methoxyphenyl)pyrro lo [3,2-F I / b]pyri din-6-yll -2-55 =,. * N fluorobenzenecarbonitrile N.
C)---N H2 41:1 Nj...1\ N 4-{3-[((3R)-3-56 0 aminopiperidypcarbonyl]-5-(2-pyridylmethoxy)pyrazolyll (Ng benzenecarbonitrile \ /
N
\\

_)--IN H2 111 NI -- N p 4- {3 - R(3R)-3-aminopiperidyl) \\
0 0 carbonyl]-5-(3-pyridylmethoxy) pyrazoly1} benzenecarbonitrile Nd N ., C-}"NH2 el õN N
4- {3 - R(3R)-3-aminopiperidyl) 58 )=-----/ '.0 carbony1]-5-(4-pyridylmethoxy) pyrazoly1} benzenecarbonitrile Cj N , F
N .., =. isi N H2 N 0- 4-[2-(4-aminopip eridin-l-y1)-5 -59 I .1. (2-methylindazol-5-yl)pyrimidin-N 4-y1]-2-fluorobenzonitrile .... 0 ¨N
N

, Chemical Synthesis ].]: ]Structure Name :
Example :
...3\1H
N
N¨(µ 4-[2-(1,2,3,3a,4,6,7,7a-60 _ . / \N octahydropyrrolo[3,2-c]pyridin-5-N_ y1)-5-(4-methylphenyl)pyrimidin-4-yllbenzonitrile I.
F
Fl \
F N
N.\ \
r N 442-(4-aminopiperidin-1-y1)-5-61 [1-(2,2,2-trifluoroethyppyrazol-4-*I N NO, y]]pyrimidin-4-ylThenzonitrile N /
/IN
4-[2-(2,8-diazaspiro[4.5]decan-8-62 y1)-54142,2,2-H NO N trifluoroethyl)pyrazol-4-G _ N
N<\ / . F
N N.....)r F yllpyrimidin-4-ylThenzonitrile N
F
SH
N
N:::--( 4-[2-(1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridin-5-63 \ iN
y1)-54142,2,2-trifluoroethyl)pyrazol-4-.--- yllpyrimidin-4-ylThenzonitrile (..1q / 41k ."'N
, \
F¨k F N\I
F

Chemical :
Synthesis ]:]! Structure] . =Name: , . ]=];: ]]: ::::::
, Example p :
N, = / \ N
4-[2-(4-aminopiperi din -1-y1)-5-64 N/ \ (1 -methylpyrazo lo [3 ,4-b]pyridin-)=-- N 5 -yOpyrimidin-4-yllb enzonitrile c.N) N
.`1\l'-.
=
ipt / \ N
Nf \ 44242,3 ,3 a,4,5,7,8,8a-octahydro-65 yr--N 1H-pyrrolo [3,4-cl] azepin-6-y1)-5 -(1-methylpyrazo lo [3 ,4-b]pyridin--yl)pyrimidin-4-yllb enzonitrile N
H

N\ /
.....- 4-[2-(4-aminopip eridin-l-y1)-5 -66 _ . \ N ,N (3-methylimidazo [4,5 -blpyridin-_ N¨( 6-yl)pyrimidin-4-yllbenzonitrile ' Chemical :
Synthesis ]: ]Structure . =Name: , k .. .õõ
Example , , :
"
N, W-. N \ /
4-[2-(4-aminopiperi din - 1 -y1)-5 -67 N/ \ (1 -methylpyrazo lo [4,3 -b]pyridin-)=-- N 5 -yOpyrimidin-4-yllb enzonitrile c) N
Nµ\ , 1\l'-.
./ \
¨N
4-[2-(4-aminop ip eridin- 1-y1)-5 -68 N/ \ (2-methylpyrazo lo [4,3 -b]pyridin-)=---- N 5 -yl)pyrimidin-4-yll b enzonitrile N
11\l'' ./ \
¨N
4-[2-(4-aminopip eridin- 1 -y1)-5 -6 9 N/ \ (1 -methylpyrazolo [3 ,4-e]pyridin-)=-- N 5 -yl)pyrimidin-4-yllb enzonitrile Chemical Synthesis ]:]!: ]tructu re : . =N \a me e:
, .:::.
Example , :

a N --/
, ....µ
\ /N 4-[2-(4-aminopip eridin-l-y1)-5 -70 [2-(1-hydroxycyclopentypethynyllpyri HO // midin-4-yl]benzonitrile =
\ µ
N
/N
.-H2N.CN N 11110 4-[2-(4-aminopip eridin-l-y1)-5 -71 N V [1-(oxolan-3-yl)pyrazol-4-\ \ N
14 yl]pyrimidin-4-ylThenzonitrile ..10 N
N
N N N 1\1.
. .
4-[2-(4-aminopip eridin-l-y1)-5 -72 N/ \ (1-m ethylb enzotriazol-5 -)=---- N yl)pyrimidin-4-ylThenzonitrile Chemical Synthesis Structure] : =Nam ].]
Example Nc 4-[2-(4-aminopip eridin-l-y1)-5 -(2-methylpyrazolo [3 ,4-e]pyridin-N \
N¨( 5-yl)pyrimi din -4-yl]benzonitri le )=N
N\/
4-[2-(4-aminopip eridin-l-y1)-5 -74 N 4), N
(2-methoxypyrimidin-5-N
yl)pyrimidin-4-ylThenzonitrile NN\ N/
=
4-[2-(4-aminopip eridin-l-y1)-5 -N/ (1,2-dimethylb enzimidazol-5 -yl)pyrimidin-4-yllbenzonitrile Chemical A
Synthesis ]:] ] Structure : =N \a me e: :
:
,. . .õõ
..
Example , , I
N
N \
\ Nc 1 ... \/N
4-[2-(4-aminopiperidin-l-y1)-5-N1 \ (2-methylp yrazolo [4,3-14yridin->=N 6-yOpyrimidin-4-yllbenzonitrile "-N
/ \ N
--.¨ 442-(4-aminopiperi din-1-y1)-5-1N (1-methylpyrrolo[3,2-b]pyridin-5-N¨ N ¨( yl)pyrimidin-4-ylThenzonitrile o N
i I
4111 ....., N, N -bo 4-[2-(4-aminopiperidin-l-y1)-5-78 -......
/
[1-(oxolan-3-ylmethyppyrazol-4-N i yl]pyrimidin-4-yllbenzonitrile 0 ' N

Chemical Synthesis ]:]! ]tructu re . =Name ]=];:
Example I.
4-[2-(4-aminopiperidin- 1-y1)-5 -11 -(difluoromethyl)b enzimidazol-N = N 5 -yllpyrimidin-4-yllbenzonitrile F N
N-\ 1 N 4-[2-(4-aminopiperidin- 1-y1)-5 -[1 -(2,2,2-trifluoroethyppyrazol-4-F N N
NH, yl]pyrimidin-4-y1]-2-fluorobenzonitrile 1\1/
N
4-[2-(4-aminopiperidin- 1-y1)-5 -\ ([1 ,2,4]triazolo[1,5 -a]pyridin-7-yl)pyrimidin-4-ylThenzonitrile Chemical Synthesis ]:]! ]Structure . =Nam ].]
Example iN
4* =
4-[2-(4-aminopiperidin- 1-y1)-5 -82 'N (4-methylphenyl)pyrimidin-4-N yllbenzonitrile =
4-[2-(4-aminopiperi din- 1 -y1)-5 -83 N_461 N
(4-methoxyphenyOpyrimidin-4-N-(yllbenzonitrile N
\)¨ND¨NH2 ¨N 4-[2-(4-aminopiperidin- 1-y1)-5 -(3 -fluoro-4-methoxyphenyl)pyrimi din-4-yllbenzonitrile //

Chemical :
Synthesis ]:!: Structure] .. . =N \a me e: ..
,. .. .:::. :..
Example ..
I
N
Nc /
N\ /
4-[2-(4-aminopiperidin- 1-y1)-5 -iN (2-methylpyrazolo [3 ,4-b]pyridin-N --- ilop \ __,( 5 -yl)pyrimi din -4-yl]benzonitri le N

I
,N
N'\ /
4,N
N 4-[2-(4-aminopiperidin- 1-y1)-5 -8 6 ¨
N (2-methylpyrazolo [4,3 -N -- 4111, \ __/, d]pyrimidin-5-yl)pyrimidin-4-N --\ ylThenzonitrile N\ N/N
N F
44# 414 ¨ 4-[2-(4-aminopiperidin- 1-y1)-5 -87 N \ / (1 -methylbenzimidazol-5-y¨ N yOpyrimidin-4-y1]-2-fluorobenzonitrile C>
N
--j Chemical :
Synthesis :::!: : Structure : . =N \a me & , . :
Example p :
N, Nµ\ .1...c 4. N \ /
N
4-[2-(4-aminopiperidin-1-y1)-5-88 N/ \ (1-methylpyrazolo[4,3-)=--N
dipyrimidin-5-yppyrimi din-4-yllbenzonitrile c.N) F
F¨H\

N. \ 1 N 2-fluoro-442-[4-89 ).)...... (methylamino)piperidin-1-y1]-5-..., F to N a / 11-(2,2,2-trifluoroethyppyrazol-4-N Apyrimidin-4-yllbenzonitrile H
Ne"
/N
)¨/ N
N ( \ #4*
4-12-(4-aminopiperidin-1-y1)-5-90 / "N (2-methylpyrimidin-5-N=( yl)pyrimidin-4-ylThenzonitrile Chemical :
Synthesis ]:]!: ] Structure . =Nam &
, . :
Example ,, :
HNN
=
¨ . ¨__N 4-[2-(4-aminop ip eridin-l-y1)-5 -91 N\ / (3H-b enzimidazol-5 -y¨N yl)pyrimidin-4-ylThenzonitrile I
N F \)N

4-[2-(4-aminopip eridin-l-y1)-5 -92 ¨ (2,3 -dimethylindazol-5-N / yl)pyrimidin-4-y1]-2-,--N fluorobenzonitrile N\ / N.

-N-N F
. .
4-[2-(4-aminopip eridin-l-y1)-5 -.......
93 N (1,3 -dimethylindazol-5-/
yl)pyrimi din -4-y1]-2---N
fluorobenzonitrile Chemical Synthesis ]:]!: ] Structure : . =Nam &
, . :
Example p :

OH
\\
F
4-[2-(4-aminopip eridin-l-y1)-5 -94 N¨_ 101 / \ N [2-(3-hydroxyoxolan-3-N=( ypethynyl]pyrimidin-4-y1]-2-0 fluorobenzonitrile I
N
l\s k He \ )N
N

4- [5 -(3-amino-2-methylind azol-5-95 ....¨ y1)-2-(4-aminopiperidin-1-N /
yl)pyrimidin-4-y1]-2---N fluorobenzonitrile Ci N\ ,N, .,...
N'" N
'a.
4-[2-(4-aminopiperidin-l-y1)-5-¨
N
96 (1-methylb enzo triazol-5 -)-- \ /
yOpyrimidin-4-y1]-2-N
fluorobenzonitrile Ci Chemical :
:
Synthesis Structure] : .Name , Example p \\
F
4-[2-(4-aminopiperi din - 1 -y1)-5 -97 NI- = / "N [2-(4-hydroxyoxan-4-N =< ypethynyl]
pyrimidin-4-y1]-2-0 flu orobenzonitrile ,N
N%'- r\j.....-\\
F 4-[2-(4-aminopiperidin- 1-y1)-5 -9 8 N 41)1 / \N [2-(3-methy ltriazol-4-N -=( ypethynyl]pyrimidin-4-y1]-2-flu orobenzonitrile I
Ns \ iN
\\
F 4-[2-(4-aminopiperi din - 1 -y1)-5 -99 [2-(1 -methylpyrazol-3 -N 4111 / \ N
ypethynyl]pyrimidin-4-y11-2-N =< fluorobenzonitrile Chemical Synthesis Structure] . .Name Example s N NNN
4-[2-(4-aminopip eridin-l-y1)-5 -100 N = \N [2-(1-methyltriazol-4-N yl)ethynyl]pyrimidin-4-y1]-2-fluorobenzonitrile N\ 1\1 4-[2-(4-amino-3-101 N , hydroxypiperidin-1-y1)-5-(1-N
methylindazol-5-yl)pyrimidin-4-¨
y1]-2-fluorobenzonitri le H 0 ¨() NN
4-[2-(4-aminopip eridin-l-y1)-5 -102 [2-(1-methylpyrazol-4-N 441)1 \ N
yl)ethynyl]pyrimidin-4-y1]-2-N fluorobenzonitrile Chemical 11 :
:
: S ]Structure =Name , , ynthesis ]:]!:
k . ]=];: :]]: :::::: .:::.
, Example F
F l l F N
N-\ \ 4-[2-(4-amino-3-V N hydroxypiperidin-1-y1)-541-[1 ., (2,2,2-trifluoroethyppyrazol-4-F . 1\1/- --.NIQ, yl]pyrimidin-4-y1]-2-NH2 fluorobenzonitrile 1\r> OH
N
N.

N N F
. 44*
4-[2-(4-amino-3-¨.0-N
104 hydroxypiperidin-1-y1)-5-(1-j y methylindazol-5-yl)pyrimidin-4-¨N
y1]-2-fluorobenzonitrile N
HO¨() N
Nk N r\l''' \ µ F
449 it F 4-[2-(4-aminopiperidin-1-y1)-5-105 Ni \ (6-fluoro-1-methylbenzotriazol-5-)."=-N yl)pyrimidin-4-y1]-2-fluorobenzonitrile c_N) Chemical :
Synthesis ]:]! ] Structure : . =Nam &
, .
Example p :
:
Ns " N--\\
F 4-[2-(4-aminopip eridin-l-y1)-5 -106 N 4* / \N [2-(2-methylpyrazol-3 -N=( yl)ethynyl]pyrimidin-4-y1]-2-fluorobenzonitrile I
N
N \
\ F \ P
lit 111 4-{2-(4-amino-3-hydroxypiperidin-1-y1)-5-(2-N I methylindazol-5-yl)pyrimidin-4-y¨ N y1]-2-fluorobenzonitrile N
HO¨() NN
\
N
F \ 1M11 4-[2-(3-aminopiperidin- 1-y1)-5-108 (2-methylindazol-5-yl)pyrimidin-N / 4-y1]-2-fluorobenzonitrile )=¨N
N

Chemical Synthesis :::!: Structure: : . =Nam & , . :
Example , :
I
N, N \
\ F \ IN
. ID
2-fluoro-4-[5 -(2 -methylindazol-5-109 N .....-y1)-2-piperazin-1 -ylpyrimidin -4-/
y'--N yllbenzonitrile N :-\l) H

N
NN\
F \)N
'SW' 4-[2-(1,4-diazep an- 1-y1)-5-(2-110 .-- methylindazo 1-5-yl)pyrimidin-4-N \ / y1]-2-fluorobenzonitrile )-- N

HN
N
, ''1\l'..
.
-- = N

"
I\1 / 44# 4-[2-(4-amino-3 -flop ¨N
F fluorobenzoni tri le N
F¨() Chemical :
Synthesis ]:] Structure] . =N \a me e: , .. ]=];: ]]: ::::::
Example , :
I
N1, \i"
442-(4-amino-3 -fluoropip eridin-112 ¨ 441* ¨__ N 1-y1)-5 -(2-m ethyl in dazol-5-N \ / yl)pyrimidin-4-y1]-2->--N
F fluorobenzonitrile N
F¨Q
1-1,1\1 HNDCN µ
N¨(/ \ 4*
N
4- [2-(2,7-diazaspiro [3. 5]nonan-7-= y1)-5-(4-methy1phenyl)pyrimidin-4-yllbenzonitrile \ µ
N\1 H
cN

....1 U
N 4-[2-(2,3 ,3a,4,5 ,7,8,8a-oetahydro-N )---2.."N 1H-pyrrolo [3,4-d] azepin-6-y1)-5 -(6-methylpyridin-3 -yOpyrimidin-/
4-y1Th enzonitrile I
, N, N , ' Chemical :
i!
Synthesis Structure] . .Name , Example p N_ , 'N-Nµ\
. =
4-[2-(1,2,3,3a,4,6,7,7a-Ni) N \ octahydropyrrolo [3 ,4-e]pyridin-y1)-5 -(1 -methylin dazol-5-77;
yl)pyrimidin-4-ylThenzonitrile N
H6-) N
I\1 N s . =
4-[2-(4-aminopiperidin- 1-y1)-5 -116 N/ \ ( 1 -methylindazol-5-yOpyrimidin-yr- ---N 4-yllbenzonitrile N
HN' I.
....... = 7._ N 44242,3 ,3 a,4,5 ,7,8,8a-octahydro-pyrrolo [3,4-cl] azepin-6-y1)-5 -y--N
(1H-indazol-6-yOpyrimidin-4-,:) yl Thenzonitri le N
H

Chemical Synthesis ]:]! ]Structure : =Nam ].]
Example 4-[2-(2,3 ,3a,4,5 ,7,8,8a-octahydro-118 1H-pyrrolo [3,4-d] azepin-6-y1)-5 -N (1,3 -dimethylpyrazol-4-yl)pyrimidin-4-yl]benzonitrile N
N
4-[2-(3,7-diazabicyclo[3.3 .11nonan-3-y1)-5-(4-methylphenyl)pyrimidin-4-yl]benzonitrile r 4-[2-(3,7-diazabicyclo[3.3 .1]nonan-3-y1)-5-.., (1-methylindazol-5-yl)pyrimi din-4-yl]benzonitrile N ¨ N

: Chemical Synthesis ]:]!: ] Structure : . =N \a me e: , .. .:::. :
Example p :, :
ir;"
442-(2,8-diazaspiro [4.5 ] dec an-8-121 y1)-54142,2,2-HNO N_ trifluoroethyppyrazol-4-C ---- N
N_<\ / . F
N \ .,..A.-- F yllpyrimidin-4-yl]benzonitrile N
F
---N/iN
.
¨ 4-[2-(4-aminopip eridin-l-y1)-5 -N-- ¨ . \ A (1-methylben zimidazol-5-N yl)pyrimidin-4-yllbenzonitrile o .........
N \ /
¨
442-(4-aminopiperi din -1-y1)-5-123 N¨_ 4* \ /N
(6-methoxypyridin-3-N yl)pyrimidin-4-yl]benzonitrile Chemical ..
Synthesis ]:] ] Structure : =Nam & , :-:
'. . ..
Example , , 4(¨ 0 ....._ N \ /
_ N2( 0 4-[2-(4-aminopip eridin-l-y1)-5 -124 NH2 [6-(cyclopropylmethoxy)pyridin-3 -yl]pyrimidin-4-yl]b enzonitrile Nk NN
\ µ
449 'SIP
F
125 N/ \ 4-[2-(4-aminopiperidin-l-y1)-5-(6-fluoro-1-methylbenzimidazol->=N 5 -yl)pyrimidin-4-yl]b enzonitrile CI) A
Chemical :
Synthesis ]:] Structure] : =N \a me e: , . .õõ
..
Example , :
i N F
A /
N F
4-[2-(4-aminopiperidin-1-y1)-5--126 \ iN (6,7-difluoro-1 -N: N ¨( m ethylb en zimi dazol-5 _ Qyl)pyrimidin-4-ylThenzonitrile N\ NCtsiN
=
N
\ /
4-[2-(4-aminopip eridin-l-y1)-5 -127 Nf \ ([1,2,4]triazolo[1,5-a]pyridin-6-)=N
yl)pyrimi d in-4-ylTh en zonitrile I
N
Nc /
S
4-[2-(4-aminopip eridin-l-y1)-5-128 ..¨
/N
(2-methylindazol-5-yl)pyrimidin-N¨ N --( 4-y1Th enzonitrile Chemical :
Synthesis ]:] ] Structure : =N \a me e: , ,. . ]=];: ]]: :::::: .õõ
, Example p :
I
N
N \
\ N c 1 4-[2-(4-aminopiperidin-l-y1)-5 -129 N' (2-methylindazol-6-yl)pyrimidin-\
N 4-ylThenzonitrile I
,,N F
µk /
N ' F
4-[2-(2,3 ,3 a,4,5,7,8,8a-oetahydro--\ / N 1H-pyrrolo [3,4-d] azepin-6-y1)-5 -methylbenzimidazol-5-y1)pyrimidin-4-yl]benzonitrile N
H
F F
F)c_0 _ N \ /
442-(4-aminopiperidin-l-y1)-5 -131 N * _ N [6-(2,2,2-trifluoroethoxy)pyridin-7,.. \ i 3 -yl]pyrimidin-4-yl]benzonitrile N

Chemical Synthesis ]:]!: Structure] . =N a m ].]
Example /41i. F
F 4-[2-(4-aminopiperidin-l-y1)-5-(6,7-difluoro-1-N= _1( methylbenzimidazol-5 -N yOpyrimidin-4-y1]-2-0 flu orobenzonitrile N\ NN
4-[2-(4-aminop ip eridin-l-y1)-5 -133 N/ (6-fluoro-1-methylbenzimidazol-)=---N 5 -yl)pyrimidin-4-y1]-2-fluorobenzonitrile N

¨N
)N
\
4-[2-(4-aminopip eridin-l-y1)-5 -134 \ N [2-(dimethyl am ino)pyrimi din-5-N =( yl]pyrimidin-4-y1]-2-fluorobenzonitrile Chemical ..
Synthesis ]:] ] Structure : =Nam &
Example , , '. . :]]: :..
, , )¨/ N
Nf \
_ F 4-[2-(4-aminopip eridin-l-y1)-5 -135 / \ N (2-pyrrolidin-1-ylpyrimidin-5 -N= yOpyrimidin-4-y1]-2-N=< fluorobenzonitrile --- N /N
N \ /
F 4-[2-(4-aminopip eridin-1-y1)-5 -136 / \ N (3-methylimidazo [4,5 -b]pyridin-N-- . N¨( 6-yOpyrimidin-4-y1]-2-Qfluorobenzonitrile ---N N
¨
N \ /
F
137 N / \ N 442-(2,8-diazaspiro[4.5]decan-8-¨
¨ N--. y1)-5-(3 -methylimidazo [4,5 _ RD b]pyridin-6-yl)pyrimidin-4-y1]-2-fluorobenzonitrile N
H

Chemical Synthesis ]:]! ]Structure . =Nam ].]
Example N\
44k 4-[2-(4-aminopip eridin-l-y1)-5 -138 (1,2-dimethylb enzimidazol-5 -N \ yOpyrimidin-4-y1]-2-fluorobenzonitrile N\
4-[2-(4-aminop ip eridin-l-y1)-5 -139 (3 -methyltriazo lo [4,5-b]pyridin-N N-4 6-yl)pyrimidin-4-y1]-2-fluorobenzonitrile HN
N()-1 N
4-[2-(4-aminop ip eridin-l-y1)-5 -140 \N [2-(methylamino)pyrimid1n-5-N yl]pyrimi din -4-y1]-2-fluorobenzonitrile Chemical Synthesis ]:]! ]Structure . =Nam ].]
Example HN
N
1\1( 4-[2-(4-aminopip eridin-l-y1)-5 -141 [2-(cyclopropylamino)pyrimidin-N: 'N 5 -yl]pyrimid in-4-y1]-2-N fluorobenzonitrile \r) F 4-[2-(4-aminopiperidin-l-y1)-5 -142 [1-(oxan-4-yl)pyrazol-4-NZ \N yl]pyrimidin-4-y1]-2-N fluorobenzonitrile Nµ\
F )N
44# = 4- [2-(3-aminopyrro lidin-1-y1)-5-143 (2-methylind azol-5-yl)pyrimid in-N4 / 4-y1]-2-fluorobenzonitrile ) Chemical :
i!
Synthesis Structure] . .Name , Example p I
N, N \
\ F \)N
.

144 , azabicyclo [3.1.0] hexan-3-y1)-5 -(2-methylindazol-5-yl)pyrimidin-N /
y-- N 4-y1]-2-fluorobenzonitrile H2N :/1µ
N
N \ /
F 4-[2-(4-aminopip eridin-l-y1)-5 -145 _ . / \ N (1-methylpyrazo lo [3 ,4-b]pyridin-N _ N:------< 5 -yl)pyrimid in-4-y1]-2-fluorobenzonitrile s N
I.
..-- 4- [2-(2,3,3 a,4,5,7,8,8a-octahydro-146 N _ =/\ i N
¨ =

1H-pyrrolo [3,4-cl] azepin-6-y1)-5 -N --1( (1,3 -benzothiazol-5-yppyrimidin-Ncl.... 4-yl]benzonitrile N
H
N. F
4-12-(4-aminopiperidin-l-y1)-6-N,%õ, I f a 147 II methoxy-5-(2-methy1-2H-indazol-%. N 5 -yl)pyrimidin-4-y1]-2-.......
¨N fluorobenzonitrile 1\1.-Chemical :
:
Synthesis Structure] : .Name , Example , , :
F
%..
(-NH 4- * [2-(1,4-diazepan-l-y1)-6-148 N'Y No... j methoxy-5 -(2-methy1-2H-ind azol-N 5 -yOpyrimidin-4-y1]-2-....,,, ¨N fluorobenzonitrile \1 F
=%.
NH
1411 N I 0 . - - - - 2 4-12-(4-aminoazep an-1-y1)-6-149 I ' r - methoxy-5-(2-methy1-2H-indazol-.. N
....., 5 -yl)pyrimidin-4-y1]-2--N fluorobenzonitrile sN-410 /
F
N=.,.
=%. oiti NH2 I 4-[2-(4-aminopiperidin-l-y1)-6-N
150 I =Y methoxy-5-(2-methy1-2H-indazol-,N, 0 .' N 6-yl)pyrimi din-4-y1]-2--N fluorobenzonitrile ...- 0 /-F
N =., =%.
N 0- 4-[2-(4-aminopip eridin-l-y1)-6-151 I methoxy-5-(1-methyl-1H-1,2,3 -NI:1Y 1111 == N benzotriazol-5-yOpyrimidin-4-y1]-2-fluorobenzonitrile N
/
N..,,.
N 0- 4-[2-(4-aminopip eridin-l-y1)-6-152 I N methoxy-5-(2-methy1-2H-indazol-,-..... 0 5 -yl)pyrimidin-4-yll b enzonitrile ¨N

N "..

Chemical :
Synthesis ]=]: ]tructu re : =Nam & , , . .:::.
Example =
:
N ...
%. NH2 411 N a 4-[2-(4-aminopip eridin-l-y1)-6-153 I methoxy-541-(2,2,2-.. N
trifluoroethyl)-1H-pyrazol-4-...
¨
ylipyrimidin-4-ylThenzonitrile N..
%., N 0-- 4-[2-(4-aminopip eridin-l-y1)-6-154 I 1.1,1 methoxy-5-(1-methyl-1H-1,2,3-- b enzotri azol-5 -yl)pyrimi din-4-N ' . 0 yllbenzonitrile /
.=. N H2 N 0- 4-[2-(4-aminopip eridin-l-y1)-..0 N [6-(dimethylamino)pyridin-3-y1]-,,, 6-metho xypyrimidin-4 -I
,N 1\r 0µ,. ylThenzonitrile I
N %, %. lot NH2 N No- 4-[2-(4-aminopip eridin-l-y1)-5 -.- N 12-(dimethylamino)pyrimidin-5-N '%. y1]-6-methoxypyrimidin-4-N A N., 0..õ, yllbenzonitrile N ...
=.. F. NH2 2-(4-aminopiperidin-l-y1)-6-N a 4-[2 -5- {3-methyl-3H-157 I N [1,2,3]triazolo[4,5-b]pyridin-6-N' .
, N.
, N
yllpyrimidin-4-y1]-2-I
IV Nr 0%. fluorobenzonitrile /

' : Chemical A
:
, ]] Synthesis Structure] : .Name , Example ' p N %..
=.. NH2 N a 4-[2-(4-aminopip eridin-l-y1)-6-158 I lr'' methoxy-5- {3-methy1-3H-N .0 N
[1,2,3]triazolo[4,5-b]pyridin-6-N ' I
N N./ 0 yl}pyrimidin-4-ylThenzonitrile ..., /
F
N ....
=%. * NH2 4-[2-(4-aminopiperidin-l-y1)-6-N a methoxy-5-11-methy1-1H-159 I %r , N pyrazolo[3,4-b]pyridin-5-N, 1 I yllpyrimidin-4-y1]-2-II Nj O. fluorobenzonitrile /
N... F
N

(11 0 4-[2-(4-aminopiperidin-l-y1)-5 -160 0 N - (2-methyl-2H-indazol-5-y1)-6-I
"' N (methylamino)pyrimidin-4-y1]-2-...,.. 0 -N fluorobenzonitrile HN
N%..
N... F
N
* NH2 N a 4-[2-(4-aminopip eridin-l-y1)-5 -161 I (1-methyl-1H-indazol-5-y1)-6-N (methylamino)pyrimidin-4-y1]-2-I-IN
fluorobenzonitrile . õ..
N
/
N N F
%..
('NH 1 4-[2-(1,4-diazepan-1-y1)-5-(2-N Nõ,.....f methy1-2H-indazol-5 -y1)-6-162 1 2:f (methylamino)pyrimidin-4-y1]-2-....
- N. SI fluorobenzonitrile N HN

i Chemical :
Synthesis ]=]: ] Structure : =Nam & :
. :
Example =
:
N....
\ * N H2 N kg. 4-[2-(4-aminopip eridin-l-y1)-5 -163 I (2 -methy1-2H-indazol-5-y1)-6-.= N (methylamino)pyrimidin-4-y1]-....., 0 ¨N ben zonitri le N HN \
N....
N. N H2 (1101 N 0- 4-[2-(4-aminopip eridin-l-y1)-5 -N ( 1 -methy1-1H-indazol-5-y1)-6-(methylamino)pyrimidin-4-.N H N\
ylThenzonitrile /
N.., F
\ 010 N H2 N 0- 4-[2-(4-aminopip eridin-l-y1)-5 -165 I *r. (1 -methy1-1H-1 ,2,3-b enzotriazol-,N * N 5-y1)-6-(methyl amino)pyrimi din-N H N 4-y1]-2-fluorobenzonitrile .
N N.
/
F
N .., \ N H2 * N or 4-[2-(4-aminopip eridin-l-y1)-6-166 I (ethylamino)-5-(2-methy1-2H-," N ind azol-5 -yl)pyrimi din-4-y1]-2-.., 010 ¨N
H N. fluorobenzonitrile N
I
N. F, \ * NH2 4-[2-(4-aminopiperidin-l-y1)-6-(methylamino)-5 -[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-.. N
..... yl]pyrimidin-4-y1]-2-r- 'NI N
H N , fluorobenzonitrile ' ' Chemical :
Synthesis Structure] : .Name , Example , F
N%
. N 0- 4-[2-(4-aminopip eridin-l-y1)-5 -168 I [2-(dimethylamino)pyrimidin-5-.. N
N %., y1]-6-(methy lamino)pyrimidin-4-N
II N H N\
y1]-2-fluorobenzonitrile ., ,.., .*
I
N.... F
N. * N H2 N 0- 4-[2-(4-aminopip eri din-1-y1)-5 -169 I .1 [6-(dimethylamino)pyridin-3 -y11-,, N
N. 6-(methylamino)pyrimidin-4-y11-.,N I14" H N,,. 2-fluorobenzonitrile N
... * NH2 4-[2-(4-aminopiperidin-l-y1)-5 -N or [3-methyl-3H41,2,3]triazolo [4,5-,I; * .- N b]pyridin-6-y1} -6-N
(methylamino)pyrimidin-4-N H Ns. yllbenzonitrile /
F
* NH2 4-[2-(4-aminopiperidin-l-y1)-5 -N 0- [3-methy1-3H41,2,3]triazolo[4,5-171 I N 9 N blpyridin-6-y1} -6-\ .
Nll' I (methylamino)pyrimidin-4-y1]-2-N N H N fluorobenzonitrile /
N
*
N N r-NNH 4-[2-(1,4-diazepan-1-y1)-5-(2-......,I
172 I Ir. methy1-2H-indazol-5 -y1)-6-.. N
(methylamino)pyrimidin-4-......
H N , ¨N yl Then zonitri le N

Chemical :
, iI Synthesis !:!!! Structure! : .N
a m e , !I Example , N'.. I
%.N.... 4- {2-[4-001 N N.D./ (dimethylamino)pip eridin-1-3/1]

173 I N (2-methyl-2H-indazol-5-y1)-6-¨N
.=
, t (methylamino)pyrimidin-4-HN
N '. yl } benzonitri le N'...
N. NH2 N 0- 4-[2-(4-aminopip eridin-l-y1)-6-(methylamino)-5-[1-(2,2,2-,, N
trifluoroethyl)-1H-pyrazol-4-.., p¨N yl]pyrimidin-4-y1]-benzonitrile F3C \j"
F
N

4-[2-(4-aminopiperidin-l-y1)-5-N 0.- t 1-methy1-1H-pyrazo10 [3,4-175 I .., N b]pyridin-5 -y1} -6-N" N N I
(methylamino)pyrimidin-4-y1]-2-d' HN flu orobenzonitrile I
N'...
%., iiii N H2 4-12-(4-aminopiperidin-l-y1)-5-N a {3-methy1-3H41,2,3]triazolo [4,5-N ., ..- N b]pyridin-6-yll -6-Ni' I
(methylamino)pyrimidin-4-N Nj H N yl Then zonitri le /
N'....

4-124(3 S,4R)-4-amino-3-N aF
fluoropip eridin-l-y1]-5 -(2-methyl-177 I ... N 2H-indazol-5-y1)-6-¨N N
.... 0 (methylamino)pyrimidin-4-HN ylf benzonitrile -.
N =%.
D

=,.. ,,N H2 4- {2-[(3R,4 S)-4-amino-3-N fluorop ip eridin-l-y1]-5 -(2-methyl-111 "F
178 I 1-. N 2H-indazol-5-y1)-6-¨N
..
.... 0 (methylamino)pyrimidin-4-HN
N N yl} benzonitrile 1001441 In some embodiments, the substituted heterocyclic derivative compound described herein has the structure provided in Table 2.

N N.
N'. . r....F N. r\CNH
NH
N I /
N I N / tilD N

44544- fluorophcny1)-1-[(3- fluoropyrrolidin-3 - 445-(4-methylpheny1)-1 -[(3-methylpyiTolidin-3-yl)methyl]pyrrolo[3,2-blpyridin-6-ylibenzonitrile yl)nictityllayrrol.o[3,2.-Npyridin.-6-Abertro [3 itrile N. 0 N ...
N
,W1 i NH
I / /

N
44544-me-thy ipheny1)-1-[j(25)-morpholin-2-yi] me-thyl]pyrrolo[3,2-.11pyrictin-6-yil benzonitile 44 I -[[(310-4,4-difluompiperidin-3-y1 1 rnethyr1-5-(4-methylpheny 1)pyrroi o [3,2-blpyridin -6-yl lbenzonitrile N =. CN H N.

,..

/OH

, 1 , N F) N
Fp F
445-(4,4-difluoropiperidin- 1 -y1)-1-[ [(3S)-pyrrolidin- 445-(4,4-difluoropiperidin-1-y1)-1 -[ [(2S)-morpholin-3-yl] methyl] pyrrolo[3 ,2-b]pyridin-6-yl] benzonitrile 2-yl] methyl]
pyrrolo[3 ,2- b]pyridin-6-yl] benzonitrile N. 0-- \

AI' .."Cy N
4- [1 - [(3 -11uoropyrrolidin-3-yl)methyl] -5-(4-methylpiperidin-1-yl)pyrrolo[3,2-b]pyridin-6-4-[5-(4-methylpiperidin-1-y1)-1-[[(2R)-morpholin-2-yl]benzonitrilc yl] methylipyrrolo [3 ,2-1)] pyridin-6-yl] benzonitrile N N, N N, N *
N pp. COH
, NrCN H
N I /

,Cly N
F 3C) 415 -(4-methylpiperidin- 1-y1)- 1 - [[(2S)-morpholin-2- 4-[ 1 - [
[(3S)-pyrrolidin-3 -yllmethyl] -5 -(2,2,2-yl] methyl]pyrrolo [3 ,2-b]pyridin-6-yl]benzonitrile trifluoroethoxy)pyrrolo [3 ,2 -b]pyridin-6-yl]benzonitrile N'...
N. 0 N..., rCIN H N.
N
0 ,...CN H
/ N
O N /

ci, v=-=' 441 -[[(3S)-pyn-ol idi n-3 -y1 ]nethyl ] -543,3,3- 4-[5-(cyclopropylmcthoxy)- 1 - [ [(3S)-pyrrolidin-3 -trifluoropropoxy)pyrrolo[3,2-b]pyridin-6- yllmethyl]pyrrolo [3 ,2-b]
pyridin-6-yll benzonitrile yllbenzonitrile N'... N
N
Si ,C1N H f-SCN H
de N N

1) egj 445-(2-cyclopropylethoxy)- 1 - [ [(3S)-pyrrolidin-3 - 4 45-(2-cyclopropylethoxy)-1 -[(3 -fluoropyrrolidin-3 -yl] me thyl]pyrrolo [3 ,2-h]pyridin-6-yl]benzonitrile yl)methylipyrrolo[3,2-b]pyridin-6-yllbenzonitrile N 0 --- N ==%
N N. 01 PK.-- 4H
N de /
N

rFj3 4 g j 4-[ 1 -[[(2S)-morpholin-2-yl]methy1]-5 -(3 ,3 ,3 -trifluoropropoxy)pyrrolo[3,2-b]pyridin-6- 4- [5 -(2-cyclopropylethoxy)- 1 -[R2S)-morpholin-2-yllbenzonitrile yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N'.. r.....F N'., \\ 0 /WO H
,e N H de N
. N
N I /

4011 *
4-[ 1-[(3 -fluoropyrrolidin-3 -yl)methyl] -5- 445 - [(4-tluorophenyl)metboxy]-1 -[[(3S)-pyrrolidin-3-phenylmethoxypyrrolo[3,2-b]pyridin-6-ylThenzonitrile yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N = 0"N N =
=
/""C-41-1 =
* ..,. Nitig.Q
'J--* *
4 - [5- [(4- fluorophenyl)methoxy] - 1 - [ [(2R)-morpholin- 4- [5 - [(4 -fluorophenyl)methoxy] - 1 - [[(2S)-morpholin-2-yl] me tit yl] pyrrol o [3 ,2-h]pyrictin -6 -1] ben zoni trile 2-yl] me tit yl] pyrrol o [3 , 2-h]pyridin -6 -yl] ben zoni trile F
N N N.
N. op / N'... 11Z)H 0111 ". Nr\QH
.% I / N i # N
# N
4-[ 1.- [R3S)-4,4-difinoropiperidin- 3 -yiltne.thyr] - 5 -(4 - 445 -(4-fluorophenyl.)- 1 -[(3-fittoropyrrolidin-3-t IIC 11 iy1p13 e;n y )py rrolo [3 ,2 -blpy rid in - 6 --y1]laciTion i ti i 1 CI y1) 111 eti 1 yl] py razol o [4,3 -kip-yr i cl i n--6---yllbe n zon i tr Fit N.... 00 /""C.-.1\f1-1 0¨N N'... N
N. I*
dur.0 H
% %
.õ I / N I / N

445-(4-methylpheny1)- 1 - [ [(2R)-morpholin-2- 4 - [5-(4-methylpheny1)- 1 -[[(2S)-morpholin-2-yl] methyl] pyrazo lo [4, 3 -b]pyridin-6-yl] benzonitrile yl]methyl]
pyrazolo [4,3 -b]pyridin-6-yl]benzonitrile F F
N N. F$b ;wt.
N,..
l N. 40 H
Opp N 41) N
4-[ 1 4 [(3.R)-4,4 -slifluoropiperidth-3-Amethyli-5-(4 - 4 -[ 1-[ [(3 S)-4,4-di flu oropiperid in-3 -yl] methyl] -5 -(4 -tnethylphenyppyrazolo[4,3-b] pyridin-6-methylphenyl)pyrazolo [4,3 -b]pyridin-6-yil berzonitile yl]benzonitrile N = 0 N ,... OTh N. # =
rCN
-'N N
I %NI I 1\1 = / = /
F) N F) N
F F
4 - [5-(4,4-di fluoropiperidin- 1 -y1)- 1-[ [(3 S)-pyrroliclin- 4- [5 -(4,4-clitluoropiperidin- 1 -y1)- 1 -[ [(2S)-morpholin-3 -yl] me thyl] pyrazolo [4,3 -1)] pyr i d i n-6-Y1] benzo n itrile 2-yllmethyll pyrazo lo [4,3 -I)] pyridin-6-yl] benzonitrile N.... \ I NcI
r.NF
* 0 \
N H N N%
1\1 ". N
\ / I 1 \ I
õCoy N \ /
."01 N
4-[ 1 - [(3 -fluoropyrrolidin-3-yl)methy1]-5-(4-445 -(4-mcthylpiperidin- 1-y1)- 1 - [[(2R)-morpholin-2-methylpiperidin- 1 -yl)pyrazolo [4,3 -b]pyridin-6-yllmethyll pyrazolo [4,3 -61pyridin-6-yll benzonitrile yl]benzonitfile N..., N.. N. 0 N. 0 o, reN H
, N.
,. Nr I 1\1 1 \ I = /
N.I / 0 N
Clil N
F3C) 415 -(4-methylpiperidin- 1 -y1)- 1 - [R2S)-morpholin-2- 4-[ 1 -[[(3S)-pynolidin-3 -yl]methyl] -5 -(2,2,2-yl]methyl]pyrazolo [4,3 -Npyridin-6-ylibenzonitrile trifluoroethoxy)pyrazolo[4,3-b]pyridin-6-yl]benzonitrile N N%, \ si N..,.
tio'CN H \
N, * rCIN H
N, 0 N N. /
e0 N v) 4-[ 1 - [[(3S)-pyrrolidin-3 -yl]methyl] -5 -(3 ,3 ,3- 4-[5-(cyclopropylmethoxy)- 1 - [R3S)-pyrrolidin-3 -trifluoropropoxy)pyrazolo [4,3 -b]pyridin-6- yl]methyl]pyrazolo [4,3 -b]pyridin-6-ylThenzonitrile yl]benzonitrile N.... N....
\
. ,,, ro H \
\ /N/INCIN H
I 1\1 I I
\ /V

/) 4) 4-[5-(2-cyclopropylethoxy)- 1 - [[(3S)-pyrrolidin-3 - 445-(2-cyc lopropylethoxy)-1 -[( 3 -fluoropyrrolidin-3 -yl]methyl]pyrazolo [4,3 -b]pyridin-6-ylibenzonitrile yflmethyl]pyrazolo [4,3 -b]pyridin-6-ylThenzonitrile N n N N% n .. 4/0 .. I*
r-C....41-1 r.C.,s,-, ,, , 11, .õ, I /N I N
\ /

e zi 4-[ 1 -[[(2S)-morpholin-2-yl]methy1]-5 -(3 ,3 ,3 -trifluoropropoxy)pyrazolo [4,3 -b]pyridin-6- 4- [5 -(2-cyclopropylethoxy)-1 - [[(2S)-morpholin-2-yl]benzonitrilc yl]methyl]pyrazolo [4,3 -b]pyridin-6-ylThenzonitrile N = r...\ciF N =
= = 0 rCIN H
N H
I µN I N
= / = /

Oki *
4-[ 1-[(3 -fluoropynolidin-3 -yl)methyl] -5 -phcnylmethoxypyrazolo [4,3 -b]pyridin-6- 445 - [(4-fluorophenyl)me thoxy]-1 -[[(3 S)-pyrrol i din-3 -yl] benzonitrile yl]methyl]pyrazolo [4,3 -b]pyridin-6-yl]benzonitrile N = Ok 40 O'N N = 0"-- \
= Ni,""C--N(H = i , N/11*--, I N I N
= / = /

(111/ (Si 445- [(4-fluorophenyl)methoxy] - 1 - [ [(2R)-morpholin- 445 - [(4-fluorophenyl)methoxy] - 1 - [[(2S)-morpholin-2-yl] methyl]pyrazolo [4,3 -b]pyrid in-6-yl]benzo n itrile 2-yl] me thyl]pyrazolo [4,3 -b]pyrid in-6-yll benzon itrile N =
= 0 0 N =
=
N
,..0 H rC, N H
.,. N

= / = /
gip N gip N
445 -(4-methylpheny1)- 1 -[[(35)-pynolidin-3 -445 -(4-fluoropheny1)- 1 - [ [(3S)-pyrrolidin-3 -yl]methyl]pyrazolo [4,3 -b]pyridin-6-yl]benzonitrilc yl]methyl]pyrazolo [4,3 -b]pyridin-6-ylibenzonitrile N = 0 N = CI
, 0 = =
/ %I" 0 H po'N H
NI NI, I N
= /
= /
0 N 111) N
C I
4- [5 -(4-methylpheny1)- 1 -[ [(3R)-pyrrolidin-3 - 415-(4-chloropheny1)- 1- [ [(3 S)-pyrrolidin-3 -yl]methyl]pyrazolo [4,3 -b]pyridin-6-ylibenzonitrile Amethyl]pyrazolo [4,3 -h]pyr id in-6-y] Thenzon itrile NC
NC
*

_ N
_NI
# \,3N H F # \ /)¨ N%1 N N H
( + )-445-(4-methylpheny1)-2- { oetahydro- 1H-N
( + )-4- [5 -(4-methylpheny1)-2- {oetahydro- 1H-pyrrolo [3 , 4- c]pyridin-2 -yl}pyrimidin-4-yl]benzonitrile pyrrolo [3 ,4-c]pyridin-2-yl}pyrimidin-4-yl]benzonitrile i . NH
&N H
NC N C
Oil N I
N Oil N N
I
Ilki .== N
* N
4-(2- {2,8-diazaspiro[4.51decan-2-y11 -5-(4- ( )-442- {2,7-diazaspiro[4.5]decan-2-y1} -544-methylphenyl)pyrimidin-4-yl)benzonitrile me thylphenyl)pyrimidin-4-yl)benzon itr ile NC

I H
HO
4-[5-(3-hydroxy-3 -methylbut-1 -yn- 1 -y1)-2- { [(3S)-4- {2-[(3aR,8aS)-decahydropyrrolo[3,4-d]azepin-2-y1]- pyrrolidin-3-ylmethyl] amino } pyrimidin-4-5-(4-methylphenyl)pyr intidin-4-y1} benzon i trite yl]benzonitrile NC NC
011,1 N kil No...CN H 14111 N 1-N-1,40CN H
I I..= N
vo r.N N

445- {6-azaspiro[2.5]octan-6-y1} -2- {R3S)-pyrrolidin- 4[5-(morpholin-4-y1)-2- {[(3S)-pyrrolidin-3 -3 -ylmethyl]amino}pyrimidin-4-yebenzonitrile ylmethyl]amino}pyrimidin-4-yl]benzonitrile NC
* NI IN N4eCN H NC
0111 N EN-1.%0=CN H
OX) 4-(5- {2-oxa-6-azaspiro[3.3]heptan-6-y1} -2- {R3S)-445-(2,2-dimethylmorpholin-4-y1)-2- { [(3S)-= pyrrolidin-3-ylmethyl] amino} pyrimidin-4-pyrrolidin-3-ylmethyl] amino} pyrinaidin-4-yObenzonitrile yl]benzonitrile NC * NC H N ifi N H
411 10C.,)N N
I I .r .e N Ø N
N N
011 Ori 4-(2- {octahydro-1H-pyrro1o[3,4-clpyridin-5-yl} -5-12- 4-(2- {octahydro-1H-pyrrolo[3,2-c]pyridin-5-y1} -5- {2-oxa-6-azaspiro[3 .3 ]heptan-6-yl}pyrimidin-4- oxa-6-azaspiro[3 .3 ]heptan-6-y1} pyrimidin-4-yl)benzonitrile yl)benzonitrile H
NC NH NC,.
. N%r N N al F
.0 N ,. N
*F
4-(2- {2,8-diazaspiro [4.5] decan- 8-y1} -5 -(4- 415 -(4-fluoropheny1)-2- {
octahydro- 1H-pyrrolo [3 ,2-fluorophenyl)pyrimidin-4-yl)benzonitrile cipyridin-5 -y1 1 pyrimidin-4-yl]benzonitrile NC NC r=,N H
. N 00 I
i *r N H . Nr N
I ' F* 0. N
/
/ .= N
*
4-(2- {2,7-diazaspiro[4.4]nonan-2-y1} -5 -(4-fluorophenyl)pyrimidin-4-yl)benzonitrile 445 -(2-cyclopentylethyny1)-2-{2,8-di azaspiro [4.5]de can-8-yl}pyr imid in-4-yl]benzonitr ile NC r=N H
* N N NC
I le) N N
/. .....
---N. , N
4-(2- {2,8-diazaspiro [4.5] decan-8-y1} -5 -( 1 -methyl-1H-4-(2- {2,8-diazaspiro[4.5] dccan- 8-y1} -5 -(pcnt- 1 -yn- 1 - pyrazol-4-yl)pyrimidin-4-y1)benzonitrilc yl)pyrimidin-4-yl)benzonitrile NC I rN H NC N N Oil N N
I I
N -N.
"=.. .....
p-N . N
F3C N" N
4-(2- {2,8-diazaspiro[4.5] decan-8-y1} -54142,2,2-trifluoroethyl)-1H-pyrazol-4-yl]pyrimidin-4- 4- { 5-[
1 -(cycl opropylmethyl)- 1 H-pyrazol-4-y1]-2- {2,8-yl)benzonitril e diazaspiro [4.5]de can- 8-yl}pyrimidin-4-yllbenzonitrile N N.
.N. INN:.
411 .... N H . , N PIO H
N N Icilimp µ NH
..., ....., *
4-[3-[[( 1R,55)-3 -azabicyclo[3 .1.0]hexan-6-445 -(4-methylpheny1)-3 -[[(3S)-pyrrolidin-3 -yl]methylamino] -5-(4-methylphenyl)pyrazol- 1-yl]methylamino]pyrazol- 1 -yl]benzonitrilc yl]benzonitrile N... N N.
=%. =
, N N , 0 H .
. ,, N r.01 H
" = H I NI \ 0 ...... .....
* *
4 45 -(4-methylpheny1)-3 -[ [(3R)-pyrrolidin-3 - 445 -(4-methylpheny1)-3 -[[(35)-pyrrolidin-3 -yl] me thyl am ino]pyrazol- 1 -yl]be nzon i trile yl]methoxy]pyrazol- 1 -yl]benzonitrile N..,. N N%
\ \
Si ,,,.N pal, = ,... N ill.0 H
.., µ 0 " = N H
, ......
* *
4 45 -(4-methylpheny1)-3 -[ [(3R)-pyrrolidin-3 - 445 -(4-fluoropheny1)-3 - [ [(3S)-pyrrolidin-3-yl] me thoxy] pyrazol -1 -Abenzon i trite yl]methylamino]pyrazol- 1 -yllbenzonitrile N'.,. N'..
\ *

N ' Nµ PIO H =s. 411 0-- \
m ' N H N
irm*._,1H

" =
......
110 *
445 -(4- duoropheny1)-3 -[[(3S)-pyrrol id in-3- 4 45-(4-methylpheny1)-3 -[[(2S)-morpholin-2 -yl]methoxy]pyrazol-1-yl]benzonitrile yl]methylamino]pyrazol- 1 -yl]benzonitrile N.. N'.
\ \
0-"\
14111 ,N /""(1) 14111 .N iQrligiH
= NH H = N H
0 *
445-(4-methylpheny1)-3 -[[(2R)-morpholin-2- 41544-fluoropheny1)-3 -[[(2S)-molpholin-2-yl]methylamino]pyrazol- 1 -yl]benzonitrile yl]methylamino]pyrazol- 1 -yl]benzonitrile N'.,. F F
N'.,.
411 m. N etH " SI õ ,... N NetH
" = NH = H
....... ......
. *
4-[3-[[(3 R)-4,4-difluorop iperid in-3 -y1] methylam ino] - 443 -[[(3 S)-4,4-difluoropiperidin-3 -yl] mcthylamino] -5-(4-methylphcnyl)pyrazol- 1 -yl]benzonitrile 5-(4-methylphenyl)pyrazol- 1-yl] benzonitrile N'.. N'.
\ 0 \ N H2 N
,N ._ * m ..N
µ 0NH2 il N, No -_.
* *
4 43 -(4-aminop iperidi n- 1 -y1)-5 -(4- 44343 -aminopiperidin- 1 -y1)-5 -(4-methylphenyl)pyrazol- 1 -yl] benzonitrile methylphenyl)pyrazol- 1 -yl]benzonitrile N'.. m N N%
N. 410 N
F
i 1 µ NH2 " µ NH
......
*
443 -(4- aminocyclohexyl)-5-(4-methylphenyl)pyrazol- 443 4(3 -fluoropyrrolidin-3-yl)methylamino] 5 (4 1 -yl]benzonitrile methylphenyl)pyrazol- 1 -yl]
benzonitrile N... N...
N * N
m.N 1101 . H
. m \ NO0H NN µ N\I
* 4 413 -(2,8-diazaspiro [4 .5] dec an- 8-y1)-5-(4- 413 -(2,7-diazaspiro [4 .4]
nonan-2-y1)-5 -(4-methylphenyl)pyrazol- 1 -yl] benzonitrile methylphenyl)pyrazol- 1 -yl]
benzonitrile . .
I\1 I\LN
1101 m..N *
H2 N-N\ 0¨N H2 .....
N/ 1 ......
N /
/
4-(3 -(4- aminopiperidin- 1 -y1)-5-(6-methylpyridin-3 - 4-( 3 -(4-aminopiperidin- 1 -y1)-5 -(1 -methy1-2-oxo- 1 ,2-y1)- 1H-pyrazol- 1 -yl)benzonitrile dihydropyridin-4-y1)- 1 H-pyrazol- 1 -yl)benzonitrile I\1 I\1 1101 NA\lµ 0--N H2 /

....õ ......
.......y... * N- NI\ 0--N H2 4-(3-(4-aminopiperidin- 1 -y1)-5 -(6-ethylpyridin-3 -y1)- 4-(3 -(4-aminopiperidin- 1 -y1)-5 -(5-methylpyridin-2-1H-pyrazol- 1 -yl)benzonitrile y1)- 1H-pyrazol- 1 -yl)benzonitrile N,. NL.
I*1 Ny rN 0-"NH2 / ......
e *
N...õ NaN H2 N / , 0 ======.,/
4-(3 -(4-aminopiperidin- 1 -y1)-5 -(1 -methy1-6-oxo- 1,6- 4-(3 -(4-aminopiperidin- 1 -y1)-5 -(1 -ethy1-2-oxo- 1,2-dihydropyridin-3 -y1)- 1 H-pyrazol- 1 -yl)benzonitrile dihydropyridin-4-y1)-1 H-pyrazol- 1 -yl)benzonitrile RZ.%.
N'..
\
I* 'N NaN H 2 * N'I\lµ 0---......
Hp I* ,/ *
N\ N
N
4-(3 -(4- aminopiperidin- 1 -y1)-5-(1 H-indazol-6-y1)- 1H-4-(3 -(4- aminopiperidin- 1 -y1)-5-(1 H-indazol-5 -y1)- 1H-pyrazol- 1 -yl)benzonitri le pyrazol- 1 -yl)benzonitrile N'., N'.'.
N. 4 \
N,NIµ HN,..oH 410 N,Nµ
HNPPOH
......
= ....-.
=
110 .
1 -(4- cyanopheny1)-5 -(4-methylpheny1)-N-[(3 R)- 1-(4-cyanopheny1)-5-(4-methylpheny1)-N-R3 S)-pyrrolidin-3 -yllpyrazole-3 -carboxamide pyrrolidin-3 -yllpyrazole-3 -carboxamide oNH 2 H2N
N'.... N
\ = \
õ,,N ISI ,,,,,N ---.) N \ I N \
...... ...
= =

4 43 -(4-aminopiperidine- 1 -carbony1)-5 -(4- 4-[3-[(3 S)-3 -aminopiperidine- 1 - c arbonyl] -544-methylphenyl)pyrazol- 1 -yl] benzonitrile methylphenyl)pyrazol- 1 -yl]benzonitrile ;
N'....
N'.'.
, N \ 4 ,N \1Y
, = =
*
ft._ =
4-[3-[(3R)-3-aminopiperidine- 1 - carbonyl] -544-m ethylphenyl)pyrazol - 1 -yl]benzon itrile 1 -(4- cyanopheny1)-N-methy1-5 -(4-methylpheny1)-N -(pyrrolidin-3 -ylmethyl)pyrazole-3 -carboxamide N N
===

N N
N
= =
1 -(4- cyanopheny1)-5-(4-methylpheny1)-N-(pyrrolidin- 1 -(4 - cyanopheny1)-5-(4 -methylpheny1)-N-piperidin-4-3 -ylmethyl)pyrazole-3 -carboxamide ylpyrazole-3 -carboxam i de N.... N

N N
=
1 -(4 - cyanopheny1)-N-methy1-5 -(4 -nacthylphcny1)-N-piperidin-4 -ylpyrazole-3 -carboxamide 4 43 -(4 aminopiperidine- 1 -carbony1)-5 cyclopropylphenyl)pyrazol- 1-yllbenzonitrile N
N
411) \ m N

=
4 43 -(4 - aminopiper ine- 1 -carbony1)-5 -(4-4 43 -(4 -aminopiperidine- 1 -carbony1)-5 -(1- methoxypheny1)-4 -methylpyrazol- 1 -yl] benzonitrile mcthylindazol-5-yl)pyrazol-1-yl]benzonitrile N
4111 N, Nµ \".0H
" N
=
1 -(4 - cyanopheny1)-N-methy1-5 -(4 -metlaylpheny1)-N-[(3 R)-pyrrolidin-3 -yl]pyrazolc-3 -carboxamide 413 -(4 - aminopiperidine-1 -carbony1)-5 -(4-methoxypheny1)-4 -methylpyrazol- 1 -yl] benzonitrile N'...
N... Q--N H 2 N= _....c31Fi 141:1 õ. N
. _NI HN N µ
= .....
.......
=
IP _ 1 -(4 -cyanopheny1)-5 -(4 -methylpheny1)-N-piperidin-3- 1\r-ylpyrazolc-3 -carboxamide 4 - [3-(3 -aminopiperidine-1 -carbonyl)-5 -( 1-methylindazol-5 -yl)pyrazol-1-yl]benzonitrile N''. N
\ \
1411 ...N 0 * s. N..N 0 \
...% ....
H
/
N / 411 H -\ i \1H2 i i N-(3 -am inopropy1)-1-(4-cyanopheny1)-5-(1- N-(3 -amino-3-methylbuty1)- 1 -(4 -cyanopheny1)-5 -(1 -methylindazol-5 -yflpyrazole-3 -c arboxamide me thylind azol-5 -yl)py razole-3-carboxam i de F-N \ N.., \
\ Q.NIN H2 * ...... r\,10111,= N
'N NM.
\
...,. a H ...%
/ µ /
IN

1 -(4-cyanopheny1)-5-(1 -methylindazol-5 -y1)-N- [(3R)- (R)-4-(3 -(3 -aminopiperidine-1 -carbony1)-5 -(6-pyrrolidin-3 -yl]pyrazole-3 -c arboxam ide (dimethylamino)pyridin-3 -y1)-11-1-pyrazol-1 -y1)-2-fluorobenzonitrile I-N ..% F H 2N
N=,% N. op NA
'=
N,N ON H2 µ . N,Nµ
.....
....., -...
--...- ....
....- , ....
1\1 4-[3-[(3R)-3-aminopiperidine-1-carbony1]-546-(dimethylamino)pyridin-3-yl]pyrazol-1-y1]-2- 443-[(3R)-3-aminopiperidine-1-carbonyl]-5-(2-fluorobenzonitrile methyl indazol-5-yflpyrazol-1-y1]-2-fluorobenzonitrile H
N
N
N
N". N
4- [3 -[(3 S)-3 -aminopytTolidinc- 1 -carbony1]-5 -(2- 4-[3-[(3 S)-3 -(di methylam ino)pyrrolidine- 1 -carbony1]-methylindazol-5 -yl)pyrazol- 1-y1]-2-fluorobenzonitrile 5 -(2-methylindazol-5-yl)pyrazol- 1 -yl] -2-fluorobenzonitrile N O N wg IH Ogg N H 2 011 N, 1\1µ ,N
)\( 4- [3 -[(3R)-3 -aminopiperidine- 1 -c arbonyl] -4-methyl- 2-fluoro-444-methy1-3 -[(3 R)-3 --(2-methylindazol-5-yl)pyrazol- 1 -yl] -2- (methylamino)piperidine- 1 -c arbonyl] -5 -(2-fluorobenzon itrile methylind azol-5 -yl)pyrazol- 1 -yl]benzoni trile N
0"11\ N
9-=is N H 2 N
\ N
=====
)\( 4-[3 -[(3 R)-3 -(dimethylamino)piperidine- 1 -c arbonyl] - 4-[3- [(3 R)-3 -aminopiperidine- 1 -c arbony1]-4-fluoro-5-4-methy1-5-(2-methylindazol-5 -yl)pyrazol- 1 -y11-2- (2-methylindazol-5-yl)pyrazol- 1 -yl] -2-fluorobenzonitrile fluorobenzonitrile N
()mg' 1H N
,N 1411 N
= N
2-fluoro-4-[4-fluoro-3 -[(3R)-3 - 4-[3-[(3R)-3 -(dimethylamino)piperidine-1 -c arbonyl] -(methylamino)piperidine- 1 -c arbonyl] -542- 4-fluoro-5-(2-methylindazol-5-yl)pyrazol- 1 -yl] -2-methyl indazol-5-yl)pyrazol- 1 -yl]benzonitrile fluorobenzonitrile Preparation of the Substituted Heterocyclic Derivative Compounds 1001451 The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. "Commercially available chemicals" are obtained from standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co.
(Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), IN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, NH), Maybridge Chemical Co. Ltd. (Cornwall, U.K.), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Spectrum Quality Product, Inc. (New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD), and Wako Chemicals USA, Inc. (Richmond, VA).
[00146] Methods known to one of ordinary skill in the art are identified through various reference books and databases. Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; S. R. Sandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; H. 0. House, "Modern Synthetic Reactions", 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972;
T. L.
Gilchrist, "Heterocyclic Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J.
March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5;
Hoffman, R.V. "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. "Comprehensive Organic Transformations:
A Guide to Functional Group Preparations" 2nd Edition (1999) Wiley-VCH, ISBN:

471-19031-4; March, J. "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J.
(editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1;
Patai, S. "Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, T. W. G. "Organic Chemistry" 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., "Intermediate Organic Chemistry" 2nd Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2;
"Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann's Encyclopedia"
(1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions"
(1942-2000) John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes.
1001471 Specific and analogous reactants may also be identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., may be contacted for more details). Chemicals that are known but not commercially available in catalogs may be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A
reference for the preparation and selection of pharmaceutical salts of the substituted heterocyclic derivative compounds described herein is P. H. Stahl & C. G. VVermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.
1001481 The substituted heterocyclic derivative compounds are prepared by the general synthetic routes described below in Schemes 1-6.
Scheme 1 Br. Br.. J ) N+

A
E. =
OH
B EM En) C I N CI N CI N
J-X OH
CI N L N

1001491 Referring to Scheme 1, Compound A is protected through the use of phenyl sulphonyl group. Compound B is oxidized and chlorinated to produce compound D.
For example, chlorination can occur through the formation of the pyridine N-oxide compound C
followed by treatment with an appropriate chlorinating agent, such as POC13.
Compound D
is converted to compound F via a palladium-mediated cross coupling reaction with a suitable coupling partner, such as boronic acid E-B(OH)2. Compound F is selectively deprotected under basic conditions to form compound G. Alkylation of compound G is carried out with alkyl halides under basic conditions to form compound K.
Compound K is subjected to a palladium-mediated cross coupling reaction with a suitable coupling partner, such as boronic acid L-B(OH)2, to give compound M.
Scheme 2 =
R,B4OH
Ozr: Oz.
"r0 En) E N
_______________________ law Epm C I N P N
s-x 1001501 Referring to Scheme 2, Compound F is converted to compound Q via a palladium-mediated cross coupling reaction with a suitable coupling partner, such as boronic acid P-B(OH)2. Compound Q is deprotected under basic hydrolysis conditions to form compound R. Alkylation of compound R is carried out with an alkyl halide under basic conditions to form compound T.
Scheme 3 W Y.,,,OH
1 'Y
Bry7yN 02 W6,...A.A. H Br y1syN 02 OH Y ..N 02 I
yõ,c,,,..1 w. -- w. ..
cr-1/41\1-' w w U x Z
H PC . AC¨X
I-0... Y I W.y %-N .0'' N/ W.V N=N W.y N /
I I
W' W' W' AA AB AD
1001511 Referring to Scheme 3, nucleophilic substitution upon chloride compound U is carried out with a nucleophile, WW'-VH, such as amines WW'-NH, or alcohols W-OH, under basic conditions to form compound X. For example, compound U can be treated with DIEA and amines WW'-NH. The biaryl compound Z is prepared from aryl halide compound X via a palladium-mediated cross coupling reaction with a suitable coupling partner, such as boronic acid Y-B(OH)2. Compound Z is converted to compound AA
by condensation with /V,N-dimethylformamide dimethyl acetal. Compound AB is obtained from compound AA by reduction of the nitro group and cyclocondensation to form the indole ring system. Alkylation of compound AB is carried out with an alkyl halide AC-X
under basic conditions to form compound AD.
Scheme 4 BrykyBr By:)...
., .A.,1 ¨)....
HO C% HO¨N"
AE AF AG
BryNNyNO2 BrykyNO2 Bry=kN H2 AH Al AJ
AK OH
...B., AM.. OH
E
(!)H AKIN H2 (!)H AKnc.:1 H 2 AKrx1:1HAc ¨a.. I
CI'N''`. . AM N AM N
AL
AO AP
Ac AS
AKmx"Nt AMr AKrikH AS-X
I

.e A N N
AM N
AQ AR AT
1001521 Referring to Scheme 4, Compound AE is brominated to produce compound AF.
Compound AF is selectively reduced by halogen-lithium exchange, such as using one equivalent of n-LiBu, followed by aqueous acidic quench. Compound AG is converted to AM using nitration condition such as aqueous HNO3. Compound AM is chlorinated to produce compound AT. For example, chlorination can occur through the use of phosphoryl chloride. Compound AJ is obtained from selective reduction, such as with iron in acetic acid, of compound Al. Compound AJ is converted to compound AL via a palladium-mediated cross coupling reaction with a suitable coupling partner, such as boronic acid AK-B(OH)2. Compound AO is prepared from aryl halide compound AL via a palladium-mediated cross coupling reaction with a suitable coupling partner, such as boronic acid AM-B(OH)2. Compound AO is acylated to give compound AP. This can be achieved by using acetic anhydride in presence of pyridine. Compound AQ was obtained from the treatment of compound AP with isoamyl nitrite and acetic acid. Compound AQ was hydrolyzed under basic conditions to form compound AR. Alkylation of compound AR is carried out with alkyl halide AS-C under basic conditions to form compound AT.

Scheme 5 AV. B -OH AX
1 AX AZ. OH AX
. I Y 1 CI =,.,,, Ny CI 6H AV,.,,, Ry CI AXN H AVX,,ly N õAx, OH AV N NAX
C C , _.,',I N ,....I N X:r ' ., N
I CI I N AZ
AU AW AY BA
1 BB ___________________________________________ =
AX

AV,,f Ny N õAx, AZ=,..,- N
BC
[00153] Referring to Scheme 5, compound AW can be made by employing palladium-catalyzed cross-coupling reaction of compound AU with a suitable coupling partner, such as boronic acid AV-B(OH)2, at temperature up to 100 C. Nucleophilic substitution reaction of compound AW with amine AX-NH-AX' under basic conditions at 100 C
furnished AY. Palladium catalyzed cross-coupling of the AY with a suitable coupling partner, such as boronic acid AZ-B(OH)2, at elevated temperature up to 120 C
afforded pyrimidine BA. Alternatively, subjecting compound AY to Sonogashira cross-coupling conditions with a terminal alkyne, such as BB-CCH, affords compound BC.
Scheme 6 NI'' N BF N 0 N'N' N
BD,k)ty ....0 B F )11... ...... )1110..
H
B B
BE BG BH
BR., _)._ Dp--NH _),...Bj¨X )...1 ...)¨=Nµ _0, :p--NH
boo Boc B BD B

[00154] Referring to Scheme 6, compound BE is condensed with monosubstitued hydrazine BF-NHNH2 to form compound BG. Compound BG is hydrolyzed under basic conditions to produce compound BH. Compound BH is converted to compound B1 by Curtius rearrangement using diphenyl phosphorazi date (DPPA). Alkylation of compound BI is carried out with a variety of electophiles, such as alkyl halides, alkyl mesylates, tosylates or the like, under basic conditions to form compound BK. Compound BK
is deprotected under acidic conditions to form compound BL.
[00155] In each of the above reaction procedures or schemes, the various substituents may be selected from among the various substituents otherwise taught herein.
Pharmaceutical Compositions [00156] In certain embodiments, the substituted heterocyclic derivative compound as described herein is administered as a pure chemical. In other embodiments, the substituted heterocyclic derivative compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).
[00157] Accordingly, provided herein is a pharmaceutical composition comprising at least one substituted heterocyclic derivative compound, or a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, together with one or more pharmaceutically acceptable carriers. The carrier(s) (or excipient(s)) is acceptable or suitable if the carrier is compatible with the other ingredients of the composition and not deleterious to the recipient (i.e., the subject) of the composition.
[00158] One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[00159] One embodiment provides a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[00160] One embodiment provides a pharmaceutical composition comprising a compound of Formula (Ha), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[00161] One embodiment provides a pharmaceutical composition comprising a compound of Formula (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Date Recue/Date Received 2021-05-21 [00162] One embodiment provides a pharmaceutical composition comprising a compound of Formula (Ina), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[00163] In certain embodiments, the substituted heterocyclic derivative compound as described by Formula (I), (II), (11a), (III) or (IIIa) is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1%, of other organic small molecules, such as contaminating intermediates or by-products that are created, for example, in one or more of the steps of a synthesis method.
[00164] Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract. Suitable nontoxic solid carriers can be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. (See, e.g., Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).
[00165] The dose of the composition comprising at least one substituted heterocyclic derivative compound as described herein may differ, depending upon the patient's (e.g., human) condition, that is, stage of the disease, general health status, age, and other factors that a person skilled in the medical art will use to determine dose.
[00166] Pharmaceutical compositions may be administered in a manner appropriate to the disease to be treated (or prevented) as determined by persons skilled in the medical arts. An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses may generally be determined using experimental models and/or clinical trials. The optimal dose may depend upon the body mass, weight, or blood volume of the patient.
[00167] Oral doses can typically range from about 1.0 mg to about 1000 mg, one to four times, or more, per day.
Biology [00168] Epigenetics is the study of heritable changes in gene expression caused by mechanisms other than the underlying DNA sequence. Molecular mechanisms that play a role in epigenetic regulation include DNA methylation and chromatin/histone modifications.
[00169] The genomes of eukaryotic organisms are highly organized within the nucleus of the cell. Tremendous compaction is required to package the 3 billion nucleotides of the human genome into the nucleus of a cell. Chromatin is the complex of DNA
and protein that makes up chromosomes. Histones are the major protein component of chromatin, acting as spools around which DNA winds. Changes in chromatin structure are affected by covalent modifications of histone proteins and by non-histone binding proteins. Several classes of enzymes are known which can modify histones at various sites.
[00170] There are a total of six classes of histones (HI, H2A, H2B, H3, H4, and H5) organized into two groups: core histones (H2A, H2B, H3, and H4) and linker histones (H1 and H5). The basic unit of chromatin is the nucleosome, which consists of about 147 base pairs of DNA wrapped around the core histone octamer, consisting of two copies each of the core histones H2A, H2B, H3, and H4.
[00171] Basic nucleosome units are then further organized and condensed by the aggregation and folding of nucleosomes to form a highly condensed chromatin structure.
A range of different states of condensation are possible, and the tightness of chromatin structure varies during the cell cycle, being most compact during the process of cell division.
[00172] Chromatin structure plays a critical role in regulating gene transcription, which cannot occur efficiently from highly condensed chromatin. The chromatin structure is controlled by a series of post translational modifications to histone proteins, notably histones H3 and H4, and most commonly within the histone tails which extend beyond the core nucleosome structure. These modifications acetylation, methylation, phosphorylation, ribosylation sumoylation, ubiquitination, citrullination, deimination, and biotinylation. The core of histones H2A and H3 can also be modified.
Histone modifications are integral to diverse biological processes such as gene regulation, DNA
repair, and chromosome condensation.
[00173] Histone methylation is one of the most important chromatin marks; these play important roles in transcriptional regulation, DNA-damage response, heterochromatin formation and maintenance, and X-chromosome inactivation. A
recent discovery also revealed that histone methylation affects the splicing outcome of pre-mRNA by influencing the recruitment of splicing regulators. Histone methylation includes mono-, di-, and tri-methylation of lysines, and mono-, symmetric di-, and asymmetric di-methylation of arginines. These modifications can be either an activating or repressing mark, depending on the site and degree of methylation.
Histone Demethylases [00174] A "demethylase" or "protein demethylase," as referred to herein, refers to an enzyme that removes at least one methyl group from polypeptide. Demethylases comprise a JmjC domain, and can be a methyl-lysine or methyl-arginine demethylase.
Some demethylases act on histones, e.g., act as a histone H3 or H4 demethylase. For example, an H3 demethylase may demethylate one or more of H3K4, H3K9, H3K27, H3K36 and/or H3K79. Alternately, an H4 demethylase may demethylate histone H4K20.
Demethylases are known which can demethylate either a mono-, di- and/or a tri-methylated substrate. Further, histone demethylases can act on a methylated core histone substrate, a mononucleosome substrate, a dinucicosome substrate and/or an oligonucleosome substrate, peptide substrate and/or chromatin (e.g., in a cell-based assay).
[00175] The first lysine demethylase discovered was lysine specific demethylase (LSD1/KDM1), which demethylates both mono- and di-methylated H3K4 or H3K9, using flavin as a cofactor. A second class of Jumonji C (JmjC) domain containing histone demthylases were predicted, and confirmed when a H3K36 demethylase was found used a formaldehyde release assay, which was named JmjC domain containing histone demethylase 1 (JHDM1/KDM2A).
[00176] More JmjC domain-containing proteins were subsequently identified and they can be phylogenetically clustered into seven subfamilies: JHDM1, JHDM2, JHDM3, JMJD2, JARID, PHF2/PHF8, UTX/UTY, and JmjC domain only.

[00177] Lysine-specific demethylase 1 (LSD1) is a histone lysine demethylase that specifically demethylates monomethylated and dimethylated histone H3 at K4 and also demethylates dimethylated histone H3 at K9. Although the main target of LSDI
appears to be mono- and di-methylated histone lysines, specifically H3K4 and H3K9, there is evidence in the literature that LSD I can demethylate methylated lysines on non-histone proteins like p53, E2F1 , Dnmtl and STAT3.

[00178] LSD 1 has a fair degree of structural similarity and amino acid identity/homology to polyamine oxidases and monoamine oxidases, all of which (i. e., MAO-A, MAO-B and LSD1) are flavin dependent amine oxidases which catalyze the oxidation of nitrogen-hydrogen bonds and/or nitrogen-carbon bonds. LSD1 also includes an N-terminal SWRIM domain. There are two transcript variants of LSD1 produced by alternative splicing.
Methods of Use [00179] In some embodiments, the compounds disclosed herein are capable of inhibiting LSD1 activity in a biological sample by contacting the biological sample with a substituted heterocyclic compound as disclosed herein. In some embodiments, a substituted heterocyclic compound as disclosed herein is capable of modulating the level of histone 4 lysine 3 methylation in the biological sample. In some embodiments, a substituted heterocyclic compound as disclosed herein is capable of modulating histone-3 lysine-9 methylation levels in the biological sample.
[00180] In some embodiments, a substituted heterocyclic compound as disclosed herein inhibits LSDI activity to a greater extent than MAO-A and/or MAO-B.
[00181] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (I).
[00182] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (II).
[00183] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (Ha).
[00184] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (III).
[00185] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (Ma).
Methods of Treatment [00186] Disclosed herein are methods of modulating demethylation in a cell or in a subject, either generally or with respect to one or more specific target genes.

Demethylation can be modulated to control a variety of cellular functions, including without limitation: differentiation; proliferation; apoptosis; tumorigenesis, leukemogenesis or other oncogenic transformation events; hair loss; or sexual differentiation.
[00187] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
[00188] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
[00189] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (Ha), or a pharmaceutically acceptable salt thereof.
[00190] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (III), or a pharmaceutically acceptable salt thereof.
[00191] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (IIIa), or a pharmaceutically acceptable salt thereof.
[00192] In a further embodiment is the method for treating cancer in a subject wherein the cancer is selected from prostate cancer, breast cancer, bladder cancer, lung cancer or melanoma.
[00193] Other embodiments and uses will be apparent to one skilled in the art in light of the present disclosures. The following examples are provided merely as illustrative of various embodiments and shall not be construed to limit the invention in any way.
EXAMPLES
1. Chemical Synthesis [00194] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Anhydrous solvents and oven-dried glassware were used for synthetic transformations sensitive to moisture and/or oxygen. Yields were not optimized. Reaction times are approximate and were not optimized. Column chromatography and thin layer chromatography (TLC) were performed on silica gel unless otherwise noted. Spectra are given in ppm (6) and coupling constants, J
are reported in Hertz. For proton spectra the solvent peak was used as the reference peak.
[00195] Preparation 1A: 1-(benzenesulfony1)-6-bromopyrrolo[3,2-b]pyridine BRUN) I /
[00196] To a solution of NaH (1.13 g, 28.05 mmol, 60 %) in THF (50 mL) at 0 C

was added 6-bromo-1H-pyrrolo[3,2-b]pyridine (5 g, 25.5 mmol) in small portions. The reaction mixture was stirred for 15 minutes. A THF (40 nit) solution of benzenesulfonyl chloride (4.86 g, 25.5 mmol) was then added dropwise at 0 C. The resulting solution was stirred at RT for 18 h. The reaction mixture was quenched by adding 50 mL
of H20.
The mixture was concentrated and the resulting solution was extracted with Et0Ac (3x).
The organic layers were combined, dried (Na2SO4) and concentrated in vacuo to give 8.54 g (99%) of the title compound as a beige solid. 11-1 NMR (400 MHz, DMSO-d6) 6 7.01 (d, J= 3.79 Hz, 1 H), 7.60 - 7.69 (m, 2 H), 7.71 -7.81 (m, 1 H), 8.09-8.16 (m, 2 H), 8.22 (d, J= 3.79 Hz, 1 H), 8.45 - 8.51 (m, 1 H), 8.64 (d, J = 2.02 Hz, 1 H). [M+H]
Calc'd for Ci3H9BrN202S, 337, 339; Found, 337, 339.
[00197] Preparation 1B: 6-bromo-1-(phenylsulfony1)-1H-pyrrolo[3,2-b]pyridine-4-oxide Br(L)I /

[00198] To a stirred solution of 6-bromo-1-(phenylsulfony1)-1H-pyrrolo[3,2-b]pyridine (8.54 g, 25.4 mmol) in DCM (120 mL) at 0 C was added 3-chloroperbenzoic acid (77 wt%, 6.83 g, 30.49 mmol). The reaction mixture was stirred overnight at rt. The solution was washed with saturated aqueous NaHCO3 (2x). The organics were dried (Na2SO4) and concentrated in vacuo. The residue was chromatographed (0-15%, McOH:DCM) to afford 6.34 g (71%) of the title compound as a white solid. 1H
NMR
(400 MHz, DMSO-d6) 6 7.05 - 7.09 (m, 1 H), 7.64 - 7.71 (m, 2 H), 7.76 - 7.84 (m, 1 H), 8.08 (s, 1 H), 8.12 - 8.18 (m, 3 H), 8.57 (d, J= 1.26 Hz, 1 H). [M+H] Calc'd for Ci3H9BrN203S, 354, 356; Found, 354, 356.
[00199] Preparation 1C: 1-(benzenesulfony1)-6-bromo-5-chloropyrrolo [3,2-b]pyridine "' I
Br N/
_ CI N
[00200] A solution of phosphorus oxychloride (1.43 mL, 15.3 mmol) in DCM (8 mL) was added dropwise to a mixture of 6-bromo-1-(phenylsulfony1)-1H-pyrrolo[3,2-b]pyridine-4-oxide (4.50 g, 12.8 mmol) and triethylamine (2.13 mL, 15.3 mmol) in DCM
(40 mL) at 0 C. The reaction mixture was stirred at 0 C for 1 h and then at rt for 3 h.
The mixture was quenched with water (100 mL). The organic layer was separated, washed with a saturated solution of NaHCO3, brine, dried (Na2SO4) and concentrated in vacuo . The residue was chromatographed (0-5%, MeOH:DCM) to afford 2.23 g (47%) of the title compound as a white solid. 'H NMR (400 MHz, DMSO-d6) 6 7.00 (d, J=
3.79 Hz, 1 H), 7.61 -7.69 (m, 2 H), 7.74 - 7.80 (m, 1 H), 8.14 (d, J= 7.33 Hz, 2 H), 8.31 (d, J= 3.79 Hz, 1 H), 8.65 (s, 1 H). [M+H] Calc'd for Ci3H8BrCIN202S, 373, 375;
Found, 373, 375.
[00201] Preparation 1D: 4-[1-(benzenesulfony1)-5-chloropyrrolo[3,2-blpyridin-6-yl]benzonitrile N

/
CI N
[00202] To a mixture of 1-(benzenesulfony1)-6-bromo-5-chloropyrrolo[3,2-b]pyridine (2.23 g, 6.04 mmol), Pd(dpp0C12 (0.25 g, 0.30 mmol), aqueous sodium carbonate (2.0 M, 10 mL) in dioxane (40 mL), was added 4-cyanophenylboronic acid (0.98 g, 6.64 mmol). The reaction mixture was stirred and heated at reflux for 30 min.
Solvent was evaporated. The residue was taken in water and extracted with DCM (3x). The organic layers were combined, washed with brine, dried (Na2SO4) and concentrated in vacuo The residue was chromatographed (0-5%, MeOH:DCM) to give 1.79 g (75%) of the title compound as a white solid. 1H NMR (400 MHz, DMSO-d6) 6 7.06 (d, J=3.79 Hz, 1 H), 7.60 - 7.67 (m, 2 H), 7.73 - 7.79 (m, 3 H), 8.01 (d, J= 8.34 Hz, 2 H), 8.12 (d, J= 7.58 Hz, 2 H), 8.31 (s, 1 H), 8.35 (d, J= 3.79 Hz, 1 H). [M+H] Calc'd for C20H12C1N302S, 394; Found, 394.
[00203] Preparation 1E: 4-(5-chloro-1H-pyrrolo[3,2-b]pyridin-6-yl)benzonitrile N
I /
CI 1\1 [00204] To a mixture of 4-[1-(benzenesulfony1)-5-chloropyrrolo[3,2-b]pyridin-6-yl]benzonitrile (1.18 g, 3.00 mmol) in MeOH:THF (3:2, 50 mL) was added NaOH
(2.5 N, 12 mL). The reaction mixture was stirred at rt for 15 min. The reaction was acidified (2 N HC1) and extracted with DCM (3x). The organics were combined and washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was triturated in DCM (20 mL) and filtered to give 580 mg (76%) of the title compound as a yellow solid.

(400 MHz, DMSO-d6) 6 6.60 (br. s., 1 H), 7.72 (d, J= 8.34 Hz, 2 H), 7.81 (t, J= 2.91 Hz, 1 H), 7.85 (s, 1 H), 7.95 (d, J= 8.34 Hz, 2 H), 11.68 (br. s., 1 H). [M+H]
Calc'd for C14H8C1N3, 254; Found, 254.
[00205] Preparation 1F: tert-butyl (35)-34[5-chloro-6-(4-cyanophenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate N
I /
CI N
[00206] (R)-N-boc-3-bromomethylpyrrolidine (96 mg, 0.37 mmol) was added to a mixture of 4-(5-chloro-1H-pyrrolo[3,2-b]pyridin-6-yObenzonitrile (100 mg, 0.33 mmol) and cesium carbonate (214 mg, 0.65 mmol) in DMF (3 mL). The reaction mixture was stirred at 90 C overnight. (R)-N-Boc-3-bromomethylpyrrolidine (96 mg, 0.37 mmol) was added and the reaction was stirred at 90 C for 2 h. DMF was concentrated in vacuo.
The residue was taken in DCM and the insoluble solids were filtered off. The filtrate was loaded on silica column and chromatographed (0-100%, Et0Ae: Hexanes) to give 125 mg (77%) of the title compound as a colorless oil. 1H NMR (400 MHz, DMSO-d6) 6 1.25 - 1.45 (m, 9 H), 1.59 (br. s., 1 H), 1.76 (br. s., 1 H), 2.67 (br. s., 2 H), 2.89 - 3.05 (m, 1 H), 3.08 - 3.30 (m, 2 H), 4.18 -4.39 (m, 2 H), 6.63 (d, J= 3.03 Hz, 1 H), 7.75 (d, J=

8.34 Hz, 2 H), 7.87 (d, J= 3.28 Hz, 1 H), 7.97 (d, J= 8.34 Hz, 2 H), 8.21 (d, J= 2.78 Hz, I H). [M+H] Calc'd for C24H25C1N302, 437; Found, 437.
[00207] Preparation 1G: tert-butyl (38)-3-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate N
o' 11"IsC\IBoc I /
* N
[00208] To a mixture of tert-butyl (3S)-34[5-chloro-6-(4-cyanophenyOpyrrolo[3,2-b] pyridin-1-yl]methyl]pyrrolidine-1-carboxylate (100 mg, 0.23 mmol), Pd(dppf)C12 (10 mg, 0.012 mmol), aqueous sodium carbonate (2.0 M, 1.0 mL, 2.00 mmol) in dioxane (2 mL), was added 4-methyphenylboronic acid (50 mg, 0.36 mmol). The reaction mixture was stirred and heated in the microwave at 143 C for 1 h. Solvent was evaporated in vacuo. The residue was taken in DCM and filtered. The filtrate was chromatographed (0-90%, Et0Ac:Hexanes) to give 90 mg (79%) of the title compound as a beige solid.
[M+H] Calc'd for C3iH32N402, 493; Found, 493.
[00209] Example 1: 4-[5-(4-methylpheny1)-1-[[(3R)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
10"01F1 I /
* N
[00210] To a mixture of tert-butyl (3S)-34[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate (90 mg, 0.18 mmol) in DCM (2 mL) was added TFA (2 mL). The reaction was stirred for 30 min.

Solvent was evaporated in vacuo. The residue was chromatographed (0-20%, MeOH:DCM) to give 56 mg (78%) of the TFA salt of the title compound as a beige solid. 1H NMR (400 MHz, DMSO-d6) 6 1.61 - 1.77 (m, 1 H), 1.84 -2.01 (m, 1 H), 2.29 (s, 3 H), 2.76 - 3.01 (m, 3 H), 3.02 - 3.16 (m, 1 H), 3.24 - 3.37 (m, 2 H), 4.29 -4.49 (m, 2 H), 6.72 (d, J=3.03 Hz, 1 H), 7.05 - 7.14 (m, 2 H), 7.14 - 7.20 (m, 2 H), 7.42 (d, J=8.34 Hz, 2 H), 7.80 (d, J=8.34 Hz, 2 H), 7.91 (br. s., 1 H), 8.23 (br. s., 1 H), 8.60 - 8.85 (m, 2 H). [M+H] Calc'd for C26H24N4, 393; Found, 393.

[00211] Example 2: 4-[5-chloro-1-[[(3R)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N"..
NePOIH
==. I /
CI N
[00212] To a mixture of tert-butyl (35)-34[5-ehloro-6-(4-cyanophenyOpyrrolo[3,2-b]pyridin-1-yllmethyl]pyrrolidine-1-carboxylate (50 mg, 0.11 mmol) in DCM (3 mL) was added TFA (1 mL). The reaction was stirred for 2 h. Solvent was evaporated in vacuo. The residue was chromatographed (0-20%, MeOH:DCM) to give 35 mg (96%) of the TFA salt of the title compound as a yellow glassy solid. 1H NMR (400 MHz, DMSO-d6) .3 1.56 - 1.71 (m, 1 H), 1.90 (td, = 12.69, 7.20 Hz, 1 H), 2.72 - 2.93 (m, 3 H), 3.05 -3.15 (m, 1 H), 3.21 - 3.30 (m, 1 H), 4.32 (dd, J = 7.20, 4.42 Hz, 2 H), 6.66 (d, J = 3.28 Hz, 1 H), 7.74 (d, J= 8.34 Hz, 2 H), 7.90 (d, J = 3.03 Hz, 1 H), 7.99 (d, J =
8.34 Hz, 2 H), 8.24 (s, 1 H), 8.62 (br. s., 2 H). [M+H] Calc'd for Ci9H17C1N4, 337;
Found, 337.
[00213] Preparation 3A: 4-[1-(benzenesulfony1)-5-(4-methylphenyl)pyrrolo[3,2-blpyridin-6-yllbenzonitrile N
4 z:o I /

0 0 2 1 4 ] To a mixture of 4-[1-(benzenesulfony1)-5-chloropyrrolo[3,2-b]pyridin-6-yl]benzonitrile (300 mg, 0.76 mmol), Pd(dppf)C12 (31 mg, 0.038 mmol), aqueous sodium carbonate (2.0 M, 1.15 naL, 2.28 mmol) in dioxane (7 mL) was added 4-methyphenylboronic acid (310 mg, 2.28 mmol). The reaction mixture was stirred and heated at 135 C for 3 h in the microwave. Solvent was evaporated in vacuo.
The residue was taken in water and extracted with DCM. The organics were combined and washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was chromatographed (0-5%, MeOH:DCM) to give 260 mg (47%) of the title compound as a beige solid.
[M+H] Calc'd for C271-119N025, 450; Found, 450.
[00215] Preparation 3B: 445-(4-methylpheny1)-1H-pyrrolo[3,2-b]pyridin-6-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N
14111 .."
I /
N
[00216] To a mixture of 4-[1-(benzenesulfony1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-6-yl]benzonitrile (260 mg, 0.58 mmol) in MeOH:THF (2:1, 15 mL) was added NaOH (2.5 N, 3 mL). The reaction mixture was stirred at rt for 3 h. The reaction was neutralized using aqueous HC1 and the solvent was evaporated. The residue was taken in water and extracted with DCM. The organics were combined and washed with brine, dried (Na2SO4) and concentrated in vacuo . The residue was chromatographed (0-5%, MeOH:DCM). The relevant fractions were combined and concentrated to afford 90 mg (49%) of the title compound as a beige solid. [M+H] Calc'd for C21H15N3, 310;
Found, 310.
[00217] Preparation 3C: tert-butyl (3R)-3-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate N
N.
rCI-Boc I /
* N
[00218] (S)-N-Boc-3-bromomethylpyrrolidine (137 mg, 0.52 mmol) was added to a mixture of 4-[5-(4-methylpheny1)-1H-pyrrolo[3,2-b]pyridin-6-yl]benzonitrile (80 mg, 0.26 mmol) and cesium carbonate (422 mg, 1.30 mmol) in DMF (3 mL). The reaction mixture was stirred at 90 C overnight. The DMF was removed in vacuo. The residue was taken in DCM, and the insoluble solids were filtered off. The filtrate was loaded on silica column and chromatographed (0-10%, MeOH:DCM) to give 45 mg (35%) of the title compound as a colorless oil. [M+H] Calc'd for C111-112N402, 493; Found, 493.
[00219] Example 3: 4-[5-(4-methylpheny1)-1-[[(35)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
ro H
110111 , I /
* N

[00220] To tert-butyl (3R)-3-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate (45 mg, 0.09 mmol) in ethanol (2 mL) was added HC1 in dioxane (4 N, 1 mL). The reaction was stirred for 2 h and the solvent was evaporated. The residue was chromatographed (0-20%, MeOH:DCM) to give 30 mg (84%) of the HC1 salt of the title compound as a beige solid. 1H NMR (400 MHz, DMSO-d6) 6 1.60 - 1.77 (m, 1 H), 1.89 -2.01 (m, 1 H), 2.32 (s, 3 H), 2.80 -3.02 (m, 3 H), 3.24 - 3.37 (m, 2 H), 4.48 (br. s., 2 H), 6.82 (br. s., 1 H), 7.12 - 7.29 (m, 4 H), 7.45 (d, J = 8.34 Hz, 2 H), 7.84 (d, J = 8.08 Hz, 2 H), 8.18 (s, 1 H), 8.63 (s, 1 H), 9.02 (br. s., 1 H), 9.28 (br. s., 1 H). [M+H] Calc'd for C26H24N4, 393; Found, 393.
[00221] Preparation 4A: tert-butyl (3R)-3-[[5-chloro-6-(4-cyanophenyOpyrrolo[3,2-b] pyridin-l-yl]methyl]pyrrolidine-l-carboxylate N
ro,Boc I /
CI N
[00222] The title compound was prepared in 25% yield from (S)-N-boc-3-bromomethylpyrrolidine and was added to a mixture of 4-(5-chloro-1H-pyrrolo[3,2-blpyridin-6-yl)benzonitrile according to the procedure for the preparation 3C.
[M+H]
Calc'd for C24H25C1N302, 437; Found, 437.
[00223] Example 4: 4-[5-chloro-1-[[(35)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b] pyridin-6-yl]benzonitrile N
rOH
I /
CI N
[00224] The title compound was prepared as the HC1 salt in 90% yield from tert-butyl (3R)-34[5-chloro-6-(4-cyanophenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate according to the procedure for the preparation of Example 3. 1H
NMR (400 MHz, DMSO-d6) 6 1.56 - 1.71 (m, 1 H), 1.84 - 1.95 (m, 1 H), 2.71 -2.92 (m, 2 H), 3.04 -3.23 (m, 3 H), 4.23 - 4.39 (m, 2 H), 6.66 (d, J= 3.28 Hz, 1 H), 7.74 (d, J =
8.59 Hz, 2 H), 7.90 (d, J=3.28 Hz, 1 H), 7.99 (d, J = 8.59 Hz, 2 H), 8.24 (s, 1 H), 8.63 (br.
s., 1 H), 8.73 (br. s., 1 H). [M+H] Calc'd for Ci9Hi7C1N4, 337; Found, 337.
[00225] Preparation 5A: 441 -(benzenesulfony1)-5-(4-fluorophenyl)pyrrolo[3,2-b]pyridin-6-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N
0:::

I /
* N
[00226] To a mixture of 441-(benzenesulfony1)-5-chloropyrrolo[3,2-b]pyridin-6-yl]benzonitrile (1 g, 2.54 mmol), Pd(dppf)C12 (100 mg, 0.13 mmol), aqueous sodium carbonate (2.0 M, 3.31 mL,7.62 mmol) in dioxane (10 mL), was added 4-fluoro-phenylboronic acid (1.42 g, 10.16 mmol). The reaction mixture was stirred and heated at 143 C for 4 h in the microwave. This crude reaction was used without purification in the next step. [M+H] Calc'd for C26H16FN302S, 454; Found, 454.
[00227] Preparation 5B: 4-[5-(4-fluoropheny1)-1H-pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
N
I /
N
[00228] To a mixture of crude 441-(benzenesulfony1)-5-(4-fluorophenyl)pyrrolo[3,2-b]pyridin-6-yl]benzonitrile (2.54 mmol) was added in Me0H (10 mL) and NaOH
(2.5N, 6 mL). The reaction mixture was stirred at RT for 5 h. The reaction was extracted with DCM. The organics were combined and washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was chromatographed (0-5 %, MeOH:DCM). The relevant fractions were combined and concentrated to afford 480 mg (60%) of the title compound as a beige solid. [M+H] Calc'd for C201-112PN3, 314; Found, 314.
[00229] Preparation 5C: tert-butyl (3R)-34[6-(4-cyanopheny1)-5-(4-fluorophenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate N
Boc I /
(10 N

[00230] The title compound was prepared in 100% yield from 445-(4-fluoropheny1)-1H-pyrrolo[3,2-b]pyridin-6-yl]benzonitrile and (R)-N-boc-3-bromomethylpyrrolidine according to the procedure for the preparation 3C. [M {-H] Calc'd for C301-129FN402, 497;
Found, 497.
[00231] Example 5: 4-[5-(4-fluoropheny1)-1-[[(3S)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
411 r011-1 I /
* N
[00232] The title compound was prepared as the HC1 salt in 14% yield from tert-butyl N-[3-[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-l-yl]propyl]carbamate according to the procedure for the preparation of Example 3. 1H
NMR (400 MHz, DMSO-d6): 6 ppm 1.68 - 1.92 (m, 2 H) 1.96 -2.23 (m, 2 H) 2.99 -3.18 (m, 1 H) 3.25 - 3.34 (m, 1 H) 3.95 (d, J= 7.07 Hz, 1 H) 4.67 (br. s., 2 H) 6.78 (d, J =
3.03 Hz, 1 H) 7.16 (t, J= 8.08 Hz, 2 H) 7.26 - 7.38 (m, 2 H) 7.44 (d, J= 8.34 Hz, 3 H) 7.83 (d, J=8.34 Hz, 2 H) 8.04 (br. s., 1 H) 8.38 (br. s., 1 H) 8.95 - 9.34 (m, 2 H). [M+H]
Calc'd for C25H2iFN4, 397; Found, 397.
[00233] Preparation 6A: 4-(3-bromo-6-methyl-5-nitropyridin-2-yl)morpholine Br.r.x:02 N -1\1 0,0J
[00234] To a mixture of 3-bromo-2-chloro-6-methyl-5-nitropyridine (2.00 g, 8.0 mmol) and morpholine (700 uL, 8.0 mmol) in DCM (20 mL), was added DIEA
(1.40 mt., 8.0 mmol). The reaction mixture was stirred at rt for 16 h. Solvent was evaporated. The residue was chromatographed (0-5%, MeOH:DCM) to give 2.21 g (92%) of the title compound as a yellow solid. 'H NMR (400 MHz, DMSO-d6) 6 2.66 (s, 3 H), 3.57 - 3.63 (m, 4 H), 3.70 - 3.75 (m, 4 H), 8.54 (s, 1 H). Calc'd for Cl0Hi2BrN303, 303, 305; Found, 303, 305.
[00235] Preparation 6B: 4-(6-methy1-2-morpholin-4-y1-5-nitropyridin-3-yl)benzonitrile WO 2015/089192 PCT[1JS2014/069562 N ==

r*N' N

[00236] To a mixture of 3-bromo-6-methyl-2-morphiline-5-nitropyridine (2.21 g, 7.34 mmol), Pd(dppf)C12 (0.31 g, 0.37mmo1) and aqueous sodium carbonate (2.0 M, 5 mL) in dioxane (15 mL) was added 4-cyanophenylboronic acid (1.30 g, 8.08 mmol). The reaction mixture was stirred and heated at 110 C for 1 h. Solvent was evaporated, the residue was taken in water and extracted with DCM (3x). The organic layers were combined, washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was chromatographed (0-5%, MeOH:DCM) to afford 2.15 g (90%) of the title compound as a yellow solid. [M+H] Calc'd for C17H16N403, 325; Found, 325.
[00237] Preparation 6C: 446-[(E)-2-(dimethylamino)etheny1]-2-morpholin-4-y1-5-nitropyridin-3-yl]benzonitrile N
===.

\ I N
N
[00238] To 3-(4-cyanonpheny1)-6-methy1-2-morphiline-5-nitropyridine (2.15 g, 7.14 mmol) in DMF (12 mL) was added N,N-dimethylformamide dimethyl acetal (5.6 mL, 42.8 mmol). The reaction mixture was stirred at rt for 30 min and heated at 100 C for 3 h. Solvent was removed in vacuo to give 2.7 g (99%) of the title compound as a burgundy red solid. This residue was used without purification in the next step. [M+H]
Calc'd for C20H21N503, 380; Found, 380.
[00239] Preparation 6D: 4-(5-morpholin-4-y1-1H-pyrrolo[3,2-b]pyridin-6-yl)benzonitrile N
I /
N
[00240] 4-[6-[(E)-2-(dimethylamino)etheny1]-2-morpholin-4-y1-5-nitropyridin-3-yllbenzonitrile (2.7 g, 7.14 mmol) was dissolved in MeOH:DCM (200 mL, 1:10).
Pd/C

(10% w, 330 mg, 0.72 mmol) was added under nitrogen. Nitrogen atmosphere was displaced by hydrogen and the reaction was stirred at rt for 3 h. The reaction mixture was filtered through CeliteTM and concentrated in vacuo. The residue was chromatographed (0-10%, MeOH:DCM) to give 1.41 g (65%) of the title compound as a beige solid. 1H

NMR (400 MHz, DMSO-d6) 6 2.83 - 2.99 (m, 4 H), 3.47 - 3.62 (m, 4 H), 6.46 (t, J=
2.15 Hz, 1 H), 7.58 (t, .1 = 2.91 Hz, 1 H), 7.65 (s, 1 H), 7.85 - 7.98 (m, 4 H), 11.25 (br. s., 1 H). [M+H] Calc'd for Ci8HI6N40, 305; Found, 305.
[00241] Preparation 6E: tert-butyl (3S)-3-[[6-(4-cyanopheny1)-5-morpholin-4-ylpyrrolo[3,2-b]pyridin-1-yl]methyllpyrrolidine-1-carboxylate N
/ Boc N " eNs-I /
N
O.%) [00242] To a solution of 4-(5-morphotin-4-y1-1H-pyrrolo[3,2-b]pyridin-6-yl)benzonitrile (100 mg, 0.33 mmol) in DMF (3 mL) was added (R)-N-boc-3-bromomethylpyrrolidine (96 mg, 0.37mmo1) followed by cesium carbonate (214 mg, 0.65 mmol) and the mixture was stirred at 90 C overnight. (R)-N-Boc-3-bromomethylpyrrolidine (96 mg, 0.37 mmol) was added and the reaction was stirred at 90 C for 2 h. The DMF was removed in vacuo. The residue was taken in DCM and the insoluble solids were filtered off The filtrate was loaded on silica column and chromatographed (0-100%, Et0Ac:Hexanes) to afford 125 mg (77%) of the title compound as a light yellow oil. [M+H] Calc'd for C281-133N503, 488; Found, 488.
[00243] Example 6: 445-morpholin-4-y1-1-[[(3R)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N

poCINH
I /
N
[00244] To tert-butyl (3S)-31[6-(4-cyanopheny1)-5-morpholin-4-ylpyrrolo[3,2-b]pyridin-1-ylimethyl]pyrrolidine-1-carboxylate (125 mg, 0.26 mmol) in ethanol (4 mL) was added HC1 in dioxanc (4 N, 3 mL). The reaction was stirred for 2 h.
Solvent was evaporated in vacuo. The residue was chromatographed (0-20%, MeOH:DCM) to give Date Recue/Date Received 2021-05-21 71 mg (70 %) of the HC1 salt of the title compound as a light yellow solid (HC1 salt). 1H
NMR (400 MHz, DMSO-d6) 6 2.73 - 2.87 (m, 2 H), 2.86 - 2.97 (m, 4 H), 3.05 -3.15 (m, 3 H), 3.22 - 3.30 (m, 2 H), 3.54 (d, J= 4.55 Hz, 4 H), 4.23 - 4.32 (m, 2 H), 6.49 (d, J=
3.03 Hz, 1 H), 7.70 (d, J= 3.03 Hz, 1 H), 7.91 - 7.99 (m, 4 H), 8.01 (s, 1 H), 9.07 (br. s., 1 H). [M+H] Calc'd for C23H25N50, 388; Found, 388.
[00245] Preparation 7A: tert-butyl (3R)-34[6-(4-cyanopheny1)-5-morpholin-4-ylpyrrolo[3,2-b]pyridin-l-yl]methyl]pyrrolidine-1-carboxylate N
rFO'Boc N
I /
N N
[00246] The title compound was prepared in 58% yield from (S)-N-boc-3-bromomethylpyrrolidine and 4-(5-morpholin-4-y1-1H-pyrrolo[3,2-b]pyridin-6-yl)benzonitrile according to the procedure for preparation 6E. 1H NMR (400 MHz, DMSO-d6) 6 1.33 (s, 9 H), 1.50 - 1.67 (m, 1 H), 1.67 - 1.88 (m, 1 H), 2.61 -2.77 (m, 2 H), 2.90 (br. s., 4 H), 2.95 - 3.23 (m, 3 H), 3.54 (br. s., 4 H), 4.23 (d, J=
7.58 Hz, 2 H), 6.46 (d, J= 2.80 Hz, 1 H), 7.63 (d, J= 2.78 Hz, 1 H), 7.83 - 8.05 (m, 5 H).
[M+H]
Calc'd for C281-131\150, 488; Found, 488.
[00247] Example 7: 4-[5-morpholin-4-y1-1-[[(3S)-pyrrolidin-3-yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
rC'NH
N
I /
N
0) [00248] To tert-butyl (3R)-3-[[6-(4-cyanopheny1)-5-morpholin-4-ylpyrrolo[3,2-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate (116 mg, 0.19 mmol) in ethanol (4 mL) was added HC1 in dioxane (4 N, 3 mL). The reaction was stirred for 2 h.
Solvent was evaporated in vacuo to give 81 mg (99 %) of the HC1 salt of the title compound as a light yellow solid. 1H NMR (400 MHz, DMSO-d6) 6 1.53 - 1.73 (m, 1 H), 1.83 - 1.97 (m, 1 H), 2.72 -2.91 (m, 2 H), 2.92 - 3.03 (m, 4 H), 3.06 - 3.20 (m, 2 H), 3.21 -3.38 (m, 1 H), 3.48 - 3.59 (m, 4 H), 4.25 - 4.39 (m, 2 H), 6.58 (br. s., 1 H), 7.82 (br. s., 1 H), 7.89 - 8.02 (m, 4 H), 8.22 (br. s., 1 H), 8.98 (br. s., 1 H), 9.25 (br. s., 1 H). [M+H]
Calc'd for C211-12N50, 388; Found, 388.

[00249] Preparation 8A: tert-butyl 3-[[6-(4-cyanopheny1)-5-morpholin-4-ylpyrro10 [3 ,2-b]pyridin-l-yl]m ethyl] -3 -fluoropyrrolidin e-1-c arboxyl ate N
[00250] The title compound was prepared in 79% yield from 1-N-boc-3-bromomethy1-3-fluoro-pyrrolidine and 4-(5-morpholin-4-y1-1H-pyrrolo[3,2-b]pyridin-6-yl)benzonitrile according to the procedure for preparation 6E. [M+H] Calc'd for C28H12FN501, 506;
Found, 506.
[00251] Example 8: 4-[1-[(3-fluoropyrrolidin-3-yl)methyl]-5-morpholin-4-ylpyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
N. I.NH
I /
N
[00252] The HCL salt of the title compound was prepared in 88% yield from tert-butyl 3-[[6-(4-cyanopheny1)-5-morpholin-4-ylpyrrolo[3,2-b]pyridin-1-yl]methy1]-fluoropyrrolidine-1-carboxylate according to the procedure for the preparation of Example 6. 1H NMR (400 MHz, DMSO-d6) 6 1.93 - 2.39 (m, 2 H), 2.89 - 3.03 (m, 4 H), 3.21 - 3.34 (m, 2 H), 3.35 - 3.48 (m, 2 H), 3.50 - 3.60 (m, 4 H), 4.73 - 4.87 (m, 2 H), 6.60 (d, J= 2.78 Hz, 1 H), 7.68 (br. s., 1 H), 7.87 - 8.02 (m, 4 H), 8.09 (br. s., 1 H), 9.44 (br.
s., 1 H), 9.66 (br. s., 1 H). [M+H] Calc'd for C23H24FN50, 406; Found, 406.
[00253] Preparation 9A: tert-butyl 3-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]methy1]-3-fluoropyrrolidine-1-carboxylate N
N/F--NCIN."Boc I /
*
[00254] The title compound was prepared in 41% yield from 1-N-boc-3-bromomethy1-3-fluoro-pyrrolidine and 445-(4-methylpheny1)-1H-pyrrolo[3,2-b]pyridin-6-yl]benzonitrile according to the procedure for preparation 3C. [M+H] Calc'd for C31f131FN402, 511; Found, 511.
[00255] Example 9: 441-[(3-fluoropyrrolidin-3-yOmethyl]-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
rSCA
*
* N
[00256] The HC1 salt of the title compound was prepared in 66% yield from tert-butyl 3-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]methy1]-3-fluoropyrrolidine-1-carboxylate according to the procedure for the preparation of Example 3. 1H NMR (400 MHz, DMSO-d6) 6 2.08 (br. s., 1 H), 2.23 - 2.31 (m, 1 H), 2.32 (s, 3 H), 3.33 (d, J= 5.05 Hz, 4 H), 4.77 - 5.15 (m, 2 H), 6.90 (br. s., 1 H), 7.17 -7.29 (m, 4 H), 7.43 (d, J= 8.34 Hz, 2 H), 7.84 (d, J= 8.34 Hz, 2 H), 8.13 (br.
s., 1 H), 8.65 (br. s., 1 H), 9.67 (br. s., 1 H), 9.98 (br. s., 1 H). [M+H] Calc'd for C26H23FN4, 411;
Found, 411.
[00257] Preparation 10A: tert-butyl (2S)-2-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]morpholine-4-carboxylate N
%.
Boc I /
N
[00258] Tert-butyl (2R)-2-(bromomethyl)morpholine-4-carboxylate (145 mg, 0.52 mmol) was added to a mixture of 4-[5-(4-methylpheny1)-1H-pyrrolo[3,2-b]pyridin-yl]benzonitrile (80 mg, 0.26 mmol) and cesium carbonate (422 mg, 1.30 mmol) in DMF
(3 mL). The reaction mixture was stirred at 90 C overnight. The insoluble solids were filtered off and DMF was concentrated in vacuo to give 282 mg (100%) of the title compound as a brown semisolid. This residue was used without purification in the next step. [M+H] Calc'd for C31H32N403, 509; Found, 509.
[00259] Example 10: 445-(4-methylpheny1)-1-[[(2R)-morpholin-2-yl]methyl]pyrrolo[3,2-b]pyridin-6-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N
N %it NH
I /
N
[00260] The title compound was prepared as the HC1 salt in 36% yield from tert-butyl (2S)-2-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-blpyridin-1-yllmethyllmorpholine-4-carboxylate according to the procedure for the preparation of Example 3. 1H NMR (400 MHz, DMSO-d6): 6 ppm 2.20 - 2.40 (m, 3 H) 2.76 (d, J =
11.37 Hz, 1 H) 2.91 (d, J= 12.13 Hz, 1 H) 3.06 - 3.24 (m, 2 H) 3.37 (d, I =
11.87 Hz, 2 H) 3.94 (d, .J= 9.60 Hz, 2 H) 4.13 (br. s., 1 H) 4.43 - 4.74 (m, 2 H) 6.84 (hr. s., 1 H) 7.14 - 7.34 (m, 4 H) 7.39 - 7.54 (m, 2 H) 7.85 (d, J= 8.34 Hz, 2 H) 8.06 (hr. s., 1 H) 8.49 -8.75 (m, 1 H) 9.25 - 9.67 (m, 2 H). [M+H] Calc'd for C26H24N40, 409; Found, 409.
[00261] Preparation 11A: tert-butyl (2S)-24[6-(4-cyanopherty1)-5-(4-fluorophenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]morpholine-4-carboxylate N

11µ...

I /
N
[00262] The title compound was prepared in 100% yield from 445-(4-fluoropheny1)-1H-pyrrolo[3,2-b]pyridin-6-yl]benzonitrile and tert-butyl (2R)-2-(bromomethyOmorpholine-4-carboxylate according to the procedure for the preparation 10A. [M+H] Calc'd for C30H29FN403, 513; Found, 513.
[00263] Example 11: 4-45 -(4-fluoropheny1)- I 4 [(2R)-rnorpho I in-2-yi jincth yl pyrrolo[3,2-b]pyridin-6-yl]benzonitrile N
=/C-4H
I /
= N
[00264] The title compound was prepared as the HC1 salt in 27% yield from tert-butyl (2S)-24[6-(4-cyanopheny1)-5-(4-fluorophenyl)pyrrolo[3,2-b]pyridin-1-yl]methyl]morpholine-4-carboxylate according to the procedure for the preparation of Example 3. 1H NMR (400 MHz, DMSO-d6) 6 ppm 2.71 - 2.81 (m, 1 H) 2.92 (d, J =
11.62 Hz, 1 H) 3.15 (d, J=13.14 Hz, 1 H) 3.35 (d, J= 12.88 Hz, 1 H) 3.94 (d, J= 9.09 Hz, 2 H) 4.11 (br. s., 1 H) 4.39 - 4.72 (m, 2 H) 6.80 (br. s., 1 H) 7.12 -7.29 (m, 2 H) 7.29 -7.53 (m, 4 H) 7.71 -7.92 (m, 2 H) 7.92 - 8.10 (m, 1 H) 8.45 (br. s., 1 H) 9.13 -9.55 (m, 2 H). [M+H] Calc'd for C25H2IFN40, 413; Found, 413.
[00265] Preparation 12A: tert-butyl N-[3-[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-1-yl]propyl]carbamate BOG
N
rx 41-1 N
I /
N
[00266] The title compound was prepared in 100% yield from 4-[5-(4-methylpheny1)-1H-pyrrolo[3,2-b]pyridin-6-yl]benzonitrile and tert-butyl N-(3-bromopropyl)carbamate according to the procedure for the preparation 10A. [M+H] Calc'd for C29H30N402, 466;
Found, 466.
[00267] Example 12: 4-[1-(3-aminopropy1)-5-(4-methylphenyl)pytTolo[3,2-b]pyridin-6-yl]benzonitrile N If NH 2 =%.
N
/
N
[00268] The title compound was prepared as the HC1 salt in 20% yield from tert-butyl N-[346-(4-cyanopheny1)-5-(4-methylphenyl)pyrrolo[3,2-b]pyridin-l-yl]propyl]carbamate according to the procedure for the preparation of Example 3. 1H
NMR (400 MHz, DMSO-d6): 6 ppm 2.05 - 2.21 (m, 2 H) 2.32 (s, 3 H) 2.78 (d, J=
5.81 Hz, 2 H) 4.51 (br. s., 2 H) 6.82 (br. s., 2 H) 7.09 - 7.31 (m, 4 H) 7.46 (d, J= 8.34 Hz, 2 H) 7.84 (d, J= 8.34 Hz, 2 H) 7.98 (br. s., 2 H) 8.16 (br. s., 1 H) 8.62 (s, 1 H). [M+H]
Calc'd for C24H22N4, 366; Found, 366.
[00269] Preparation 13A: 3,5-dibromo-6-methylpyridin-2-ol Bryz.y Br HO)L'Nr.' [00270] To a 1-L three-necked reaction flask packed with aluminum foil was added a solution of 2-hydroxy-6-methyl-pyridine (27.4 g, 0.25 mol) in dry acetonitrile (300 mL).
NBS (89 g, 0.5 mol) was added portion-wise to the mixture over 20 min at 0 C.
As the suspension was difficult to stir, additional dry acetonitrile (200 ml) was added and stirring continued at 30 C for 1.5 h. The suspension was filtered. The filter cake was thoroughly washed with methanol (50 mL x 3) and dried to give 58.6 g (88%) of the title compound as a white solid. 1H NMR (400 MHz, CDC13) 6 7.90 (s, 1 H), 2.46 (s, 3 H).
[M+H] Calc'd for C6H5Br2NO, 268, 270; Found, 268, 270.
[00271] Preparation 13B: 3-bromo-6-methylpyridin-2-ol Bria, HO N
[00272] In a 2-L three-necked reaction flask (flame-dried), 3,5-dibromo-6-methylpyridin-2-ol (51.6 g, 193 mmol) in dry THF (500 mL) was stirred under N2 at room temperature. The mixture was cooled to -67 C. n-BuLi (178 mL, 445 mmol) was added dropwise over 1 h at a temperature maintained below -60 C. The mixture was stirred for 1.5 h at -60 C. Saturated aqueous NH4C1 (100 mL) was added dropwise over 1 h at a temperature between -65 C and -40 C. The reaction mixture was stirred at -40 C for 15 min, allowed to reach 25 C and then stirred overnight. The mixture was concentrated to remove THF and the aqueous layer was extracted with Et0Ac (300 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried over Na2SO4, filtered, concentrated and purified by column chromatography on silica gel (10-50%, Et0Ac:PE) to give 6.07 g (17%) of the title compound as an off-white solid. 1H
NMR (400 MHz, CDC13) 6 12.94 (s, 1 H), 7.72 (d, J = 7.2 Hz, 1 H), 5.99 (d, J =
7.2 Hz, 1 H), 2.37 (t, J = 8.4 Hz, 3 H). [M+H] Calc'd for C6H6BrNO, 189, 191; Found, 189, 191.
[00273] Preparation 13C: 3-bromo-6-methyl-5-nitropyridin-2-ol B(z,x, NO2 I
HO N
[00274] In a 500-mL round-bottomed flask, a 65% aqueous HNO3 was stirred at 0 C
and 3-bromo-6-methylpyridin-2-ol (5.7 g, 30.3 mmol) was introduced dropwise.
The reaction mixture was stirred at room temperature for 3.5 h. After pouring the mixture into ice water (200 mL), the aqueous layer was extracted with Et0Ac (300 mL x 2).
The combined organic layers were washed with water, brine (200 mL x 2), dried over Na2SO4, filtered, concentrated and purified by column chromatography on silica gel (25%, Et0Ac:PE) to give 4.7 g (67%) of the title compound as an off-white solid. 1H

NMR (400 MHz, CDC13) 6 12.85 (s, 3 H), 8.66 (s, 1 H), 2.86 (s, 1 H). [M+H]
Calc'd for C6H3BrN203, 235, 237; Found, 235, 237.
[00275] Preparation 13D: 3-bromo-2-chloro-6-methyl-5-nitropyridine Brx) .102 I
CI N
[00276] In a 500-mL single round-bottomed flask, P0C13 (12 g, 78.1 mmol) was added dropwise to 3-bromo-6-methyl-5-nitropyridin-2-ol (4 g, 15.87 mmol). This mixture was then stirred at reflux for 7 h. The reaction mixture was cooled to 30 C, poured into ice water and stirred for 10 min. Saturated NaHCO3 solution (30 mL) was then added. The aqueous layer was extracted with Et0Ac (200 mL x 3). The combined organic layers were washed with water, brine (200 mL x 2), dried over Na2SO4, filtered and concentrated to give 2.8 g (65 %) of the title compound as a yellow solid.
NMR
(400 MHz, CDC13) 6 8.55 (s, 1 H), 2.83 (s, 3 H).
[00277] Preparation 13E: 5-bromo-6-chloro-2-methylpyridin-3-amine Brn:1H2 I
CI N
[00278] To a solution of 3-bromo-2-chloro-6-methyl-5-nitropyridine (2.2 g, 8.7 mmol) in Et0H (100 mL) was added Fe (4.8 g, 85.7 mmol) and HOAc (300 mL). The mixture was stirred at 30 C for 13 h. The solids were filtered and the filtrate was concentrated in vacuo to remove Et0H and most of HOAc. The remaining aqueous was extracted with DCM (100 mL x 3). The combined organic layers were washed with water, brine (100 mL x 2), dried over Na2SO4, filtered and concentrated to give 1.66 g (86%) of the title compound as a brown solid. [M+H] Calc'd for C6H6BrC1N2, 221, 223; Found, 221, 223.
[00279] Preparation 13F: 4-(5-amino-2-chloro-6-methylpyridin-3-yObenzonitrile N

CI N
[00280] To a solution of 5-bromo-6-chloro-2-methylpyridin-3-amine (1.66 g, 7.48 mmol) in dioxane (50 mL) was added 4-cyanophenylboronic acid (1.2 g, 8.97 mmol), Na2CO3 (2.5 g, 23.6 mmol), Pd(dppf)C12 (306 mg, 0.37 mmol) and a few drops of water.
The mixture was degassed with N2 for 5 min and heated to 70 C for 13 h. The solids were filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography (15-25%, Et0Ac:PE) to afford 1.42 g (79%) of the title compound as a brown solid. [M+H] Calc'd for Ci3H10C1N3, 244; Found, 244.
[00281] Preparation 13G: 445-amino-6-methyl-2-(4-methylphenyl)pyridin-3-yl]benzonitrile N
= #NH2 \
N
[00282] To a solution of 4-(5-amino-2-chloro-6-methylpyridin-3-yObenzonitrile (1.4 g, 5.76 mmol) in dioxane (50 mL) was added 4-(5-amino-2-chloro-6-methylpyridin-yl)benzonitrile (1.1 g, 8.15 mmol), Na2CO3 (2.2 g, 20.7 mmol), Pd(dppf)C12 (0.8 g, 1.09 mmol) and a few drops of water. The mixture was degassed with N2 for 5 min and heated to 110 C for 14 h. The solids were filtered and the filtrate was concentrated in vacuo.
The residue was purified by silica gel chromatography (15-25%, Et0Ac:PE) to afford 1.3 g (76%) of the title compound as a light yellow solid. IFT NMR (400 MHz, CDC13) 6 7.54 (d, J = 8.0 Hz, 2 H), 7.26 (d, J = 6.0 Hz, 2 H), 7.12 (d, J = 8.0 Hz, 2 H), 7.02 (d, J =
8.0 Hz, 2 H), 6.96 (s, 1 H), 3.77 (s, 2 H), 2.56 (s, 3 H), 2.30 (s, 3 H).
[M+H] Calc'd for C201-117N1, 300; Found, 300.
[00283] Preparation 13H: N45 -(4-cyanopheny1)-2-methyl-6-(4-methylphenyl)pyridin-3-yl]acetamide N
=
NHAc * N
[00284] To a solution of 445-amino-6-methy1-2-(4-methylphenyOpyridin-3-yl]benzonitrile (1.3 g, 4.35 mmol) in DCM (50 mL) was added pyridine (1.4 mL, mmol) and Ac20 (1.3 mL, 13 mmol). The mixture was stirred at 30 C for 16 h. To the reaction mixture was added saturated aqueous sodium bicarbonate solution in portions.
The reaction mixture was stirred for 10 min. The aqueous layer was extracted with DCM
(100 mL x 3). The combined organic layers were washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo to give 1.3 g (86%) of the title compound as a yellow oil. [M+H] Calc'd for C22Hi9N30, 342; Found, 342.

[00285] Preparation 131: 4-[1-acety1-5-(4-methylphenyl)pyrazolo[4,3-b]pyridin-yl]benzonitrile N
11411 Ac =
N
, I N
* N
[00286] To a solution of N45-(4-cyanopheny1)-2-methyl-6-(4-methylphenyl)pyridin-3-yl]acetamide (1.3 g, 3.81 mmol) in toluene (20 mL) was added tert-butyl nitrite (630 mg, 6.1 mmol), Ac20 (1.1 mL, 11.5 mmol) and KOAc (452 mg, 4.6 mmol). The mixture was heated at 80 C for 2 h, and then cooled to room temperature. 10% NaHCO3 (150 mL) was added and the mixture was extracted with Et0Ac (100 ml x 3). The combined organic layers were washed with water, NaHCO3, brine, dried over Na2SO4, filtered and concentrated in vactio to give 0.8 g (60%) of the title compound as brown solid. [M+H]
Calc'd for C22Hi6N40, 353; Found, 353.
[00287] Preparation 13J: 4-[5-(4-methylpheny1)-1H-pyrazolo[4,3-b]pyridin-6-yl]benzonitrile N
%.
I N
* N
[00288] To 4-[1-acety1-5-(4-methylphenyl)pyrazolo[4,3-b]pyridin-6-yl]benzonitrile (0.8 g, 2.27 mmol) in THF/Me0H (30 mL, 2:1) was added NaOH (2.3 M, 3 mL). The resulting mixture was stirred at room temperature for 1 h. The solvent was removed in vacuo. The residue was taken in water (30 mL) and the aqueous was extracted with Et0Ac (20 nil x 3). The combined organic layers were washed with water, brine, dried over Na2SO4 and concentrated. The crude product was further purified by column chromatography (33%, Et0Ac:PE) to give 0.41 g (58%) of the title compound as a yellow solid. 1H NMR (400 MHz, CD30D): 6 8.29 (s, 1 H), 8.07 (s, 1 H), 7.65 (d, J = 8.0 Hz, 2 H), 7.42 (d, J = 8.0 Hz, 2 H), 7.19 (d, J = 8.0 Hz, 2 H), 7.12 (d, J =
8.0 Hz, 2 H), 2.33 (s, 3 H). [M+H] Calc'd for C20Hi4N4, 311; Found, 311.
[00289] Preparation 13K: tert-butyl 3-116-(4-cyanopheny1)-5-(4-methylphenyOpyrazolo[4,3-b]pyridin-1-yl]methyl]pyrrolidine-1-carboxylate WO 2015/089192 PCT[1JS2014/069562 ,1:3oc N
4111 Ns N
* N
[00290] To a solution of 445-(4-methylpheny1)-1H-pyrazolo[4,3-b]pyridin-6-yl]benzonitrile (100 mg, 0.32 mmol) and tert-butyl 344-ethylphenyOsulfonyloxymethyl]pyrrolidine-1-carboxylate (185 mg, 0.52 mmol) in DMF
(5 mL) was added potassium carbonate (209 mg, 0.96 mmol). The mixture was then stirred at RT overnight. The mixture was diluted with Et0Ac (20 mL) and water (20 mL). The aqueous layer was extracted with Et0Ac (30 mL x 3). The combined organic layers were washed with water (20 mL x 2), brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by prep-HPLC to give 66 mg (43%) of the title compound as a white solid. 1H NMR (CDC13, 400 MHz): 6 8.32 (s, 1 H), 7.71 (s, 1 H), 7.57 (d, J = 8.4 Hz, 2 H), 7.35 (d, J = 5.6 Hz, 2 H), 7.18 (d, J = 8.0 Hz, 2 H), 7.07 (d, J =
8.0 Hz, 2 H), 4.41 (d, J = 7.2 Hz, 2 H), 3.48-3.43 (m, 2 H), 3.34-3.32 (m, 1 H), 3.18 (t, J
= 4.8 Hz, 1 H), 2.90-2.91 (m, 1 H), 2.33 (s, 3 H), 2.00-1.98 (m, 1 H), 1.75-1.73 (m, 1 H), 1.42 (s, 9 FI). [M+H] Calc'd for C30H3iN502, 494; Found, 494.
[00291] Example 13: 4-15-(4-methylpheny1)-1-(pyrrolidin-3-ylmethyppyrazolo[4,3 pyridin-6-yllbenzonitrile N
Ns N
[00292] A solution of hydrochloric acid in dioxane (4 M, 3 mL) was added to methylpheny1)-1-(pyrrolidin-3-ylmethyl)pyrazolo[4,3-b]pyridin-6-yl]benzonitrile (66 mg, 0.13 mmol). The mixture was then stirred at room temperature for 30 min.
The resulting mixture was concentrated to afford 49 mg (94%) of the title compound as a white solid. IH NMR (CD30D, 400 MHz): 6 9.10 (s, 1 H), 8.54 (s, 1 H), 7.73 (d, J = 8.0 Hz, 2 H), 7.56 (d, J = 8.0 Hz, 2 H), 7.35 (d, J = 8.0 Hz, 2 H), 7.28 (d, J =
8.0 Hz, 2 H), 4.87-4.85 (m, 2 H), 3.62-3.49 (m, 3 H), 3.29-3.17 (m, 2 H), 2.39 (s, 3 H), 2.28-2.24 (m, 1 H), 1.99-1.93 (m, 1 H). [M+H] Calc'd for C25H23N5, 394; Found, 394.
[00293] Preparation 14A: tert-butyl 4-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrazolo[4,3 -b] pyridin-l-yl]methyl]piperidine-l-carboxylate WO 2015/089192 PCT[1JS2014/069562 N

(11) [00294] To a solution of 4-15-(4-methylpheny1)-1H-pyrazolo[4,3-blpyridin-6-yllbenzonitrile (80 mg, 0.26 mmol) and tert-butyl 4-(bromomethyppiperidine-1-carboxylate (138 mg, 0.49 mmol) in DMF (3 mL) was added potassium carbonate (120 mg, 0.55 mmol). The mixture was stirred at RT overnight. The mixture was diluted with Et0Ac (20 mL) and water (20 mL). The aqueous layer was extracted with Et0Ac (30 mL x 3). The combined organic layers were washed with water (20 mL x 2), brine, dried over Na2SO4, filtered and concentrated to give the title compound as yellow oil. This oil was used without purification in the next step. [M+H] Calc'd for C31H33N502, 508;
Found, 508.
[00295] Example 14: 4-[5-(4-methylpheny1)-1-(piperidin-4-ylmethyl)pyrazolo[4,3-b]pyridin-6-yl]benzonitrile N
=%. *
r E1 /1\1 N
[00296] To tert-butyl 4-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrazolo[4,3-b]pyridin-1-yl]methyl]piperidine-1-carboxylate (76 mg, 0.15 mmol) was added hydrochloric acid in dioxane (4 M, 4 mL) at 0 C. The mixture was warmed to room temperature and stirred for 30 min. The reaction mixture was concentrated and the residue was purified by prep-HPLC to afford 25 mg (41%) of the title compound as white solid.. 1H NMR (D20, 400 MHz): 6 8.18 (s, 1 H), 8.06 (s, 1 H), 7.45 (d, J = 8.4 Hz, 2 H), 7.16 (d, J = 8.0 Hz, 2 H), 6.94 (s, 4 H), 4.33 (d, J = 6.8 Hz, 2 H), 3.31 (d, J = 13.2 Hz, 2 H), 2.83 (t, J = 10.4 Hz, 2 H), 2.24-2.23 (m, 1 H), 2.14 (s, 3 H), 1.69 (d, J = 11.6 Hz, 2 H), 1.47-1.29 (m, 2 H). Calc'd for C26H25N5, 408; Found, 408.
[00297] Preparation 15A: tert-butyl (/S,5R)-6-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrazolo[4,3-blpyridin-l-yllmethyll-3-azabicyclo[3.1.01hexane-3-carboxylate WO 2015/089192 PCT[1JS2014/069562 NC raw2pN-Boc N, H
N
[00298] A mixture of 4-[5-(4-methylpheny1)-1H-pyrazolo[4,3-b]pyridin-6-yl]benzonitrile (100 mg, 0.32 mmol), tert-butyl (/S,5R)-6-(chloromethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (115 mg, 0.49 mmol) and K2CO3 (150 mg, 0.69 mmol) in DMF (8 mL) was stirred at 60 C overnight. The mixture was cooled down to room temperature, diluted with water (50 mL) and ethyl acetate (50 mL). The solution was extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with water (50 mL x 3), brine (50 mL), dried over Na2SO4, filtered and concentrated.
The residue was purified by pre-HPLC to give 62 mg (38 %) of the title compound as a white solid. 1H NMR (CDC13, 400 MHz): 6 8.35 (s, 1 H), 7.76 (s, 1 H), 7.61 (d, J = 7.8 Hz, 2 H), 7.36 (d, J = 8.2 Hz, 2 H), 7.21 (d, J = 7.4 Hz, 2 H), 7.09 (d, J =
7.8 Hz, 2 H), 4.41 -4.35 (m, 2 H), 3.63 - 3.61 (m, 1 H), 3.50 - 3.48 (m, 1 H), 3.37 - 3.36 (m, 2 H), 2.35 (s, 3 H), 1.62 - 1.67 (m, 2 H), 1.40 (s, 9 H), 1.26 - 1.14 (m, 1 H). [M+H]
Calc'd for C311-131N502, 506; Found, 506.
[00299] Example 15: 441-[[(/S,5R)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-5-(4-methylphenyl)pyrazolo[4,3-b]pyridin-6-yllbenzonitrile NC 010 tow.2pNH
Nõ.N H
I 1\I
* N
[00300] To a solution of tert-butyl (IS,5R)-6-[[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrazolo[4,3-blpyridin-l-yllmethyll-3-azabicyclo[3.1.01hexane-3-carboxylate (62 mg, 0.12 mmol) in DCM (5 mL) was added hydrochloric acid in dioxane (4 M, 2 mL). The mixture was then stirred at room temperature for 30 min. The resulting mixture was concentrated to give 35 mg (72 %) of the HC1 salt of the title compound as a yellow oil. 1H NMR (C1)3OD, 400 MHz): 6 8.85 (s, 1 H), 8.45 (s, 1 H), 7.72 (d, J = 6.9 Hz, 2 H), 7.54 (d, J = 7.4 Hz, 2 H), 7.24 - 7.31 (m, 4 H), 4.64 (d, J = 6.4 Hz, 2 H), 3.61 -3.59 (m, 4 H), 2.38 (s, 3 H), 2.08 -2.10 (m, 2 H), 1.72 - 1.74 (m, 1 H). [M+H]
Calc'd for C26H23N5, 406; Found, 406.

[00301] Preparation 16A: 4-(2,5-dichloropyrimidin-4-yl)benzonitrile N
N IC
I
N
CI
[00302] To a 100 mL pressure vessel charged with 2,4,5-trichloropyrimidine (1.83 g, mmol) in dioxane (20 mL) was added (4-cyanophenyl)boronic acid (1.47 g, 10 mmol), PdC12(dppf) (146 mg, 0.2 mmol), and Na2CO3 (10 mL, 2M). The mixture was purged with N2 for 5 min and sealed. The reaction was kept at 70 C for 1 h with vigorous stirring. Water was added and the heterogeneous mixture was filtered.
The filter cake was taken up in ethanol, stirred for 10 min, filtered, and dried in vacuo to afford the title compound (2.2 g, 89%) as off-white crystals. [M+H] calc'd for C11H5N3C12, 250;
found 250.
[00303] Preparation 16B: tert-butyl (3R)-3-(I[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolmethyl)pyrrolidine-1-carboxylate N
= N %,40eCN.-Boc N.
H N
I
N
CI
[00304] To a vial containing 4-(2,5-dichloropyrimidin-4-yObenzonitrile (496 mg, 2 mmol) in ethanol (5 mL), was added tert-butyl (3S)-3-(aminomethyl)pyrrolidine-carboxylate (400 mg, 2 mmol), and DIEA (694 gL, 4 mmol). The reaction was stirred at 100 C for 16 h. The reaction was concentrated in vacuo, and the residue purified by column chromatography (0-50% gradient of Et0Ac in hexanes) to afford the title compound (743 mg, 90%) as a yellow amorphous solid. [M+H] calc'd for C21f124N302C1, 414; found 414.
[00305] Example 16: 445-(4-methylpheny1)-2-{[(3S)-pyrrolidin-3-ylmethyl]amino}pyrimidin-4-yl]benzonitrile N
= N H,..eCNH
N
I
(00 N
[00306] To a microwave vial charged with tert-butyl (3R)-3-0[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolmethyppyrrolidine-1-carboxylate (206 mg, 0.5 mmol) in dioxane (3 mL) was added (4-methylphenyl)boronic acid (136 mg, 1 mmol), PdC12(dppf) (36 mg, 0.05 mmol), and Na2CO3 (1 mL, 2M). The mixture was purged with N2 for 2 min and sealed. The reaction was irradiated in the microwave at 120 C for 2 h or kept at 120 C on a heating block for 16 h. Water was added, and the mixture was extracted with Et0Ac (3X). The combined organic layers were dried over Na2SO4 and concentrated in vacua. The residue was purified by column chromatography (0-50%
gradient of Et0Ac in hexanes) to afford a yellow amorphous foam that was further purified by prep-HPLC (75%-95% gradient of ACN in water with 0.1% HCO2H) to afford tert-butyl (3R)-3-({[4-(4-cyanopheny1)-5-(4-methylphenyl)pyrimidin-2-yl]amino}methyl)pyrrolidine-1-carboxylate as a yellow amorphous foam. The foam was dissolved in DCM (2 mL) followed by dropwise addition of TFA (2 mL). The reaction was stirred at ambient temperature for 30 min and concentrated in vacua to afford the TFA salt of the title compound (109 mg, 47%) as an off-white amorphous foam.

NMR (400 MHz, CDC13) 6 1.79- 1.95 (m, 1 H), 2.12 - 2.29 (m, 1 H), 2.35 (s, 3 H), 2.78 - 2.93 (m, 1 H), 3.12 - 3.26 (m, 1 H), 3.26 - 3.49 (m, 3 H), 3.49 - 3.61 (m, 1 H), 3.61 -3.70 (m, 1 H), 5.76 - 6.01 (m, 1 H), 6.88 - 7.02 (m, 2 H), 7.08 - 7.18 (m, 2 H), 7.47 - 7.62 (m, 4 H), 8.09 - 8.29 (m, 1 H), 8.29 - 8.39 (m, 1 H). [M+H] calc'd for C23H23N5, 370;
found 370.
[00307] Example 17: 4-(5-chloro-2- {[(3S)-pyrrolidin-3-ylmethyl]amino}pyrimidin-4-yl)benzonitrile N
N NH.,40eCNH
CI N
[00308] tert-butyl (3R)-3-(t[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolmethyppyrrolidine-1-carboxylate dissolved in DCM (2 mL) was added TFA
(2 mL) dropwise. The reaction was stirred at ambient temperature for 30 min and concentrated in vacua to afford the TFA salt of the title compound (59 mg, 47%) as an off-white amorphous foam. 1H NMR (400 MHz, CDC13-d): 6 ppm 1.68 - 2.08 (m, 1 H), 2.12 - 2.49 (m, 1 H), 2.66 - 3.11 (m, 1 H), 3.37-3.90 (m, 6 H), 7.67 - 8.13 (m, 4 H), 8.44 - 8.83 (s, 1 H), 9.45 - 10.14 (br. s., 2 H). [M+H] calc'd for Ci6H16N5C1, 314;
found 314.
[00309] Example 18: 4-[5-(4-fluoropheny1)-2- [(35)-pyrrolidin-3 -ylmethyl]amino}pyrimidin-4-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N
N NH NeCNH
I N) N
[00310] The TFA salt of the title compound was prepared in 34% yield using tert-butyl (3R)-3-(([5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolmethyl)pyrrolidine-1-carboxylate and (4-fluorophenyl)boronic acid according to the procedure for the preparation of Example 16. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.59 - 1.85 (m, 1 H), 1.97 - 2.17 (m, 1 H), 2.59 - 2.72 (m, 1 H), 2.82 - 3.01 (m, 1 H), 3.06 - 3.36 (m, 2 H), 3.37 - 3.50 (m, 2 H), 7.15 (d, J=7.07 Hz, 4 H), 7.40 - 7.56 (m, 2 H), 7.67 -7.79 (m, 1 H), 7.79 - 7.88 (m, 2 H), 8.38 (s, 1 H), 8.54 - 8.78 (m, 2 H). [M+H] calc'd for C22H20N5F, 374;
found 374.
[00311] Example 19: 4-[5-(4-chloropheny1)-2- )[(35)-pyrrolidin-3-ylmethyl]amino)pyrimidin-4-yl]benzonitrile N
N NH%....eCNH
I
cl [00312] The TFA salt of the title compound was prepared in 31% yield using tert-butyl (3R)-3-(([5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminoImethyl)pyrrolidine-1-carboxylate and (4-chlorophenyl)boronic acid, pinacol ester according to the procedure for the preparation of Example 16. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.62 -1.83 (m, 1 H), 1.94 -2.17 (m, 1 H), 2.62 -2.74 (m, 1 H), 2.86 - 3.02 (m, 1 H), 3.13 (m, 1 H), 3.27 (m, 2 H), 3.43 (m, 2 H), 7.07 - 7.19 (m, 2 H), 7.29 - 7.43 (m, 2 H), 7.44 - 7.56 (m, 2 H), 7.62 - 7.75 (m, 1 H), 7.77 - 7.89 (m, 2 H), 8.40 (s, 1 H), 8.60 (br. s., 1 H). [M+H]
calc'd for C22H20N5C1, 390; found 390.
[00313] Preparation 20A: tert-butyl (3R)-3-0[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]oxylmethyl)pyrrolidine-1-carboxylate CN--Boc N

4,=,re I I
N
CI

[00314] To a round-bottom flask charged with tert-butyl (3R)-3-(hydroxymethyppyrrolidine-1-carboxylate (664 mg, 3.3 mmol) in DMF (10 mL) at 0 C
was added NaH (144 mg, 3.6 mmol, 60%). The reaction was allowed to stir for 30 min at ambient temperature before adding 4-(2,5-dichloropyrimidin-4-yl)benzonitrile (744 mg, 3 mmol) at 0 C. The reaction was allowed to warm to ambient temperature and stirred for 16 h. The reaction was quenched with saturated NH4C1 and taken up in Et0Ac. The organic layers were sequentially washed with water (3X) and brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (0-40%
gradient of Et0Ac in hexanes) to afford the title compound (655 mg, 53%) as a yellow amorphous solid. [M+H] calc'd for C211-123N403C1, 415; found 415.
[00315] Example 20: 445-(4-methylpheny1)-2-[(3R)-pyrrolidin-3-ylmethoxy]pyrimidin-4-yl]benzonitrile N

[00316] To a microwave vial charged with tert-butyl (3R)-3-( ([5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]oxy}methyppyrrolidine-1-carboxylate (103 mg, 0.25 mmol) in dioxane (3 mL) was added (4-methylphenyl)boronic acid (68 mg, 0.5 mmol), PdC12(dppf) (36 mg, 0.05 mmol), and Na2CO3 (1 mL, 2M). The mixture was purged with N2 for 2 min and sealed. The reaction was irradiated in the microwave at 120 C for 2 h. Water was added and the mixture extracted with Et0Ac (3X). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (0-40% gradient of Et0Ac in hexanes) to afford a yellow amorphous foam that was further purified by prep-HPLC (75%-95% gradient of ACN
in water with 0.1% HCO2H) to afford tert-butyl (3R)-3-(114-(4-cyanopheny1)-5-(4-methylphenyOpyrimidin-2-ylloxy}methyppyrrolidine-1-carboxylate as a yellow amorphous foam. The foam was dissolved in DCM (2 mL) and followed by dropwise addition of TFA (2 mL). The reaction was stirred at ambient temperature for 30 min and concentrated in vacuo to afford the TFA salt of the title compound (35 mg, 30%) as an off-white amorphous foam. 1H NMR (400 MHz, DMSO-do): 6 ppm 1.70 - 1.96 (m, 1 H), 2.05 -2.23 (m, 1 H), 2.31 (s, 3 H), 2.76 - 2.91 (m, 1 H), 3.00 - 3.13 (m, 1 H), 3.13 -3.24 (m, 1 H), 3.25 - 3.35 (m, 1 H), 3.35 - 3.48 (m, 1 H), 4.34 - 4.52 (m, 2 H), 7.01 - 7.13 (m, 2 H), 7.18 (d, J=8.08 Hz, 2 H), 7.55 (d, J=8.34 Hz, 2 H), 7.83 (d, J=8.34 Hz, 2 H), 8.67 (s, 1 H), 8.69 - 8.87 (m, 2 H). [M+H] calc'd for C23H22N40, 371; found 371.
[00317] Preparation 21A: tert-butyl (3aR,6aS)-5-[5-chloro-4-(4-cyanophenyl)pyrimidin-2-y1]-octahydropyrrolo[3,4-c]pyn-ole-2-carboxylate N
*
N 1*-:
[00318] To a vial containing 4-(2,5-dichloropyrimidin-4-yObenzonitrile (144 mg, 0.58 mmol) in ethanol (2 mL) was added tert-butyl (3aR,6a5)-octahydropyrrolo[3,4-c]pyrrole-2-carboxylate (123 mg, 0.58 mmol), and DIEA (144 4, 1.2 mmol). The reaction was stirred at 100 C for 1 h. The reaction was concentrated in yam and the residue purified by column chromatography (0-50% gradient of Et0Ac in hexanes) to afford the title compound (242 mg, 98%) as a yellow amorphous solid. [M+H] calc'd for C22H24N502C1, 426; found 426.
[00319] Example 21: 4-{2-[(3aR,6a5)-octahydropyrrolo[3,4-c]pyrrol-2-y1]-5-(4-methylphenyl)pyrimidin-4-yllbenzonitrile N

=Zr N
[00320] The TFA salt of the title compound was prepared in 33% yield using tert-butyl (3aR,6a5)-545-chloro-4-(4-cyanophenyl)pyrimidin-2-y1]-octahydropyrrolo[3,4-c]pyrrole-2-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 16.1H NMR (400 MHz, DMSO-d6): 6 ppm 2.29 (s, 3 H), 2.98 - 3.27 (m, 4 H), 3.46 (m, 2 H), 3.60 - 3.70 (m, 2 H), 3.72 - 3.83 (m, 2 H), 7.01 (d, J
= 8.08 Hz, 2 H), 7.13 (d, J= 7.83 Hz, 2 H), 7.52 (d, J= 8.34 Hz, 2 H), 7.81 (d, J= 8.08 Hz, 2 H), 8.44 (s, 1 H), 8.78 - 8.98 (m, 2 H). [M+H] calc'd for C24H23N5, 382;
found 382.
[00321] Example 22: 445-(4-methylpheny1)-2-{octahydro-1H-pyrrolo[3,4-c]pyridin-5-yl}pyrimidin-4-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N
N Nri #NH
I
N
[00322] The TFA salt of the title compound was prepared in 37% yield starting from tert-butyl octahydro-1H-pyrrolo[3,4-c]pyridine-2-carboxylate according to the procedure for the preparation of Example 21.1H NMR (400 MHz, METHANOL-d4): 6 ppm 1.53 -1.70 (m, 1 H), 1.84- 1.99 (m, 1 H), 2.32 (s, 3 H), 2.59 - 2.75 (m, 2 H), 2.99 -3.11 (m, 1 H), 3.18 -3.28 (m, 1 H), 3.37 - 3.48 (m, 3 H), 3.68 -3.82 (m, 1 H), 4.41 -4.61 (m, 2 H), 6.94 - 7.06 (d, J= 8.08 Hz, 2 H), 7.13 (d, J= 8.08 Hz, 2 H), 7.54 - 7.59 (d, J= 8.08 Hz, 2 H), 7.63 (d, J= 8.08 Hz, 3 H), 8.38 (s, 1 H). [M+H] calc'd for C25H25N5, 396;
found 396.
[00323] Example 23: 4- {2-[(3 aR,8aS)-decahydropyrrolo [3 ,4-d]azepin-6-y1]-5-(4-methylphenyl)pyrimidin-4-ylf benzonitrile N
NJ' N
[00324] The TFA salt of the title compound was prepared in 28% yield starting from tert-butyl (3aR,8aS)-decahydropyrrolo[3,4-d]azepine-2-carboxylate according to the procedure for the preparation of Example 21.1H NMR (400 MHz, DMSO-d6): 6 ppm 1.62 - 1.79 (m, 2 H), 1.82 - 1.99 (m, 2 H), 2.29 (s, 3 H), 2.55 -2.65 (m, 2 H), 2.76 - 2.95 (m, 2 H), 3.28 - 3.40 (m, 2 H), 3.40 - 3.54 (m, 2 H), 4.25 - 4.43 (m, 2 H), 7.00 (d, J=
8.08 Hz, 2 H), 7.13 (d, J= 7.83 Hz, 2 H), 7.51 (d, J= 8.59 Hz, 2 H), 7.80 (d, J= 8.59 Hz, 2 H), 8.43 (s, 1 H), 8.53 - 8.64 (m, 1 H), 8.64 - 8.79 (m, 1 H). [M+H]
calc'd for C26H27N5, 410; found 410.
[00325] Example 24: 4-{2-[(3aR,8aS)-decahydropyrrolo[3,4-d]azepin-6-y1]-5-(4-fluorophenyl)pyrimidin-4-yl)benzonitrile N
00 N N (5...111H 1 I
N

[00326] The TFA salt of the title compound was prepared in 32% yield using tert-butyl (3aR,8aS)-6-[5-chloro-4-(4-cyanophenyl)pyrimidin-2-y1]-decahydropyrrolo[3,4-d]azepine-2-carboxy1ate and (4-fluorophenyl)boronic acid according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.62 - 1.79 (m, 2 H), 1.82 - 1.99 (m, 2 H), 2.50 - 2.62(m, 2 H), 2.77 - 2.93 (m, 2 H), 3.30 -3.42 (m, 2 H), 3.42 - 3.55 (m, 2 H), 4.26 - 4.42 (m, 2 H), 7.14 - 7.20 (m, 4 H), 7.50 (d, J=
8.34 Hz, 2 H), 7.81 (d, J= 8.34 Hz, 2 H), 8.40 - 8.52 (m, 1 H), 8.52 - 8.64 (m, 1 H), 8.67 - 8.79 (m, 1 H). [M+H] calc'd for C25H24N5F, 414; found 414.
[00327] Example 25: 4-(2- ([(35)-pyrrolidin-3-ylmethyl]aminof -5-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl)benzonitrilc N
N
I
N

[00328] The TFA salt of the title compound was prepared in 46% yield using ten-butyl (3R)-3-({[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]amino}methyl)pyrrolidine-1-carboxylate and (4-trifluoromethylphenyOboronic acid according to the procedure for the preparation of Example 16. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.65 - 1.81 (m, 1 H), 2.00 - 2.14 (m, 1 H), 2.59 - 2.73 (m, 1 H), 2.89 - 2.99 (m, 1 H), 3.09 - 3.20 (m, 1 H), 3.21 - 3.37 (m, 2 H), 3.38 - 3.50 (m, 2 H), 7.35 (d, J= 8.08 Hz, 2 H), 7.44 - 7.57 (m, 2 H), 7.67 (d, J= 8.08 Hz, 2 H), 7.80 (d, J= 8.34 Hz, 2 H), 8.46 (s, 1 H), 8.65 (br.
s., 2 H).
[M+H] calc'd for C23H20N3F3, 424; found 424.
[00329] Example 26: 445-(2-cyclopropylethyny1)-2-{[(35)-pyrrolidin-3-ylmethyl]amino}pyrimidin-4-yllbenzonitrile N
=%. =
NNH
N
N
V
[00330] To a vial charged with tert-butyl (3R)-3-M5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolmethyl)pyrrolidine-1-carboxylate (103 mg, 0.25 mmol) in ACN (3 mL) was added cyclopropane acetylene (33 mg, 0.5 mmol), PdC12(ACN)2 (2.6 mg, 0.01 mmol), XPhos (4 mg, 0.02), and K2CO3 (103 mg, 0.75 mmol). The mixture was purged with N2 for 2 min and sealed. The reaction was kept at 100 C for 16 h. Water was added and the mixture was extracted with Et0Ac (3X). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (0-50% gradient of Et0Ac in hexanes) to afford a yellow amorphous residue. The residue was dissolved in DCM (2 mL) followed by dropwise addition of TFA (2 mL). The reaction was stirred at ambient temperature for 30 min and concentrated in vacuo. The residue was further purified by prep-HPLC
(5%-95% gradient of ACN in water with 0.1% HCO2H) to afford the formic acid salt of the title compound as a yellow amorphous foam (3 mg, 3%). 1H NMR (400 MHz, CD30D):

6 ppm 0.58 - 0.75 (m, 2 H), 0.80 - 0.96 (m, 2 H), 1.36 - 1.53 (m, 1 H), 1.72-1.93 (m, 1 H), 2.10 -2.31 (m, 1 H), 2.66 -2.82 (m, 1 H), 2.95 - 3.09 (m, 1 H), 3.51 -3.62 (m, 5 H), 7.76 - 7.90 (m, 2 H), 8.14 - 8.27 (m, 2 H), 8.34 - 8.45 (m, 1 H). [M+H] calc'd for C211-121N5, 344; found 344.
[00331] Example 27: 4-(2-1[(3aR,5 S ,6aS)-octahydrocyclopenta[c]pyrrol-5-yl] amino} -5 -(4-methylphenyl)pyrimidin-4-yObenzonitrile N
===.
N
I
* ./ N
'T-11 [00332] To a vial containing tert-butyl (3aR,5S,6aS)-5-1[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl] amino -octahydrocyclopenta[c]pyrrole-2-carboxylate (250.0 mg, 0.57 mmol), prepared according to the procedure for preparation 16B, in dioxane (3 mL) was added (4-methylphenyl)boronic acid (155.0 mg, 1.14 mmol), Pd(dppf)C12 (80.0 mg, 0.11 mmol), and Na2CO3 (1 mL, 2 M). The mixture was purged with N2 for 2 min and sealed. The reaction mixture was irradiated in the microwave at 130 C for 4 hrs. Water was added, and the mixture was extracted with Et0Ac (3X). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to afford a crude residue. HCI (5 mL, 4 M in dioxane) was added the mixture and for stirred at 30 C for 1 h. The mixture was concentrated in vacuo and purified by prep-HPLC to afford the title compound (40.0 mg, yield 33.7 %) as a light-yellow foam. 1H NMR
(Methanol-d4, 400 MHz): 6 1.87 - 1.84 (m, 4 H), 2.32 (s, 3 H), 2.63 -2.59 (m, 2 H), 2.80 - 2.70 (m, 2 H), 3.12 - 3.07 (m, 2 H), 4.47 -4.40 (m, 1 H), 6.98 (d, J = 8.0 Hz, 2 H), 7.12 (d, J = 8.0 Hz, 2 H), 7.54 (d, J = 8.4 Hz, 2 H), 7.62 (d, J = 8.4 Hz, 2 H), 8.29 (s, 1 H).
[M+H] calc'd for C25H25N5, 396; found 396.
[00333] Example 28: -C9-4-(2-}[(3-fluoropyrrolidin-3-y1)methyl]amino}-5-(4-methylphenyl)pyrimidin-4-y1)benzonitrile N
N ,:)ON H
I
(1101 .,=1\1 [00334] The title compound was prepared in 29% yield using ( )-tert-butyl -3-(115-chloro-4-(4-cyanophenyl)pyrimidin-2-yllaminoImethyl)-3-fluoropyrrolidine-1-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 27.1H NMR (Methanol-d4, 400 MHz): 6 2.00 - 2.15 (m, 2 H), 2.34 (s, 3 H), 3.17 - 2.96 (m, 4 H), 3.95 (d, J= 19.2 Hz, 2 H), 7.02(d, J =
8.8 Hz, 2 H), 7.14 (d, J= 8.8 Hz, 2 H), 7.57 (d, J= 8.8 Hz, 2 H), 7.65 (d, J= 8.8 Hz, 2 H), 8.35 (s, 1 H). [M+H] calc'd for C23H22N5F, 388; found 388.
[00335] Example 29: -W-445-(4-methylpheny1)-2-[(piperidin-3-yl)amino]pyrimidin-4-yl]benzonitrile N
N "11C11 'N
[00336] The title compound was prepared in 29% yield using tert-butyl 3-}[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolpiperidine-1-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 27. 1H NMR (CDC13, 400 MHz): 6 8.34 (s, 1 H), 7.56 - 7.50 (m, 4 H), 7.11 (d, J= 8.0 Hz, 2 H), 6.97 (d, J= 8.0 Hz, 2 H), 5.53 - 5.51 (m, 1 H),4.11 - 4.07 (m, 1 H),3.31 -3.27 (m, 1 H), 2.95 -2.85 (m, 1 H), 2.79 -2.67 (m, 2 H), 2.36 (s, 3 H), 2.05 - 1.95 (m, 1 H), 1.83 - 1.79 (m, 2 H), 1.70 - 1.60 (m, 2 H). [M+H] calc'd for C23H23N5, 370;
found 370.
[00337] Example 30: 445-(4-methylpheny1)-2-[(piperidin-4-y1)amino]pyrimidin-4-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N
N
'TCNH
[00338] The title compound was prepared in 17% yield using tert-butyl -4-{[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]amino}piperidine-1-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 27. 11-INMR (Methanol-c14, 400 MHz): 6 8.31 (s, 1 H), 7.64 (d, J= 8.4 Hz, 2 H), 7.55 (d, J= 8.4 Hz, 2 H), 7.13 (d, J= 8.0 Hz, 2 H), 7.05 (d, J= 8.0 Hz, 2 H), 4.03 -4.01 (m, 1 H), 3.14 - 3.10 (m, 2 H), 2.77 -2.71 (m, 2 H), 2.34 (s, 3 H), 2.10 -2.07 (m, 2 H), 1.58 -1.52 (m, 2 H). [M+H] calc'd for C23H23N5, 370; found 370.
[00339] Example 31: ( )-445-(4-methylpheny1)-2-[(piperidin-3-ylmethyDamino]pyrimidin-4-yl]benzonitrile N
N. I*
NJJ N
H
I
N
[00340] The title compound was prepared in 18% yield using -W-tert-butyl -3-({{5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolmethyl)piperidine-1-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 27. 1H NMR (Methanol-d4, 400 MHz): 6 8.29 (s, 1 H), 7.63 (d, J= 8.4 Hz, 2 H), 7.55 (d, J= 8.4 Hz, 2 H), 7.12 (d, J= 8.0 Hz, 2 H), 6.99 (d, J= 8.0 Hz, 2 H), 3.35 -3.31 (m, 2 H), 3.14 - 3.11 (m, 1 H), 3.00 -2.97 (m, 1 H), 2.57 -2.56 (m, 1 H), 2.40 -2.32 (m, 4 H), 1.93 - 1.91 (m, 2 H), 1.75 - 1.72 (m, 1 H), 1.54 - 1.47 (m, 2 H). [M+H] calc'd for C24H25N5, 384; found 384.
[00341] Example 32: 4-15-(4-methylpheny1)-2-[(piperidin-4-ylmethypamino]pyrimidin-4-ylThenzonitrile N
NLCJ
N
[00342] The title compound was prepared in 35% yield using tert-butyl -4-({[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminoImethyl)piperidine-1-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 27. 1H NMR (Methanol-di, 400 MHz): 6 8.29 (s, 1 H), 7.64 (d, ../= 8.0 Hz, 2 H), 7.56 (d, J= 8.0 Hz, 2 H), 7.13 (d, J= 8.0 Hz, 2 H), 7.00 (d, J= 8.0 Hz, 2 H), 3.39 -3.36 (m, 2 H), 3.09 - 3.05 (m, 2 H), 2.63 - 2.59 (m, 2 H), 2.34 (s, 3 H), 1.83 - 1.79 (m, 3 H), 1.31 -1.23 (m, 2 H). [M+H] calc'd for C24H25N5, 384; found 384.
[00343] Example 33: ( )-445-(4-methylpheny1)-2-[(morpholin-2-ylmethyl)amino]pyrimidin-4-yl]benzonitrile N
(14111 NI NI0) N
[00344] The TFA salt of the title compound was prepared in 19% yield using ( )-tert-butyl 2-(t[5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]amino}methyl)morpholine-4-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6): 6 ppm 2.28 (s, 3 H), 2.75 -2.91 (m, 1 H), 2.92 - 3.09 (m, 1 H), 3.10-3.17 (m, 1 H), 3.24 - 3.34 (m, 1 H), 3.36 - 3.59 (m, 2 H), 3.62 - 3.77 (m, 1 H), 3.86 - 3.94 (m, 1 H), 3.94 - 4.02 (m, 1 H), 7.00 (d, J=
8.08 Hz, 2 H), 7.12 (d, J= 7.83 Hz, 2 H), 7.42 - 7.53 (rn, 2 H), 7.55 - 7.65 (rn, 1 H), 7.80 (d, J= 8.08 Hz, 2 H), 8.37 (s, 1 H), 8.64 - 8.94 (rn, 2 H). [M+H] calc'd for C22H22N50, 386; found 386.
[00345] Example 34: ( )-445-(4-fluoropheny1)-2-[(morpholin-2-ylmethyDamino]pyrimidin-4-yl]benzonitrile = N
N 11-11o) N
[00346] The TFA salt of the title compound was prepared in 44% yield using ( )-tert-butyl 2-( [5-chloro-4-(4-cyanophenyl)pyrimidin-2-yl]aminolmethyl)morpholine-4-carboxylate and (4-fluorophenyl)boronic acid according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6): 6 ppm 2.74 - 2.93 (rn, 1 H), 2.93 -3.10 (m, 1 H), 3.17 - 3.22 (m, 1 H), 3.24 - 3.34 (m, 1 H), 3.36 - 3.59 (m, 2 H), 3.61 - 3.77 (m, 1 H), 3.84 - 3.95 (m, 1 H), 3.96-4.00 (m, 1 H), 7.16 (d, J= 7.07 Hz, 4 H), 7.40 - 7.59 (m, 2 H), 7.60 - 7.74 (m, 1 H), 7.81 (d, J = 8.34 Hz, 2 H), 8.40 (s, 1 H), 8.65 - 8.98 (m, 2 H). [M+H] calc'd for C22H20N50F, 390; found 390.
[00347] Example 35: 4-(2- {2,7-diazaspiro[4.4]nonan-2-yl} -544-methylphenyl)pyrimidin-4-yl)benzonitrile N
*
N
NH
I
N
[00348] The TFA salt of the title compound was prepared in 24% yield starting tert-butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6 ): 6 ppm 1.88 -2.17 (m, 4 H), 2.28 (s, 3 H), 3.08 - 3.41 (m, 4 H), 3.55 - 3.63 (m, 1 H), 3.63 - 3.73 (m, 3 H), 7.00 (d, .1 = 8.08 Hz, 2 H), 7.12 (dõI= 7.83 Hz, 2 H), 7.51 (dõI= 8.08 Hz, 2 H), 7.80 (d, 1 = 8.34 Hz, 2 H), 8.45 (s, 1 H), 8.74 - 9.01 (hr. s., 2 H). [M+H] calc'd for C25H25N5, 396; found 396.
[00349] Example 36: 4-(2-{2,8-diazaspiro[4.5]decan-2-y1}-5-(4-methylphenyl)pyrimidin-4-yl)benzonitrile rs)-1 N

Y
* N
[00350] The TFA salt of the title compound was prepared in 42% yield using ten-butyl 2-[5-chloro-4-(4-cyanophenyl)pyrimidin-2-y1]-2,8-diazaspiro[4.5]decane-8-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 21. 'H NMR (400 MHz, DMSO-d6): 6 ppm 1.65 - 1.82 (m, 4 H), 1.90 - 1.99 (m, 2 H), 2.28 (m, 3 H), 3.13 (hr. s., 4 H), 3.52 (s, 2 H), 3.66 (t, J= 6.95 Hz, 2 H), 7.00 (s, 2 H), 7.12 (d, 1= 7.83 Hz, 2 H), 7.52 (d, J= 8.34 Hz, 2 H), 7.80 (d, J =
8.59 Hz, 2 H), 8.29 - 8.54 (m, 3 H). [M+H] calc'd for C26H27N5, 410; found 410.
[00351] Example 37: 445 -(4-methylpheny1)-2- {octahydro-1H-pyrrolo[3,4-c]pyridin-2-yl}pyrimidin-4-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N
N N
I
opi N
[00352] The TFA salt of the title compound was prepared in 42% yield using tert-buty1-2-[5-chloro-4-(4-cyanophenyOpyrimidin-2-yl]-octahydro-1H-pyrrolo[3,4-c]pyridine-5-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 21. 1HNMR (400 MHz, DMSO-d6): 6 ppm 1.60 - 1.79 (m, 1 H), 1.84 - 2.01 (m, 1 H), 2.28 (s, 3 H), 2.50-2.62 (m, 2 H), 2.96 - 3.20 (m, 3 H), 3.20 - 3.35 (m, 1 H), 3.53 - 3.76 (m, 4 H), 7.01 (d, J= 8.08 Hz, 2 H), 7.13 (d, J= 7.83 Hz, 2 H), 7.52 (d, J= 8.34 Hz, 2 H), 7.80 (d, J= 8.34 Hz, 2 H), 8.42 (s, 1 H), 8.47 - 8.69 (m, 1 H). [M+H] calc'd for C25H25N5, 396; found 396.
[00353] Example 38: 445-(4-methylpheny1)-2-toctahydro-1H-pyrrolo[3,2-c]pyridin-5-yllpyrimidin-4-ylThenzonitrile N
N N
I N%T

[00354] The TFA salt of the title compound was prepared in 48% yield starting tert-butyl octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate according to the procedure for the preparation of Example 21. 'H NMR (400 MHz, METHANOL-d4): 6 ppm 1.77 -2.00 (m, 2 H), 2.05 - 2.23 (m, 2 H), 2.32 (s, 3 H), 2.56 - 2.69 (m, 1 H), 3.42 - 3.55 (m, 3 H), 3.79 - 3.88 (m, 1 H), 3.90 - 4.02 (m, 1 H), 4.30 - 4.40 (m, 1 H), 4.40 -4.52 (m, 1 H), 6.99 (d, J= 8.08 Hz, 2 H), 7.13 (d, J= 7.83 Hz, 2 H), 7.52 - 7.59 (d, J= 8.14 Hz, 2 H), 7.63 (d, J= 8.34 Hz, 2 H), 8.34 - 8.44 (m, 1 H). [M+H] calc'd for C25H25N5, 396; found 396.
[00355] Example 39: 4-(242,8-diazaspiro[4.5]decan-8-y11-5-(4-methylphenyl)pyrimidin-4-y1)benzonitrile N

ir=NH 4:1 I
N

[00356] The TFA salt of the title compound was prepared in 62% yield starting tert-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6 ): 6 ppm 1.50 - 1.71 (m, 4 H), 1.84- 1.94 (m, 2 H), 2.28 (s, 3 H), 3.02 - 3.11 (m, 2 H), 3.23 -3.38 (m, 2 H), 3.73 -3.95 (m, 4 H), 7.01 (d, J= 8.08 Hz, 2 H), 7.13 (d, J= 8.08 Hz, 2 H), 7.51 (d, J= 8.34 Hz, 2 H), 7.80 (d, J= 8.34 Hz, 2 H), 8.43 (s, 1 H), 8.84 (br. s., 2 H). [M+H]
calc'd for C26H27Ns, 410; found 410.
[00357] Example 40: 4-(2- {1,8-diazaspiro[4.5]decan-8-ylf -5-(4-methylphenyl)pyrimidin-4-yl)benzonitrile N
=%. =
NNOR
I
N
[00358] The TFA salt of the title compound was prepared in 64% yield tert-butyl 1,8-diazaspiro[4.5]decane-1-carboxylate according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6 ): 6 ppm 1.77 - 1.92 (m, 4 H), 1.93 -2.08 (m, 4 H), 2.29 (s, 3 H), 3.20 - 3.35 (m, 2 H), 3.45 - 3.58 (m, 2 H), 4.27 -4.41 (m, 2 H), 7.02 (d, J= 7.83 Hz, 2 H), 7.13 (d, J= 7.83 Hz, 2 H), 7.52 (d, J= 8.34 Hz, 2 H), 7.81 (d, J= 8.34 Hz, 2 H), 8.46 (s, 1 H) 8.64 - 8.79 (m, 1 H). [M+H] calc'd for C26H271\15, 410;
found 410.
[00359] Example 41: 445-(4-methylpheny1)-2- {9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}pyrimidin-4-yl]benzonitrile N
%. =NH
N
[00360] The HC1 salt of the title compound was prepared in 26% yield using tert-butyl -7-[5-chloro-4-(4-cyanophenyl)pyrimidin-2-y1]-9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate and (4-methylphenyl)boronic acid according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6): 6 ppm 2.30 (s, 3 H), 3.27 -3.44 (m, 4 H), 3.44 - 3.55 (m, 1 H), 3.62 - 3.75 (m, 1 H), 4.27 (m, 2 H), 4.25 - 4.33 (m, 4 H), 4.57 (d, J= 13.39 Hz, 2 H), 7.04 (d, J= 8.08 Hz, 2 H), 7.17 (d, J= 7.83 Hz, 2 H), 7.56 (d, J= 8.59 Hz, 2 H), 7.83 (d, I = 8.59 Hz, 2 H), 8.13 - 8.38 (m, 1 H), 8.52 - 8.64 (m, 1 H), 9.43 (hr. s., 1 H). [M+H] calc'd for C24H23N50, 398; found 398.
[00361] Example 42: 4-[5-(4-fluoropheny1)-2- {9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}pyrimidin-4-yl]benzonitrile N
N
I

[00362] The HC1 salt of the title compound was prepared in 20% yield using tert-butyl -745-chloro-4-(4-cyanophenyl)pyrimidin-2-y1]-9-oxa-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate and (4-fluorophenyl)boronic acid according to the procedure for the preparation of Example 21. 1H NMR (400 MHz, DMSO-d6): 6 ppm 3.25 - 3.44 (m, 4 H), 3.44 - 3.53 (m, 2 H), 3.66-3.69 (m, 2 H), 4.28 (hr. s., 2 H), 4.57 (d, J=
13.39 Hz, 2 H), 7.17 - 7.25 (m, 4 H), 7.54 (d, J= 8.59 Hz, 2 H), 7.85 (d, J= 8.59 Hz, 2 H), 8.13 - 8.31 (m, 1 H), 8.60 (s, 1 H), 9.20 - 9.41 (m, 1 H). [M+H] calc'd for C23H20N50F, 402; found 402.
[00363] Preparation 43A: methyl 1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazole-3-carboxylate N
,N 0 N
=-[00364] A mixture of methyl 4-(4-methylpheny1)-2,4-dioxobutanoate (1.0 g, 4.55 mmol) and 4-hydrazinylbenzonitrile (0.85 g, 5.0 mmol) in AcOH (20 mL) was stirred at 118 C for 16 h. The solvent was removed in vacuo and the residue was purified by column chromatography (0-80%, Et0Ac:PE) to give 1.3 g (90%) the title compound as yellow solid. 1H NMR (CDCh, 400 MHz): 6 7.65 (d, J = 8.0 Hz, 2 H), 7.48 (d, J
= 8.0 Hz, 2 H), 7.18 (d, J = 8.0 Hz, 2 H), 7.10 (d, J = 8.0 Hz, 2 H), 7.02 (s, 1 H), 3.99 (s, 3 H), 2.39 (s, 3 H). [M+H] Calc'd for Ci9Hi5N302, 318; Found, 318.
[00365] Preparation 43B: 1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazole-3-carboxylic acid WO 2015/089192 PCT[1JS2014/069562 N
I* N 0 N
= H
[00366] A mixture of methyl 1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazole-3-carboxylate (1.3 g, 4.1 mmol) and LiOH (0.3 g, 12.3 mmol) in Me0H/H20 (20 mL/20 mL) was stirred at room temperature for 3 h. Me0H was removed in vacuo and H20 (20 mL) was added. The pH of the solution was adjusted to 4 using HC1 (0.6 M) solution.
The mixture was extracted with DCM (80 mL x 3), washed with brine (50 mL x 2) and dried over Na2SO4. The solvent was evaporated in vacuo to give 1.1 g (88%) of the title compound as yellow solid. 1H NMR (Methanol-d4, 400 MHz): 6 7.78 (d, J = 8.4 Hz, 2 H), 7.52 (d, J = 8.8 Hz, 2 H), 7.21 (d, J= 8.0 Hz, 2 H), 7.15 (d, J = 8.0 Hz, 2 H), 7.02 (s, 1 H), 2.35 (s, 3 H). [M+H] Calc'd for C18H13N302, 304; Found, 304.
[00367] Preparation 43C: tert-butyl N-[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-yl]carbamate N
N N
NH
13oc 100368] A mixture of 1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazole-3-carboxylic acid (1.1 g, 3.63 mmol), DPPA (1.2 g, 4.36 mmol) and TEA (0.44 g, 4.36 mmol) in dioxane/t-BuOH (20 mL/20 mL) was stirred at 110 C for 16 h. The solvent was removed in vacuo and the crude residue was purified by column chromatography (0-50%, Et0Ac:PE) to give 0.3 g (22%) of the title compound as yellow solid. 1H
NMR
(CDC13, 400 MHz): 6 7.58-7.56 (d, J = 8.0 Hz, 2 H), 7.36-7.34 (d, J = 8.0 Hz, 2 H), 7.18-7.13 (m, 5 H), 6.81 (br. S., 1 H), 2.38 (s, 3 H), 1.54 (s, 9 H). [M+H] Calc'd for C22H22N402, 375; Found, 375.
[00369] Preparation 43D: tert-butyl 3-[[[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-y1]-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]pyrrolidine-l-carboxylate N ==
= NI
N kr-CILBoc )3oc [00370] A mixture of tert-butyl N41-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-ylicarbamate (80 mg, 0.21 mmol), tert-butyl 3-[(4-methylphenyl)sulfonyloxymethyl]pyrrolidine-1-carboxylate (92 mg, 0.25 mmol) and Cs2CO3 (210 mg, 0.64 mmol) in DMF (6 mL) was refluxed at 90 C for 16 h. The mixture was extracted with Et0Ac (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2) and dried over Na2SO4. The solvent was removed in vacuo and the crude residue was purified by prep-HPLC to give 76 mg (63%) of the title compound as a yellow oil. 1H NMR (CDC13, 400 MHz): 6 7.57 (d, J = 8.4 Hz, 2 H), 7.37 (d, J = 8.4 Hz, 2 H), 7.19-7.12 (m, 4 H), 6.80 (brs, 1 H), 4.05-3.95 (m, 2 H), 3.51 (m, 2 H), 3.38-3.26 (m, 1 H), 3.17 (dd, J1= 8.0 Hz, J2= 12.0 Hz, 1 H), 2.75 (m, 1 H), 2.39 (s, 3 H), 2.03-1.93 (m, 1 H), 1.78-1.68 (m, 1 H), 1.57 (s, 9 H), 1.45 (s, 9 H).
[M+H] Calc'd for C32H39N504, 558; Found, 558.
[00371] Example 43: 445-(4-methylpheny1)-3-(pyrrolidin-3-ylmethylamino)pyrazol-1-yl]benzonitrile N
=.1\1 -OH
N NHr [00372] To a solution of tert-butyl 3-[[[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-y1]-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]pyrrolidine-1-carboxylate (76 mg, 0.09 mmol) in DCM (2 mL) was added HC1/dioxane (4 M, 5 mL) dropwise at 0 C - -10 C. The mixture was stirred at RT for 2 h and concentrated in vacuo. The crude residue was purified by prep-HPLC to give 24 mg (39%) of the title compound as a yellow oil. 1H NMR
(Methanol-d4, 400 MHz): 6 8.53 (brs, 1 H), 7.63 (d, J = 8.0 Hz, 2 H), 7.35 (d, J = 8.0 Hz, 2 H), 7.20 (d, J = 8.0 Hz, 2 H), 7.13 (d, J = 8.0 Hz, 2 H), 5.94 (s, 1 H), 3.46-3.38 (m, 2 H), 3.38-3.32 (m, 2 H), 3.30-3.25 (m, 1 H), 3.12 (dd, J1= 8.0 Hz, J2= 12.0 Hz, 1 H), 2.78 (m, 1 H), 2.36 (s, 3 H), 2.27-2.17 (m, 1 H), 1.86 (m, 1 H). [M+H] Calc'd for C22H23N5, 358;
Found, 358.
[00373] Preparation 44A: tert-butyl (35)-3-[[[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-y1]-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]pyrrolidine-1-carboxylate N
===. 001 N"-r\jµ rC1LBoc )3oc [00374] The title compound was prepared in 34% from tert-butyl N41-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-yl]carbamate and tert-butyl (38)-3-[(4-methylphenyl)sulfonyloxymethyl]pyrrolidine-1-carboxylate according to the procedure for preparation 43D. 1H NMR (CDC13, 400 MHz) 6 7.57 (d, J = 8.4 Hz, 2 H), 7.37 (d, J =
8.4 Hz, 2 H), 7.21 - 7.09 (m, 4 H), 6.82 (br. s., 1 H), 4.07 - 3.91 (m, 2 H), 3.58 - 3.41 (m, 2 H), 3.32 (m, 1 H), 3.16 (br. s., 1 H), 2.75 (m, 1 H), 2.38 (s, 3 H), 1.98 (m, 1 H), 1.73 (m, 1 H), 1.60 - 1.53 (s, 9 H), 1.45 (s, 9 H). [M+H] Calc'd for C32H39N504, 558; Found, 558.
[00375] Example 44: 445-(4-methylpheny1)-3-[[(3S)-pyrrolidin-3-yl]methylamino]pyrazol-1-yl]benzonitrile N

NH
[00376] The title compound was prepared in 59% yield tert-butyl (35)-3-[[[1-(4-cyanopheny1)-5-(4-methylphcnyppyrazol-3-y1]-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]pyrrolidine-1-carboxylate according to the procedure for the preparation of Example 43. 1f1NMR (Methanol-d4, 400 MHz): 6 7.80 - 7.74 (m, 2 H), 7.51 -7.45 (m, 2 H), 7.26 - 7.17 (m, 4 H), 3.52 (dd, Ji = 8.0 Hz, J2= 12.0 Hz, 1 H), 3.48 - 3.40 (m, 3 H), 3.35-3.27 (m, 1 H), 3.12 (dd, J1= 8.0 Hz, J2= 12.0 Hz, 1 H), 2.84 -2.76 (m, 1 H), 2.36 (s, 3 H), 2.33 -2.23 (m, 1 H), 1.87 - 1.84 (m, 1 H). [M+H]
Calc'd for C22H23N5, 358; Found, 358.

1003771 Preparation 45A: tert-butyl (3R)-3-[[[1-(4-cyanophcny1)-5-(4-methylphenyl)pyrazol-3-y11-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl ]pyrroli din e-1-c arboxylate N
=
Boc )3oc [00378] The title compound was prepared in 40% from tert-butyl /V-[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-yl]carbamate and tert-butyl (3R)-3-[(4-methylphenyl)sulfonyloxymethyl]pyrrolidine-1-carboxylate according to the procedure for preparation 43D. 11-1 NMR (CDC13, 400 MHz): 6 7.57 (d, J = 8.0 Hz, 2 H), 7.37 (J =
8.0 Hz, 2 H), 7.21 - 7.09 (m, 4 H), 6.82 (br. s, 1 H), 4.08 - 3.90 (m, 2 H), 3.58 - 3.41 (m, 2 H), 3.34 - 3.30 (m, 1 H), 3.17 (br. s, 1 H), 2.75 (m, 1 H), 2.39 (s, 3 H), 2.04 - 1.93 (m, 1 H), 1.73 (m, 1 H), 1.53 - 1.61 (s, 9 H), 1.45 (s, 9 H). [M+H] Calc'd for C32H39N504, 558;
Found, 558.
[00379] Example 45: 445-(4-methylpheny1)-3-[[(3R)-pyrrolidin-3-yl]methylamino]pyrazol-1-yl]benzonitrile N
* N't. 0, N,H
[00380] The title compound was prepared in 33% yield tert-butyl (3R)-3-[[[1-(4-cyanopheny1)-5-(4-methylphenyOpyrazol-3-y11-[(2-methylpropan-2-y1)oxycarbonyl]amino]methyl]pyrrolidine-1-carboxylate according to the procedure for the preparation of Example 43. IFI NMR (Methanol-d4, 400 MHz): 6 7.79 - 7.70 (d, J =
8.4 Hz, 2 H), 7.46 (d, J = 8.4 Hz, 2 H), 7.26 - 7.15 (m, 4 H), 3.51 (m, 1 H), 3.47 - 3.39 (m, 3 H), 3.34 - 3.30 (m, 1 H), 3.12 (m, 1 H), 2.86 - 2.75 (m, 1 H), 2.36 (s, 3 H), 2.32 -2.22 (m, 1 H), 1.87 (m, 1H). [M+H] Calc'd for C22H23N5, 358; Found, 358.
[00381] Preparation 46A: tert-butyl 4-[[[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-y11-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyllpiperidine-1-carboxylate N
41:1 -Boc N INµ
)3oc [00382] A mixture of tert-butyl N41-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-ylicarbamate (80 mg, 0.21 mmol), tert-butyl 4-[(4-methylphenyl)sulfonyloxymethyl]piperidine-1-carboxylate (72 mg, 0.26 mmol) and Cs2CO3 (210 mg, 0.64 mmol) in DMF (6 mL) was refluxed at 90 C for 16 h. The mixture was extracted with Et0Ac (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2) and dried over Na2SO4. The solvent was removed in vacuo and the crude residue was purified by column chromatography (0-33%, Et0Ac:PE) to give 82 mg (67%) of the title compound as yellow solid. 1H NMR
(CDC13, 400 MHz): 6 7.57 (d, J = 8.4 Hz, 2 H), 7.37 (d, J = 8.4 Hz, 2 H), 7.20 - 7.12 (m, 4 H), 6.80 (br. S., 1 H), 4.17 - 4.04 (m, 2 H), 3.87 (d, J = 7.2 Hz, 2 H), 2.70 (t, J = 12.4 Hz, 2 H), 2.41 (s, 3 H), 2.09 - 1.98 (m, 1 H), 1.70 (d, J = 12.4 Hz, 2 H), 1.56 (s, 9 H), 1.47 (s, 9 H), 1.32-1.19 (m, 2 H). [M+H] Calc'd for C33H4iN504, 572; Found, 572.
[00383] Example 46: 445-(4-methylpheny1)-3-(piperidin-4-ylmethylamino)pyrazol-1-yl]benzonitrile N
10111 rOH
\ NH

[00384] The HC1 salt of the title compound was prepared in 57% yield from tert-butyl 4-[[[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-y1]-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]piperidine-1-carboxylate according to the procedure for the preparation of Example 43. 1H NMR (Methanol-d4, 400 MHz): 6 8.51 (brs, 2 H), 7.65 (d, J = 8.0 Hz, 2 H), 7.36 (d, J = 8.0 Hz, 2 H), 7.22 (d, J = 8.0 Hz, 2 H), 7.15 (d, J =
8.0 Hz, 2 H), 5.95 (s, 1 H), 3.44 (d, J = 12.0 Hz, 2 H), 3.22 (d, J = 6.4 Hz, 2 H), 3.05-2.98 (m, 2 H), 2.38 (s, 3 H), 2.16-1.98 (m, 3 H), 1.56-1.41 (m, 2 H). [M+H]
Calc'd for C23H25N5, 372; Found, 372.

[00385] Preparation 47A: tert-butyl (15,5R)-6-[[[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-y1]-[(2-methylpropan-2-yl)oxycarbonyljamino]methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate NC
N
Boc H
.
N N
NvispõõN-Boc [00386] A mixture of tert-butyl N41-(4-cyanopheny1)-5-(4-methylphenyOpyrazol-3-yl]carbamate (50.0 mg, 0.133 mmol), tert-butyl (is,5R)-6-(chloromethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (41.0 mg, 0.14 mmol), Cs2C01 (130.0 mg, 0.4 mmol) in DMF (6 mL) was refluxed at 90 C for 16 h. The mixture was extracted with EA (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2) and dried over Na2SO4. The solvent was evaporated under vacuum to give a crude product, which was purified by prep-HPLC to give the title compound (38.0 mg, 50.0 %) as yellow oil. 1H NMR (CDC13, 400 MHz): 6 7.58 (d, J = 8.0 Hz, 2 H), 7.37 (d, J =
8.0 Hz, 2 H), 7.19 - 7.13 (m, 4 H), 6.80 (hr. s, 1 H), 3.88 (d, J = 6.8 Hz, 2 H), 3.62 - 3.47 (m, 2 H), 3.39 - 3.28 (m, 2 H), 2.39 (s, 3 H), 1.62 (s, 2 H), 1.57 (s, 9 H), 1.44 -1.40 (s, 9 H), 1.17 (m, 1 H). [M+H] Calc'd for C33H39N504, 570; Found, 570.
[00387] Example 47: 443 -[[(1 S, 5R)-3 -azabicy clo [3.1.0]hexan-6-yl]methylamino]-5-(4-methylphenyl)pyrazol-1-yl]benzonitrile NC
" Ntliew<rNH
[00388] To a solution of tert-butyl (15, 5R)-6-[[[1-(4-cyanopheny1)-5-(4-methylphenyl)pyrazol-3-y1]-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (38.0 mg, 0.067 mmol) in DCM (5 mL) was added HClidioxane (4 M, 10 mL) dropwise at 0 C -10 -10 C. The mixture was stirred at RT for 2 h. The mixture was concentrated under vacuum to give a crude product, which was purified by prep-HPLC to give the title compound (24.0 mg, 38.7 %) as yellow oil.
1H NMR (Methanol-d4, 400 MHz): 6 7.72 (d, J = 8.0 Hz, 2 H), 7.43 (d, J = 7.6 Hz, 2 H), 7.24 - 7.14 (m, 4 H), 3.47 - 3.39 (m, 4 H), 3.34 - 3.31 (m, 2 H), 2.35 (s, 3 H), 1.91 (br. s., 2 H), 1.36 (m, 1 H). [M+H] Calc'd for C23H23N5, 370; Found, 370.

[00389] Preparation 48: tert-butyl 4-[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrazolo[4,3-b]pyridin-l-yl]piperidine-l-carboxylate N c3 N, I , N
N
[00390] To a mixture of 4-[5-(4-methylpheny1)-1H-pyrazolo[4,3-b]pyridin-6-yllbenzonitrile (80 mg, 0.258 mmol) and tert-butyl 4-bromopiperidine-1-carboxylate (341 mg, 1.29 mmol) in DMF (10 mL) was added Cs2CO3 (252 mg, 0.77 mmol). The mixture was stirred at 60 C overnight. The mixture was diluted with Et0Ac (30 mL) and water (30 mL). The aqueous layer was extracted with Et0Ac (50 mL x 3). The combined organic layers were washed with water (30 mL x 2), brine, dried over Na2SO4, filtered, concentrated and purified by prep-HPLC to give 48 mg (38%) the title compound as a white solid. 1H NMR (CDC13, 400 MHz) 6 8.32 (s, 1 H), 7.78 (s, 1 H), 7.59 (d, J = 8.4 Hz, 2 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.19 (d, J = 8.0 Hz, 2 H), 7.07 (d, J =
8.0 Hz, 2 H), 4.64 - 4.58 (m, 1 H), 4.36-4.32 (m, 2 H), 3.00-2.95 (m, 2 H), 2.34 (s, 3 H), 2.30-2.23 (m, 2 H) 2.07 (d, J = 10.8 Hz, 2 H), 1.50 (s, 9 H). [M+H] Calc'd for C30H3iN502, 494; Found, 494.
[00391] Example 48: 445-(4-methylpheny1)-1-piperidin-4-ylpyrazolo[4,3-b]pyridin-6-yl]benzonitrile r-11 N
===
I Iv N
[00392] The title compound was prepared as the HC1 salt in 75% yield from tert-butyl 4-[6-(4-cyanopheny1)-5-(4-methylphenyl)pyrazolo[4,3-b]pyridin-1-yl]piperidine-carboxylate according to the procedure for the preparation of Example 3. 1H
NMR
(DMSO-d6, 400 MHz) 6 9.67-9.64 (brs, 1 H), 9.50-9.48 (brs, 1 H), 8.45 (s, 1 H), 8.43 (s, 1 H), 7.81 (d, J = 8.4 Hz, 2 H), 7.25 (d, J = 8.4 Hz, 2 H), 7.16 (d, J = 8.4 Hz, 2 H), 7.09 (d, J = 8.0 Hz, 2 H), 5.18-5.13 (m, 1 H), 3.45-3.41 (m, 2 H), 3.12-3.08 (m, 2 H), 2.50 -2.45 (m, 2 H), 2.27 (s, 3 H), 2.15-2.13 (m, 2 H). [M+H] Calc'd for C25H23N, 394; Found, 394.
[00393] Using the general synthetic method described in Scheme 1, the synthesis example shown in Table 3 were prepared.
Table 3 Synthesis ;Hi] Structure : , =::]]] (ESI) .;NIVIR spectrum datai: i Example ]] :]:]: ::]:] :]:]: :. nil,:
111 NMR (400 MHz, Me0D-d4): 3 N ., 1.77-1.82 (m, 1H), 2.03-2.07 (m, N.
411 d 0" H 1H), 2.97-3.06 (m, 2H), 3.20-3.23 (m, 1H), 3.12-3.43 (m, 2H), 3.78 (s, /
49 ,%. I / 409 3H), 4.52-4.60 (m, 2H), 6.84 (d, J=
2.8 Hz, 1H), 6.90 (dd, J= 3.2, 12.0 Hz, 2H), 7.24 (dd, J= 3.2, 12.0 Hz, I 2H), 7.43 (d, J= 8.0 Hz, 2 H), 7.63 (d, J= 8.0 Hz, 2 H), 8.19 (d, J= 3.2 Hz, 1H), 8.85 (s, 1H) N ... 1H NMR (400 MHz, Me0H-d4): 6 . 1.80-1.83 (m, 1 H), 2.03-2.07 (m, /WO H
1H), 2.97-3.06 (m, 2H), 3.20-3.23 ./ N
(m, 1H), 3.32-3.43 (m, 2H), 3.82 (s, NI 50 F / . 3H), 4.54-4.60 (m, 2H), 6.87 (d, J=
427 2.8 Hz, 1H), 7.08 (d, J= 3.6 Hz, 0 2H), 7.15 (d, J= 11.6 Hz, 1H), 7.45 I (d, J= 8.4 Hz, 2H), 7.65 (d, J= 8.0 Hz, 2 H), 8.24 (d, J= 2.8 Hz, 1H), _ 8.85 (s, 1H) 1H NMR (400 MHz, Me0D-d4): 6 N'.
.% Oil r0 H 1.80-1.83 (m, 1H) 2.03-2.07 (m, 1H), 2.97-3.06 (m, 2H), 3.20-3.23 (m, 1H), 3.32-3.43 (m, 2H), 3.82(s, 51 F I / 3H), 4.54-4.60 (m, 2H), 6.87 (d, .1- =
N,. * N 427 2.8 Hz, 1H), 7.07(d, J= 5.2 Hz, 2H), 7.16 (d, J= 11.2 Hz, 1H), 7.45 (d, J= 8.4 Hz, 2 H) 7.65 (d, J= 8.4 Hz, 2H), 8.23 (d, ./ = 3.6 Hz, 1H), 8.88 (s, 1H).
N ..õ 1H NMR (400 MHz, Me0D-d4): 6 "% op 1.78-1.81 (m, 1H) 2.03-2.07 (m, /WON
1H),2.97-3.16 (m, 2H), 3.27-3.41 ./ N
(m, 3H), 3.76 (s, 3H), 4.49-4.53 (m, I /
52 ,-110 N 427 2H), 6.83 (d, J = 2.8 Hz, 1H), 6.92 (d, J= 8.8 Hz, 2H), 7.17 (d, J= 8.4 0 Hz, 1H), 7.26 (d, J= 8.8 Hz, 2H), I 7.32 (d, J= 9.2 Hz, 1H), 8.62 (t, J=
8.0 Hz, 1H), 8.15 (d, J= 2.0 Hz, 1H), 8.77 (s, 1H) ]" Chemical F
MS
]]
Snthesis Structure N' (17:S1) 1!=111/1R spectrum data Example In]!]
Ill NMR (400 MHz, Me011-d4):
N
1.78-1.83 (m, 1H), 2.04-2.08 (m, polOH 1H), 3.00-3.17 (m, 2H), 3.20-3.21 N (m, 1H), 3.22-3.44 (m, 2H), 3.84 (s, /
445 3H), 4.50-4.61 (m, 2H), 6.87 (d, 3.2Hz, 1H), 7.09-7.14 (m, 2H), 7.20-7.23 (m, 2H), 7.39 (d, J= 9.6 Hz, 1H), 7.65 (t, J= 7.2Hz, 111), 8.25 (d, J= 3.2 Hz, 1H), 8.93 (s, 1H) 1H NMR (400 MHz, Me0D-d4): 6 N 1.80-1.83 (m, 1H) 2.04-2.06 (m, lel ral H 1H),2.97-3.07 (m, 2H), 3.20-3.23 (m, 1H), 3.31-3.42 (m, 2H), 3.75 (s, 3H), 4.52-4.56 (m, 2 H), 6.85 (d, J=

427 3.2 Hz, 1H), 6.93 (d, J= 9.2Hz, 2H), 7.19 (dd,.T= 1.2, 8.0 Hz, 1H), 0 7.27 (d, J= 8.8 Hz, 2H) 7.34 (dd, J
= 0.8, 10.0 Hz, 1H), 7.63 (t, J= 6.4 Hz, 1H), 8.20 (d, J= 2.8 Hz, 1H), 8.86 (s, 1H).
1H NMR (400 MHz, Me0D-d4): 6 N
ro H 1.76-1.82 (m, 1H) 2.02-2.07 (m, 1H), 2.96-3.17 (m, 2H), 3.20-3.21 (m, 1H), 3.31-3.43 (m, 2H), 3.83 (s, 55 / 3H), 4.46-4.58 (m, 2H), 6.84 (d, J=
445 2.4 Hz, 1H), 7.04-7.09 (m, 2H), 7.18-7.20 (m, 2H), 7.36 (dd, J= 1.6, 10.4 Hz, 1H), 7.64 (t, J= 6.4Hz, 1H), 8.18 (d, J= 3.2 Hz, 1H), 8.80 (1,1H).
Preparation 56A: Ethyl 1-(4-cyanopheny1)-5-hydroxypyrazole-3-carboxylate N

HO
[00394] A mixture of and 4-hydrazinylbenzonitrile hydrochloride (7.7 g, 38 mmol), diethylacetylenecarboxylate (6.4 g, 38 mmol) and potassium carbonate (10.4 g, mmol) in ethanol (100 mL) was stirred at reflux for 5 h. The mixture was cooled to rt, diluted with water and acidified with 2M HC1. The mixture was stirred for 20 min and the suspension was collected by filtration, washed with water and dried to give 7.7 g (100%) of the title compound as a pale yellow solid.

Preparation 56B: ethyl 1-(4-cyanopheny1)-5-(2- pyridylmethoxy)pyrazole-3-carboxylate N

/
[00395] To a solution of ethyl 1-(4-cyanopheny1)-5-hydroxypyrazole-3-carboxylate (1.5 g, 5.84 mmol) in THF (30 mL) was added 2-pyridylmethan-1-ol (719 mg, 6.60 mmol), PPh3 (3.058 g, 11.67 mmol) and DIAD (2.36 g, 11.67 mmol) at ice-bath.
The mixture was stirred at rt overnight, quenched with water and extracted with EA
(3x). The combined organics were dried and concentrated to give the title compound (2.0 g, 100%) as a yellow solid. [M+H] Calc'd for C19H16N403, 349; Found, 349.
Preparation 56C: 1-(4-cyanopheny1)-5-(2-pyridylmethoxy)pyrazole-3-carboxylic acid N

(N,j) /
[00396] To a solution of ethyl 1-(4-cyanopheny1)-5-(2-pyridylmethoxy)pyrazole-carboxylate (2.0 g, 5.84 mmol) in THF/H20 (30 mL/10 mL) was added Li0H.H20 (491 mg, 11.68 mmol). The mixture was stirred overnight at RT, acidified to pH= 3-4 with 5N
HC1, and extracted with EA. The combined organics were dried and concentrated to give the title compound (960 mg, 52%) as a yellow solid. [M+H] Calc'd for C17H12N403, 321;
Found, 321.
Preparation 56D: N-((3R)-1-}[1-(4-cyanopheny1)-5-(2-pyridyl-methoxy) pyrazol -3-yl]
carbonyl} (3-piperidy1)) (tert-butoxy) carboxamide N
cp¨ANH
-N )L
N)LI

[00397] A mixture of 1-(4-cyanopheny1)-5-(2-pyridylmethoxy) pyrazolc -3-carboxylic acid (960 mg, 3 mmol), N-((3R) (3-piperidy1)) (tert-butoxy) carboxamide (600 mg, 3 mmol), HATU (1.263 g, 3.3 mmol) and NMM (606 mg, 2 mmol) in DMF (25 mL) was stirred for lh at RT. The reaction was quenched with water and extracted with EA. The combined organics were washed with brine, dried and concentrated in yam() to give the title crude compound (1.2 g, 80%) as a yellow solid. [M+H] Calc'd for C27H30N604, 503;
Found, 503.
Example 56: 4-13 -[((3R)-3 -Aminopiperidyl)carbonyll -5-(2-pyridylmethoxy)pyrazoly1}
benzenecarbonitrile N
c)--ENH2 IX:y4k I

ICgs [00398] A solution of N-((3R)-1-1[1-(4-cyanopheny1)-5-(2-pyridyl-methoxy) pyrazol-3-ylicarbonyll(3-piperidy1))(tert- butoxy)carboxamide (1.2 g, 2.39 mmol) in HC1/EA (25 mL) was stirred for lh at RT. The reaction was completed, concentrated and purified by prep-HPLC to afford the title compound (450 mg, 47%) as a white solid. 1H NMR
(400 MHz, CD30D+D20): 3 1.71-1.94 (3H, m), 2.21-2.25 (1H, m), 3.33-3.64 (3H, m), 4.16-4.72 (2H, m), 5.71 (2H, s), 6.42 (1H, s), 7.91-8.12 (6H, m), 8.52-8.56 (1H, m), 8.85-8.87 (I H, m). LCMS [M+H] Calc'd for C22H22N602, 403; Found, 403 Example 57: 4- {3-[((3R)-3-Aminopiperidyl) carbonyl]-5-(3-pyridylmethoxy) pyrazoly1}
benzenecarbonitrile NH

[00399] The title compound was prepared in 80% yield as a white solid according to the general procedure for the preparation of Example 56. 'H NMR (400 MHz, DMSO-d6): 6 1.50-1.53 (1H, m), 1.63-1.67 (1H, m), 1.76-1.81 (1H, m), 2.05-2.07 (1H, m), 3.06-3.46 (3H, m), 4.14-4.69 (2H, m), 5.55 (2H, J= 11.2 Hz, d), 6.43 (1H, s), 7.89-8.07 (5H, m), 8.33-8.48 (4H, m), 8.84 (1H, J = 5.2 Hz, d), 9.00 (1H, s). [M+H] Calc'd for C22H22N602, 403; Found, 403.
Example 58: 4- {3-[((3R)-3-aminopiperidyl) carbony1]-5-(4-pyridylmethoxy) pyrazoly1}
benzenecarbonitrile N

-1=2-40 I, N
[00400] The title compound was prepared in 60% yield as a pink solid according to the general procedure for the preparation of Example 56. 1H NMR (400 MHz, CD30D):
6 1.74-1.82 (2H, m), 1.93-1.95 (1H, m), 2.21-2.25 (1H, m), 3.33-3.40 (3H, m), 4.18-4.77 (2H, m), 5.77 (2H, s), 6.39 (1H, s), 7.95-7.97 (2H, m), 8.07-8.12 (2H, m), 8.17-8.19 (2H, m), 8.93-8.94 (2H, m). [M+H] Calc'd for C22H22N602, 403; Found, 403.
Example 59. 4-[2-(4-aminopiperidin-1-y1)-5-(2-methylindazol-5-yl)pyrimidin-4-y1]-2-fluorobenzonitrile N

N
Ir ¨N
[00401] To a 100 mL pressure vessel charged with 5-bromo-2,4-dichloropyrimidine (9.11 g, 40 mmol) in ACN-H20 (50 mL, 5:1) was added (4-cyanophenyl)boronic acid (6.6 g, 40 mmol), Pd(OAc)2 (450 mg, 2 mmol), PPh3 (1.0 g, 4 mmol)and K3P03 (12.7 g, 60 mmol). The mixture was purged with N2 for 5 min and sealed. The reaction was kept at 50 C for 2 h with vigorous stirring. Water was added and the heterogeneous mixture was filtered. The filter cake was taken up in ethanol, stirred for 10 min, filtered, and dried in vacuo to afford 4-(5-bromo-2-chloropyrimidin-4-y1)-2-fluorobenzonitrile (6.6 g, 53%) as off-white crystals. [M+H] calc'd for C11H4N3BrCl2F, 312; found 312 [00402] To a round-bottom flask containing 4-(5-bromo-2-chloropyrimidin-4-y1)-fluorobenzonitrile (2 g, 6.4 mmol) in ethanol (40 mL), was added 4-boc-aminopiperidine (1.28 g, 6.4 mmol), and DIEA (1.67 mL, 9.6 mmol). The reaction was stirred at for 2 h. The reaction was concentrated in vacuo, and the residue purified by column chromatography (0-50% gradient of Et0Ac in hexanes) to afford tert-butyl N-{1-[5-bromo-4-(4-cyano-3-fluorophenyl)pyrimidin-2-yl]piperidin-4-yllcarbamate (2.47 g, 81%) as a yellow amorphous solid. [M+H] calc'd for C21H23N502Br, 476; found 476.
[00403] To a microwave vial charged with afford tert-butyl N- {145-bromo-4-(4-cyano-3-fluorophenyl)pyrimidin-2-yl]piperidin-4-yll carbamate (190 mg, 0.4 mmol) in dioxane (4 mL) was added 2-methy1-5-(tetramethy1-1,3,2-dioxaborolan-2-y1)-2H-indazole (129 mg, 0.5 mmol), PdC12(dppf) (50 mg, 0.07 mmol), and Na2CO3 (2 mL, 2M, 4 mmol). The reaction mixture was purged with nitrogen and irradiated in the microwave at 130 C for 2 h. Upon completion, the reaction mixture was taken up in ethyl acetate and successively washed with brine, dried with Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (gradient of 0-50% ethyl acetate in hexanes) to afford a yellow foam. The foam was taken up in DCM and HCI (4 mL, in dioxane) added and allowed to stir for 2 h. Upon completion, the reaction was concentrated in vacuo to afford the title compound (203 mg, 94%) as a yellow solid. '11 NMR (400 MHz, METHANOL-d4): 6 ppm 1.46 - 1.69 (m, 2 H), 2.00 - 2.21 (m, 2 H), 2.96 - 3.15 (m, 2 H), 3.43 - 3.51 (m, 2 H), 4.21 (s, 3 H), 4.96 - 5.05 (m, 2 H), 6.96 (d, J=7.07 Hz, 1 H), 7.33 (d, J=9.60 Hz, 1 H), 7.41 - 7.68 (m, 4 H), 8.19 (s, 1 H), 8.51 (s, 1 H). [M+H] calc'd for C24H22FN7, 428; Found 428.
[00404] The synthesis examples shown in Table 4 were synthesized following the general method as indicated in the table.
Table 4 Chemical ** 'structure m ms Synthesis (ESI) MN MR spectrurn tlat4! I
(prepared ly:s. procedure of cited Example) , ]i] Example H NMR (400 MHz, CD30D): 8 S H
1.86-1.98 (2H, m), 2.10-2.22 (2H, 111), 2.35 (3H, s), 2.63-2.66 (1H, m), 3.33-3.40 (1H, m), N-4 3.45-3.54 (2H, m), 3.84-3.89 441, / N
60 N 396 (1H, m), 3.95-4.00 (1H, m), 4.36-4.40 (1H, m), 4.45-4.51 (1H, m), 7.02 (2H, d, J= 8.0 Hz), 7.15 (2H, d, J= 8.0 Hz), 7.58 (2H, d, J= 8.0 Hz), 7.66 Prepared by the procedure of Example 59 (2H, d, J= 8.0 Hz), 8.42 (1H, s).

Structure:
.
:::
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , 111/ Z
, F H NMR (400 MHz, D30D): 8 F-1¨\ 1.73-1.76 (2H, m), 2.18-2.20 F N
(2H, m), 3.32-3.35 (2H, m), Nk \ , N
3.51-3.54 (1H, m), 4.80-4.95 61 -. N l 0 ) 428 (4H, m), 7.45 (1H, s), 7.64 (1H, 1111 a N H2 s), 7.72 (2H, d, .1=
8.4 Hz), 7.80 .. (2H, d, J= 7.6 Hz), 8.52 (1H, s).
N "
Prepared by the procedure of Example 59 /IN Iii NMR (400 MHz, CD30D): 6 1.89-2.13 (6H, m), 3.27 (2H, s), 3.49 (2H, t, J= 7.2 Hz), 3.97-62 HNOC¨( N_ 11 468 4.10 (4H, N\ / N F
F 7.48 (1H, s), 7.66 (1H, s), 7.72 N \-X
F (2H, d, J= 8.4 Hz), 7.81 (2H, d, Prepared by the procedure of Example 59 J= 8.4 Hz), 8.50 (1H, s).
1H NMR (400 MHz, CD30D): 6 1.67-1.94 (2H, m), 2.10-2.20 (2H, m), 2.63-2.65 (1H, m), NI 3.35-3.38 (1H, m), 3.46-3.51 N( (2H, m), 3.85-3.96 (2H, m), \ iN
4.28-4.43 (2H, m), 4.86-4.93 (2H, m), 7.36 (1H, s), 7.54 (1H, N------/ 4litt s), 7.63 (2H, d, J=
7.6 Hz), 7.73 (2H, d, J= 8.4 Hz), 8.47 (1H, s).
F1F \\N
F
Prepared by the procedure of Example 59 Chemical Structure:
MS
]] Synthesis =
(ESI) spectrum datal:
(prepared by procedure of cited Example) !! Example , 4 111/Z
N, H NMR (400 MHz, DMSO-c4):
N. 'N
6 1.47-1.50 (2H, m), 1.99-2.02 \N (2H, m), 3.04-3.10 (2H, m), 3.34-3.40 (1H, m), 4.78-4.81 (2H, m), 7.52 (2H, d, J= 8.4 Hz 64 N 411 ), 7.80 (2H, d,./= 8.4 Hz ),7.89 )=--N (2H, bs), 8.10 (1H, s), 8.14 (1H, s), 8.20 (1H, s), 8.58 (1H, s).
H,N
Prepared by the procedure of Example 59 N, 1H NMR (400 MHz, DMSO-d6):
Nix\ "NJ-6 1.70-1.72 (211, al), 1.88-1.92 \N (2H, m), 2.55-2.57 (2H, m), 2.82-2.86 (2H, m), 3.45-3.46 (2H, m), 3.47-3.51 (2H, m), 4.03 Nt (3H, s), 4.31-4.36 (2H, m), 7.52 65 451 (2H, d, J= 8.4 Hz ), 7.79 (2H, d, J= 8.4 Hz ), 8.09 (1H, s), 8.13 (1H, s), 8.19 (1H, s), 8.56 (111, s).
Prepared by the procedure of Example 59 1H NMR (400 MHz, CD30D): 6 1.61-1.65 (2H, m), 2.12-2.15 N\ (2H, m), 3.10-3.17 (2H, m), 3.48-3.50 (1H, m),4.01 (3H, s), 5.04-5.08 (2H, m), 7.57 (2H, d, 66 N¨ iN
N J= 8.8 Hz), 7.66 (2H, d, J= 8.4 0 Hz), 7.97 (1H, dõ I=
2.0 Hz), 8.24 (1H, d, J= 2.0 Hz), 8.57 NH, (1H, s), 8.80 (1H, s).
Prepared by the procedure of Example 59 ]]i Chemical ,-:: - :: Structure::: fl . MS
Synthesis 0 (ES!) NIVIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , N ni, Z
, N, ,.. H NMR (400 MHz, CD30D): 8 N. , 'N¨

N 1.50-1.54 (2H, m), 2.01-2.04 (2H, m), 2.99-3.05 (2H, m), . N \ /
3.40-3.45 (1H, m), 3.99 (311, s), 4.85-4.95 (2H, m), 7.00 (1H, d, N/ \
67 411 ./ = 8.8 Hz), 7.41 (2H, d,./= 8.4 )=--N Hz), 7.53 (2H, d, J=
8.4 Hz), 01 7.83 (1H, d, J= 8.8 Hz), 8.04 ( 1H, s), 8.56 (1H, s).

Prepared by the procedure of Example 59 N, _. 1H NMR (400 MHz, CD30D): 6 N
= 1.63-1.70 (2H, m), 2.15-2.18 . 1 \ (2H, m), 3.14-3.20 (2H, m), ¨ N 3.50-3.52 (1H, m), 4.34 (3H, s), 5.07-5.10 (2H, m), 7.20 (1H, d, N/ \
68 411 ./ = 8.8 Hz), 7.59 (2H, d, .I = 8.4 >7.---N Hz), 7.68 (2H, d, J=
8.4 Hz), 01 8.23 (1H, d, J= 8.8 Hz), 8.54 ( 1H, s), 8.72 (1H, s).

Prepared by the procedure of Example 59 N, _. 1H NMR (400 MHz, CD30D): 6 N\
= 1.64-1.71 (2H, m), 2.16-2.19 .0 1 \ (2H, m), 3.14-3.21 (2H, m), ¨N 3.50-3.52 (1H, m), 4.34 (3H, s), 5.08-5.11 (2H, m), 7.57 (2H, d, Nl \
69 411 J= 8.4 Hz), 7.66 (2H, d, J= 8.4 )=---N Hz), 8.15 (1H, s), 8.43 ( 1H, s), 01 8.67 (1H, s), 9.46 (1H, s).

Prepared by the procedure of Example 59 hemical """
Structure:
MS
Synthesis (ESI) NINIR spectrum dat4:
]] (prepared by procedure of cited Example) !! Example , 111/Z
NH, 1H NMR (400 MHz, DMSO-d6): 6 1.15-1.23 (2H, m), 1.62-1.86 (10H, m), 2.88-2.89 (1H, m), 3.07-3.14 (2H, m), 4.54-5.58 /N (2H, m), 5.28 (1H, s), 7.98 (2H, 70 388 d, .T= 8.4 Hz), 8.19 (2H, d, .J
HO * 8.4 Hz), 8.50 (1H, s).
=
Prepared by the procedure of Example 26 N 1HNMR (400 MHz, CD30D): 6 1.57-1.61 (2H, m), 2.08-2.11 H,N,O...../N
(2H, m), 2.23-2.24 (1H, m), 2.44-2.49 (1H, m), 3.04-3.10 N 416 (2H, m), 3.44-3.46 (1H, m), N
3.87-3.91 (1H, m), 3.99-4.02 (3H, m), 4.94-5.00 (3H, m), 7.22 (1H, s), 7.49 (1H, s), 7.65 (2H, d, J= 8.4 Hz), 7.74 (2H, d, J=
Prepared by the procedure of Example 59 8.4 Hz), 8.48 (1H, s).
N 114 NMR (400 MHz, CD301)): 6 , 1.49-1.53 (2H, m), 1.99-2.02 (2H, m), 2.97-3.03 (2H, m), 3.20-3.21 (1H, m), 4.22 (3H, s), 4.90-4.94 (2H, m), 7.12 (1H, dd, /
72 N 411 J= 1.2 Hz, 8.4 Hz), 7.46 (2H, d, J= 8.4 Hz), 7.51 (2H, d, J= 8.4 Hz), 8.24 (111, d, J= 8.4 Hz), 7.74 ( 1H, s), 8.43 (1H, s).

Prepared by the procedure of Example 59 Structure, MS
Synthesis (ESI) ININIR spectrum dat4:
]] (prepared by procedure of cited Example) Example 4 111/Z
H NMR (400 MHz, D30D): 8 ,N
N.\
1.64-1.68 (2H, m), 2.15-2.17 (2H, m), 3.11-3.20 (2H, m), 3.50-3.52 (1H, m), 4.49 (311, s), 5.08-5.12 (2H, m), 7.61 (2H, d, 73 411 ./ = 8.4 Hz), 7.68 (2H, d,./= 8.4 N:- N- j( ( Hz), 8.15 (1H, s), 8.67 (1H, s), 0 8.75 (1H, s), 9.57 ( 1H, s).
NH, Prepared by the procedure of Example 59 ¨0 1H NMR (400 MHz, CD30D): 6 1.57-1.67 (2H, m), 2.12-2.15 N\ (2H, m), 3.08-3.15 (2H, m), 3.45-3.51 (1H, m), 4.08 (3H, s), N 4.97-5.04 (2H, m), 7.61 (2H, d, =. N
74 N 388 J= 8.4 Hz), 7.75 (2H, d, J= 8.4 Hz), 8.33 (2H, s), 8.50 (1H, s).

Prepared by the procedure of Example 59 NMR (400 MHz, CD30D): 6 N NLN 1.61-1.65 (2H, m), 2.12-2.15 (2H, m), 2.87 (3H, s), 3.12-3.15 (2H, Ti!), 3.46-3.49 (1H, m), 4.00 (3H, s), 5.02-5.06 (2H, m), 7.36 75 N 424 (1H, dd, J= 1.2 Hz, 8.4 Hz), 7.54-7.56 (3H, m), 7.62-7.66 c_N) (2H, m),7.78-7.80 (1H, d, J = 8.4 Hz), 8.54 (1H, s).

Prepared by the procedure of Example 59 ]]i Chemical Structure:
MS
Synthesis (ESI) NINIR spectrum data: .]
]] (prepared by procedure of cited Example) !:! Example , H NMR (400 MHz, D30D): 8 N N 1.64-1.68 (2H, m), 2.15-2.17 N c (2H, m), 3.11-3.17 (2H, m), /N 3.49-3.51 (1H, m), 4.36 (311, s), 5.02-5.05 (2H, m), 7.60 (2H, d, 76 Nf 411 ./ = 8.4 Hz), 7.64 (2H, d,./= 8.0 Hz), 8.36 (1H, s), 8.40 (1H, s), 8.58 (1H, s), 8.66 ( 1H, s).

Prepared by the procedure of Example 59 1H NMR (400 MHz, CD30D): 6 1.64-1.70 (2H, Tn), 2.17-2.20 (2H, m), 3.15-3.22 (2H, m), 3.51-3.53 (1H, m), 4.06 (3H, s), 5.08-5.11 (2H, m), 6.76 (1H, s), N
77 ¨
¨ /11 0 (2H, d, J= 8.4 Hz), 7.69 (2H, d, J= 8.4 Hz), 8.06 (1H, s), 8.53 NH2 (1H, d, I = 8.4 Hz), 8.73 ( 1H, Prepared by the procedure of Example 59 s).
1H NMR (400 MHz, CD30D): 6 1.57-1.63 (3H, m), 2.09-2.12 (3H, m), 2.74-2.76 (1H, m), 3.06-3.09 (2H, m), 3.48-3.51 (2H, m), 3.70-3.75 (2H, m), 78 N/. 10 430 10 3.86-3.87 (1H, m), 4.09-4.11 (2H, m), 4.90-4.99 (2H, m), 7.27 H2N (1H, s), 7.45 (1H, s), 7.65 (2H, ) d, J= 8.4 Hz), 7.76 (2H, d, J =
Prepared by the procedure of Example 59 8.4 Hz), 8.47 (1H, s).

chemical Structure .:
Synthesis q (ESI) L NMR spectrum datIt (prepared by procedure of cited Example) ::: , :]:: - =
!! Example , H iniz ..
L.,...
F H NMIt.... . (.400 MHz, D30b): 8 F)---1\l/N 1.61-1.65 (2H, m), 2.12-2.14 . (2H, m), 3.10-3.16 (2H, m), 3.46-3.49 (1H, m), 5.03-5.06 (2H, m), 7.19 (1H, dd, J = 1.2 ....-79 447 Hz, 8.4 Hz), 7.52 (1H, s), 7.57 NZ = \ 1(N
N (2H, d, J= 8.4 Hz), 7.65 (2H, d, Q J = 8.4 Hz), 7.71 (1H, d, J= 8.4 Hz), 7.78 (11-1, s), 8.52 (1H, s), NH2 8.54 (1H, s).
Prepared by the procedure of Example 59 F 1H NMR (400 MHz, CD30D): 6 F-1¨\ 1.64-1.66 (2H, m), 2.08-2.11 F N (2H, m), 3.21-3.35 (2H, m), N \ \
/ N 3.48-3.50 (1H, m), 4.74-7.79 80 -, )--... 446 (4H, m), 7.38-7.44 (3H, m), 7.56 F *I N Na (1H, s), 7.69 ( 1H, s), 8.42 (1H, s).
N/
Prepared by the procedure of Example 59 N
'ET NMR (400 MHz, CD30D): 6 ) N 7 1.63-1.69 (2H, m), 2.15-2.18 -N
\ / (2H, m), 3.11-3.17 (2H, m), 3.48-3.50 (1H, m), 5.00-5.13 --N
(2H, m), 6.98 (1H, d, .J= 7.6 N
81 ¨ =
¨ \ i N -A 397 Hz), 7.64 (2H, d, J=
8.4 Hz), NO 7.70 (2H, d, J= 8.4 Hz), 7.76 (1H, s), 8.59 ( 1H, s), 8.64 (1H, NH2 s), 8.73 (1H, d,./=
7.6 Hz).
Prepared by the procedure of Example 59 , hemical ]i" """
Structure:
MS
Synthesis (ESI) NMR spectrum dat4:
]] (prepared by procedure of cited Example) !! Example , 111,Z
H NMR (400 MHz, DMSO-d6):
/IN
6 1.48-1.56 (2H, m), 2.01-2.03 = = (2H, m), 2.28 (3H, s), 3.05 (2H, t, J= 12.8 Hz), 3.32-3.35 (1H, m), 3.70 (1H, br), 4.76 (2H, d, J
\ N
82 370 = 13.6 Hz), 7.01 (2H, d, J= 8.0 N=( Hz), 7.12 (2H, d, J=
8.0 Hz), 7.52 (2H, d,J= 8.4 Hz), 7.80 (2H, d, J = 8.4 Hz), 8.24 (2H, NH2 br), 8.45 (1H, s).
Prepared by the procedure of Example 59 ¨0 1H NMR (400 MHz, DMSO-d6):
6 1.51-1.60 (2H, m), 2.03-2.06 (2H, m), 3.08 (2H, t, J= 12.0 Hz), 3.33-3.35 (1H, m), 3.75 N N (3H, s), 4.76 (2H, d, J= 13.6 Z *I
83 N¨( 386 Hz), 6.88 (2H, d, J=
8.0 Hz), 7.05 (2H, d,J = 8.0 Hz), 7.53 (2H, d, J= 8.4 Hz), 7.80 (1H, d, NH2 J= 8.4 Hz), 8.24 (2H, br), 8.44 (1H, s).
Prepared by the procedure of Example 59 114 NMR (400 MHz, DMSO-d6):
N

µ ¨N 6 1.50-1.54 (2H, m), 2.02-2.04 0 \) -1\¨}NH, (2H, m), 3.06 (2H, t, J= 12.0 Hz), 3.33-3.35 (1H, m), 3.83 84 404 (3H, s), 4.76 (2H, d, 13.2 Hz), 6.86 (1H, d, J= 8.0 Hz), Nf 7.03-7.12 (2H, m), 7.54 (2H, d, J
=
Prepared by the procedure of Example 59 = 8.0 Hz), 7.82 (1H, d, J 8.0 Hz), 8.28 (2H, br), 8.46 (1H, s).

Chemical Structure:
MS
Synthesis (ESI) NINIR
spectrum data: .]
(prepared by procedure of cited Example) 1 Example 4 111/ Z
H NMR (400 MHz, D30D): 8 ,N
N.\
1.63-1.67 (2H, m), 2.14-2.16 (2H, m), 3.11-3.17 (2H, m), N\ 3.48-3.50 (1H, m), 4.34 (311, s), 5.01-5.03 (2H, m), 7.61 (2H, d, 85 411 ./ = 8.4 Hz), 7.68 (2H, d,./= 8.4 N:- \i(N
Hz), 8.50 (2H, s), 8.58 ( 1H, s), 8.59 (1H, s).
NH, Prepared by the procedure of Example 59 1H NMR (400 MHz, CD30D): 6 N j 1.60-1.67 (2H, m), 2.18-2.20 c (2H, m), 3.17-3.20 (2H, m), /N 3.49-3.52 (1H, m), 4.00 (3H, s), 5.05-5.09 (2H, m), 6.14 (1H, s), 86 412 7.79 (1H, s), 7.82-7.88 (4H, m), 8.73 (1H, s).

Prepared by the procedure of Example 59 N\ NN 1H NMR (400 MHz, CD30D): 6 1.60-1.67 (2H, m), 2.00-2.12 49 44# (2H, m), 2.97-3.00 (2H, m), 2.34-2.36 (1H, m), 4.00 (3H, s), 4.89-4.93 (2H, m), 7.17 (1H, d, J

428 = 8.0 Hz), 7.27-7.30 (2H, m), 7.48-7.50 (1H, m), 7.57 (1H, s), 7.73 (1H, d, J= 8.8 Hz), 8.42 (1H, s), 9.23 (1H, s).

Prepared by the procedure of Example 59 ]]i Chemical :,-:: - :::
Structure:::
. MS
:::
Synthesis 0 (ES!) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , 111/ Z
, N, _ H NMR (400 MHz, D30D): 8 Nµ\ GN-1.62-1.70 (2H, m), 2.15-2.18 .
(2H, m), 3.11-3.18 (2H, m), NIT
' N 3.49-3.53 (1H, m), 4.20 (311, s), 5.00-5.04 (2H, m), 7.47 (2H, d, J
N/ \
88 412 - 8.8 Hz), 7.61 (2H, d, 1-= 8.8 y"--N
Hz), 8.14 (1H, s), 8.86 (1H, s), 01 9.19 (1H, s).

Prepared by the procedure of Example 59 F 1H NMR (400 MHz, CD30D): 6 F¨I¨\ 1.57-1.60 (2H, m), 2.14-2.17 F N i NI\ I (2H, m), 2.66 (3H, s), 3.10-3.13 , ,N (2H, m), 3.35-3.40 (1H, m), 89 ===== F N 0 460 4.81-4.85 (4H, m), 7.36-7.42 401 , N/ (3H, m), 7.52 (1H, s), 7.67 ( 1H, H N/ m), 8.41 (1H, s).
Prepared by the procedure of Example 59 1H NMR (400 MHz, DMSO-d6):
/IN
¨/N 6 1.50-1.54 (2H, m), 2.02-2.04 Nf \
(2H, m), 2.60 (3H, s), 3.05-3.11 (2H, m), 3.35-3.37 (1H, m), 4.76-4.80 (2H, m), 7.54 (2H, d, /\ N
372 J= 8.4 Hz), 7.85 (2H, d, J= 8.4 N¨( Hz), 8.28 ( 2H, bs), 8.46 (2H, s), 0 8.58 (1H, s).

Prepared by the procedure of Example 59 Structure: fl .
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , N ni, Z
, HN /N H NMR (400 MHz, D30D): 8 1.61-1.65 (2H, m), 2.11-2.14 . (2H, m), 3.09-3.14 (2H, m), 3.33-3.48 (1H, m), 5.01-5.05 . --__N (2H, m), 7.04 (1H, d, J= 8.0 y--N 396 Hz), 7.43 (1H, s), 7.56-7.63 (5H, m), 8.22 (1H, s), 8.51 (1H, c_N) s).

Prepared by the procedure of Example 59 1 Iii NMR (400 MHz, CD30D): 6 N \ F N
1.30-1.40 (2H, m), 1.91-1.94 \ \N) (2H, m), 2.62 (3H, s), 2.92-2.97 49 ilt (1H, m), 3.05 (2H, t, J= 12.0 Hz), 4.09 (3H, s), 4.2-4.85 (2H, .--- m), 6.87 (1H, d, J= 8.4 Hz), 92 Nkk / 442 --N 7.34-7.44 (3H, m), 7.54-7.59 0 (2H, m), 8.44 (1H, s).

Prepared by the procedure of Example 59 N '14 NMR (400 MHz, CD301)): 6 N
\' F 1.63-1.73 (2H, m), 2.16-2.18 = = (2H, m), 2.55 (3H, s), 3.19 (2H, d, J= 12.0 Hz), 3.48-3.54 (1H, m), 4.01 (3H, s), 4.98-5.02 (2H, 93 N / 44/ m), 7.08 (1H, d, J= 8.4 Hz), .--N 7.32 (1H, d, J= 8.0 Hz), 7.44 c..N) (1H, d,,J= 8.4 Hz), 7.50 (1H, d, J= 9.6 Hz), 7.61-7.64 (1H, m), H2N 7.69 (1H, s), 8.55 (1H, s).
Prepared by the procedure of Example 59 ]]i Chemical Structure: fl .
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , N ni, Z
, 0 H NMR (400 MHz, D30D): 8 OH
1.32-1.42 (2H, m), 1.95-1.96 \\ (2H, m), 2.25-2.33 (2H, m), F 3.00-3.12 (3H, m), 3.84-3.88 NZ . / \N (2H, m), 3.97-4.07 (2H, m), 94 N=( 408 4.86-4.88 (2H, m), 7.90 (1H, t, .I
Q = 7.2 Hz), 8.06-8.12 (2H, m), 8.52 (1H, s).

Prepared by the procedure of Example 26 1 'H NMR (400 MHz, CD30D): 6 N, N\ Hel \ i N 1.71-1.79 (2H, m), 2.17-2.22 \
(2H, m), 3.24-3.29 (2H, m), 49 111' 3.52-3.58 (1H, m), 3.89 (3H, s), 4.88-4.94 (2H, in), 7.35 (111, d, J
= 8.0 Hz), 7.40-7.46 (2H, m), 95 N \ / 443 .y--N 7.52 (1H, d, J= 10.0 Hz), 7.65-r ,N
----1 7.69 (1H, m), 7.93 (1H, s), 8.53 (1H, s).

Prepared by the procedure of Example 59 N 1H NMR (400 MHz, CD30D): 6 ,....
N. N' N
µ F 1.79-1.83 (2H, m), 2.24-2.26 4. . (2H, m), 3.32-3.39 (2H, m), 3.59-3.62 (1H, m), 4.40 (3H, s), -- 4.92-4.94 (2H, m), 7.35-7.37 96 N \ / 429 (2H, m), 7.54-7.57 (1H, m), ¨N 7.65-7.68 (1H, m), 7.80 (1H, d, J
0 =8.4 Hz), 8.00 (1H, s), 8.61 (1H, s).

Prepared by the procedure of Example 59 ]]i Chemical Structure:::
MS
Synthesis 0 (ES!) NINIR spectrum dat4:
(prepared by procedure of cited Example) 1 Example 4 111/ Z
H NMR (400 MHz, CD30D): 8 0 OH 1.32-1.37 (2H, m), 1.79-1.84 (2H, m), 1.94-1.97 (4H, m), 3.02-3.12 (3H, m), 3.58-3.63 NZ 41), \N (2H, m), 3.87-3.90 (2H, m), 97 N=( 422 4.87-4.90 (2H, m), 7.89-7.92 (1H, m), 8.07-8.11 (2H, m), 8.53 (1H, s).

Prepared by the procedure of Example 26 1H NMR (400 MHz, CD30D): 6 1.43-1.54 (2H, m), 2.01-2.04 (2H, m), 3.00-3.07 (2H, m), 3.34-3.40 (1H, m), 3.97 (3H, s), 4.92-4.95 (2H, m), 7.78 (1H, s), 98 N'Z = "N 403 7.82-7.86 (1H, m), 7.93-8.00 N=( (2H, m), 8.62 (1H, s).

Prepared by the procedure of Example 26 1H NMR (400 MHz, CD30D): 6 1.59-1.65 (2H, m), 2.12-2.15 )N
(2H, m), 3.09-3.16 (2H, m), 3.47-3.49 (1H, m), 3.91 (3H, s), 4.90-5.04 (2H, m), 6.44 (1H, d, J
99 NZ = \ N 402 = 2.4 Hz), 7.63 (1H, d, J= 2.4 N=( Hz), 7.89-7.93 (1H, m), 8.10 (1H, dd, J= 1.2 Hz, 10.4 Hz), 8.19 (1H, dd, J= 1.6 Hz, 8.0 Hz), 8.65 (1H, s).

Prepared by the procedure of Example 26 Structure: fl .
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) Example 4 111/Z
N 1H NMR (400 MHz, CD30D): 8 ..õ , N
1.61-1.67 (2H, m), 2.12-2.16 (2H, m), 3.09-3.15 (2H, m), \\ 3.48-3.50 (1H, m), 4.12 (3H, s), F
4.98-5.01 (2H, m), 7.85 (1H, dd, 100 NZ = / 'N 403 .T= 6.8 Hz, 8.0 Hz), 8.02 (111, N =( dd, J= 1.2 Hz, 10.4 Hz), 8.13-8.15 (2H, m), 8.59 (1H, s).
NH, Prepared by the procedure of Example 26 N, _. 1H NMR (400 MHz, CD30D): 6 N \ r -N-\ F 1.66-1.70 (1H, m), 2.14-2.19 . . (1H, m), 2.83-2.89 (1H, m), 3.03-3.10 (1H, m), 3.23-3.26 ____ (1H, m), 3.56-3.591 (1H, m), 101 N / 444 4.08 (3H, s), 5.01-5.04 (1H, nl), --N 5.14-5.19 (1H, m), 7.12 (1H, d, J
N
HO --c") = 8.4 Hz), 7.29 (1H, dd, J= 2.0 Hz, 8.0 Hz), 7.47-7.53 (2H, m), H2N 7.58-7.61 (1H, m), 7.67 (1H, s), 8.02 (1H, s), 8.53 (111, s).
Prepared by the procedure of Example 59 i 1H NMR (400 MHz, CD30D): 6 NN
1.59-1.63 (2H, m), 2.12-2.15 /
(2H, m), 3.08-3.14 (2H, m), \\ 3.32-3.34 (1H, m), 3.91 (3H, s), F 4.97-5.01 (2H, m), 7.58 (1H, s), 7.80 (1H, s), 7.87-7.91 (1H, m)õ
102 N = / \ N 402 N=( 8.09 (1H, dd, J= 1.2 Hz, 6.4 No Hz), 8.16-8.18 (1H, dd, J= 1.6 Hz, 8.0 Hz), 8.56 (1H, s).

Prepared by the procedure of Example 26 Structure: fl .
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , H 111,Z
, F H NMR (400 MHz, D30D): 8 F-1-\ 1.66-1.71 (1H, m), 2.15-2.18 F N (1H, m), 2.79-2.85 (1H, m), N\ \
7 N 2.99-3.05 (1H, m), 3.22-3.24 103 --- 3-..., 462 (1H, m), 3.56-3.61 (1H, m), F Olki N NQ,. 4.88-4.97 (2H, m), 4.98-4.51 (2H, m), 7.38-7.46 (3H, m), 7.58 OH
N/ (1H, s), 7.70-7.74 (1H, m), 8.47 Prepared by the procedure of Example 59 (1H, s).
N, _.. 1H NMR (400 MHz, CD30D): 8 N.
, \= F 1.71-1.74 (1H, m), 2.18-2.21 41 . (1H, m), 2.82-2.88 (1H, m), 3.01-3.07 (1H, m), 3.24-3.26 (1H, m), 3.61-3.64 (1H, m), 4.04(3H, s), 4.98-4.99 (1H, m), 5.11-5.15 (1H, m), 7.04-7.06 HO -QN (1H, dd, J =1.6 Hz, 8.8 Hz), 7.24-7.26 (1H, dd, J= 1.6 Hz, H2N 8.8 Hz), 7.38-7.46 (2H, m), 7.51-7.53 (1H, m), 7.58 (1H, s), Prepared by the procedure of Example 59 7.96 (1H, s), 8.42 (1H, s).
N 1H NMR (400 MHz, CD30D): 6 N.
N N 1\1.
= F 1.59-1.68 (2H, m), 2.12-2.15 49 41O' (2H, m), 3.11-3.18 (2H, m), 3.45-3.51 (1H, m), 4.30 (s, 3H), F 4.86-5.04 (2H, m), 7.28-7.30 Ni \ (1H, m), 7.47-7.52 (2H, m), )=--N 7.58-7.62 (1H, m), 8.03 (1H, d, J
01 =6.0 Hz), 8.51 (1H, s).

Prepared by the procedure of Example 59 Structure: fl .
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , H 111,Z
, N H NMR (400 MHz, CD30D): 8 1.59-1.63 (2H, m), 2.13-2.16 (2H, m), 3.11-3.18 (2H, m), \\ 3.32-3.34 (1H, m), 3.89 (3H, s), F
5.03-5.06 (2H, m), 6.51 (1H, d, J
106 NZ . / \N 402 ¨ 2.4 Hz), 7.49 (1H, d,.I= 2.0 N=( Hz), 7.95 (1H, dd,J=
6.8 Hz, _\1 8.0 Hz), 8.07-8.14 (2H, m), 8.71 (1H, s).
NH, Prepared by the procedure of Example 26 I 1H NMR (400 MHz, CD30D): 6 N
N \ F N
1.66-1.70 (1H, m), 2.14-2.19 N \ ) (1H, m), 2.83-2.88 (1H, m), 41110 11 3.03-3.10 (1H, m), 3.20-3.26 (1H, m), 3.55-3.61 (1H, m), 4.24 -- (3H, s), 5.00-5.05 (1H, m), 5.13---N 5.18 (1H, m), 6.98 (1H, dd, J=
1.6 Hz, 8.8 Hz), 7.35 (1H, dd,J
N
HO = 1.6 Hz, 8.8 Hz), 7.48-7.53 ---Q
(2H, m), 7.59-7.62 (2H, m), 8.22 H2N (1H, s), 8.53 (1H, s).
Prepared by the procedure of Example 59 i 1H NMR (400 MHz, CD30D): 6 N \ , F N)N 1.78-1.87 (2H, m), 1.96-1.99 \ \ /
(1H, m), 2.21-2.25 (1H, m), IIIIP . 3.42-3.46 (1H, m), 3.62-3.74 (2H, m), 4.31-4.35 (1H, m), 4.37 108 428 (3H, s), 4.67-4.71 (1H, m), 7.30-N /
y--N 7.33 (1H, m), 7.35-7.38 (1H, dd, N J= 1.2, 8), 7.53-7.56 (1H, cid, J
H2N.---C) = 1.2, 10.0 Hz), 7.63-7.67 (2H, m), 7.84 (1H, s), 8.58 (1H,$), Prepared by the procedure of Example 59 8.64 (1H, s).

Structure:
.
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , H 111/Z fl , I H NMR (400 MHz, D30D): 8 Nk N F N 3.37-3.39 (4H, m), 4.23-4.25 µ ' \ i (4H, m), 4.33 (3H, s), 7.23 (1H, = 1111' dd, J=1.2 Hz, 8.8 Hz), 7.36 (1H, dd, J=1.6 Hz, 8 Hz), 7.51 (1H, dd, .T= 1.6 Hz, 10.4 Hz), 7.62-y--N 7.65 (2H, m), 7.78 (1H, s), 8.53 N (1H, s), 8.62 (1H, s).
CjN
H
Prepared by the procedure of Example 59 i 1H NMR (400 MHz, CD30D): 6 N, N \ 2.21-2.24 (2H, m), 3.38-3.40 \ ' F \ r (2H, m), 3.48-3.51 (2H, m), = = 4.09-4.12 (2H, m), 4.22-4.25 (5H, m), 6.99 (1H, dd, J= 2.0 110 428 Hz, 9.2 Hz), 7.36 (1H, d, J = 1.6 N \ /
y-- N Hz, 8.0 Hz), 7.49-7.52 (2H, m), 0 7.61-7.63 (2H, m), 8.22 (1H, s), 8.57 (1H, s).
HN
Prepared by the procedure of Example 59 N, 1H NMR (400 MHz, DMS0-r -N-d6): 6 1.49-1.59 (1H, m), 1.67-* 1.78 (3H, m), 2.90-3.01 (1H, m), 3.07-3.16 (1H, m), 3.25-3.38 N \ / . (1H, m), 4.03 (3H, s), 4.64-4.78 . . ¨
(2H, m), 4.90-4.98 (1H, m), 7.05 1 1 1 y--N
F 446 (1H, dd, J= 1.6 Hz, 8.8 Hz), F-QN 7.24 ( 1H, dd, J= 1.2 Hz, 8.0 Hz), 7.51 (1H, d, J= 10.4 Hz), H2N 7.51 (1H, d, J= 8.8 Hz), 7.65 (1H, s), 7.81 (1H, dd, J= 6.8 Hz, Prepared by the procedure of Example 59 8.0 Hz), 8.03 (1H, s), 8.50 (1H, s).

Structure, .
Synthesis 0 (ESI) NIVIII spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , N 111,Z
, I H NMR (400 MHz, CD30D): 8 N, \ )1\1 1.72-1.85 (2H, m), 2.97-3.14 . (2H, m), 3.19-3.32 (1H, m), 4.21 (3H, s), 4.69-4.82 (1H, m), 4.84-4.92 (1H, m), 5.16-5.23 (1H, m), --- -N
. - 6.97 (1H, dd, J= 1.6 Hz, 8.8 112 N_/ 446 y-N
F Hz), 7.34 (1H, dd, J= 1.6 Hz, 8.0 Hz), 7.44 ( 1H, dd, J= 0.8 N
F Hz, 6.4 Hz), 7.52 (1H, d, I =
-Q
8.8 Hz), 7.57-7.60 (2H, m), 8.18 H2N (1H, s), 8.46 (1H, s).
Prepared by the procedure of Example 59 1H NMR (400 MHz, H N DCN -(,I \ 100 METHANOL-d4) 6 ppm 1.84 -N- 2.02 (in, 4 H) 2.32 (s, 3 H) 3.85 -=
113 396 4.01 (m, 8 H) 6.99 (d, J=8.08 Hz, 2 H) 7.12 (d, J=8.08 Hz, 2 % \ H) 7.49 - 7.58 (m, 2 H) 7.62 (d, )1\1 J=8.34 Hz, 2 H) 8.37 (s, 1 H) Prepared by the procedure of Example 59 8.55 (br. s., 1 H) H 1H NMR (400 MHz, C....1 METHANOL-d4) 6 ppm 0.48 -(-. ) 0.65 (m, 2 H) 0.68 - 0.84 (m, 2 H) 1.39 - 1.47 (m, 2 H) 1.49 (s, 3 N
H) 1.68 - 1.79 (m, 2 H) 2.17 -2.26 (m, 2 H) 2.27 - 2.30 (m, 1 N/ L-..N
114 411 H)2.31-2.40 (m, 2H) 2.42 - 2.49 t /
40 ....õ (m, 2 H) 3.08 - 3.21 (m, 2 H) 6.33 (d, J=8.08 Hz, 2 H) 6.45 (d, , J=8.08 Hz, 2 H) 6.51 (d, J=8.34 N/ N , Hz, 1 H) 6.82 - 6.93 (m, 1 H) 7.29 (s, 1 H) 7.32 (s, 1 H) Prepared by the procedure of Example 59 fl Structure:
.
Synthesis 0 (ESI) NIVIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , N 111,-:
, N 1H NMR (400 MHz, N\
µ METHANOL-d4) 6 ppm 1.71 -. . 1.84 (m, 1 H) 1.97- 2.15 (m, 1 H) 2.68 - 2.86 (m, 2 H) 3.07 -3.19 (m, 1 H) 3.21 - 3.28 (m, 1 Ni \
H) 3.34 (s, 3H) 3.55 -3.62 (m, 2 115 )-7---N
:1 436 H) 3.63 - 3.70 (m, 1 H) 3.71 -rs.) 3.82 (m, 1 H) 3.95 - 4.03 (m, 1 H) 4.27 - 4.41 (m, 2 H) 7.10 (d, HN
J=8.59 Hz, 1 H) 7.50 (d, J=8.59 Prepared by the procedure of Example 59 Hz, 1 H) 7.57 - 7.66 (m, 4 H) 7.70 (s, 1 H) 8.01 (s, 1 H) 8.47 (s, 1 H) N, , 1H NMR (400 MHz, N.
= METHANOL-d4) 6 ppm 1.70 -. li 1.90 (m, 2 H) 2.16 - 2.34 (m, 2 H) 3.34 (s, 3 H) 3.35-3.48 (m, 2H) 3.56 - 3.76 (m, 4 H) 3.86 -N' \
116 N 410 4.02(m, 1 H) 4.78 - 4.88 (m, 1 )=----N H) 7.14 (d, J=8.59 Hz, 1 H) 7.53 cN

..) (d, J=8.59 Hz, 1 H) 7.66 (m, 4 H) 7.74 - 7.82 (m, 1 H) 8.01 -FI,N 8.09 (m, 1 H) 8.50 (s, 1 H) Prepared by the procedure of Example 59 ,N 1H NMR (400 MHz, HNI" METHANOL-d4) 6 ppm 1.91 -= 2.34 (m, 2 H) 2.70 - 2.89 (m, 2 H) 3.06 - 3.22 (m, 2 H) 3.48 -4. :-..N 3.62 (m, 3 H) 3.65 (s, 2 H) 3.87 -N \ / 4.01 (in, 2 H) 6.98 (d, J=8.34 117 )-- N 4:36 Hz, 1 H) 7.59 -7.66 (m, 1 H) :,)1 7.73 (d, J=8.59 Hz, 1 H) 7.81 (d, J=8.34 Hz, 2 H) 8.00 (s, 1 H) 8.07 (d, J=8.59 Hz, 1 H) 8.31 (s, N
H 1 H) 8.52 (s, 1 H) 8.58 (s, 1 H) Prepared by the procedure of Example 59 ]]ichemical Structure::: fl .
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , H 111,Z
, H 1H NMR (400 MHz, C.....1 METHANOL-d4) 6 ppm 1.69 (s, U
3 H) 1.79 - 1.98 (m, 4 H) 2.40 -2.60 (m, 2 H) 3.10 - 3.25 (m, 2 N
H) 3.46 - 3.58 (m, 2 H) 3.72 -118 )---1\1/ 1;1 414 3.80 (m, 2 H) 3.81 (s, 3 H) 4.04 -t 4.07 (m, 1 H) 7.38 - 7.48 (m, 1 =..., H) 7.67 (s, 4 H) 8.26 (s, 1 H) ...
.--.N
s..
\
N-\
Prepared by the procedure of Example 59 H 1H NMR (400 MHz, METHANOL-d4) 6 ppm 1.93 -...s..... 2.22 (m, 2 H) 2.34 (s, 3 H) 2.35 -N 2.40 (m, 2 H) 3.40 -3.61 (m, 6 A H) 3.63 - 3.71 (m, 1 H) 3.71 -N ..`,N
119 1 ..'" 396 3.79 (m, 1 H) 7.03 (d, J=8.08 Hz, 2 H) 7.16 (d, J=8.08 Hz, 2 -, I411 H) 7.63 (q, J=8.42 Hz, 4 H) 8.50 N' IS (s, 1 H) Prepared by the procedure of Example 59 H 1H NMR (400 MHz, N r ..,\
........ METHANOL-d4) 6 ppm 1.11 -1.24 (m, 2 H) 1.92 - 2.19 (m, 2 N H) 2.32 - 2.48 (m, 3 H) 3.34 ( s, N N 3 H) 3.51 - 3.69 (m, 4 H) 3.71 -I 3.77 (m, 1 H) 7.09 (d, J=8.59 =.,_ Hz, 1 H) 7.49 (d, J=8.59 Hz, 1 H) 7.62 (s, 4 H) 7.66 - 7.70 (m, 1 H) 8.00 (s, 1 H) 8.58 (s, 1 H) \
N-N
Prepared by the procedure of Example 59 ]]ir hemical Structure:
MS
Synthesis (ESI) NINIR spectrum datal:
]] (prepared by procedure of cited Example) !! Example , 111/Z ::=
1H NMR (400 MHz, II
METHANOL-d4) 6 ppm 1.20 (s, 3 H) 1.79 (br. s., 4 H) 2.06 (s, 2 H) 3.12- 3.25 (m, 2 H) 3.39-H NOCN N
N F
3.50 (m, 4 H) 3.55 - 3.76 (m, 2 \ F 468 H) 3.83 - 3.97 (m, 2 H) 4.00 -4.15(m 2 H) 4.88 - 4.96 (m, 3 Prepared by the procedure of Example 59 H) 7.40 (s, 1 H) 7.56 (s, 1 H) 7.66 (d, J=8.59 Hz, 2 H) 7.76 (d, J=8.34 Hz, 2 H) 8.46 (s, 1 H) 1H NMR (400 MHz, N
METHANOL-d4) 6 ppm 1.52 -= 1.76 (m, 2 H) 2.06 - 2.22 (m, 2 H) 3.07 - 3.21 (m, 2 H) 3.44 ---/
3.53 (m, 2 H) 3.56 - 3.78 (m, 1 N-410 H) 4.13 (s, 3 H) 4.97 - 5.09 (m, 2 H) 7.40 (d, J=10.10 Hz, 1 H) 7.52 - 7.59 (m, 2 H) 7.59 - 7.65 NH, (rn, 2 H) 7.67 (s, 1 H) 7.85 (d, J=8.59 Hz, 1 H) 8.53 (s, 1 H) Prepared by the procedure of Example 59 9.39 (s, 1 H) -0 1H NMR (400 MHz, METHANOL-d4) 6 ppm 1.49 -N 1.70 (m, 2 H) 2.03 - 2.16 (m, 2 H) 3.02 - 3.18 (m, 2 H) 3.41 -N _ N
3.51 (m, 2 H) 3.89 (s, 3 H) 4.99 =
123 386 (d, J=14.15 Hz, 1 H) 6.74 (d, J=8.59 Hz, 1 H) 7.39 (dcl, J=8.59, 2.53 Hz, 1 H) 7.57 (d, NH, J=8.59 Hz, 2 H) 7.69 (m, J=8.59 Hz, 2 H) 7.89 (d, J=2.02 Hz, 1 Prepared by the procedure of Example 59 H) 8.43 (s, 1 H) 8.48 (br. s., 1 H) ]]ichemical Structure:::
MS
Synthesis 0 (ES!) NINIR spectrum dat4:
]] (prepared by procedure of cited Example) !! Example , 111,Z
1H NMR (400 MHz, METHANOL-d4) 6 ppm 0.26 -<0 0.39 (m, 2 H) 0.51 -0.63 (m, 2 N H) 1.20 - 1.35 (m, 1 H) 1.49 -1.66 (m, 2 H) 2.03 -2.17 (m, 2 H) 3.01 - 3.18 (m, 2 H) 3.40 -N: = 427 3.50 (m, 2 H) 4.08 (d, J=7.07 N-µ
Hz, 2 H) 4.96 - 5.05 (m, 2 H) 6.73 (d, J=8.59 Hz, 1 H) 7.38 (dd, J=8.59, 2.53 Hz, 1 H) 7.57 NH, (d, J=8.59 Hz, 2 H) 7.69 (d, Prepared by the procedure of Example 59 J=8.34 Hz, 2 H) 7.86 (d, J=2.02 Hz, 1 H) 8.43 (s, 1 H) 8.49 (s, 1 H) 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.41 - 1.61 (m, 2 H) 1.97 - 2.10 (m, 2 H) 3.02 - 3.20 (m, 2 F H) 3.28 - 3.44 (m, 1 H) 3.44 -N 3.55 (m, 1 H) 3.62-3.74 (m, 1 125 pN 428 H) 3.92 - 3.97 (s, 3 H) 4.76 -4.86 (m, 2 H) 7.50 - 7.59 (m, 1 H) 7.72 (d, J=10.36 Hz, 1 H) 7.77 (d, J=7.83 Hz, 2 H) 7.86 (d, J=7.33 Hz, 1 H) 8.12 (m., 3 H) Prepared by the procedure of Example 59 8.51 (s, 1 H) 9.11 (s, 1 H) 1H NMR (400 MHz, DMSO-d6) / d ppm 1.41 - 1.65 (m, 2 H) 1.94 N ' - 2.11 (m, 2 H) 2.94 - 3.19 (m, 2 -- H) 3.30- 3.53 (m, 2 H) 3.63 -/N 3.78 (m, 1 H) 3.98 (s, 3 H) 4.80 (d, J=16.67 Hz, 2 H) 7.55 (m, 3 0 H) 7.79 (d, J=7.58 Hz, 2 H) 8.00 NH2 (br. s., 3 H) 8.32 ( s, 1 H) 8.51 (s, 1 H) Prc,pareci by the procedure of Example 59 hemical """
Structure:
MS
Synthesis (ESI) NINIR spectrum dat4:
]] (prepared by procedure of cited Example) !! Example , 111,Z
Nµ\ NN 1H NMR (400 MHz, METHANOL-d4) d ppm 1.55 -\ 1.69 (m, 2 H) 2.06 - 2.18 (m, 2 H) 3.06 - 3.18 (m, 2 H) 3.45 -N/ 3.52 (m, 2 H) 5.01 -5.08 (m, 1 127 )=7"--N 396 H) 7.59 (d, J=9.09 Hz, 1 H) 7.62 - 7.74 (m, 4 H) 7.83 (d, J=9.85 Hz, 1 H) 8.59 (s, 1 H) 8.92 (s, 1 H2N H) 9.07 (s, 1 H) Prepared by the procedure of Example 59 1H NMR (400 MHz, N METHANOL-d4) 6 ppm 1.56 -O
1.78 (m, 2 H) 2.07 - 2.24 (m, 2 H) 3.10 - 3.26 (1n, 2 H) 3.44 -3.56 (m, 2 H) 4.28 (s, 3 H) 4.92 ----128 410 5.03 (m, 2 H) 7.14 (d, J=9.09 Hz, 1 H) 7.56 (d, J=8.84 Hz, 1 0 H) 7.59 - 7.67 (1n, 4 H) 7.72 (s, 1 H) 8.45 (s, 1 H) 8.50 (s, 1 H) NH, Prepared by the procedure of Example 59 1H NMR (400 MHz, N METHANOL-d4) 6 ppm 1.69 -V = Nc 1.98 (m, 2 H) 2.13 -2.38 (m, 2 H) 3.37 - 3.51 (m, 2 H) 3.52 -3.67 (m, 2 H) 4.38 (s, 3 H) 7.10 (s, 1 H) 7.67 (m, 4 H) 7.88 (m, 1 129 Ni 410 N H) 8.59 (br. s., 1 H) 8.76 (br. s., 1 H) Prepared by ate procedure of Example 59 Structure:
.
Synthesis 0 (ESI) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , N 111,Z
, I 1H NMR (400 MHz, N F
N = F METHANOL-d4) 6 ppm 1.80 -2.24 (m, 4 H) 2.64 - 2.81 (m, 2 H) 2.98- 3.19 (m, 2 H) 3.46------ WI' \ 1N 3.80 (m, 3 H) 4.26 (s, 3 H) 4.33 -N
130 486 4.52 (m, 2 H) 7.57 - 7.83 (m, 6 1\cl. H) 8.52 (br. s., 1 H) 9.49 (s, 1 H) N
H
Prepared by the procedure of Example 59 F 1H NMR (400 MHz, F
F)c....
0 METHANOL-d4) d ppm 1.53 -1.69 (m, 2 H) 2.02 - 2.20 (m, 2 -H) 3.04 - 3.20 (m, 2 H) 3A3 -N \ /
3.58 (m, 2 H) 4.95 - 5.02 (m, 2 H) 6.87 (d, J=8.08 Hz, 1 H) 7.49 131 N-L-- * \ / N 455 (dd, J=8.72, 2.40 Hz, 1 H) 7.58 N
(d, J=8.59 Hz, 2 H) 7.55 - 7.62 0 (m, 1 H) 7.70 (d, J=8.34 Hz, 2 H) 7.96 (d, J=1.77 Hz, 1 H) 8.46 NH2 (S, 1 H) Prepared by the procedure of Example 59 I 1H NMR (400 MHz, N F
METHANOL-d4) 6 ppm 1.54 -1 4 F 1.68 (m, 2 H) 1.97 -2.24 (m, 2 F H) 3.04 - 3.21 (m, 2 H) 3.56 ----3.77 (m, 1 H) 4.23 (s, 3 H) 4.99 -132 N:-. . \ ..../(N 464 5.09 (m, 2 H) 7.31 (d, J=9.35 N
NO Hz, 1 H) 7.49 (d, J=11.12 Hz, 1 H) 7.58 - 7.73 (m, 2 H) 8.50 (s, 1 NH2 H) 9.32 (s, 1 H) Prepared by the procedure of Exainpie 59 Fithernicatq----------------- -i,---------------w-------v-----u------------------Structure . MS
Synthesis (ES!) IN;11.1R spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , N 111,Z
N\ NN 1H NMR (400 MHz, = F METHANOL-d4) 6 ppm 1.53 -. 411D 1.79 (m, 2 H) 1.96 - 2.24 (m, 2 H) 3.06- 3.19 (m, 2 H) 3.56 -F
N i \ 3.81 (m, 1 H) 4.11 (s, 3 H) 4.99 -133 )=---N 446 5.10 (m, 2 H) 7.19 - 7.37 (m, 1 H) 7.45 (d, J=10.61 Hz, 1 H) c.N.) 7.61 (d, J=6.57 Hz, 1 H) 7.75 (d, J=9.09 Hz, 1 H) 7.89 (d, J=6.06 H2N Hz, 1 H) 8.50 (s, 1 H) 9.46 (s, 1 Prepared by the procedure of Example 59 H) / 1H NMR (400 MHz, -N
)N METHANOL-d4) 6 ppm 1.49 -N( \ 1.69 (m, 2 H) 2.03 -2.16 (m, 2 F H) 3.01 - 3.13 (m, 2 H) 3.16 (s, 6 NZ / \ H N 3.39 - 3.50 m 2 H4.93 -) ( , ) N=( 41c). 5.04 (m, 2 H) 7.35 (d, J=7.58 Hz, 1 H) 7.52 (d, J=9.60 Hz, 1 Q H) 7.73 (t, J=7.07 Hz, 1 H) 8.03 - 8.10(m, 2 H) 8.39- 8.47(m, 2 NH2 H) Prepared by the procedure of Example 59 1H NMR (400 MHz, 01 METHANOL-d4) 6 ppm 1.50 -)-N 1.70 (m, 2 H) 2.06 - 2.24 (m, 7 N/ \ H) 3.04 - 3.21 (m, 2 H) 3.67 -F 3.73 (m, 4 H) 4.95 - 5.05 (m, 2 135 N: / \N 445 H) 7.46 (d, J=8.08 Hz, 1 H) 7.63 N=( (d, J=9.85 Hz, 1 H) 7.78 (t, 0 J=7.07 Hz, 1 H) 8.38 (s, 2 H) 8.53 (s, 1 H) 8.51 - 8.54 (m, 1 H) 8.58 (d, J=5.56 Hz, 1 H) Prepared by the procedure of Example 59 .....:.: . . ..
.....,..õ.:....................................................... ....
...................................................................
,............õ.................................................................
.............
Structure:
.:
:i::
Synthesis q (ESI) L NMR spectrum datIt (prepared by procedure of cited Example) ]]: , :]:: -= :::::
Example i].....
"--NN 1H NM-- R. (400 MHz, METHANOL-d4) 6 ppm 1.05 ---N \ / 1.25 (m, 1 H) 1.54 - 1.72 (m, 2 F H) 2.07 - 2.39 (m, 2 H) 3.06 -_ . / \N 3.22 (m, 2 H) 3.44 - 3.52 (m, 1 136 N----( 429 N - H) 3.57 - 3.70 (m, 1 H) 4.14 (s, 3 N H) 5.03 (d, J=13.64 Hz, 2 H) 7.29 (d, J=8.34 Hz, 1 H) 7.50 (d, NH, J=9.85 Hz, 1 H) 7.65 (t, J=7.20 Hz, 1 H) 8.13 - 8.24 (m, 1 H) Prepared by the procedure of Example 59 8.47 (s, 1 H) 8.59 (s, 1 H) 9.63 (s, 1 H) --NN 1H NMR (400 MHz, -- METHANOL-d4) 6 ppm 1.09 -N\ / 1.26 (m, 1 H) 1.53 - 1.78 (m, 2 F H) 2.06 - 2.24(m, 2H) 3.08-/ \ N
N::: N-----.< 3.23 (m, 2 H) 3.38 - 3.78 (m, 5 137 KR 469 H) 4.14 (s, 3 H) 4.96 - 5.09 (m, 2 ) H) 7.29 (d, J=8.34 Hz, 1 H) 7.50 (d, J=9.85 Hz, 1 H) 7.65 (t, N J=7.20 Hz, 1 H) 8.17 -8.23 (m, H
1 H) 8.47 (s, 1 H) 8.59 (s, 1 H) Prepared by the procedure of Example 59 9.63 (s, 1 H) F n/a NC r.,-.,,,N H2 N .- N 442 N
/
Prepared by the procedure of Example 59 ]]ichemical :,-:: -fl Structure:::
. MS
Synthesis 0 (ES!) NINIR spectrum dat4: .]
]] (prepared by procedure of cited Example) !! Example , A 111,Z
, N, 1H NMR (400 MHz, DMSO-d6) "---N' N 6 ppm 1.46- 1.61 (m, 2 H) 2.00 -- 2.12 (m, 2 H) 3.05 - 3.15 (m, 2 N \ /
H) 3.33 - 3.43 (m, 1 H) 4.29 (s, 3 F
N H) 4.81 (m, 4 H) 7.22 - 7.26 (m, 430 1 11) 7.63 (d, J=10.11 Hz, 1 H) 0 7.82 (t, J=7.45 Hz, 1 H) 8.15 (br.
s.,1 H) 8.42 (d, J=1.77 Hz, 1 H) NH 8.50 (d, J=1.77 Hz, 1 H) 8.66 (s, , 1H) Prepared by the procedure of Example 59 / 1H NMR (400 MHz, HN
)-, N METHANOL-d4) 6 ppm 1.40 -N/ \ 1.70 (m, 2 H) 1.99 -2.21 (m, 2 F _ H) 3.07 (s, 3 H) 3.35 - 3.67 (m, 4 H) 4.98 - 5.08 (m, 2 H) 7.44 (d, 140 N=( 40S J=8.08 Hz, 1 H) 7.62 (d, J=11.12 Hz, 1 H) 7.74 - 7.85 (m, 1 H) No 8.35 (s, 2 H) 8.52 (s, 1 H) Prepared by the procedure of Example 59 1> 1H NMR (400 MHz, METHANOL-d4) 6 ppm 0.64 -HN
)-N 0.85 (in, 2 H) 0.94-1.07 (m, 2 N/ \ H) 1.10 - 1.24 (m, 1 H) 1.46 -F 1.77 (m, 2 H) 2.01 -2.22 (m, 2 141 NI- / \ N 431 H) 2.60 - 2.83 (m, 1 H) 3.03 -3.20 (m, 3 H) 3.43 - 3.55 (m, 1 N=( H) 4.95 - 5.07 (m, 2 H) 7.39 -0 7.52 (m, 1 H) 7.55 -7.69 (m, 1 H) 7.71 - 7.89 (m, 1 H) 8.25 -8.50 (m, 2 H) 8.53 - 8.62 (m, 1 Prepared by the procedure of Example 59 H) hemical Structure:
MS
Synthesis (ESI) NINIR spectrum dat4:
]] (prepared by procedure of cited Example) !! Example , 111,Z
(,1 0 1H NMR (400 MHz, 1/4Nr) METHANOL-d4) 6 ppm 1.14 -1.22 (m, 2 H) 1.57 - 1.79 (m, 2 N' H) 2.01 (m, 4 H) 2.11 - 2.24(m, N
2 H) 3.45 - 3.63 (m, 6 H) 3.97 -F
4.10(n, 2 H) 4.35 -4.49 (m, 1 142 \N 448 H) 7.35 (s, 1 H) 7.48 (d, J=8.34 N=< Hz, 1 H) 7.55 (d, J=9.85 Hz, 1 H) 7.70 (s, 1 H) 7.75 - 7.83 (m, 1 H) 8.49 (s, 1 H) Prepared by the procedure of Example. 59 1H NMR (400 MHz, N
N

F N
METHANOL-d4) 6 ppm 2.22 -i 2.41 (m, 1 H) 2.52 - 2.68 (m, 1 = H) 3.85 - 4.04 (m, 3 H) 4.05 -4.20 (m, 2 H) 4.31 (s, 3 H) 7.21 414 (d, 143 J=7.58 Hz, 1 H) 7.37 (d, N /
N J=8.08 Hz, 1 H) 7.48 - 7.59 (m, 2 H) 7.59 - 7.69 (m, 3 H) 7.79 (s, 1 H) 8.53 (d, J=13.39 Hz, 2 H) H2NN) Prepared by the procedure of Example 59 1H NMR (400 MHz, , N N METHANOL-d4) 6 ppm 1.14-F iN
1.20 (m, 1 H) 2.23 - 2.39 (m, 2 H) 2.57 - 2.68 (m, 1 H) 3.55 -3.70 (m, 2 H) 3.82 - 3.97 (m, 2 144 426 H) 4.07 - 4.25 (m, 2 H) 4.31 (s, 3 N /
)N--N H) 7.21 (d, J=8.84 Hz, 1 H) 7.36 (d, J=7.83 Hz, 1 H) 7.51 (d, J=10.11 Hz, 1 H) 7.57 - 7.71 (m, H2N 2 H) 7.80 (s, 1 H) 8.52 (d, Prepared by the procedure of Example 59 J=8.84 Hz, 2 H) i]]chemical Structure:
MS
]] Synthesis (ESI) NIVIR spectrum dat4:
=
(prepared by procedure of cited Example) !! Example 1H NMR (400 MHz, DMSO-d6) 6 1.02- 1.10 (m, 2 H) 1.42 - 1.58 (m, 2 H) 1.97 - 2.09 (m, 2 H) N \
3.09 (t, J=12.38 Hz, 2 H) 3.32 -F
N 3.40 (m, 1 H) 4.05 (s, 3 H) 4.80 145 429 (d, J=14.15 Hz, 2 H) 7.23 (d, 0 J=7.58 Hz, 1 H) 7.61 (d, J=8.84 Hz, 1 H) 7.82 (t, J=7.20 Hz, 1 H) NH 8.14 (d, J=9.35 Hz, 2 H) 8.25 , (br. s., 1 H) 8.60 (s, 1 H) Prepared by the procedure of Example 59 SN 1H NMR (400 MHz, CD30D): 6 1.91-1.95 (2H, m), 2.08-2.12 (2H, m), 2.74-2.77 (2H, m), 3.03-3.08 (2H, m), 3.52-3.56 N
(2H, m), 3.70-3.76 (2H, m), N__<
\/
146 453 4.39-4.43 (2H, m), 7.27 (1H, d, J
= 8.0 Hz), 7.62 (2H, d, J= 8.0 Hz), 7.67 (2H, d, J= 8.0 Hz), 7.94 (1H, s), 8.05 (1H, d, J = 8.0 Hz), 8.56 (1H, s), 9.33 (1H, s).
Prepared by the procedure of Example 59 Example 147. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5-(2-methy1-2H-indazol-5-yl)pyrimidin-4-y11-2-fluorobenzonitrile N

N
-N

[00405] To a round-bottom flask charged with 2,4,6-trichloropyrimidine (30 g, 0.160 mol) in ACN1/1-120 (3:1, 800 mL) was added (4-cyano-3-fluorophenyl)boronic acid (27.2 g, 0.160 mol), Pd(OAc)2 (1.84 g, 8.2 mmol), PPh3(4.35 g, 16.5 mmol), and K3PO4 (52 g, 0.245 mol). The reaction was kept at 50 C under nitrogen atmosphere for 2hrs.
Upon completion, the mixture was poured into ice-water (1L) and filtered. The filter cake was suspended in ethanol (500 mL) and stirred for 30 min. The suspension was filtered and the filter cake dried in vacuo to furnish 4-(2,6-dichloropyrimidin-4-y1)-2-fluorobenzonitrile (30 g, 68%) as an off-white solid. 11-INMR (400 MHz, DMSO-d6): 6 8.24-8.27 (2H, m), 8.32-8.35 (1H, dd, J= 1.2 Hz, 10.4 Hz), 8.58 (1H, s). [M+H]
Calc'd for C11H4C12FN3, 266; Found, 266.
[00406] To a round-bottom flask charged with 4-(2,6-dichloropyrimidin-4-y1)-2-fluorobenzonitrile (30 g, 0.11 mol) in Me0H (500 naL) was added Na0Me (6.0 g, 0.11 mol) portionwise. The reaction was kept at 50 C for 16hrs under nitrogen atmosphere.
Upon completion, the reaction mixture was poured into ice-water and extracted with DCM (3 X 300 mL). The combined organic layers were successively washed with brine, dried with Na2SO4, and concentrated in vacuo to afford 4-(2-chloro-6-methoxypyrimidin-4-y1)-2-fluorobenzonitrile (26 g, 90%). 1FINMR (400 MHz, DMSO-d6): 6 4.02 (3H, s), 7.77 (1H, s), 8.09-8.14 (1H, dd, J= 1.2 Hz, 10.4 Hz), 8.15-8.19 (2H, m). [M+H] Calc'd for C12H7C1FN30, 262; Found, 262.
[00407] To a round-bottom flask charged with 4-(2-chloro-6-methoxypyrimidin-4-y1)-2-fluorobenzonitrile (26.0 g, 98 mmol), 4-(N-boc-amino)piperidine (19.7 g, 98 mmol) and DIPEA (25.5 g, 196 mmol) in DMF (200 mL) was heated at 100 C for 4 hrs.
The reaction mixture was poured into ice-water and extracted with ethyl acetate (3 mL). The combined organic layers were successively washed with brine, dried with Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (gradient of 10-20% ethyl acetate in PE) to afford tert-butyl-N-{144-(4-cyano-fluoropheny1)-6-methoxypyrimidin-2-yl]piperidin-4-ylIcarbamate (15g, 35%).
[M+H]
Calc'd for C22H26FN503, 428; Found, 428.
[00408] To a round-bottom flask charged with tert-butyl-N-{144-(4-cyano-3-fluoropheny1)-6-methoxypyrimidin-2-yl]piperidin-4-ylIcarbamate (15 g, 0.035 mol, 1.0 eq) in DMF (25 mL) was added NBS (6.25 g, 1.0 eq) portionwise. The reaction was stirred for 2 hrs at ambient temperature. Upon completion, ice-water (200 mL) was added, and the content extracted with ethyl acetate (3 X 200 mL). The combined organic layers were washed successively with brine, dried with Na2SO4, and concentrated in vacuo. The residue was purified with column chromatography (PE/EA/DCM= 10:1:1) to afford tert-butyl N-1145-bromo-4-(4-cyano-3-fluoropheny1)-6-methoxypyrimidin-2-yl]piperidin-4-ylIcarbamate (7 g, Yield 39%). 1LINMR (300 MHz, DMSO-d6): 6 1.26-1.30 (2H, m), 1.36 (9H, s), 1.74-1.78 (2H, m), 2.97-3.05 (2H, m), 3.49-3.52 (1H, m), 3.94 (3H, s), 4.44-4.49 (2H, m), 6.83-6.86 (1H, d, J = 7.8 Hz), 7.60-7.63 (1H, dd, J = 1.5 Hz, 7.8 Hz), 7.71-7.75 (1H, d, J = 9.9 Hz), 8.00-8.05 (1H, m). [M+H] Calc'd for C22H25BrFN503, 506; Found, 506.
[00409] To a round-bottom flask charged with tert-butyl N-{145-bromo-4-(4-cyano-3-fluoropheny1)-6-methoxypyrimidin-2-yl]piperidin-4-yHcarbarnate (1 g, 1.9 mmol) in dioxane/H20 (5:1, 20 mL) was added (2-methyl-2H-indazol-5-Aboronic acid (0.34 g, 2.85 mmol), 1,1 bis(di-tert-butylphosphino)ferrocene palladium dichloride (120 mg, 0.19 mmol) and Na2CO3 (0.41 g, 3.8 mmol). The mixture was irradiated at 140 C in the microwave for 2 hrs. Upon completion, the reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (gradient of 50-66% ethyl acetate in PE) and prep-HPLC to give a yellow solid.
The solid was suspended in ethyl acetate (5 mL) and HC1 (10 mL, 4M in dioxane) was added and allowed to stir for 2 h. Upon completion, the reaction was concentrated in vacuo to afford the title compound (300 mg, 33%) a yellow solid. 1H NMR (400 MHz, CDOD): 6 1.61-1.71 (2H, m), 2.13-2.16 (2H, m), 3.09-3.15 (2H, m), 3.32-3.34 (1H, m), 3.97 (3H, s), 4.21 (3H, s), 4.92-4.97 (2H, m), 7.09-7.11 (1H, m), 7.24-7.26 (1H, m), 7.34-7.39 (2H, m), 7.48-7.55 (2H, m), 8.14 (1H, s). [M+H] Calc'd for C25H24FN70, 458; Found, 458.
Example 148. 4-[2-(1,4-diazepan-l-y1)-6-methoxy-5-(2-methyl-2H-indazol-5-Apyrimidin-4-y1]-2-fluorobenzonitrile N
N ,J10111 N NH

N
¨N
1\( oeC) [00410] The HC1 salt of the title compound was prepared in 4% overall yield according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, CD30D): 6 2.28-2.30 (2H, m), 3.43-3.45 (2H, m), 3.53-3.55 (2H, m), 4.03 (3H, s), 4.03-4.06 (2H, m), 4.25-4.27 (2H, m), 4.33 (3H, s), 7.32 (1H, d, ./-= 8.4 Hz), 7.43-7.48 (2H, m), 7.60-7.63 (2H, m), 7.65 (1H, s), 8.58 (1H, s). [M+H] Calc'd for C25H24FN70, 458;
Found, 458.
Example 149. 4-[2-(4-aminoazepan-1-y1)-6-methoxy-5-(2-methyl-2H-indazol-5-yl)pyrimidin-4-y1]-2-fluorobenzonitrile WO 2015/089192 PCT[1JS2014/069562 N
N 0--"N H2 I
N
.#o [00411] The HC1 salt of the title compound was prepared in 4% overall yield according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, CD30D): 6 1.86-2.44 (6H, m), 3.46-3.49 (1H, m), 3.82-4.42 (4H, m), 4.10 (3H, s), 4.31 (3H, s), 7.41-7.46 (2H, m), 7.58-7.71 (4H, m), 8.56 (1H, s). [M+H] Calc'd for C26H26FN70, 472; Found, 472.
Example 150. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5-(2-methyl-2H-indazol-6-y1)pyrimidin-4-y1]-2-fluorobenzonitrile N

N
1-y .= N

[00412] The HC1 salt of the title compound was prepared in 3% overall yield according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, CD30D): 6 1.78-1.82 (2H, m), 2.18-2.23 (2H, m), 3.28-3.34 (2H, m), 3.52-3.59 (1H, m), 4.06 (3H, s), 4.32 (3H, s), 4.85-4.90 (2H, m), 7.13 (1H, d, J= 8.4 Hz), 7.36 (1H, d, J=
8.4 Hz), 7.48 (1H, s), 7.52 (1H, d, J= 9.6 Hz), 7.65 (1H, dd, J= 8.0 Hz, 6.8 Hz), 7.82 (1H, d, J= 8.0 Hz), 8.62 (1H, s). [M+H] Calc'd for C25H24FN70, 458; Found, 458.
Example 151. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5-(1-methyl-1H-1,2,3-benzotriazol-5-yl)pyrimidin-4-y1]-2-fluorobenzonitrile N
N ii\caN H2 N
I
, NeN *o [00413] The HC1 salt of the title compound was prepared in 2% overall yield according to the procedure for the preparation of Example 147. 1H NMR (300 MHz, CD30D): 6 1.68-1.82 (2H, m), 2.14-2.22 (2H, m), 3.19-3.33 (2H, m), 3.47-3.58 (1H, m), 4.03 (3H, s), 4.33 (3H, s), 4.87-4.93 (2H, m), 7.28 (1H, ddõ1 = 8.1 Hz, 0.9 Hz), 7.33 (1H, dd, J = 8.7 Hz, 1.2 Hz), 7.47 (1H, dd, J = 9.6 Hz, 0.9 Hz), 7.59 (1H, dd, J= 8.1 Hz, 6.9 Hz), 7.70 (1H, d, .1-= 8.7 Hz), 7.76 (1H, s). [M+H] Calc'd for C24H23FNg0, 459;
Found, 459.
Example 152. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5-(2-methy1-2H-indazol-5-yl)pyrimidin-4-yl]benzonitrile N

I
1\1.- 4WF
1004141 The HC1 salt of the title compound was prepared in 13% overall yield according to the procedure for the preparation of Example 147.1H NMR (300 MHz, CD30D): 6 1.74-1.87 (2H, m), 2.18-2.25 (2H, m), 3.28-3.37 (2H, m), 3.51-3.59 (1H, m), 4.06 (3H, s), 4.25 (3H, s), 4.82-4.88 (2H, m), 7.22 (1H, dd, J= 8.7 Hz, 1.2 Hz), 7.54-7.65 (6H, m), 8.35 (1H, s). [M+H] Calc'd for C25H25N70, 440; Found, 440.
Example 153. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yllpyrimidin-4-yl]benzonitrile N
NH2 %.
N
Ff-N3c µ:: ON%
1004151 The HC1 salt of the title compound was prepared in 19% overall yield according to the procedure for the preparation of Example 147. NMR (400 MHz, CD30D): 6 1.76-1.86 (2H, m), 2.18-2.23 (2H, m), 3.32-3.38 (2H, m), 3.52-3.58 (1H, m), 4.16 (3H, s), 4.75-4.80 (2H, m), 4.84 (2H, clJ= 8.8 Hz), 7.27 (1H, s), 7.54 (1H, s), 7.66 (2H, dJ= 8.0 Hz), 7.82 (2H, dJ= 8.0 Hz). [M+H] Calc'd for C22H22F3N70, 458;
Found, 458.
Example 154. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5-(1-methy1-1H-1,2,3-benzotriazol-5-yppyrimidin-4-yllbenzonitrile N

N
N N
N, N *

[00416] The HC1 salt of the title compound was prepared in 7% overall yield starting according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, CD30D): 6 1.72-1.82 (2H, m), 2.18-2.23 (2H, m), 3.24-3.30 (2H, m), 3.52-3.58 (1H, m), 4.05 (3H, s), 4.35 (3H, s), 4.92-4.98 (2H, m), 7.33 (1H, dJ= 8.4 Hz), 7.56 (2H, dJ= 8.0 Hz), 7.63 (2H, dJ= 8.0 Hz), 7.70 (1H, dJ= 8.4 Hz), 7.76 (1H, s) . [M+H] Calc'd for C24H24N80, 441; Found, 441.
Example 155. 4-[2-(4-aminopiperidin-1-y1)-546-(dimethylamino)pyridin-3-y1]-6-methoxypyrimidin-4-yl]benzonitrile N

x, , .
[00417] The HC1 salt of the title compound was prepared in 19% overall yield starting according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, CD30D): 6 1.74-1.84 (2H, m), 2.17-2.21 (2H, m), 3.26-3.37 (2H, m), 3.26 (6H, s), 3.50-3.57 (1H, m), 4.07 (3H, s), 4.82-4.88 (2H, m), 7.16 (1H, dJ= 10.0 Hz), 7.68 (1H, s), 7.69 (2H, dJ= 8.0 Hz), 7.75 (1H, dJ= 10.0 Hz), 7.79 (2H, dJ= 8.0 Hz). [M+H]
Calc'd for C24H27N70, 430; Found, 430.
Example 156. 4-[2-(4-aminopiperidin-1-y1)-542-(dimethylamino)pyrimidin-5-y1]-6-methoxypyrimidin-4-yl]benzonitrile N
N. N N H2 I
N
N
N. 0' 0.,%
N N
[00418] The HC1 salt of the title compound was prepared in 25% overall yield according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, CD30D): 6 1.74-1.81 (2H, m), 2.16-2.20 (2H, m), 3.23-3.27 (2H, m), 3.32 (6H, s), 3.49-3.56 (1H, m), 4.08 (3H, s), 4.87-4.89 (2H, m), 7.72 (2H, dJ= 8.0 Hz), 7.81 (2H, dJ=
8.0 Hz), 8.35 (2H, s). [M+H] Calc'd for C23H26Ns0, 431; Found, 431.
Example 157. 4-[2-(4-aminopiperidin-l-y1)-6-methoxy-5- {3 -methy1-3H-[1,2,3]triazolo[4,5-b]pyri din-6-y1 {pyrimidin-4-y1]-2-fluorobenzonitrile WO 2015/089192 PCT[1JS2014/069562 N
N NorN H2 y -1\1' I
µN Cs=
[00419] The HC1 salt of the title compound was prepared in 4% overall yield starting according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, CD30D): 6 1.75-1.86 (2H, m), 2.18-2.24 (2H, m), 3.29-3.35 (2H, m), 3.52-3.59 (1H, m), 4.07 (3H, s), 4.33 (3H, s), 4.89-4.91 (2H, m), 7.32 (1H, d, J= 8.0 Hz), 7.58 (1H, d, J=
9.6 Hz), 7.66 (1H, dd, J= 8.0 Hz, 7.2 Hz), 8.30 (1H, s), 8.45 (1H, s).
[M+H1Calc'd for C23H22FN90, 460; Found, 460.
Example 158. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5-{3-methyl-3H-[1,2,3]triazolo[4,5-b]pyridin-6-y1)pyrimidin-4-ylThenzonitrile N
==. N N FI2 ,N N
N I
=' 0 N
[00420] The HC1 salt of the title compound was prepared in 34% overall yield starting according to the procedure for the preparation of Example 147. 1H NMR (400 MHz, DMSO-d6): 6 1.51-1.60 (2H, m), 2.02-2.07 (2H, m), 3.04-3.11 (2H, m), 3.31-3.37 (1H, m), 3.88 (3H, s), 4.26 (3H, s), 4.70-4.81 (2H, m), 7.45 (2H, d, J= 7.6 Hz), 7.70 (2H, d, J
= 7.6 Hz), 8.29 (1H, s), 8.30 (2H, s), 8.41 (1H, s). 1M+141 Calc'd for C23H23N90, 442;
Found, 442.
Example 159. 4-[2-(4-aminopiperidin-1-y1)-6-methoxy-5- 1-methyl-1H-pyrazolo [3,4-lApyridin-5-ylIpyrimidin-4-y1]-2-fluorobenzonitrile N
N 0,N H2 =:Ir I N
/
N õ
*N1 [00421] The HC1 salt of the title compound was prepared in 1% overall yield starting according to the procedure for the preparation of Example 147. 1HNMR (300 MHz, CD30D): 6 1.77-1.86 (2H, m), 2.00-2.24 (2H, m), 2.97-3.05 (2H, m), 3.54-3.58 (1H, m), 4.08 (3H, s), 4.10 (3H, s), 4.84-4.86 (2H, m), 7.32 (1H, d, J= 10.8 Hz), 7.57-7.60 (1H, m), 7.65-7.70 (1H, m), 8.30 (1H, s), 8.09 (1H, s), 8.15 (1H, s). [M+H] Calc'd for C24H23FN80, 459; Found, 459.
Example 160. 4-[2-(4-aminopiperidin-1-y1)-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile N
* N 0,N H2 I
N
-N
`Nr H
[00422] To a round-bottom flask charged with 4-(2,6-diehloropyrimidin-4-y1)-2-fluorobenzonitrile (1.6 g, 6 mmol) in THF (50 mL) was added CH3NH2 (40% in water, 2 mL) dropwise. The reaction was kept at ambient temperature for 16hrs. The reaction mixture was poured into ice-water and extracted with DCM (3*100 mL). The combined organic layers were successively washed with brine, dried with Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography to afford 4-[2-chloro-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile (700 mg, 44%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6): 6 2.87 (3H, s), 7.00 (1H, s), 7.92-7.97 (1H, m), 8.00-8.09 (2H, m). [M+H] Calc'd for C12H8C1FN4, 263; Found, 263.
[00423] To a round-bottom flask charged with 4-[2-chloro-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile (0.7 g, 2.67 mmol) in DMF (5 mL) was added NBS
(0.57 g, 3.2 mmol) portionwise. The mixture was stirred for 2hrs at ambient temperature. Upon completion, the reaction mixture was poured into ice-water and the slurry was filtered.
The filter cake was taken up in ethyl acetate and the organic layers were successively washed with water, brine, dried with Na2SO4, and concentrated in vacuo to afford 445-bromo-2-chloro-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile (900 mg, 99%) as a yellow solid. [M+H] Calc'd for C12H7BrC1FN4 341; Found, 341.
[00424] To a round-bottom flask charged with 4-[5-bromo-2-chloro-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile (900 mg, 2.64 mmol), 4-(N-boc-amino)piperidine (530 mg, 2.64 mmol), and DIPEA (680 mg, 5.28 mmol) in DMF (10 mL) was kept at 100 C for 4 hrs. The reaction mixture was poured into ice-water and extracted with ethyl acetate (3 *50 mL). The combined organic layers were successively washed with brine, dried with Na2SO4, and concentrated in vacuo to afford crude tert-butyl N- {1-[5-bromo-4-(4-eyano-3-fluoropheny1)-6-(methylamino)pyrimidin-2-yl]piperidin-4-ylIcarbamate (1.0 g, 75%). [M+H] Calc'd for C22H26BrFN602, 505;

Found, 505.
[00425] To a round-bottom flask charged with tert-butyl-N-}1-[5-bromo-4-(4-cyano-3-fluoropheny1)-6-(methylarnino)pyrimidin-2-yl]piperidin-4-yl}carbamate (0.5 g, 1.0 mmol) in dioxane/H20 (5:1, 20 mL) was added (2-methyl-2H-indazol-5-y1)boronic acid (0.34 g, 2.85 mmol), 1,1 bis(di-tert-butylphosphino)ferrocene palladium dichloride (64 mg, 0.1 mmol) and Na2CO3 (310 mg, 3.0 mmol). The reaction was reflux for 16hrs under nitrogen atmosphere. Upon completion, the reaction mixture was filtered and the filtrate concentrated in vacuo. The residue was purified by column chromatography (gradient of 50-75% ethyl acetate in petroleum ether) and prep-HPLC to give a yellow solid.
The solid was suspended in ethyl acetate (5 mL) and HC1 (5 mL, 4M in dioxane) was added and the reaction stirred for 2 hrs. The content was concentrated in vacuo to afford the title compound (350 mg, 77%) a yellow solid. 1H NMR (400 MHz, CD30D): 6 1.81-1.90 (2H, m), 2.23-2.25 (2H, m), 3.04 (3H, s), 3.34-3.39 (2H, m), 3.56-3.61 (1H, m), 4.36 (3H, s), 4.73-4.76 (2H, m), 7.40-7.45 (2H, m), 7.55-7.58 (1H, d, J= 9.2 Hz), 7.66-7.74 (2H, m), 7.84 (1H, s), 8.71 (1H, s). [M+H] Calc'd for C25H25EN8, 457; Found, 457.
Example 161. 4-[2-(4-aminopiperi din-1-y1)-5-(1-methyl -1 H-indazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile N
N NaN H2 .1=.
I N
N' `N 1101 [00426] The HC1 salt of the title compound was prepared in 10% overall yield according to the procedure for the preparation of Example 160. 1H NMR (300 MHz, CD30D): 6 1.74-1.80 (2H, m), 2.14-2.24 (2H, m), 3.01 (3H, s), 3.25-3.27 (2H, m), 3.50-3.56 (1H, m), 4.05 (3H, s), 4.71-4.76 (2H, m), 7.15 (1H, d, J= 9.0 Hz), 7.28 (1H, d, J=
8.1 Hz), 7.45 (1H, d, J= 6.6 Hz), 7.56-7.64 (3H, m), 7.99 (1H, s). [M+H]
Calc'd for C25H25FN8, 457; Found, 457.
Example 162. 4-[2-(1,4-diazepan-1-y1)-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile WO 2015/089192 PCT[1JS2014/069562 N
=== *
r\NH
N
N
_N% HN=..
[00427] The HC1 salt of the title compound was prepared in 13% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD30D): 6 2.30-2.33 (2H, m), 3.02 (3H, s), 3.47-3.49 (2H, m), 3.57-3.61 (2H, m), 3.97-3.99 (2H, m), 4.22 (3H, s), 4.24-4.26 (2H, m), 7.05 (1H, d, J= 9.2 Hz), 7.31 (1H, d, J=
8.0 Hz), 7.46 (1H, d, J= 9.2 Hz), 7.57 (1H, s), 7.62-7.65 (2H, m), 8.22 (1H, s). [M+H]
Calc'd for C25H25F-1\18, 457; Found, 457.
Example 163. 4-[2-(4-aminopiperidin-1-y1)-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-benzonitrile N

N
N
¨N 116 µ11. HNN%
[00428] The HC1 salt of the title compound was prepared in 13% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD10D): 6 1.36-1.40 (2H, m), 1.90-1.92 (2H, m), 2.90-2.99 (6H, m), 4.20 (3H, s), 4.84-4.87 (2H, m), 7.01 (1H, d, J= 8.4 Hz), 7.41-7.45 (5H, m), 7.58 (1H, d, J= 8.8 Hz), 8.11 (1H, s). [M+H] Calc'd for C25H26N8, 439; Found, 439.
Example 164. 4-[2-(4-aminopiperidin-l-y1)-5-(1-methy1-1H-indazol-5-y1)-6-(methylamino)pyrimidin-4-yllbenzonitrile N
io N aNH2 =kr N
N' `N H1\1..
[00429] The HC1 salt of the title compound was prepared in 11% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD10D): 6 1.84-1.87 (2H, m), 2.24-2.27 (2H, m), 3.03 (3H, s), 3.35-3.39 (2H, m), 3.56-3.61 (1H, m), 4.05 (3H, s), 4.72-4.76 (2H, m), 7.19 (1H, d, J= 8.4 Hz), 7.56-7.58 (3H, m), 7.63-7.67 (3H, m), 7.99 (1H, s). [M+H] Calc'd for C25H26N8, 439; Found, 439.

Example 165. 4-[2-(4-aminopiperidin-l-y1)-5-(1-methy1-1H-1,2,3-benzotriazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile N
* N i\rjaN H2 I
N
N:N
HN
[00430] The HC1 salt of the title compound was prepared in 7% overall yield according to the procedure for the preparation of Example 160. ITINMR (400 MHz, CD30D): 6 1.74-1.80 (2H, m), 2.18-2.21 (2H, m), 2.99 (3H, s), 3.25-3.27 (2H, m), 3.50-3.54 (1H, m), 4.32 (3H, s), 4.73-4.77 (2H, m), 7.30-7.32 (2H, m), 7.49 (1H, d, J= 9.2 Hz), 7.60-7.64 (1H, m), 7.77 (1H, d, J= 8.4 Hz), 7.89 (1H, s). [M+H] Calc'd for C24H24FN9, 458; Found, 458.
Example 166. 4-[2-(4-aminopiperidin-1-y1)-6-(ethylamino)-5-(2-methy1-2H-indazol-5-yl)pyrimidin-4-y11-2-fluorobenzonitrile N
'= ,,N H2 NN
I
N
-Ns HN1 [00431] The HC1 salt of the title compound was prepared in 13% overall yield according to the procedure for the preparation of Example 160.114NMR (300 MHz, CD30D): 6 1.19-1.24 (3H, t, J= 6.9 Hz), 1.83-1.87 (2H, m), 2.21-2.25 (2H, m), 3.35-3.39 (2H, m), 3.53-3.60 (3H, m), 4.36 (3H, s), 4.68-4.73 (2H, m), 7.38-7.45 (2H, m), 7.53-7.57 (1H, m), 7.65-7.74 (2H, m), 7.87 (1H, s), 8.71 (1H, s). [M+H] Calc'd for C26H27FN8, 471; Found, 471.
Example 167. 4-[2-(4-aminopiperidin-1-y1)-6-(methylamino)-541-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]pyrimidin-4-y1]-2-fluorobenzonitrile N
N 0,N H2 I
r"'"N
F3C N HN.s, [00432] The HC1 salt of the title compound was prepared in 15% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, DMSO-d6): 6 ppm 1.47 - 1.68 (m, 2 H), 1.94 -2.10 (m, 2 H), 2.82 - 3.00 (m, 3 H), 3.16 (s, 2 H), 3.31 - 3.41 (m, 1 H), 4.50 - 4.71 (m, 2 H), 4.95 - 5.13 (m, 2 H), 7.31 - 7.37 (m, 1 H), 7.42 - 7.45 (m, 1 H), 7.46 - 7.52 (m, 1 H), 7.57 - 7.65 (m, 1 H), 7.87 -7.98 (m, 1 H).
[M+H] Calc'd for C23H27FN10, 471; Found, 471.
Example 168. 4-[2-(4-aminopiperidin-1-y1)-542-(dimethylamino)pyrimidin-5-y1]-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile N

*N
Ir N N
HNN.
[00433] The HC1 salt of the title compound was prepared in 19% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD30D): 6 1.85-1.88 (2H, m), 2.21-2.24 (2H, m), 3.07 (3H, s), 3.33-3.35 (8H, m), 3.58-3.60 (1H, m), 4.72-4.75 (2H, m), 7.55 (1H, d, J= 6.4 Hz), 7.73 (1H, d, J= 8.8 Hz), 7.88 (1H, s), 8.54 (2H, s). [M+H] Calc'd for C23H26FN9, 448; Found, 448.
Example 169. 4-[2-(4-aminopiperidin-1-y1)-546-(dimethylamino)pyridin-3-y1]-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile N
* N 1-12 =Zr N
, N N." HN'N.
[00434] The HC1 salt of the title compound was prepared in 7% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD30D): 6 1.81-1.84 (2H, m), 2.17-2.20 (2H, m), 3.03 (3H, s), 3.30-3.34 (8H, m), 3.54-3.55 (1H, m), 4.68-4.71 (2H, m), 7.21 (1H, d, J= 8.8 Hz), 7.47-7.49 (1H, m), 7.64-7.65 (1H, m), 7374-7.83 (2H, m), 7.90 (1H, s). [M+H] Calc'd for C23H27FN8, 447;
Found, 447.
Example 170. 4-[2-(4-aminopiperidin-l-y1)-5- }3-methyl-3H-[1,2,3]triazolo [4,5-b]pyridin-6-y1} -6-(methylamino)pyrimidin-4-yl]benzonitrile WO 2015/089192 PCT[1JS2014/069562 N

* No-NcIr ry *HN
[00435] The HC1 salt of the title compound was prepared in 14% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD30D): 6 1.84-1.87 (2H, m), 2.23-2.26 (2H, m), 3.03 (3H, s), 3.33-3.39 (2H, m), 3.57-3.59 (1H, m), 4.35 (3H, s), 4.73-4.76 (2H, m), 7.37 (1H, d, J= 8.4 Hz), 7.59 (2H, d, J =
8.4 Hz), 7.65 (2H, d, J = 8.8 Hz), 7.80 (1H, d, J = 8.8 Hz), 7.94 (1H, s).
[M+H] Calc'd for C24H25N9, 440; Found, 440.
Example 171. 4-[2-(4-aminopiperidin-l-y1)-5- {3-methyl-3H41 ,2,3]triazolo [4,5-b]pyridin-6-y1}-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile N
=%. NN aN FI2 N I
`NI N.0 HN
[00436] The HC1 salt of the title compound was prepared in 24% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, DMSO-d6) 6 ppm 1.41 - 1.71 (m, 2 H), 1.91 - 2.05 (m, 2 H), 2.80 (s, 3 H), 2.91 - 3.12 (m, 2 H), 3.12 - 3.19 (m, 1 H), 3.25 - 3.40 (m, 1 H), 4.29 (s, 3 H), 4.68 -4.80 (m, 2 H), 7.12 - 7.29 (m, 1 H), 7.40 - 7.63 (m, 1 H), 7.69 - 7.83 (m, 1 H), 8.05 - 8.28 (m, 2 H), 8.33 - 8.62 (m, 2 H). [M+H] Calc'd for C23H23Ni0F, 459; Found, 459.
Example 172. 4-[2-(1,4-diazepan-1-y1)-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-yl]benzonitrile N
*
H
N N
I
-N N
H N s..
[00437] The HC1 salt of the title compound was prepared in 29% overall yield according to the procedure for the preparation of Example 160.1H NMR (400 MHz, CD30D): 6 2.36-2.37 (2H, m), 3.04 (3H, s), 3.51-3.52 (2H, m), 3.60-3.61 (2H, m), 3.95-3.98 (2H, m), 4.25-4.36 (5H, m), 7.34-7.36 (1H, m), 7.60-7.67 (6H, m), 8.61-8.63 (1H, m). [M+H] Calc'd for C25H26Ng, 439; Found, 439.
Example 173. 4- {2- [4-(dimethylamino)piperidin-l-y1]-5-(2-methy1-2H-indazol -5-y1)-6-(methylamino)pyrimidin-4-y1} benzonitrile N = \
*
N
¨NI\r" Itor HNN.
[00438] The HC1 salt of the title compound was prepared in 10% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD30D): 6 1.95-1.99 (2H, m), 2.32-2.35 (2H, m), 2.96 (6H, s), 3.05 (3H, s), 3.28-3.33 (2H, m), 3.68-3.70 (1H, m), 4.29 (3H, s), 4.81-4.85 (2H, m), 7.25 (1H, dõJ=
9.2 Hz), 7.59 (2H, d, = 8.0 Hz), 7.66 (2H, d, .1= 8.0 Hz), 7.73 (1H, s), 8.47 (1H, s).
[M+H]
Calc'd for C27H301\18, 467; Found, 467.
Example 174. 4-[2-(4-aminopiperidin-1-y1)-6-(methylamino)-541-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]pyrimidin-4-y1]-benzonitrile N
* N 0,N,2 F3 HN.%.
[00439] The HC1 salt of the title compound was prepared in 4% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CD30D): 6 1.67-1.79 (2H, m), 2.13-2.19 (2H, m), 3.02 (3H, s), 3.21-3.31 (2H, m), 3.47-3.52 (1H, m), 4.68-4.77 (2H, m), 4.87 (2H, q, J= 8.4 Hz), 7.42 (1H, s), 7.53 (2H, d, J=
8.0 Hz), 7.59 (1H, s), 7.71 (2H, d, J= 8.0 Hz). [M+H] Calc'd for C22H23F3N8, 457;
Found, 457.
Example 175. 4-[2-(4-aminopiperidin-l-y1)-5-{1-methy1-1H-pyrazolo[3,4-blpyridin-5-y1}-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile N

N
N
1\1µm N HN

[00440] The HC1 salt of the title compound was prepared in 14% overall yield according to the procedure for the preparation of Example 160.1H NMR (400 MHz, DMSO-d6): 6 ppm 1.46 - 1.77 (m, 2 H), 1.99 -2.15 (m, 2 H), 2.82 (s, 3 H), 3.02 - 3.22 (m, 2 H), 3.31 - 3.43 (m, 1 H), 3.43 - 3.55 (m, 1 H), 3.43 - 3.77 (m, 1 H), 3.62 - 3.80 (m, 1 H), 4.04 (s, 3 H), 4.67 - 4.74 (br., m, 3 H), 7.14 - 7.38 (m, 1 H), 7.42 -7.71 (m, 1 H), 7.73 - 7.89 (m, 1 H), 8.01 - 8.10 (m, 1 H), 8.10 - 8.19 (m, 1 H), 8.19 - 8.40 (m, 4 H).
[M+H] Calc'd for C24H24F1N9, 458; Found, 458.
Example 176. 4-[2-(4-aminopiperidin-l-y1)-5- {3-methy1-3H-[1,2,3 ]triazolo [4,5-b]pyridin-6-y1}-6-(methylamino)pyrimidin-4-yl]benzonitrile N

I Y
N
N I
=Ni HN.
[00441] The HC1 salt of the title compound was prepared in 19% overall yield according to the procedure for the preparation of Example 160.1H NMR (400 MHz, CD30D): 6 1.79-1.84 (2H, m), 2.21-2.25 (2H, m), 3.03 (3H, s), 3.29-3.33 (2H, m), 3.56-3.57 (1H, m), 4.34 (3H, s), 4.76-4.80 (2H, m), 7.58 (2H, d, J= 8.0 Hz), 7.68 (2H, d, J =
8.0 Hz), 8.40 (1H, s), 8.46 (1H, s). [M+H] Calc'd for C23H24Ni0, 441; Found, 441.
Example 177. 4- {2-[(3 S ,4R)-4-amino-3 -fluoropiperidin-l-yl] -5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-yllbenzonitrile * N ir\ H2 I
N
-N
µ11-- HN
[00442] The HC1 salt of the title compound was prepared in 3% overall yield according to the procedure for the preparation of Example 160.1H NMR (400 MHz, CD30D): 6 1.74-1.79 (2H, m), 2.89 (3H, s) 2.95-3.06 (2H, m), 3.12-3.25 (1H, m), 4.18 (3H, s), 4.65-4.88 (2H, m), 5.12-5.19 (1H, m), 6.99-7.02 (1H, m), 7.38-7.44 (5H, m), 7.56 (1H, d, J = 8.8 Hz), 8.09 (1H, s). [M+H] Calc'd for C25H25FN8, 457;
Found, 457.
Example 178. 4- {2- [(3R,4 S)-4-amino-3 -fluoropiperidin-l-yl] -5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-yl}benzonitrile WO 2015/089192 PCT[1JS2014/069562 N

1101 04,F
N
-N
H N
µNr.
[00443] The HC1 salt of the title compound was prepared in 5% overall yield according to the procedure for the preparation of Example 160. 1H NMR (400 MHz, CDIOD): ö 1.74-1.79 (2H, m), 2.89 (3H, s) 2.93-3.06 (2H, m), 3.12-3.25 (1H, m), 4.19 (3H, s), 4.65-4.88 (2H, m), 5.12-5.19 (1H, m), 6.99-7.02 (1H, m), 7.36-7.44 (5H, m), 7.56 (1H, d, J= 8.4 Hz), 8.10 (1H, s). [M+H] Calc'd for C25H25FN8, 457; Found, 457.
II. Biological Evaluation Example la: In Vitro Enzyme Inhibition Assay ¨ LSD-1 [00444] This assay determines the ability of a test compound to inhibit LSD1 demethylase activity. E.coli expressed full-length human LSDI (Accession number 060341) was purchased from Active Motif (Cat#31334).
[00445] The enzymatic assay of LSD1 activity is based on Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) detection. The inhibitory properties of compounds to LSD1 were determined in 384-well plate format under the following reaction conditions: 0.1 nM LSD1, 50 nM H3K4me1-biotin labeled peptide (Anaspec cat # 64355), 2 jtM FAD in assay buffer of 50 mM HEPES, pH7.3, 10 mM
NaCl, 0.005% Brij35, 0.5 mM TCEP, 0.2 mg/ml BSA. Reaction product was determined quantitatively by TR-FRET after the addition of detection reagent Phycolink Streptavidin-allophycocyanin (Prozyme) and Europium-anti-unmodified histone H3 lysine 4 (H3K4) antibody (PerkinElmer) in the presence of LSD1 inhibitor such as 1.8 mM of Tranylcypromine hydrochloride (2-PCPA) in LANCE detection buffer (PerkinElmer) to final concentration of 12.5 nM and 0.25 nM respectively.
[00446] The assay reaction was performed according to the following procedure:
2 jiL
of the mixture of 150 nM H3K4me1-biotin labeled peptide with 2 !IL of 11-point serial diluted test compound in 3% DMSO was added to each well of plate, followed by the addition of 2 !IL of 0.3 nM LSD1 and 6 jtM of FAD to initiate the reaction.
The reaction mixture was then incubated at room temperature for one hour, and terminated by the addition of 6 jtL of 1.8 mM 2-F'CPA in LANCE detection buffer containing 25 nM

Phycolink Streptavidin-allophycocyanin and 0.5 nM Europium-anti-unmodified antibody. Plates were read by EnVision Multilabel Reader in TR-FRET mode (excitation at 320nm, emission at 615nm and 66511m) after 1 hour incubation at room temperature. A ratio was calculated (665/615) for each well and fitted to determine inhibition constant (IC50.
[00447] The ability of the compounds disclosed herein to inhibit LSD1 activity was quantified and the respective 1050 value was determined. Table 5 provides the ICso values of various substituted heterocyclic compounds disclosed herein.

= , f Chemical LSD1 1C5o Synthesis """ ]]]] !Plamq (nM) Example 1 445-(4-methylpheny1)-1-[[(3R)-pyrrolidin-3- A
yl]methyllpyrrolo[3,2-14yridin-6-yl]benzonitrile 2 4-[5-chloro-1-[[(3R)-pyrrolidin-3-yl]methyllpyrrolo[3,2-b]pyridin-6-yl]benzonitrile 3 4-[5-(4-methylpheny1)-1-[[(35)-pyrrolidin-3-A
yl]methyllpyrrolo[3,2-b]pyridin-6-yl]benzonitrile 4 4-[5-chloro-1-[[(38)-pyrrolidin-3-yl]methyllpyrrolo[3,2-14yridin-6-yl]benzonitrile 4-[5-(4-fluoropheny1)-1-[[(3S)-pyrrolidin-3- A
yl]methyllpyrrolo[3,2-b]pyridin-6-yl]benzonitrile 6 445-morpholin-4-y1-1-[[(3R)-pyrrolidin-3-yl]methyllpyrrolo[3,2-b]pyridin-6-ylibenzonitrile 7 4-[5-morpholin-4-y1-1-[[(35)-pyrrolidin-3-A
yl]methyllpyrrolo[3,2-b]pyridin-6-yl]benzonitrile 8 4- [1-[(3 -fluoropyrrolidin-3 -yl)methyl] -5 -morpho lin-4-ylpyrrolo[3,2-14yridin-6-yl]benzonitrile 9 4-[1-[(3-fluoropyrrolidin-3-yl)methyl]-5-(4-A
methylphenyl)pyrrolo[3,2-b]pyridin-6-ylThenzonitrile 44544-methyl cnyt)-1 -[[(21)-morpho tin-2-A
yl]methy ljpyrroio[3 ,2-b]pyrid I Menzoni tri I e 11 4 45 -(4-fluoropheny1)- -[[(2R)-morpholin-2- A
y1]methy1lpyrroio[3,2-blpyridirt-6-yllbenzonitrile 12 4-[1-(3-aminopropy1)-5-(4-methylphenyl)pyrrolo[3,2- A
b]pyridine-6-yl]benzonitrile 13 445-(4-methylpheny1)-1-(pyrrolidin-3-A
ylmethyl)pyrazolo[4,3-b]pyridin-6-yllbenzonitrile ________________________________________________________________ .x.o Chemical Synthesis ''"' 1Naing Example 14 4- [5-(4-methylpheny1)-1-(piperidin-4-A
ylmethyl)pyrazolo[4,3-b]pyridin-6-yl]benzonitrile 4- [1-[[(IS, 5R)-3-azabicyclo [3.1.0]hexan-6-yl]methy1]-15 5-(4-methylphenyl)pyrazolo [4,3-b]pyridin-6- A
yl]benzonitrile 16 445-(4-methylpheny1)-2- {[(3S)-pyrrolidin-3-A
ylmethyl] amino) pyrimidin-4-yl]benzonitrile 17 4-(5-chloro-2- {[(3S)-pyrrolidin-3-ylmethyl]amino pyrimidin-4-yl)benzonitrile 18 445-(4-fluoropheny1)-2- {[(3S)-pyrrolidin-3-A
ylmethyl] amino } pyrimidin-4-yl]benzonitrile 19 4- [5-(4-chloropheny1)-2- {[(3S)-pyrrolidin-3-A
ylmethyl] amino }pyrimidin-4-yl]benzonitrile 20 445-(4-methylpheny1)-2-[(3R)-pyrrolidin-3-A
ylmethoxy]pyrimidin-4-yl]benzonitrile 21 4- {2-[(3aR,6aS)-octahydropyrrolo [3,4-c]pyrrol-2-yl] -5-A
(4-methylphenyl)pyrimidin-4-yllbenzonitrile 22 4- [5-(4-methylpheny1)-2- octahydro-1H-pyrrolo[3,4-A
c]pyridin-5-yllpyrimidin-4-yl]benzonitrile 23 4- {2-[(3aR,8aS)-decahydropyrrolo[3,4-d]azepin-6-y1]-A
5-(4-methylphenyl)pyrimidin-4-yl}benzonitrile 24 4- {2-[(3aR,8aS)-decahydropyrrolo[3,4-d]azepin-6-y1]-A
5-(4-fluorophenyOpyrimidin-4-yl}benzonitrile 25 4-(2- { [(3 S)-pyrrolidin-3-ylmethyl] amino} -5- [4-A
(trifluoromethyl)phenyl]pyrimidin-4-yl)benzonitrile 26 4- [5-(2-cyclopropylethyny1)-2- {[(3S)-pyrrolidin-3-A
ylmethyl] amino } pyrimidin-4-yl]benzonitrile 4-(2- f [(3aR,5 S ,6aS)-octahydrocyclopenta[c]pyrrol-5-27 yl]amino } -5-(4-methylphenyl)pyrimidin-4-yl)benzonitrile 28 ( )-4-(2- { [(3-fluoropyrrolidin-3-yOmethyl] amino } -5-A
(4-methylphenyl)pyrimidin-4-yl)benzonitrile 29 ( )-4-[5-(4-methylpheny1)-2-[(piperidin-3-A
yl)amino]pyrimidin-4-yl]benzonitrile Chemical 1..SD1 IC50 Synthesis ''"' (nIV1) Example 30 ( )-445-(4-methylpheny1)-2-[(piperidin-3-A
yl)amino]pyrimidin-4-yl]benzonitrile 31 ( )-4-15-(4-methy1pheny1)-2-[(piperidin-3-A
ylmethyl)amino]pyrimidin-4-yl]benzonitrile 32 445-(4-methylpheny1)-2-[(piperidin-4-A
ylmethyl)amino]pyrimidin-4-yl]benzonitrile 33 ( )-4-[5-(4-methylpheny1)-2-[(morpho1in-2-A
ylmethyl)amino]pyrimidin-4-yl]benzonitrile 34 (+)-445-(4-fluoropheny1)-2-[(morpholin-2-ylmethyl)amino]pyrimidin-4-yl]benzonitri le 35 4-(2- (2,7-diazaspiro[4.4]nonan-2-y1) -5-(4-A
methylphenyl)pyrimidin-4-yl)benzonitrile 36 4-(2- {2,8-diazaspiro[4.5]decan-2-y1} -5-(4-A
methylphenyl)pyrimidin-4-yl)benzonitrile 37 4- [5-(4-methylpheny1)-2- {octahydro-1H-pyrrolo [3,4-A
c]pyridin-2-yl}pyrimidin-4-yl]benzonitrile 38 4- [5-(4-methylpheny1)-2- foctahydro-1H-pyrrolo [3,2-A
c]pyridin-5-yllpyrimidin-4-yl]benzonitrile 39 4-(2- {2,8-diazaspiro[4.5]decan-8-y1} -544-A
methylphenyl)pyrimidin-4-yl)benzonitrile 40 4-(2- {1,8-diazaspiro[4.5]decan-8-y1} -544-A
methylphenyl)pyrimidin-4-yl)benzonitrile 445-(4-methylpheny1)-2-19-oxa-3,7-41 diazabicyclo [3 .3.1]nonan-3-y11pyrimidin-4-yl]benzonitrile 4- [5-(4-fluoropheny1)-2- {9-oxa-3,7-42 diazabicyclo [3 .3.1]nonan-3-y1} pyrimidin-4-yl]benzonitrile 43 445-(4-methylpheny1)-3-(pyrrolidin-3-A
ylmethylamino)pyrazol-1-yl]benzonitrile 44 4- [5-(4-methylpheny1)-34 [ (3S)-pyrrolidin-3- A
yl]methylamino]pyrazol-1-yllbenzonitrfle
45 445-(4-methylpheny1)-3-[[(3R)-pyrrolidin-3- A
yl]methylamino]pyrazol-1-yl]benzonitri1e _____________________________________________________ ------------Chemical 1..SD1 IC50 Synthesis Name.
( nIVI) Example
46 4- [5 -(4-methylpheny0-3 -(pip eridin-4-A
ylmethylamino)pyrazol-1-yl]benzonitrile 4-[3 - [[(I S,5R)-3 -azabicyclo [3.1.0]hexan-6-
47 ylimethylamino]-5-(4-methylphenyl)pyrazol-1- A
ylThenzonitrile
48 445-(4-metbylpheny1)-1-[[(2R)-morpholin-2-Arnett-1y ipyrrolo[3,2-b]pyrid [Thenzon i e 4- { 1-[((3 R)pyrrolidin-3-y prnethyl]-5-(4-
49 methoxyphenyOpyrro lo [3,2-bipyri din-6- A
241 benzenecarbonittil e, FIC1 salt 4- { 1-[((3R)pyrrolidin-3 -Arne thyli-5 -(3 -11 oro-4-
50 m ethowhenyppyrro lo [3,2- b]p yridin-6- A
y benzeneearbonitri HC salt 4- { 1 -[((3 S)pyrroi i di n-3-y thyI]-5-(3- uoro-4-
51 methoxyphertyppyrrolo[3,2-b]pyridin-6- A
yl benzenecarbonitri e, VICI salt 4- -[((3R)pyrTolidin -3-y1)Triethyli-5 -(4-
52 methowhenyppyrrolo[3,2-b]pyridin-6-y1}-2- A
fitiorobenzenecarbortitrile HO salt 4-1.1 -[((3 R)pyrrolidin-3 -y1)11-astli y[]-5 -(3 -fluoro-4-
53 methoxyphenyl)pyrrolo[3,2-b]py-ridin-6-y1}-2- A
fluorobenzeneearbonitri lIC1 salt
54 4- [5 -morph in-4-y 1-[[(3R)-pyrroli di n-3 - A
y] irn ethyllpyrrolo[3 ,2-bipyri din -6-yl]benzonitri le 4-11 -[( (3 R)pynolidin-3 -yOmethy11-5 -(3 -fluoro-4-
55 thoxyphenyl )pyrrolo [3,2-b] pyri d in-6-y } -2- A
fluorobenzenecarbonitrile HCl salt
56 4- .,.µ3 -[((3R)-3-am inop ip eridypearbony11-5 -(2- A
p yridytmetb oxy)p yrazo benzenecarbortitrile
57 4- It 3-[((3R)-3-a m Mop i peridy1) carbon y ]-5-(3- A
pyridylmetboxy) pyrazolyi benzeneearbonitrile
58 4- {3-[( (3 R)-3 -aminop eri dy carbonyl]-5-(4- A
pyridyiniethoxy) pyrazoly1) bet-v.7,cm eca rbonitrile
59 -[2-(4-aminop in-1-y1)-5-(2-methy lind a zol-5 A
yi )pyrimidin-4-y,,11-2-fluorobenzoninile
60 442-(I ,2,3,3 a,4,6,7,7a-octah vdropyrrolo[3,2-clpyridin- A
5-y1)-5 -(4 -methylphenyl)pyrimidin-4-yli b enzonitrile _____________________________________________________ ------------Chemical 1..SD1 IC50 Synthesis Name.
(Oil) Example
61 442-(4-ami1opiperid A
trifluoroediy1)pyrazo1-4-yr]pyrimidin-4-yllbenzonitrile
62 4-12(2,8-diazaspiro[4.51decan-8-y1)-54142,2,2- A
trill uoroet hyl)py razo I -4-yl]pyrirni d in-4-y1Then zo rti (rile 44241,2,3 ,3 a,4,6,7,7a -octahydropyrrolo[3,2-c]pyridin-
63 5-y1)-541-(2,2,2-trifinoroethy1)pyrazol-4-Apyrimi din- A
4-ylibenzonitrile
64 442-(4-aAninopiperid1n-1-y1)-5-(1 --inethy pyrazolo [3,4- A
b]pyridna-5-yppyrirnidin-4-ylibenzonitrile 442-(2,3,3a,4,5,7,8,8a-octahydro-11-1-pyrro lo [3,4-
65 d]azepin-6-y1)-5-(1-methy1pyrazo10 [3,4-bjpyri din -5- A
yl)nyrimidin-4-ylMenzonitrile
66 4- [2-(4-aminopiperidin-1-y1)-5-(3 -methylimidazo [4,5- A
Npyridin-6-y1 )pyrimid in-4-y 1 Menzonitrile
67 4- [2-(4-arni ilopiperi di T1- -y1)-5-(1-1/1 eth yipyra zolo [4,3 -A
blpyridin-5-Apyrimidin-4-yllbenzonitrile
68 4[244-arninopiperidin-1-y1)-542-n-!ethylpyrazolo[4,3- A
bipyridin-5-yl)pyrimidin-4-y1Thenzonitrile
69 4- [2-(4-ami nopiperi din-1-y1)-5-(1-methylpyrazolo [3,4- A
c]pyridin-5-:õ71)pyriniidin-4-ylThenzonitrile 44.2-(4-arninopiperidin-1 -y1)-512-(1-
70 hydroxycyc1opentypethynApyrimidin-4- A
yl jbenzonitri le
71 442-(4-amin opi pe rid-y1)-541-(oxolan-3- A
yl)pyrazol-4-yl]pyrimidin-4-y1 lbenzonitri le
72 442-(4-arninopiperidin-l-y1)-5-(1-methylbenzotriazol- A
5-yl)pyrii ti din -4-y1 Theazoni tri le
73 44244-al n opi perid in-1-y1)-5-(2-methy pyra zolo [3,4- A
cipyridirt-5-yl)pyrimidin-4-yl]benzonitrile
74 4-[2-(4-arn inopiperidin-l-y1)-5 -( 2-me th oxypy rimi di A
5-y)pyrimidin-4-yt]benzoiiiirik
75 4-[2-(4-a minopiperidin-1-y1)-5 -(1,2- A
dirnethylbe 1121i Mid azol-5-yl)pyri i di n-4-y benzoni trile
76 4- [2-(4-ami n opi peri d n-1-)71)-5-(2-m eth ylpyra zolo [4,3 -A
Npyridin-6-y1)pyrimidin-I-ylibenzonitrile _____________________________________________________ ------------Chemical 1..SD1 IC50 Synthesis isamw (nN11) Example
77 442-(4-a ino pi N. ridin-l-y t)-5-(1 411 (Ally tpyrro o [3,2- A
78 442-(4-aminopiperidin-1-y1)-5-{1 -(oxo A
ylmethyppyrazol-4-yllpyrimidin-4-yflbenzointrile 442-(4-al n opiperi d in-1-y1)-541-
79 (di fluoromethypbenzimislazol-5 A
yll benzonitrile 4- [2-(4-aminopiperi di r3-1-y1)-541 -(222-
80 triffuoroethy1)pyrazo1-4-y1byrimidin-4-y1J-2- A
fluorobenzonitrile
81 442-(4-arn1nopi perid [1,2,4] triazo lo [1,5-)pyrimidin-4-yiThenzonitrile
82 442-(4-aminopiperidin-1-y1)-5-(4- A
e thy 1ph eny ei1ZOIlitri le
83 4-[2-(4-aminopiperidin-1-y1)-5-(4- A
meth oxyphenyl)pyrimi din-414] benzonitrile
84 442-(4-arn in opi peri d )-54341130m-4- A
methoxyphenyl)pyrimidin-4-yllbenzonirrile
85 4- [2-(4-a mi nopiperi din-1-y1)-5-(2 -methylpyrazolo [3,4- A
1.)] pyri din-5 -yl)pyrimidin-4-yi]benzoni e
86 442-(4-a ini n op i net- id in-1-y1)-5-(2-methy pyra zolo [4,3-dipyrimidin-5-yppyrimidin-4-yilbenzonitrile
87 4-[2-(4-aminop ip eridin-i-y1)-5-(1-me thy enz m idazol- A
5-yl)pyrimidin-4-y1]-2-1-Thorobenzoni trile
88 4- [2-(4 -a rninopiperidin-l-yi)-5-(1-rnethylpyrazolo [4,3 -dipyrimidin-5-34)pyrimidin-4-yllbenzointrile 2-fluoro-44244-(met ny amino)piperidin-l-y1]-5-[1-8 9 (2,2,2-trif1uoroethyl)pyrazol.-4-yl]pyTimidin-4- A
yilbenzonitrile 90 442-(4-aminop ip eridi n-1-34)-5 -(2-me thylpyrimi A
yi )pyrimi di r3-4-y1 Penzonitrile 91 44244 -aminopip eridin-l-y1)-5-(3H-benzimid azo1-5- A
yl)pyrimidin-4-y1Thenzon itri le 92 4-[2-(4-am inOp ip eri di r3-1-y1)-5 -(2,3-diTnerhy1 in d azo1-5-A
yl)pyrimidin-4-y111-2-fittorobenzonitri1e _____________________________________________________ ------------Chemical Synthesis is am w ( Example 93 442-(4-arninopiperi n -1-y1)-5 -( I ,3-d i neth y indazol-5- .. A
yl) p yrimidin-4-y111-2-fluorob enzoni (rile 94 44244-an-tin opiperidin-1-y -5 42-(3 -11ydroxyoxo lan-3 A
2,4)ethy nylipyrimi di n-4-yi]-2-fluorobenzon .. e 445 -(3 n 0-2-111 e11/ ylind azol-5-y 95 a:minopipericlin4-y1)pyrimidin-4-y1] -2- A
fi [or benzon it rile 96 442-(4-aminopiperidin-l-y1)-5-(1 -rnetitylbenzotriazol- A
-yl)pyri idin-4-y11-2-fluorob enzoni trile 97 442-(4-aminop iperi n -1-y1)-5 -424 4- hy drox yoxan-4- A
yl)et hynylipyrirni -4-y1]-2-11 uombe,nzoni e 98 4 -[2-(4-aminop ip erid in-1-y1)-5 -[2-(3 -rnethyltria zo1-4- A
yl)ethynyl]pyrimidin-4-yill-2-fluorobenzonitrile 99 4- [2-(4-arni nopin eri di n-1-y1)-542-( e thylpyrazol-3-A
ypethynylipyrirnidin-4-y11-2-fluorobenzonitrile 100 4-12(4-mai nopiperidin-1-y1)-5 42-(1-rn othyltri azol-4- A
yl)ethy nyi ipyri mi di n-4-y11-2-fluombenzon trile 442-(4-araino-3-hyd roxypip eri d in -1 -y 1 )-5 -( 1 -1 01 tnethylindazol-5-yl)pyrimidin-4-y11-2- .. A
1. [aro enz.on it rile 102 442-(4-aminopiperid in-1-y1)-542-(1-rnethylpyrazol -4- A
.y1)ethynylip-yrimidin-4-yli-2-fluorobenzonitrile 4-12-(4-amino-3- droxyp ip eri din-1-y1)-5 -[1-(2 õ2,2-103 trifluoroethyl)pyrazol.-4-yl]p)Timidin-4-y11-2- A
fluOrObell zon tri I e 442-(4-arnino-3-hydrox3piperidin- I -y1)-5--( 1-104 nn...thy lind azol-5-yl)p yrimichn-4-yrj-2- A
fluorobenzonitrile 442-(4-aminopiperidin-1-y1)-54 6-fluoro-1-105 rn et hy-lb enzotri A
fluorobenzonitrile 106 4-- [2- (4-arninopip eri di n-1-y1)-5 - [2 --(2--me thylpyrazol-3 ..
A
yl)ethynylipyrimidin-4-y11-2-fliwobenzonitrile 4-[2-(4 -a mino-3-by droxyp p eridi I -y1)-5 -(2-107 methylindazol-5-Apyrimidin-4-y11-2- A
fluoroben zoni e Chemical 1..SD1 IC50 Synthesis isamw (nN11) Example 108 442-(3-annnopipc rid in-1-y!)-5-(2-methylin dazo1-5- A
yl)pyrimidin-4-y11-2-fluorobenzonitrile 109 2-fluoro-4- [542 -mealy I in dazol-5 -y1)-2-p inera zin-1- A
ylpyrimidin -4-y ] benzoni trile 110 44241,4 -diazepan-1-y1)-5-(2-metbyl ind azol A
yi)pyrirnidin-4-y11-2-fluorobenzonitrile 442-(4-arn ino-3-11 uoropiperidin-1 -y1)-54 1-111 methy ind.azo1-5-Aprimidin--4-y11-2- A
fluorobenzonitriie 442-(4-ani in o-3 -11tioropip eri di n-1 -y1)-5-(2-112 methy1indazo1-5-yl)pyrimidin-4-y11-2- A
11 uo robenzonitri le 113 4[242,7-diazaspiro[3.5]nonan-7-y1)-5-(4- A
e thy 1ph eny ei1ZOIlitri le 44242,3,3 a ,4,5,7,8,8a-octallydro-IH-pyrro lo [3,4-114 diazepin-6-A-5-(6-methy1py-ridin.-3-y1)pyrimidin-4- A
ylibenzonitri le 4-[2-(1,2,3,3 a,4,6,7,7a-o otallydropyrrolo [3,44.]pyridin-115 5-y1)-541-methy1indazo1-5-y1)pyrimi din-4- A
yliberrzordtrile 116 4 -[244-aminop iperidin-1-y1)-541-mettly Find a zo1-5 A
y Opyrimi l]benzonitrile 4[242,3,3a,4,5,7,8,8a-octahydro-11-1-pyrro lo [3,4-117 if] azepin-6-y1)-5-(i Ii-indazol-6-yl)pyrimid A
yl]benzonitrile 44242,3,3 a.,4,5,7,8,8a-octahydro-1H -pyrrolo [3,4-118 d] aze pi n-6-y1)-5-(1,3-dim.ethylpyrazol-4-Apyrimidi A
4-ylThenzonitrile 119 4-[2(7-diazabicy lo[3 .1]nonan-3-y A
methyl phenyl)pyriro id in-4-y1Thenzon e 120 4 42-(3,7-diaza bicy cloL3 3 .11nonan-3 -y1)-5-( 1- A
Tnethy dazol-5 -yl)pyrimi di n-4-yl] b enzoni trile 121 44242,8-di azaspiro[4.5]decan-8-y1)-541-(2,2,2- A
trifluoroethyl)pyrazo1-4-yllpyrimidirt-4-y1Thenzonitrile 122 442-(4-arn inon ip eri din- I -y1)-5 -(1-rn e thylb enzi A
5-yl)pyrimidin-4-y1Thenzon itril e Chemical 1..SD1 IC50 Synthesis 4Namw (nM) Example 123 442-(4-a 3 ni nopiperid in- -y1)-5-(6-Incthoxypyrid!!1-3- A
yppyrimidin-4-ylibenzonitrile 4-[2-(4-ami nopiperi din- 1 )-546-(cyclopropylmetho,;.y)pyridi rt-3-y1byrimi di 11-4-ylibenzonitrile 125 442 -(4-aminop ip eri n- 1 -y1)-5 -(6-fluoro- 1- A
methyl benzimidazo 1-5-y 1 )pyri tn id in-4-y [Then zon e 126 4- [2-(4-a rninop ip eridi n- 1 -y1)-5 -(6,7-d ifluoro- 1 - A
meth ylb enzimi dazo1-5-yl)pyrimidi n-4-yli benzonitrile 127 442-f4-arn inopiperidin-1 -y1)-54 [1,2,41Itriazo lo [ 1,5-a]pyridin-6--y1)pyrim1 di n-z1-yi CT1Zoni trile 128 44244 -aminopiperidin- 1 -y1)-5-(2-methylindazo1-5 A
yl)pyri en zon itrii 129 442-(4-aini nopiperi d in- 1 -y )-5-(2-methy n dazo1-6- A
y! )pyrimidin-4-ylibenzonitri le 44242,3,3 a ,4,5,7,8,8a-ociallydro-1 H-pyrro lo [3,4-130 d] az epin fluoro-1 -rnethylberizi A
5-yppyrimidin-4-yliberizonftrile [2-(4-a mi nop iperi di n- 1-y1)-54642,2,2-131 tritiuoroethoxy)pyrid I mid midin-4- A
yllbenzonitrile 44244 -aminopip eridin- 1 -371)-5 -(6,7-d ifluoro-1 132 meth y lb enz imi dazol-5-yl)pyrim -y1] -2- A
fluorobenzonitriie 4-[2-(4-arn inopiperi 1 -y1)-5 -(6-fluoro- 1 -133 ethy1benzimidazol-5-y1)pyrimi A
fluorobenzonitrile 44244 -aminopiperidin- 1 -y1)-542-@it-n(1T. hy 1 arn ino)pyrimidirt-5-ylipyrirnidi n-4-y1]-2-ihioroben zon tri1 e 135 4 -L2-(4-annnopip eridin- 1 -y1)-5 -(2-pyrrolidin- 1- A
y yrimi din-5 -y1 )pyrimi 11]-2-fi uoro benzorntri le 136 4- [2-(4-ami n opip eri d in- I -y 1)-5 -( 3 -Tneth y dazo [4,5-A
lApyTidin-6-3/1)pyrimidin-4-341-2-fluorobenzonittile 4-{2-(2,8-diazaspiro[4.51decan-8-y1)-5-(3-137 methy 1 midazo [4,5-bi A
fluorobenzonitrile _____________________________________________________ ------------Chemical 1..SD1 IC50 Synthesis Name.
nIVI) Example 442-(4-aminopipc ri n -1-y1)-54 I ,2-138 d ime thy lb enzimid A
fluorobenzonitrile 139 4424 zl-a min op iperid in-1-y1)-5-(3-meth y:Itriazolo [4,5- A
b]pyridin-6-yl)pyrimidin-4-y11-2-fluorobenzonitrile 442-(4-aminopiperidin- I -A-542-140 (met hy lamino)pyri m A
fi OrOb Clizonitri I e 442-(4-ami nopiperi din-1-yI)-542 141 eye1opropylamino)pyrimidin-5-y1]pylimidin-4-y1]-2- A
fluorobenzonitrile 142 4-[2-(4-a mi nor iperidin-l-y1)-5-[i -(ox an-4-Apyrazo I- A
4-yl]pyrimidin-4-y1.1-2-fluorobenzonitri 143 442-(3-amiriopyrrol n -1-y I)-5-(2-me thyl in clazot-5- A
yl)pyrimidin-4-y11-2-fluorobenzonitrile 4-[2-(6-am ino-3-aza bicyclo [3. I (.)]hexan-3-34)-5-(2-144 methy1inda7o1-5--Apyrimidin-4-y1]-2- A
fluorobenzonitrile 145 4- [2-(4-ami nopiperidin-1-y1 )-5-( I ipyrazolo [3,4- A
pyridin-5-yl)pyrimidin-4-y1] -241 uorobenzoni trile 4-[2-(2,3,3a ,4,5,7,8,8a-octahydro-11-1-pyrrolo[3,4-146 azepin-6.-y1)-5-(1,3-benzothiazo I-5-y1)pyrimidin-4- A
ylibenzonitrile 147 4-[2-(4-am I)-6-m e thoxy-5-(2-meth y I- A
2 H-inda zol-5 -yppyrimi di n-4-y1]-2-fluorob zon itrile 148 4-4241 ,4-diazepah-1-y1)-6-methoxy-542-met1iy I -2 A
d azol-5-34)pyrimi cli ri-4-y11-2-fluorob zop i e 149 ,142-(4-aminoazepan-l-y1)-6-methoxy-5-(2-methyl-2H- A
ndazo I-5-y )pyrim idin-4-y11-2-fluorobenzonitrile 150 442-(4-aminopiperidin-1-y1)-6-methoxy-5-(2-methyl- A
2H-indazol-6-3/1)pyrimidin-4-y1]-2-fikl oroberizonitrile 4-42 44-mail-top ip eri di n-1.-y1)--6 - methoxy-5 --(1-methyl-151 1 1-1-1,2,3-berizotriazol.-5-y1)pyrimidin-4-yll-2- A
fluorobenzonitrile 152 nopipe ri d I -y[)-6-methoxy-5-(2-methyl- A
21-1-indazol-5 -yi)pyrimi zon i tril e Chemical 1..SD1 IC50 Synthesis Name.
(nN11) Example 442-(4-aminopiperidi T1- -y1)-6-rn c-thoxy-5-[1-(2,2,2-153 trifluorodhyl)-111-pyrazol-4-y1] pyrimid A
ylibenzonitri le 154 442-(4-aminopiperidin-l-y1)-6-rhethoxy-5-(1 -methyl- A
1H-1.23-1) enzotriazoi-5-yl)pyrimidin-4-yli benzonitrile 442-(4-aminopiperidin-1-y1)-546-155 (dim ethylarn in Opyridin-3-y1]-6-methoxypyrimidi n-4- A
yl Then zon itri e 442-(4-ami nopiperi din-1-y1)-542 156 (d in ethylarn ino)pyri midin-5-341-6-m ethoxypyri A
4-yllibenzonitrile 442-(4-aminopiperidin-1-y1)-6-mcdloxy-5- {3-me thy -157 3 I-I-[1,2,3] triazoto[4,5-Npyridin-6-yl}primi din -4-y 11- A
2-fltiorob C117011 itri 1 C
4-[2-(4-amin opip eridin-1 -y1)-6-methoxy-5- {3-methyl-158 3 I-141,2,3] triazo [4,5-blipyridin-6-yl}pyrimidin -4- A
Abell-Lon itri e, 4-[2-(4-aminopip eridin-1-y1)-6-methoxy-5 1-methyl-159 1/1-pyrazolo[3,4-bipyridin-5-yl}pyrimidin-4.-y11-2- A
uorob (Mani tri le 4- [2-(4-aminopip eridin-1 -y1)-5 -(2-methyl-211-indazol-5-14)-6-(methylamino)pyrimidin--4-y11-2-fluorobenzonitriie 4 - [2-(4-aniinopip eri ^ 0-5 -(1 -methyl d a zo -161 5-y1)-64m et hylamino)pyrimidin-4-yili -2- A
littorobenzonitrile 162 44241 ,4-d iazep an- I -y1)-5(2-methy1-2H-indazol-5-y1)- A
6-(methylamino)pyrimidin-4-yli-2-fluorobenzonitrile 163 4- [2-(4-aminopip eri di n-1-y1)-5 -(2-rn et hy1-2H n dazoi- A
-y1)-6-(methylamino)pyrimid in-4 -yll-b enzonitrile 164 4- [2-( 4-amin opip e ridin-l-y1)-5 -( 1-methyl-1H-inda zol- A
5-y1 )-6-(met hy am ino)pyri m idi n-4-yli ben zon itri le 442-(4-am inopiperidin-1-y1)-54 1-m ethyl- I I-I-1,2,3-165 benzotriazol-5-y1)-6-(methy1amino)pyrimidin-4-yli-2- A
fluorobenzonitrile 4-[2-(4-amino piperid n -1-y1)-6-(e thyla mino)-5-(2-166 methy1-214-indazoi-5-Apyrimidim-4 -y11-2- A
uoro benzonitri le Chemical 1..SD1 IC50 Synthesis is am w ( nIVI) Example 442-(4-arni T1011 eri di n - 1 -y1)-6-(mc.*;_;/1 a ni 1310-5 -[ 1 -167 (22,2-trifle oroethyl)-1H-pyrazol-4-yf]p yrimidin-4-yil A
2-fluorobetIZOIlitri le 442-(4-ami flop iperi din- 1 -y I )-542-168 (dimethylamino)pyrimidin-5-y1]-6- A
(met hylarnino)pyrimidi ri-4-y11-2-fluo rob enzoni trile 4 4 24 4-am ino p iperidin- 1 -y1)-546-169 (dimethyl a In ino)pyridin-3-yll -6- A
(me thylami no )pyrirnidin-4-vll-2-fluorobenzonitrile 442-(4-ami nopiperid in- 1 -y 1 )-5- {3-methyl-3H-170 [1,2,3]triazolo [4,5-Npyridin-6-y1) -6- A
m et hylam o )pyrimidin-4-yllbenzonitriie 4-[2-(4-am ino p iperidin-1-y1)-5- {3 -In e th-y1-311 -171 [1,2,3]triazolo [4,5 -blpytidin-6-y1) -6- A
(me thylami no )pyrirnidiii-4-vll-2-fluorohenzonitrile 172 4-{2-(1,4-diazepan- I -y1)-5 42-methy1-211-i ndazo I-5 -y1)- A
6-(rn eihylamino)pyritn id in-4-y Denzoni e 4- [2-[4-(d imethylarnino)p iperid in- 1 -y1]-5 -(2-methyl-173 2H -i n dazol-5-y0-6-(methylamin Opyrimi din -4- A
yllbenzonitrile 442-(4 -a minop ip eri din-1-y1)-6-(methyla mino)-5 [ 1 -174 (n . .
,2,2,41111uot ethyl)-1 H-pyrazo I -4-yl ]pyrimi din -4-yil A
berizoni t rile 4 42-(4-aminopiperidin- -y1)-5- I -methyl-175 pyrazolo [3,4-b]pyridin-5-y1) -6- A
(methylamitio)pyrimidin-4-yil-2-fluorobenzoni true 44244 -aminopiperidin- 1-y1)-S- { 3 -methy1-314-176 [1,2,3jtriazolo[4,5-bipyridin-6-y1) -6- A
(thethylami n Opyrimi di n-4-yl The azonitrile 4- f 2-[(3 S,410-4-amino-3 -fluoropip eridin- 1 -y11-5 -(2-177 methy1-2H-indazo1-5-y1)-6-(methy1arnino)pyrimidin-4- A
11benzonitri I e 4- [ 2-[(3 R,4S)-4-a mino-3 -fluoropip 1 -y11-5 -(2-178 methyl-2H-indazol-5 -y1)-6-(methylamino)pyrimidi n-4- A
y I thetrzonitrile Note: Biochemical assay IC50 data are designated within the following ranges:
A: < 100 nM

B:> 100 nM to < 1,000 nM
C:> 1,000 nM to < 10,000 nM
D: > 10,000 nM
Example 2: In Vitro Enzyme Inhibition Assay ¨ MAO selectivity [00448] Human recombinant monoamine oxidase proteins MAO-A and MAO-B are obtained. MAOs catalyze the oxidative deamination of primary, secondary and tertiary amines. In order to monitor MAO enzymatic activities and/or their inhibition rate by inhibitor(s) of interest, a fluorescent-based (inhibitor)-screening assay is performed. 3-(2-Aminopheny1)-3-oxopropanamine (kynuramine dihydrobromide, Sigma Aldrich), a non-fluorescent compound is chosen as a substrate. Kynuramine is a non-specific substrate for both MAOs activities. While undergoing oxidative deamination by MAO
activities, kynuramine is converted into 4-hydroxyquinoline (4-HQ), a resulting fluorescent product.
[00449] The monoamine oxidasc activity is estimated by measuring the conversion of kynuramine into 4-hydroxyquinoline. Assays are conducted in 96-well black plates with clear bottom (Corning) in a final volume of 100 jil. The assay buffer is 100 mM HEPES, pH 7.5. Each experiment is performed in triplicate within the same experiment.
[00450] Briefly, a fixed amount of MAO (0.25 [tg for MAO-A and 0.5 ng for AO-B) is incubated on ice for 15 minutes in the reaction buffer, in the absence and/or in the presence of various concentrations of compounds as disclosed herein (e.g., from 0 to 50 [tM, depending on the inhibitor strength). Tranylcypromine (Biomol International) is used as a control for inhibition.
[00451] After leaving the enzyme(s) interacting with the test compound, 60 to 90 [tM of kynuramine is added to each reaction for MAO-B and MAO-A assay respectively, and the reaction is left for 1 hour at 37 C in the dark. The oxidative deamination of the substrate is stopped by adding 50 n1 of 2N NaOH. The conversion of kynuramine to 4-hydroxyquinoline, is monitored by fluorescence (excitation at 320 nm, emission at 360 nm) using a microplate reader (Infinite 200, Tecan). Arbitrary units are used to measure levels of fluorescence produced in the absence and/or in the presence of test compound.
[00452] The maximum of oxidative deamination activity is obtained by measuring the amount of 4-hydroxyquinoline formed from kynuramine deamination in the absence of test compound and corrected for background fluorescence. The Ki (IC50) of each inhibitor is determined at Vmax/2.

Example 3: LSD1 CD1lb cellular assay [00453] To analyze LSD] inhibitor efficacy in cells, a CD1lb flow cytometry assay was performed. LSD1 inhibition induces CD1lb expression in THP-1 (AML) cells which can be measured by flow cytometry. THP-1 cells were seeded at 100,000 cells/well in 10%
Fetal Bovine Serum containing RPMI 1640 media in a 24 well plate with a final volume of 500 uL per well. LSD1 test compounds were serially diluted in DMSO. The dilutions were added to each well accordingly to a final concentration of 0.2% DMSO. The cells were incubated at 37 degrees Celsius in 5% CO2 for 4 days. 250 uL of each well was transferred to a well in a 96 well round bottom plate. The plate was centrifuged at 1200 rpm at 4 degrees Celsius in a Beckman Coulter Alegra 6KR centrifuge for 5 minutes.
The media was removed leaving the cells at the bottom of the wells. The cells were washed in 100 [IL cold HBSS (Hank's Balanced Salt Solution) plus 2% BSA
(Bovine Scrum Albumin) solution and centrifuged at 1200 rpm at 4 degrees Celsius for 5 minutes. The wash was removed. The cells were resuspended in 100 uL HBSS plus 2%
BSA containing 1:15 dilution of APC conjugated mouse anti-CD1lb antibody (BD
Pharmingen Cat# 555751) and incubated on ice for 25 minutes. The cells were centrifuged and washed two times in 100 jul HBSS plus 2% BSA. After the final spin the cells were resuspended in 100 ILL HBSS plus 2% BSA containing lug/mL DAPI
(4',6-diamidino-2-phenylindole). The cells were then analyzed by flow cytometry in a BD
FACSAria machine. Cells were analyzed for CD 1 lb expression. The percent of CD11b expressing cells for each inhibitor concentration was used to determine an IC50 curve for each compound analyzed.
[00454] Table 6 provides the cellular IC50 values of various substituted heterocyclic compounds disclosed herein.

Chemical n Cellular Synthesis = IC50 (pM) Example 1 4-[544-methylpheny1)-1-[[(3R)-pyrrolidin-3-A
yllmethyllpyrrolo[3,2-b]pyridin-6-yllbenzonitrile 2 4-[5-chloro-1-[[(3R)-pyrrolidin-3-yl]methyllpyrrolo[3,2-b]pyridin-6-yl]benzonitrile 3 445-(4-methylpheny1)-1-1[(35)-pyrrolidin-3-A
yl]methyllpyrrolo[3,2-b]pyridin-6-yllbenzonitrile Chemical Cellular Synthesis ''"'Namei IC50 (1..tM) Example 4 4-[5-chloro-1-[[(3S)-pyrrolidin-3-yl]methyflpyrrolo [3 ,2-b]pyridin-6-yl]benzonitrile 4-15-(4-fluoropheny1)-1-[[(3S)-pyrrolidin-3-yl]methyl]pyrrolo [3 ,2-b]pyridin-6-yl] benzonitrile 6 4- [5-morpholin-4-y1-1-[[(3R)-pyrrolidin-3-yl]methyllpyrrolo [3,2-b]pyridin-6-yl]benzonitrile 7 4-[5-morpholin-4-y1-1-[[(3S)-pyrrolidin-3-ylimethyllpyrrolo [3 ,2-b]pyridin-6-ylThenzonitrile 8 4-[1- [(3-fluoropyrrolidin-3-yl)methyl]-5-morpholin-4-ylpyrrolo [3 ,2-b]pyridin-6-yl] benzonitrile 9 4-11-[(3-fluoropyrrolidin-3-yl)methyl]-5-(4-methylphenyppyrro1o[3,2-b]pyridin-6-yl]benzonitrile 4-[5--(4.-methylpheny1)-1-[[(2R)-morpholin-2-yi]methylip,yrrolo[322-b]pyridin-6-ylThenzonitrile 11 4-[5-(4-fluotophetiy:1)-1-11:(2R)-Triolpholin-2-Arnethylipyrrolo[3,2-b]pyridin-6-Abenzonitrile 12 4-[1-(3-aminopropy1)-5-(4-methylphenyl)pyrrolo [3,2-M224yridine-6-ylThenzonitrile 13 4- [5-(4-methy1pheny1)-1-(pyrrolidin-3-ylmethyl)pyrazolo [4,3-A
b]pyridin-6-ylThenzonitrile 14 445-(4-methylpheny1)-1-(piperidin-4-ylmethyl)pyrazo10 [4,3-A
b]pyridin-6-ylThenzonitrile 4-[14R/S,5R)-3-azabicyclo[3.1.0]hexan-6-ylimethyl]-5-(4-A
methylphenyl)pyrazolo[4,3-b]pyridin-6-yl]benzonitrile 16 4- [5-(4-methylpheny1)-2- {[(3S)-pyrro1i din-3-A
ylmethyl] amino} pyrimidin-4-yllbenzonitrile 17 4-(5-chloro-2- {[(3S)-pyrrolidin-3-ylmethy1] amino } pyrimidin-4-yObenzonitrile 18 445-(4-fluoropheny1)-2- {[(3S)-pyrrolidin-3-ylmethyl] amino} pyrimidin-4-ylibenzonitrile 19 445-(4-chloropheny1)-2- {[(3S)-pyrrolidin-3-ylmethyl] amino pyrimidin-4-yllbenzonitrile 445-(4-methylpheny1)-2-[(3R)-pyrrolidin-3-ylmethoxy]pyrimidin-4-y1]benzonitrile Chemical Cellular Synthesis ''"' Name IC50 (11M) Example 21 4- {2- [(3aR,6aS)-octahydropyrrolo ,4-c]pyrrol-2-y1]-5 -(4-A
rnethylphenyl)pyrimidin-4-ylIbenzonitrile 22 4- [5-(4-methylpheny1)-2- loctahydro-1H-pyrrolo[3,4-c]pyridin-5-A
yllpyrimidin-4-Abenzonitrile 23 4- {2-[(3aR,8aS)-decahydropynolo ,4-d]azepin-6-yl] -544-A
methylphenyOpyrimidin-4-ylIbenzonitrile 24 4- {2-[(3aR,8aS)-decahydropyrrolo ,4-diazepin-6-y1]-5-(4-fluorophenyl)pyrimidin-4-y1} benzonitrile 25 4-(2- [(3S)-pyrrolidin-3 -ylmethyl] amino I -5-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl)benzonitrile 26 445 -(2-cyclopropylethyny1)-2- { [(3S)-pyrrolidin-3-ylmethyl] amino} p yrimidin-4-y libenzonitrile 27 4-(2- {R3aR,5S,6aS)-octahydrocyclopenta[c]pyrrol-5-yl]amino}--(4-methylphenyl)pyrimidin-4-yl)b enzonitrile 28 ( )-4-(2- {[(3-fluoropyrrolidin-3-yl)methyl]amino -5-(4-methylphenyl)pyrimidin-4-yl)benzonitrile 29 ( )-445-(4-methylpheny1)-2-[(piperidin-3-yl)amino]pyrimidin-4-y enzonitrile 30 ( )-445-(4-methylpheny1)-2-Rpiperidin-3-y1)aminolpyrimidin-4-yl]benzonitrile 31 ( )-445-(4-methylpheny1)-2- [(pip eridin-3 -ylmethyDamino]pyrimidin-4-y1 Thenzonitrile 32 445 -(4-methylpheny1)-2-[(piperidin-4-ylmethyDamino]pyrimidin-4-y1 Thenzonitrile 33 (+)-4-[5-(4-methylpheny1)-2-[(morpholin-2-ylmethyDamino]pyrimidin-4-yl]benzonitrile 34 (-0-445-(4-fluoropheny1)-2-[(morpholin-2-ylmethyDamino]pyrimidin-4-yl]benzonitrile 35 4-(2- {2,7-diazaspiro[4.4]nonan-2-yl} -5 -(4-methylphenyl)pyrimidin-4-yl)b enzonitrile 36 4-(2- {2,8-diazaspiro [4.5] decan-2-yl} -5-(4-methylphenyl)pyrimidin-4-yl)benzonitrile 37 4- [5-(4-methylpheny1)-2- {octahydro-1H-pyrrolo[3 ,4-c]pyri din-2-yl}pyrimidin-4-yl]benzonitrile ____________________________________________________________ -----Chemical Cellular Synthesis Namei IC50 (11M) Example 38 4- [5-(4-methylpheny1)-2- {octahydro-1H-pyrrolo[3,2-c]pyridin-5-yl}pyrimidin-4-yl]benzonitrile 39 4-(2- {2,8-diazaspiro [4.5] decan-8-y1} -5-(4-methylphenyl)pyrimidin-4-yl)benzonitrile 40 4-(2- {1,8-diazaspiro [4.5] decan-8-y1} -544-methylphenyOpyrimidin-4-yObenzonitrile 41 4- [5-(4-methylpheny1)-2- {9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}pyrimidin-4-yl]benzonitrile 42 445-(4-fluoropheny1)-2- {9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-y1) pyrimidin-4-Abenzonitrile 43 4- [5-(4-methylpheny1)-3-(pyrrolidin-3-ylmethylamino)pyrazol-1- A
yllbenzonitrile 44 445-(4-methylpheny1)-3-[[(3S)-pyrroli din-3-yl]methylamino]pyrazol-1-yllbenzonitrile 45 445-(4-methylpheny1)-3-[[(3R)-pyrroli din-3-yl]methylaminolpyrazol-1-yllbenzonitrile 46 445-(4-methylpheny1)-3-(piperidin-4-ylmethylamino)pyrazol-1-ylThenzonitrile 47 4- [3- [ [(ZS, 5R)-3-az abicyclo [3.1.0]hexan-6-yl]methylamino]-5-(4-methylphenyl)pyrazol-1-yllbenzonitrile 48 445 -(4-metIty 1phetty1)- R2R)-rnorpholin-2-yilmethylipyrrolo[3,2-b]pyridin-6-yllbenzonitrile 4.4 -{((3 R)pyrro I id in-3-yOrnettly1]-5-(4-49 methoxypheny1)pyn-o1o[3,2-b]pyridin-6-y1}benzenecarbonitri1e, .. A
HO salt 4- 1 -R(3 R)pyrroli d 1)m e thyl] -5 -(3 -fluoro-4-50 methoxypheny1)pyno1o[3,2-b]midin-6-y1lbenzenecarbonitrile, A
HCI salt 4-{ -143 S)py,Troli din -3-y Ornetily1]-5 -t 3-ti I R)ro-4-51 methoxypheny1)pyrro1o[3,2-b]pyridin-6-y1}benzenecarbonitri1e, A
HO salt 4- t 1 -[((3IR. )pyrroli di n-3-yr)inethyli -5-(4-52 methoxyphenyl)pyrrolo[3,2-b]pyridin-6-y1) -2- A
fluorobenzertecarbonitrile HO salt ----- ______________________________________________________________ --, Chemical :.:,õ. , Cellular Synthesis :.:: ,* ,I.N a rn e]]
IC50 (11M) Example 4-11-R(3 P)pyrro lid i rt-3-yOmethy li -5 -(3-fluoro-4-53 methoxyphenyppyrrolo [3,2-b] pyridin-6-y1) -2- A
fluoro benzenecafbonitrile HC1 salt 54 4[5-morpholia-4-y1-1-[[(3 R)-pyrrolidia-3-y I] tuethy 1 jpy rrolo [3,2-A
OM yrid in-6-y lib enzonitrile 4- 1-[((3 R)pyrro lidin-3-yOmethy I] -5 -(3 -fluoro-4-55 m e thoxyphenyppyrrolor3 ,2-hipyridin-6-yi ) -2- A
fluorobenzenecarbon itri 1 e ,HC1 salt 56 4- "(3-R(3R)-3-arninopipetidyl)carbony11-5-(2-A
pyridylmethoxy)pyrazo1y1) benzenecarboni trite, 1-Ril salt 57 4-13 -[((3R)-3 -a.rn ino pip eridy1) c arbony1]-5 -(3-pyri dylineth oxy) B
pyrazoly1} benzenecarbonitri le, HO salt 58 4- {3-{U 3 R)-3 -ami nopip cri dy1) carbonyli-5-(4-pyridylmethoxy) C
pyrazoly1} benzenecarbonitri le, I-1El salt 59 4 - [2-(4-ami nopip eri d i n- I -y1)-5-(2-methyl indazol-5-yl)p yrimi din-A
4-y1]-2-flitorobenzonitri I e 60 4424 1,2,3,3 a,4,6,7,7 a-oe tahydropyrrolo [3,2-c]pyri di n -5-y1)-5-(4-A
methylphertyppyrimidin-4-yllbenzonitrile , , , 61 442 -(4-arn inopip oridin-1 -y1)-541-(2,2,2-trifluoroothyl jpyrazo I -A
yllpyrimidin-4-ylThenzonitri le , ' "
62 442-(2,8-diazaspiro[4.5]decan-8-y1)-5-{142,2,2-A
triflooroethylt yrazol-4-yllpyrimidin-4-yllbenzonitrile 63 4424 1,2,3,3 a,4,6,7,7a-oc ta hy dropyrrol o [3,2-c]pyri din-5-y1)-541-B
(2,2,2-trilluoroodayl )pyrazol-4-ylipyr im i di n -4,-:/l jbenzonitrile 64 4-12-(4-a mitiopip eridin-l-y1)-5 -(1-methylp yrazolo [3,4-1Apyrid in-A
5-34)pyriraidin-4-ylibenzonitrile 442-(2,3,3a,4,5,7,8,8a-octahydro-1 H -pyrrolo [3,4-d] azepin-6-yl )-65 5-(1-methy 1pyrazo to [3,4-b]pyridin-5-yl)pyrimi din-4- A
ylThenzonitrile 66 4424 4-am ino p iporidirt-1-34)-54 3-me thy1imi dazo [4,5 -1)] pyr i din-A
6-3/ I )pyri m id in -4 -y 1 ib en zon itri le 67 4-12-(4-a minopip criclin-l-y1)-5 -(1-methylp yrazolo [4,3-bip yrid in-B
5-yl)pyrimi di :a-4-yr] b enzoni trite 68 4- [2-(4-ami nor ip eri di ri -1-y1)-5 -(2-me thylpyrazolo [4,3 -b]pyri dill-B
5-y1)pyrimidiri-4-ylibenzonittile ------- ____________________________________________________________ --, Chemical Cellular Synthesis g :.:: Name 1050 (11M) Example 69 4-[2-(4-a in inop ip eri din- 1 -y1)-5 -( 1-rn e 11 wipyrazol o [3 ,4-cipyri d i n-B
5-y1)pyrimid in-4-ylib enzonitrile 70 442-(4-aminop ip rich n- 1 -y1)-5 424 1-A
hydmxycyclopeR tyl)ethy ny rjpyrimidin-4-y 1] benzonitrile 71 4-[2-(4-ami riop ip eridi n - 1 -y1)-5 - [ 1 -(oxola r3 -3-y Opyrazo B
yliipyrimidin-4-yllbenzanitrile 72 442-(4-aminopi peridi n-1 -y1)-54 1 -inethylbenzotriazol-5-A
yl)pyri midin-4-ylThenzonitri le 73 44244 -aminopiperidin - I -y1)-5 -(2-rn ethylpyrazol o [3 4 -c]pyri din -B
5-y1 )pyri rn id in-4-y 1Then zon i tri le , , , 74 442-(4-ami n op ip cri d irl- 1 -y1)-5 -(2-methoxypyrimid i 11-5 -yOpyrimidin-4,-y lib enzonitrile 75 442-14-am inop ip eridin- 1 -y1)-5 4 1,2-d i m et hy thenzinaidazo 1-y Opyrimidin-4--y1Therizonitri le 76 4- [2-(4-amiriopip eri di n - 1 -y1)-5 -(2-1-r1,. thy 1pyrazolo [4,3 -b ]pyridin-B
6-y1)pyrimidin-4-yllibenzonitril e 77 4- [244-arni n o p i peri d in- 1 -,,z1)-5-( 1 -meth y 1pyrrolo [3 ,2-bipyrid in-5-B
y1)/1 yrimi di rl -4-y1.1b erizoni tril c 78 4- [2-(4-aminopip eridin- 1 -y1)-5 - [ 1 -(oxo lan-3-ylmethyl)pyra zol-B
y Ilipyri rn idin-4-yllb en zon itrile 79 4424 4-am i n opi p erid in- 1 -y1)-5- [ 1 -(difl 1.10TOMethy 1 ).benzimi da zo 1-A
5-yillpyrimidin-4-ylibenzonitrile , 80 442-(4-aminopiperidin- 1 -y1)-5-41 -(2,2,2-trif1uoroethyppyrazo1-4 -A
y 1 i p,yii rn idin-4-y11-2-1:11Loro benz.onitri le 81 442-(4-a rn ino pi periclin-1 - y1)-5 4[1 ,2,4] tria zolo [1 ,5 -a]pyrid in-7-yl)pyrimi din -4-y1 Thenzonitril c 82 442-(4-arninop ip eridin- 1 -y1)-5 -(4-rn et hylp henyl)pyrimi di n-4-A
yl]benzonitril c, 83 4 -[2-(4-aminopip erid in- 1 -y1)-5 -(4-methox:allenyl)pyrimidin-4-A
ylThenzonitrile 84 442-(4-aminopiperidin- 1 -y1)-5-(3-11tioro-4-A
Ine thoxyp limy 1)p yrimi din-4 -:,7 1 lb erizonitrile 85 4- [2-(4-a minopip cridin- 1 -y1)-5 -(2-rnethylp yrazolo [3 ,4-bip yrici in-B
5-yl)pyritai di :a-4-yr] b erizoni tri le ------- _________________________________________________________ --, Chemical .i,., Cellular Synthesis g :.:: ,* Isjani6 IC50 (11M) Example "''''' ...õ..........,.
86 4-[2-(4-arrn n opipe rid in-1 -y!)-5-(2-meth ylpyra zo to[4,3-di pyrimidin-5 -Apyrimidin-4-yli b enzonitrile 87 442-(4-amin opip eridin-1-y!)-5 -(1 -methy lb en zimidazol-5 -A
y Om/ ri rnidin-4-y1]-2-fluorobenzonitrile 88 4-[2-(4-a minop ip eridi n-1-y1)-5 -(1-rn e thylpyrazolo [4,3 -di pyrirnidin-5 -Apyrimi di n-4-yli b enzoni trite
89 2-fittoro-4[2- [4-(in eth y I ami n o)p ip eri di n -1-yi ] -5 - [1-(2,2,2-A
trifluoroe(hyppyrazol-4-yl]pyrimidin-4-Abenzonitrile
90 442-(4-arninopiperidin-1 -y1)-5-(2-methylpyrinndin-5-yl)pyrimi di n -4-yi I benzoni true , , ,
91 442-(4-arni riopip eri di n -1-y1 )-5-(3H-benzimida701-5-B
yOpyrimidin-4-y lib enzonitrile
92 442-(4-aminopiperidin-l-y1)-5-(2,3-dimethy1indazol-5-A
Apyrimi di n-4-y11-2-fluorobenzon i trile
93 4- [2-(4-ami nopiperi di n-1-y 1 )-5-(1 ,3 -dime thy tind azol-5-A
yppyrimidin-4-y1]-2-fluorobenzonitrile
94 4-[2-(4-arn ill opi p erid in-1-y1)-542-(3-hydroxyox oft an-3-A
ypet hynyll pyrimidi n-4-yll -2-fluorob en zon i (rile
95 4 -[5 -(3-amino-2-methylind azo1-5 -y1)-2-(4 -aminopiperidin-1-A
yl)pyrimidin-4-yli-2-fluorobenzonitrile
96 4- [2-(4-aminopiperidin-1-y1)-5-( 1-inethy ibenzotri azol-5-A
yppyrimidin-4-y111-2-fluorobenzonitrile ,
97 4- [2-(4-aminopip eridi n-1-y1)-5- [2-(4-hydroxyoxan-4-B
Act [Tull pyrimi din-4-yli -2-fluorob en zon i trile
98 4 42-(4-ami n opip eri d i n-l-y1)-542-(3-rn ellyltri azo I -4-B
yl)eth y nyi 1 p-yri Ill i din-4-yll -2-fluorob en zon i trile
99 4-[2-(4-aminopip eri di n-1-y1)-5 - [2-(1-m ethylpyrazol-3 -A
y I )eillynyl]pyrimidin-4-y11-2-fluorobenzonitrile
100 4-[2-(4-aminopiperidin-1-y1)-5-[2-(1-methy1triazo1-4-A
ypet hynyll pyrimid i n-4-yll -2-fluorob en zon itrile
101 442-(4-arnino-3-hydroxypiperidin-l-y1)-5-(1-inethylindazol-5-A
yl)pyrimidin-4 -y-1]-2-fluorobenzonitrile
102 4-[2-(4-aminopip eridin-1 -y1)-5 - [2-(1-methy 1pyra zol-4 -A
y I )ethyn sy I jpyri rn idin-4-y1]-2-fhiorobenzoni trite ------- ____________________________________________________________ = -, Chemical - Cellular Synthesis g ::.:: Nam 1050 (11M) Example ¨ ¨
103 442-(4-amino-3-hydroxypi1crid in-1-y1)-541-(2,2,2-B
trifluomethyl)pyrazol-4-ylipyrimidin-4-y11-2-fluombenzonitrile
104 4-[2 -(4-arn ino-3 -hydrovp iperidin-1-yI)-5-( 1-me thylinda zol-5 -A
yl)pyri midin-4-y1]-2-11ttorobenzonitrile
105 4- [2-(4-ann nopiperid in-l-y1)-5-(6-fluoro-l-rnedlylbenzotriazoi-5-A
Apyrimidin-4-y11-2-fluorobenzonitrile
106 4-[2-(4-ami nop ip eri di n -1-y1)-5 - [2-(2-rn ethylpyrazo1-3 -B
yl)e thyn y I] pyri rn idi-11-4-3/11-2-fluorobenzonitrile
107 4-[2-(4-a1in o-3 -hydro x2,piperidin-1-y1)-5-(2-m et-hylinda zo1-5 -A
y ppyri m i d in-4-y1.1-2-fluoro b eilZ011itri le , , ,
108 4-[2-(3-arnino p i p e tidin-1-y1)-5 -(2-m ethylind azo I -5-Apyrimi d i il -A
4 -y11-2-fluorobenzonitrile
109 241 uo ro-4- [5-(2-methylinda zo1-5 -y1)-2-p ipe razin-1-ylpy ri in idin-B
4-ylThenzon itri le
110 442-(1,4-d iaze p an-1-y1)-5 -(2-Ineth ylin d azo1-5-yl)pyriali di n -A
y11-2-fluorob enzoni trile
111 4- [2-(4-ami no-3 -fi uoropi p eri d in-1-y1)-5 -(1 -Tile th y tin d azol-5-A
yl)pyrinild in-4-yl]-2-fluorobenzonitrile
112 4- [2-(4-amino-3 -fluoropip erid in-1-y1)-5 -(2-methylind azol-5-A
yOpyrifilidi n-4-yli -2 -fluorobe rizoni trile
113 442-42,7-dia2.aspito[3.5]nonan-7-y1)-5-(4-B
methylphenyOpyrimidin-4-ylThenzonitrile ,
114 442-(2,3,3a,4,5,7,8,8a-octahydro-1H-py1ro1o[3,4-d]azepin-6-y1)-B
-(6-methylpyri d in-3 -yl)pyri midin-4-yljbenZOD it'd 1 e
115 4424 1,2,3,3a,4,6,7,7a-oe tally dm pyrrolo [3,4-cipyri di n -5-y1)-5-(1 -A
methyl ill& zo1-5 -yl)p yrirni clin-4-yl]ben zon i trile
116 442-(4-aminopiperidin-l-y1)-5-(1-methylindazol-5-yOpyrimidin-A
4-ylibenzon itii le
117 44242.3,3a A5,7,8,8a-octahydro-Iii-pyrrolo [3,4-d]azepin-6-y1)-A
541 H-indazol-6-Apyrimidirt-4-ylibenzonitrile
118 442-(2,3,3a,4,5,7,8,8a-oe ta hydro-111-pyrrolo [3,4-d] azepin-6-y 0-5-(1 ,3-dimethylpyrazo1-4-yl)pyrimidin-4-ylibenzonitrile
119 442-(3,7-diazabicyc1o[3.31]nonan-3-y1)-5-(4-B
m e thy 1ph enyl)pyritni di n-4-yli b enzonitrile ------- ____________________________________________________________ --, Chemical Cellular Synthesis g :.:: Name 1050 (11M) Example
120 442-(3,7-d1 azabicyc to [3 .3.1]tion an-3-y1)-5-(1 -meth y 1 indazol-5-B
yl)pyrimidin-4-ylThenzonitrile
121 442-(2,8-diazaspiro [4.5jdecan-8-y1)-541-(2,2,2-trill t [oroethy I )pyrazo1-4-y I ipyri rn i d in-4-y I Then zon i dri I e
122 442-(4-arn in opi p erid in-1-:,,r1)-5 -(1-methy lb eh zimi da zol-5 -A
yl)pyri midin-4-yllbenzan itri I e
123 442-(4-ami nopi peri d in-1-y)-5-( 6-rn eth oxypyri din-3 -A
yl)pyri midilt-4-ylThenzonitri le
124 442-( -a minopip eridin-1-y1)-5 - [64c y el opropylm etho xy)pyri d in -A
3-y Hpyrimidin-4-y1Then zon itri le , , ,
125 4-[2-(4-ami hop ip eri din-l-y1)-5-(6-fluoro-1-methylbenzimidazol-A
5-yl)pyrirrndin-4-yfibenzonitrile
126 442 -(4-am inop iperidin-1 -y1)-5-(6,7-difluoro-1-A
methylbenzimi dazol-5-yl)pyrimidin-4-y1Thenzonitrile
127 4-[2-(4-aminopiperi di n -1-y1)-5-([1,2,4]tri azol o [1,5-ajpyri di n -yl)p yrimi di n-4-ylib enzonitrile
128 4- [244-arhino pipetidin-1-y1)-5 -d 2-meth ylindazo 1 -5-yl)pyrinai din -A
4-yl]benzonitri le
129 4- [2-(4-aminopip etidin-1-y1)-5 -(2-methylind azol-6-y Opyrimid in-A
4-yilb en zon itrile 4[2-(2,3,3a,4,5,7,8,8a-oetahydro-1H -pyrrolo [3,4-d] azepi n-6-y1)-
130 5-(6,7-difluoro-1-methylbenzimidazol-5-Apyrimidin-4- A
yllbertzonitrile
131 4- [2-(4-arhino piperidin-1-y0-5 - [6-(2,2,2-trifluoro et hoxy)pyri din -B
3-y lipyrimid in-4-ylib enzonitrile
132 4-{244-aminopiperidin-1-y1)-5-(6,7-difi uoro-1-A
methylbenzimidazo1-5-Apyrimidin-4-y11-2-tluorobenzonitri1e
133 442-(4-arninopiperidhi-1-y1)-546-fluoro-1-methylbenzimid a Z01-A
-:!,? Opy rimi d in-4 -yll -2- fluo rob enz onitril e , , 134 442-(4-a mi nop ip eri din-l-y1)-542-(dimethyl amino)pyr i midi ti-A
yl] pyri mid in-4-y (1-2-iluorobellzonitrile 135 4- [244 -a rninopip eridin-1-y1)-5-(2-pyrrolidin-1-y 1py rimid in-5-A
yl)pyrimidin-4-y1]-2 - fhtorobe nzoni trile 136 4-[2-(4-ami hop i peri dill - 1-y I )-5-(3 -Met hylifflidazo [4,5 -NI) yr idin-A
6-y Opyrini i d in-4-y1]-2-fluorobenzonitrile ------- ____________________________________________________________ --, Chemical , Cellular Synthesis g Isalud IC50 (11M) Example 137 442-(2,8-d iaza spiro [4 5-_1 decan-8-y1)-5-(3 -methy 1 i midazo[4,5-A
blpyridin-6-yl)pyrimidin-4-y1]-2-fluorobenzonitrile 138 4-[2-(4-aminopip eri din- 1 -y1)-5 -( I. ,2-dimethylbenzimi dazol-5 -A
y Om/ ri midin-4-y1]-2-11uorobenzonitrile 139 442-(4-aminopiperidin- i -y1)-5-(3 -Tr3 ethyltriazolo[4,5-b] pyrid in-6-A
yl)pyrnnidin-4-y11-2-fluorobenzonitrile 140 4- [2-(4-ami nopiperi din- 1 -y 1 )-542-(rn ethy I aillino)pyrimidin-B
ylipyrimidin-4-y1]-2-fluorobenzoninile 141 44244-an-lin opip eri (h in - 1 -yI)-5 - [2-(cycl opropylamin o)pyrimi d in -A
-yilj pyrimidin-4-y1]-2-11 uorobenzonitrile 142 442-(4-ani in op i p erid in- I -y1)-5 -[ 1 -(o X an-4-y Opy,Tazol-A
yll pyrimid in-4 -y1]-2-fluorobenzonitrile 143 4424 3 -a min opyffolid i n-1 -y 1)-5 -(2-m et hy lindazol-5 -A
Apyrimi di n-4-y11-2-fluorobenzon i trile 144 442-((-aTnitio-3-azabicyc1o[3.1.0]hexan-3-y1)-542-B
methyi in dazol-5 -yOpyrimidin-4-yli-2 -fluorobenzoni tril e 145 4-[2-(4-amino piperidin- 1 -y!)-5-( 1 -methylpyrazolo [3 ,4-b] pyrid in-A
5 -Apyrimidin-4-y1]-2-fluorobenzoni trile 146 4-[2-(2,3,3a,4 ,5,7,8,8 a -octahydro- 1 H-p yrrolo [3 A-d] a zepin-6-y1)-A
5-( 1 ,3 -ben zo th iazo 1-5-y1)pyrimidin-4-ylliben zon itril e 147 4- [2-(4-ami nopiperi din - 1 -y 1 )-6-meth oxy-5 -(2-m et hy1-2 H -in dazol-A
5 -yppy rian d in-4 -yli -2- fluo ro b enz o nitri le , 148 4 -[2-(11,4-di azepan- I -y1)- 6-rnethoxy -5 -(2-me thyl -2H-indazol-A
y 1 )p,yri ni idin-4-y (1-2411Loro benzonitri le 149 4- [2-(4-a rn in o azepan-1 -y1)-6-methoxy-5-(2-methy1-2H-indazot-5-A
Apyrimidin-4 -y1]-2-fluorobenzonitri le 150 4- [2-(4-ami nopiperi din- 1-y1 )-6-meth oxy-5 -(2-in et liy1-2H -in dazol-A
6-y I )pyrini i d in-4-y 1]-2-fl uorobenzonitrile 151 4 -[2-(4-aminopip erid in- 1 -y1)-6-atethoxy-5-(1 -methy 1- 1 H-1,2,3 -A
benzo tria zo 1-5 -yl)pyrimi din-4-y 11-2-fluorobenzon itrile 152 4- [2-( 4-arn ino p iperidin- I -y1)-6-rn et hoxy-5 -(2-me th y I-2H-indazo I -A
5-yl)pyrimidin-4-ylibenzonitrile 153 4 42-(4-arninop ip c..-rid in- 1 -y1)-6-rnethoxy-5 -[ 1 -(2,2,2-A
tri 11 u oro e th y1)- 1 H-pyrazo I -4-yl]p yrimi dili-4-y I ] b enzoni trite ------- ____________________________________________________________ --, Chemical - Cellular Synthesis g ::.:: Na rn d.]]
IC50 (11M) Example 154 442-(4-aini nopip:.-; ri d in- 1 -A-6-the thoxy-54 1 -111Cthy ] - I H-1,2,3-A
benzotriazol-5-yl)pyrimidin-4-ylMenzonitrile 155 442-(4-amin opip cridin- 1 -y1)-5 - [6-(dimethylami no )pyridin-3 -yll -A
6-methoxypyrimi din-4-y1] benzoni trite 156 442-0-anti nopiperid in- I -y1 )-542-(d imeth y 1 arnino)pyrimidin-5-A
y11-6-methoxypyrimi di n-4-yli b enzoni trite 4- [244-ami n opi peri d ill- 1 -y)-6-inethoxy-5- j3-meth y 1-3 1-1-157 [1,2,3]thazolo[4,5-bipyridin-6-yllpyrimidin-4-y11-2- A
fluorob en zonitril e 158 4- [2-(4-aminop ip eri din-1 -y1)-6-met hoxy-5- -,(- 3-m e thy1-3 H -A
[I ,2,3]tri azolo [4,5 -6] pyri d in-6-y I 1 pyri tn idin-4-y libenzon itri !e 159 4- [244 -aminopip eridin- 1 -yI)-6-methoxy-5- 1 I-methyl-1H-A
pyrazolo [3,4-blipyridin-5 -yi pyrimi din-4-y11-2-fluorob enzonitri le 160 442-(4-ami n opi r) eri d in- 1 -yI)-5-(2-methy 1 -2 H-in d azol -5-y1)-6-A
(m. eth y I amino)pyri illi din -4-y1]-2-fluoroben 7011 itti I e 161 4- [2 -(4-am inopip eridin- 1 -yI)-5-( I -methyl- I H-indazol-5-y1)-6-A
( n) ethyl am in o )p,yri m i d in -4-y 1]-2-fluarobe nzon itri le 162 4-L2-(1 ,4-diazepan- 1 -yl)-5-(2-tnethyl-21-I-inciazol-5-y1)-6-A
(methylamino)pyrililidin-4-y11-2 -fluomb e nzo hi trii e 163 4- [2-(4-ami nopip eri din- 1 -yI)-5-(2 -methyl -2 H-in dazol-5-y1)-6-A
(methyl a mino)py ri miclin-4-yll-benzon itrii e 164 4 - [2-(4-aminopip ericlin- I -yI)-5-( 1 -methyl- IH-ind azol-5-y1)-6-A
(meth ylamino)p y rimi d in-4-y lj b enzo ni trite 165 4- [2-(4-amino p iperidin- I -y.i)-5-( 1 -methy t-1 14- 1 ,2,3 -ben zotriazol-A
-yl)-6-(methy lamino)p yrimidin-4-y11-2-flu orob enzonitrile 166 4- [2-(4-aminopip eri din- 1 -y1)-6-(ethylaTil ill 0-5 -(2-m ethyl-2H-A
in d azo1-5 -yl)pyrimi di n-4-y1 1-2-fluoroben zon itri le 442-(4-al ill nopi peri d in- I -y1)-6-(in ethy I ami n())-5 -111 -(2,2,2-167 trifluoroethyl)- I H-p yrazol-4-ylipyrimidin-4-y11-2- A
fluorobenzonitril c , 168 442-(4-aminopiperid in-1-y 0-542-(d imethylarnino)pyrimidin-5-A
yfj-6-(methylamino)pyrimid in-4 -yl] -2-fluorob enzonitrile , 169 4- [2 -(4-aminopip cricli II-1 -y1)-5 -[6-( dim ethylamino)pyridi n-3-yll -A
6-(rncillylarnino)pyrimidin-4-y1]-2-fluorobenzonini le 170 4- [2-(4-a rn ino p ip eridi n-1 -y1)-5- [3-me d iy1-3H - [ i ,2,3 i triazolo [4,5-A
bi pyrid in -6-y1) -6-(m ethyl arni n o)pyrimi di n -4-yl] benzoni tri le ____________________________________________________________ -----Chemical Cellular Synthesis Name IC50 (1..tM) Example 442-(4-a ":3-rneilly1-3H-[ I
,2,3] triazo lo [4,5-171 b]pyridin-6-y1)-6-(methylarnino)pyrimidin-4-y11-2-= A
finorobenzonitril e 172 44241 ,4-diazepan-1-yI)-5-( 2-Tneth y I-2 ii-indazo I -5-y I )-6-A
(rnethylaminOpyrimidin-'l -yl]benzonitrile 173 4- (2- [4-(dimettrylarnino)pip eridi n-1-yl] ethy1-2H-in dazol-A
-y1)-64 niethylarnino )pyrimid in-4- ) benzonitrie 174 442-(4-aminopiperici in-1 -y1)-6-(Inethytamino)-5-p -(2,22-A
trifluoroethyl -pyrazol-4-yilpyri -b enzon itril e 4-[2-(4-aininopiperidin-1 -y1)-5-11-niethyl-1H-pyrazoio[3,4-175 b] pyridin.-5-y1.}-6-(metbylarnino)pyrirnidin-4-A-2- A
11 Liorobenzonitrile 176 4- [2-( 4-arninopip eridna- I -y1)-5- .{3-methy1-3H-[ I ,2,3] tria zo I o [4,5-A
]pyri n -6-yi -6-(methyla mino)pyrinndin-4-ylibenzonitri le 177 4-1.2-{(3S,4R)-4-amino-3-fittoropiperidin-1-yill-5-(2-rnethyi-214-A
in ciazol-5-y1)-6-(m et hylarnino)pyri midin-4-y1} bC112011itrile 178 442431:-1,4S)-4-arn1n0-3-fluor0piperidin-l-y1]-5-(2-i-nethyl-2H-A
indazol-5-yl)-6-(methylamino)pyrimidin.-4-yl}bdnzonitrile Note: Cellular assay IC50 data are designated within the following ranges:
A: < 0.10 M C: > 1.0 to < 10 M
B: > 0.10 litM to < 1.0 laM D: > 10 iuM
Example 4: In Vivo Xenograph Study ¨ MCF-7 Xenograph [00455] Time release pellets containing 0.72 mg 17-13 Estradiol are subcutaneously implanted into nu/nu mice. MCF-7 cells are grown in RPMI containing 10% FBS at 5%
CO2, 37 C. Cells are spun down and re-suspended in 50% RPMI (serum free) and 50%
Matrigel at 1X107cells/mL. MCF-7 cells are subcutaneously injected (100 L/animal) on the right flank 2-3 days post pellet implantation and tumor volume (length x width2/2) is monitored bi-weekly. When tumors reach an average volume of ¨200 mm3 animals are randomized and treatment is started. Animals are treated with vehicle or compound daily for 4 weeks. Tumor volume and body weight are monitored bi-weekly throughout the study. At the conclusion of the treatment period, plasma and tumor samples are taken for pharmacokinctic and pharmacodynamic analyses, respectively.
Example 5: In Vivo Xcnograph Study ¨ LNCaP Xcnograph [00456] LNCaP cells with a stable knockdown of LSD1 (shLSD1 cells) or control cells (such as shNTC cells) are inoculated in the dorsal flank of nude mice by subcutaneous injection (such as 3 x 106 cells in 100 l of 50% RPMI 1640/BD Matrigel). Mouse weight and tumor size are measured once per week and tumor volume is estimated using the formula (7i/6)(LxW), where L = length of tumor and W = width of tumor. A
two sample t-test is performed to determine statistical differences in mean tumor volume between the two groups.
[00457] Unmodified LNCaP cells are inoculated by subcutaneous injection into the dorsal flank of nude mice (such as 3 x 106 cells in 100 pi of 50% RPMI 1640/BD

Matrigel). After three weeks, mice are injected intraperitoneally once per day with water (control), pargyline (0.53 mg or 1.59 mg; 1 or 3 mM final concentration, assuming 70%
bioavailability), or XB154 (4 or 20 pg; 1 or 5 [tM final concentration, assuming 70%
bioavailability) or treated with a test compound (5 mg/kg each week or 10 mg/kg each week). Treatment continues for three weeks, during which time mouse weight and tumor volume are measured as above.
[00458] shLSD1LNCaP cells or control cells are injected in nude mice as above.
After three weeks, mice are treated with 2.6 [tg mitomycin C (predicted final concentration of 1 uM assuming 40% bioavailability), olaparib (for example, about 0.5 mg/kg to mg/kg), or vehicle intraperitoneally once per day for three weeks. In other examples, unmodified LNCaP cells are injected in nude mice as above.
[00459] After three weeks, mice are treated with test compounds, or vehicle as above, plus MMC or olaparib. Treatment continues for three weeks, during which time mouse weight and tumor volume are measured as above.
[00460] A decrease in tumor volume compared to control in mice injected with shLSD1 cells indicates that LSD1 inhibition decreases tumor growth in vivo.
[00461] Similarly, a decrease in tumor volume compared to control in mice injected with LNCaP cells and treated with a compound disclosed herein indicates that inhibition decreases tumor growth in vivo. Finally, a decrease in tumor volume in mice injected with LNCaP cells and treated with a compound disclosed herein plus olaparib as compared to mice treated with a compound disclosed herein alone indicates that inhibition of LSD1 plus inhibition of PARP decreases tumor growth in vivo.
[00462] The harvested xenograft tissue is examined for evidence of LSD1 inhibition.
This is assessed with Western blots to examine global levels of the 2MK4 and histone marks, expression of FA/BRCA genes, FANCD2 ubiquitination, and LSD1 protein levels in the cases of the shRNA cells. A decrease in one or more of these parameters indicates the effective inhibition of LSD 1. Additionally, effects on DNA
damage repair are assessed with staining for H2AX foci.
III. Preparation of Pharmaceutical Dosage Forms Example I: Oral Tablet [00463] A tablet is prepared by mixing 48% by weight of a compound of Formula (I), (II), (Ha), (111a) or (III), or a pharmaceutically acceptable salt thereof, 45% by weight of microcrystalline cellulose, 5% by weight of low-substituted hydroxypropyl cellulose, and 2% by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg.

Claims (22)

THE EMBODIMENTS OF THE INVENTION FOR WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof, wherein, X and Y are each independently chosen from C-H, C-F, C-CH3, or N;
Z is chosen ¨G, -CH2-G, ¨CH2-CH2-G, ¨N(R1)-G, ¨N(R1)-CH2-G, ¨0-G, -0-CH2-G, or ¨
C(0)N(R2)(R3);
G is an optionally substituted carbocyclyl, an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl;
Rl is hydrogen or alkyl;
R2 and R3 are independently selected from hydrogen, alkyl, heterocyclyl, heterocyclylalkyl, or optionally, R2 and R3 join to form an optionally substituted N-linked heterocyclyl ring system;
R is chosen from optionally substituted 5 or 6-membered heteroaryl containing 2 nitrogen atoms, optionally substituted bicyclic nitrogen containing ring, optionally substituted heterocyclylalkynyl, or optionally substituted heteroarylalkynyl; and (i) R4 is hydrogen when R is optionally substituted heterocyclylalkynyl or optionally substituted heteroarylalkynyl; or (ii) R4 is ¨N(R2)(R3) when R is an optionally substituted 5 or 6-membered heteroaryl containing 2 nitrogen atoms or an optionally substituted bicyclic nitrogen containing ring.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is C-H.
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is C-F.
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is C-CH3.
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is N.
6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein Y is C-H.
7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein Y is C-F.
8. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein Y is C-CH3.
9. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein Y is N.
10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is C-H and Y is C-H.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein Z is:
(a) -0-CH2-G;
(b) ¨0-G;
(c) ¨N(R1)-CH2-G;
(d) ¨N(R1)-CH2-G and Rl is hydrogen;
(e) ¨N(R1)-CH2-G and Rl is alkyl;
¨N(R1)-G;
(h) ¨N(R1)-G, and Rl is hydrogen;
¨N(R1)-G, and Rl is alkyl;

(j) ¨CH2-CH2-G;
(k) -CH2-G;
(1) ¨G;
(m) ¨C(0)N(R2)(R3);
(n) ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, or alkyl;
(o) ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclyl;
(p) ¨C(0)N(R2)(R3), and R2 and R3 are independently selected from hydrogen, alkyl, or heterocyclylalkyl;
(q) ¨C(0)N(R2)(R3), and R2 and R3 join to form an optionally substituted N-linked heterocyclyl ring system;
(r) ¨C(0)N(R2)(R3), R2 and R3 join to fonn an optionally substituted N-linked heterocyclyl ring system, and the heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group; or (s) ¨C(0)N(R2)(R3), R2 and R3 are both alkyl, and R2 and R3 join to fonn an optionally substituted N-linked heterocyclyl ring system.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R is an optionally substituted 5 or 6-membered heteroaryl containing 2 nitrogen atoms or an optionally substituted bicyclic nitrogen containing ring, and R4 is:
(a) ¨N(R2)(R3) and R2 is hydrogen and R3 is methyl;
(b) ¨N(R2)(R3) and R2 is hydrogen and R3 is ethyl; or (c) ¨N(R2)(R3) and R2 is methyl and R3 is methyl.
13. The compound of any one of claims 1-12, or a phannaceutically acceptable salt thereof, wherein G is:
(a) an optionally substituted heterocyclyl;
(b) an optionally substituted nitrogen-containing heterocyclyl;
(c) an optionally substituted nitrogen-containing heterocyclyl, and the optionally substituted nitrogen-containing heterocyclyl is an optionally substituted 5-or 6-membered heterocyclyl;
(d) an optionally substituted nitrogen-containing heterocyclyl, and the optionally substituted heterocyclyl is chosen from:
(e) an optionally substituted nitrogen-containing heterocyclyl, and the optionally substituted heterocyclyl is chosen from:

(0 an optionally substituted heterocyclyl, and the optionally substituted heterocyclyl is chosen from an optionally substituted piperdinyl, piperizinyl, morpholinyl, or pyrrolidinyl group.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein when R is an optionally substituted 5 or 6-membered heteroaryl containing 2 nitrogen atoms, then R is optionally substituted pyrrazolyl, imidazolyl, pyrimidinyl, pyrazinyl, or pyridazinyl.
15. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein when R is an optionally substituted bicyclic nitrogen-containing ring, then R is chosen from:

, wherein R5 is hydrogen, C1-C6 aryl, or Ci-C6 alkoxy.
16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
4-[2-(4-aminopiperidin-l-y1)-5-[2-(3-hydroxyoxolan-3-yOethynyl]pyrimidin-4-y1]-fluorobenzonitrile;
4-[2-(4-aminopiperidin-l-y1)-5-[2-(4-hydroxyoxan-4-yl)ethynyl]pyrimidin-4-y1]-fluorobenzonitrile;
442-(4-aminopiperidin-l-y1)-542-(3-methyltriazol-4-yl)ethynyl]pyrimidin-4-y1]-fluorobenzonitrile;
4-[2-(4-aminopiperidin-1-y1)-5-[2-(1-methy1pyrazo1-3-y1)ethyny1]pyrimidin-4-y1]-2-fluorobenzonitrile;
442-(4-aminopiperidin-l-y1)-542-(1-methyltriazol-4-yl)ethynyl]pyrimidin-4-y1]-fluorobenzonitrile;
4-[2-(4-aminopiperidin-l-y1)-5-[2-(1-methylpyrazol-4-yeethynyl]pyrimidin-4-y1]-fluorobenzonitrile;

4- [2-(4-aminopiperidin-l-y1)-542-(2-methylpyrazol-3-yOethynyl]pyrimidin-4-yl]

fluorobenzonitrile;
4- [2-(4-aminopiperidin-l-y1)-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-yl] -2-fluorobenzonitrile;
442-(4-aminopiperidin-1-y1)-5-(1-methyl-1H-indazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile;
4- [2-(1,4-di az epan-l-y1)-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile;
4- [2-(4-aminopiperidin-l-y1)-5-(2-methyl-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-yl] -benzonitrile;
4- [2-(4-aminopiperidin-l-y1)-5-(1-methy1-1H-indazol-5-y1)-6-(methylamino)pyrimi din-4-ylThenzonitrile;
442-(4-aminopiperidin-1-y1)-5-(1-methyl-1H-1,2,3-benzotriazol-5-y1)-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile;
4- [2-(4-aminopiperidin-l-y1)-6-(ethylamino)-5-(2-methyl-2H-indazol-5-yOpyrimidin-4-y1]-2-fluorobenzonitrile;
4- [2-(4-aminopiperidin-l-y1)-6-(methylamino)-5- [1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]pyrimidin-4-y1]-2-fluorobenzonitrile;
4- [2-(4-aminopiperidin-l-y1)-542-(dimethylamino)pyrimidin-5-yl] -6-(methylamino)pyrimidin-4-yl] -2-fluorobenzonitrile;
4- [2-(4-aminopiperidin-l-y1)-546-(dimethylamino)pyridin-3-y1]-6-(methylamino)pyrimidin-4-yl] -2-fluorobenzonitrile;
442-(4-aminopiperidin-1-y1)-5- {3-methy1-3H-[1,2,3]triazolo[4,5-b]pyridin-6-y1 (methylamino)pyrimidin-4-ylThenzonitrile;
442-(4-aminopiperidin-1-y1)-5- {3-methy1-3H-[1,2,3]triazolo[4,5-b]pyridin-6-y1 (methylamino)pyrimidin-4-yl] -2-fluorob enzonitrile;
4- [2-(1,4-di az epan-l-y1)-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-ylThenzonitrile;
4- {2-[4-(dimethylamino)piperidin-1-y1]-5-(2-methy1-2H-indazol-5-y1)-6-(methylamino)pyrimidin-4-y1 benzonitrile;

4-[2-(4-aminopiperidin-1-y1)-6-(methylamino)-5-[1-(2,2,2-trifluoroethyl)-111-pyrazol-4-yl]pyrimidin-4-y1]-benzonitrile;
4- [2-(4-aminopiperidin-l-y1)-5- {1-methy1-111-pyrazolo [3,4-b]pyridin-5-y1}-6-(methylamino)pyrimidin-4-y1]-2-fluorobenzonitrile;
442-(4-aminopiperidin-1-y1)-5-{3-methy1-3H-[1,2,3]triazolo[4,5-b]pyridin-6-y11-(methylamino)pyrimidin-4-yl]benzonitrile;
4- {2-[(3S,4R)-4-amino-3-fluoropiperidin-1-y1]-5-(2-methy1-211-indazol-5-y1)-6-(methylamino)pyrimidin-4-yllbenzonitrile; and 4- {243R,45)-4-amino-3-fluoropiperidin-1-y1]-5-(2-methy1-211-indazol-5-y1)-6-(methylamino)pyrimidin-4-yl}benzonitrile.
17. A phamiaceutical composition comprising a compound of Fommla (III) of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
18. An in vitro method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (III) of any one of claims 1-16 or the phamiaceutical composition of claim 17.
19. Use of a compound as defined in any one of claims 1-16, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition as defined in claim 17, to regulate gene transcription in a cell by inhibition of lysine-specific demethylase 1 activity.
20. Use of a compound as defined in any one of claims 1-16, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition as defined in claim 17, for the treatment of cancer in a patient in need thereof.
21. Use of a compound of Formula (III) as defined in any one of claims 1-16, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient in need thereof.
22.
The use of claim 20 or 21, wherein the cancer is acute myeloid leukemia, breast cancer, or prostate cancer.
CA2933480A 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1 Active CA2933480C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3161836A CA3161836A1 (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914927P 2013-12-11 2013-12-11
US61/914,927 2013-12-11
PCT/US2014/069562 WO2015089192A1 (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3161836A Division CA3161836A1 (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1

Publications (2)

Publication Number Publication Date
CA2933480A1 CA2933480A1 (en) 2015-06-18
CA2933480C true CA2933480C (en) 2022-08-23

Family

ID=53371806

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3161836A Pending CA3161836A1 (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1
CA2933480A Active CA2933480C (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3161836A Pending CA3161836A1 (en) 2013-12-11 2014-12-10 Inhibitors of lysine specific demethylase-1

Country Status (16)

Country Link
US (3) US9944636B2 (en)
EP (2) EP3080100B1 (en)
JP (1) JP6430512B2 (en)
CA (2) CA3161836A1 (en)
DK (1) DK3080100T3 (en)
ES (1) ES2935746T3 (en)
FI (1) FI3080100T3 (en)
HR (1) HRP20230086T1 (en)
HU (1) HUE061252T2 (en)
LT (1) LT3080100T (en)
MX (2) MX2016007585A (en)
PL (1) PL3080100T3 (en)
PT (1) PT3080100T (en)
RS (1) RS63939B1 (en)
SI (1) SI3080100T1 (en)
WO (1) WO2015089192A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (en) 2014-02-13 2019-11-06 インサイト・コーポレイション Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
LT3105218T (en) 2014-02-13 2019-12-10 Incyte Corp Cyclopropylamines as lsd1 inhibitors
KR102400920B1 (en) * 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. Inhibitors of lysine specific demethylase-1
JP6587241B2 (en) * 2014-06-27 2019-10-09 セルジーン クオンティセル リサーチ，インク． Lysine-specific inhibitors of demethylase-1
HRP20230595T1 (en) * 2014-07-03 2023-09-15 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
TWI687419B (en) 2014-07-10 2020-03-11 美商英塞特公司 Imidazopyridines and imidazopyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3189038B1 (en) * 2014-09-05 2022-11-23 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CA2981661C (en) 2015-04-03 2023-10-03 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
KR20180011331A (en) 2015-06-12 2018-01-31 오리존 지노믹스 에스.에이. Biomarkers associated with LSDl inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EP3334709A1 (en) 2015-08-12 2018-06-20 Incyte Corporation Salts of an lsd1 inhibitor
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
AU2016360481B2 (en) * 2015-11-27 2019-09-12 Taiho Pharmaceutical Co., Ltd. Novel biphenyl compound or salt thereof
WO2017116558A1 (en) 2015-12-29 2017-07-06 Mirati Therapeutics, Inc. Lsd1 inhibitors
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP3430015A1 (en) 2016-03-16 2019-01-23 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2018012901A (en) 2016-04-22 2019-06-06 Incyte Corp Formulations of an lsd1 inhibitor.
CN105924397B (en) * 2016-04-29 2017-11-24 河南省农业科学院植物保护研究所 A kind of formic acid esters pyrazole compound of 1,5 diaryl 3, Preparation method and use
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
CN110914265B (en) * 2017-05-15 2022-12-23 密歇根大学董事会 Pyrrolo [2,3-C ] pyridines and related analogs as LSD-1 inhibitors
MA50466A (en) 2017-05-26 2020-09-02 Taiho Pharmaceutical Co Ltd NEW BIPHENYL COMPOUND OR SALT
WO2018216795A1 (en) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 Anti-tumor effect potentiator using novel biphenyl compound
MA50518A (en) 2017-05-31 2020-09-09 Taiho Pharmaceutical Co Ltd METHOD OF PREDICTING THE THERAPEUTIC EFFECT OF AN LSD1 INHIBITOR BASED ON INSM1 EXPRESSION
EP3661510B1 (en) 2017-08-03 2024-10-09 Oryzon Genomics, S.A. Methods of treating behavior alterations
TWI794294B (en) * 2017-09-13 2023-03-01 南韓商韓美藥品股份有限公司 Pyrazole derivative compound and use thereof
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
US20220151999A1 (en) 2019-03-20 2022-05-19 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
JP2022546908A (en) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Biomarkers and methods for personalized treatment of small cell lung cancer using KDM1A inhibitors
CN114105950B (en) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 Pyrazole compound and application thereof
BR112023020554A2 (en) 2021-04-08 2023-12-05 Oryzon Genomics Sa LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF MYELOID CANCERS
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
WO2002102313A2 (en) * 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
KR20050013534A (en) * 2002-03-28 2005-02-04 에자이 가부시키가이샤 Azaindoles as Inhibitors of c-Jun N-terminal Kinase
PT2316831E (en) 2002-11-21 2013-06-06 Novartis Ag 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7858395B2 (en) 2005-07-13 2010-12-28 Universitaetsklinikum Freiburg Antibodies for use in identifying and/or scoring prostate cancer and androgen receptor-dependent gene expression control
AU2007209928B2 (en) * 2006-01-30 2013-03-28 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and pharmaceutical compositions containing them
CN104030990B (en) * 2007-03-12 2017-01-04 Ym生物科学澳大利亚私人有限公司 Phenyl amino pyrimidine compounds and application thereof
US8916548B2 (en) * 2008-07-29 2014-12-23 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
WO2010046780A2 (en) * 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
TWI435874B (en) * 2008-10-31 2014-05-01 Toray Industries A cyclohexane derivative and the medical and pharmaceutical use
EP2258865A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
EP2258858A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Transgenic LSD1 animal model for cancer
US9708255B2 (en) * 2009-08-18 2017-07-18 Robert A. Casero (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
TW201111378A (en) * 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011143057A1 (en) * 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2012013727A1 (en) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
GB201106829D0 (en) * 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2013033688A1 (en) * 2011-09-01 2013-03-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
AR088351A1 (en) * 2011-10-31 2014-05-28 Lilly Co Eli REPLACED PIRAZOL ANALOGS
PL2770994T3 (en) * 2012-05-04 2020-03-31 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2013175789A1 (en) 2012-05-24 2013-11-28 出光興産株式会社 Material for organic electroluminescent elements, and organic electroluminescent element using same

Also Published As

Publication number Publication date
US20190055242A1 (en) 2019-02-21
MX2016007585A (en) 2016-12-16
EP3080100B1 (en) 2022-11-30
US20160304516A1 (en) 2016-10-20
ES2935746T3 (en) 2023-03-09
JP2017502940A (en) 2017-01-26
HUE061252T2 (en) 2023-05-28
WO2015089192A1 (en) 2015-06-18
US20180179204A1 (en) 2018-06-28
US10385051B2 (en) 2019-08-20
CA2933480A1 (en) 2015-06-18
US10131664B2 (en) 2018-11-20
EP4257591A2 (en) 2023-10-11
SI3080100T1 (en) 2023-04-28
DK3080100T3 (en) 2023-02-06
JP6430512B2 (en) 2018-11-28
EP3080100A1 (en) 2016-10-19
RS63939B1 (en) 2023-02-28
PL3080100T3 (en) 2023-03-06
PT3080100T (en) 2023-01-19
FI3080100T3 (en) 2023-03-15
LT3080100T (en) 2023-02-27
MX2020010496A (en) 2020-10-28
HRP20230086T1 (en) 2023-03-31
US9944636B2 (en) 2018-04-17
EP3080100A4 (en) 2017-09-06
EP4257591A3 (en) 2023-11-22
CA3161836A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
CA2933480C (en) Inhibitors of lysine specific demethylase-1
JP6983273B2 (en) Lysine-specific inhibitor of demethylase-1
EP2124951B1 (en) 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AU2014235280A1 (en) Histone demethylase inhibitors
AU2021314416B2 (en) Compound having kinase inhibitory activity
US20160297815A1 (en) 7-azaindole or 4,7-diazaindole derivatives as ikk epsilon and tbk1 inhibitor and pharmaceutical composition comprising same
EP3999498A1 (en) Inhibitors of cyclin-dependent kinases
AU2023263382A1 (en) Heterocyclic compounds as modulators of bcl6 as ligand directed degraders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191113

EEER Examination request

Effective date: 20191113